Evidence Extractions

Question: How effective and cost-effective are anti-epileptic drugs for partial with/without secondary generalisation
Grading: 1+  
Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias

Anhut H;Ashman P;Feuerstein TJ;Sauermann W;Saunders M;Schmidt B;

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group

Ref ID  4753  
1994

Study Type  Randomised Controlled Trial  
Funding  Parke Davis

Number of participants  272 patients total; 109 placebo; 111 Gabapentin (GBP) 900 mg/day; 52 Gabapentin 1200 mg/day

Inclusion/Exclusion Criteria  
Inclusion: Stable AED dose during the 3 months before screening with four partial seizures per month despite medication; males and females greater than or equal to 12 years with body weight of 40-110 kg and women of childbearing potential using adequate contraception. Excluded: Patients with progressive structural lesions in CNS, severe hepatic or renal disease, low WBC, or neutropenia or chronic drug or alcohol abuse.

Patient Characteristics  
There were 56% men and 44% women with a mean age of 32 years (range 12-67) and median baseline seizure frequency of 10.2 (range 0.5-634.3). Most patients were receiving one (24%) or two (68%) concurrent AEDs, most frequently CBZ (75%), VPA (31%) and PHT (28%). The only significant difference between groups was body mass with 900 mg/day group smaller (P=0.015)

Recruitment  Unknown

Setting  24 centres: Europe, Canada, South Africa and Australia

Interventions/Test/Factor being investigated  GBP as an add on therapy in patients with refractory partial seizures in doses of 900 mg/day and 1200 mg/day to evaluate safety, efficacy and dose response.

Comparisons  Comparisons are between treatments (2) and placebo

Length of Study/Follow-up  12 week open label extension phase.

Outcome measures studied  
Primary: Percentage of change in the frequency of partial seizures relative baseline; response and responder rate and response ratio.  
Secondary: Response ratio for all seizures and global evaluations of patients overall ability to perform ADLs

Results  
The ITT analysis (2 patients missing) and the analysis for the evaluable population (32 patients missing) were in close agreement. In the ITT analysis the responder rate was 22% for the 900 mg/day group and 10.1% for the placebo group (p=0.026); rate ratio was -0.138 for the 900 mg/day group and -0.017 for the placebo group (p=0.0002). For the 1200 mg/day group, responder rate was 27% and the rate ratio was -0.184. GBP produced a dose related reduction in seizure frequency in all types of partial seizures.

Safety and adverse effects  
Adverse events occurred in 69% of patients in the 900 mg/day group and 64% in the 1200 mg/day group compared with 52% in placebo group. The most frequent events among those on GBP were somnolence, dizziness and fatigue. There were no clinically important effects.

Does the study answer the question?  
GBP appears to be safe and effective in treating some patients with refractory partial seizures.

Effect due to factor in study?  
Consistency of results with other studies?
Directly applicable to guideline population?

Internal Validity

Multi centre

Appleton R; Fichtner K; LaMoreaux L; Alexander J; Halsall G; Murray G; Garofalo E;

Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group

Ref ID 4604 1999

Study Type Randomised Controlled Trial

Funding Parke Davis

Number of participant Total: 247; placebo: 128; Gabapentin: 119

Inclusion/Exclusion Criteria

Inclusion: Patients with history of medically uncontrolled seizures classified as simple partial, complex partial, or partial becoming generalized, aged 12 years or younger, weigh 17-72 kg at screening and were to be receiving one to three AEDs. Exclusion: Patients with absence seizures or seizures related to drugs, alcohol or acute medical illness; patients with structural CNS lesions or encephalopathies, diagnosed as progressive within 2 years before screening; children with benign epilepsy syndromes

Patient Characteristics

Gender, n(%)  Total (n=247)

male  134 (54.3%)

female  113 (45.7%)

Age (yr)  8.4 +/- 2.6

Race

White  226 (91.5%)

Other  21 (8.5%)

Recruitment

Not described

Setting

54 centres in Europe, South Africa and the US from

Interventions/ Test/ Factor being investigated

Gagapentin vs. placebo

Comparisons

Treatment vs. placebo

Length of Study/ Follow-up

6 week baseline phase followed by a 12 week double blind treatment phase

Outcome measures studied

Primary: Seizure frequency as a Response Ratio; Secondary: responder rate, percentage change (PCH) in the frequency of all partial seizures from baseline to treatment phase, PCH and RRatio for individual types of partial seizures.

Results

RRatio for all partial seizures was significantly lower (better) for GBP treated patients: p=0.0407. Responder rate favoured GBP but the difference between treatment groups was not statistically significant. Median PCH for all partial seizures for the GBP treatment group (-17.0%) was better than that for the placebo group (-6.5%). Median PCH for specific seizure types showed GBP to be most effective in controlling complex partial seizures (-35%) and secondarily generalized seizures (-28%) when compared with placebo (112% and +13%) respectively.

Safety and adverse effects

The most frequently reported treatment related adverse events were somnolence, hostility, nausea and/or vomiting, fatigue, headache, convulsions, hyperkinesia and emotional lability.

Does the study answer the question?

GBP was effective and well tolerated as an add on therapy for partial seizures in paediatric patients with previously drug resistant seizures.
Internal Validity

Multicentre trial in Europe, US and South Africa

Consistency of results with other studies?

See GRADE

Directly applicable to guideline population?

See GRADE

Effect due to factor in study?

Yes

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Pregabalin</th>
<th>Pregabalin</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/day</td>
<td>150 mg/day</td>
<td>600 mg/day</td>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
<td>96</td>
<td>99</td>
<td>92</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>38.1 (12.4)</td>
<td>36.5 (11.3)</td>
<td>36.4</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>(10.5)</td>
<td>(11.3)</td>
<td></td>
</tr>
<tr>
<td>Gender, N (%)</td>
<td>54 (56.3)</td>
<td>44 (44.4)</td>
<td>47</td>
</tr>
<tr>
<td>Men</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race, N (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>89 (92.7)</td>
<td>93 (93.9)</td>
<td>84</td>
</tr>
<tr>
<td>(91.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>1 (1.0)</td>
<td>2 (2.0)</td>
<td>2</td>
</tr>
<tr>
<td>(2.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>2 (2.1)</td>
<td>2 (2.0)</td>
<td>1</td>
</tr>
<tr>
<td>(1.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>73.00 (14.49)</td>
<td>75.12 (18.39)</td>
<td>71.22</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>(16.21)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine clearance at baseline</td>
<td>105.7</td>
<td>114.3</td>
<td></td>
</tr>
<tr>
<td>Mean (ml/min)</td>
<td>110.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years with epilepsy</td>
<td>22.78 (13.58)</td>
<td>24.8 (12.65)</td>
<td>25.06</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>(11.63)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline 28-day seizure rate</td>
<td>23.5 (41.1)</td>
<td>26.2 (40.8)</td>
<td>19.3</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>(24.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizure history at screening, N (%)</td>
<td>47 (49.0)</td>
<td>40 (40.4)</td>
<td>37</td>
</tr>
<tr>
<td>Simple partial</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Study Type: Randomised Controlled Trial

Funding: Not reported.

Number of participant

n=288 (n=99 on 150mg/d, n=92 on 600mg/d and n=97 on placebo)

Inclusion/Exclusion Criteria

Men or women aged 18 years or older, weighing 50–135 kg, with partial seizures were allowed to enter. They were required to have unsuccessfully tried at least one AED at the maximum tolerated dose, to have had at least three partial seizures in the month before screening, and were receiving one to three AEDs. Patients were required to have at least six partial seizures during the 8-week period before randomization and not to have been free of seizures for any 4-week period during this time.

Exclusion criteria: patients with absence seizures, Lennox–Gastaut syndrome, status epilepticus in the past year, clinically relevant medical illness or electrocardiogram (ECG) abnormalities or a significant psychiatric disorder.

Ref ID: 4409

Arroyo S; Anhut H; Kugler AR; Lee CM; Knapp LE; Garofalo EA; Messmer S; International Study Group;
Complex partial 88 (91.7) 89 (89.9) 88
Partial secondarily generalized 72 (75.0) 65 (65.7) 69
Generalized 3 (3.1) 9 (9.1) 6
Concurrent AED, N (%) 24 (26.1)
AEDs 30 (31.3) 31 (31.3)
Pregabalin (PGB) 150mg/day (50mg three times a day) and PGB 600mg/day (200mg three times a day). Comparisons are made between two doses of PGB and placebo as adjunctive therapy to currently used AEDs.

**Interventions/Test/Factor being investigated**

Comparisons are made between two doses of PGB and placebo as adjunctive therapy to currently used AEDs.

**Length of Study/Follow-up**

20 weeks: 8 week baseline period and 12 week treatment period.

**Outcome measures studied**

The primary efficacy criterion was seizure-frequency change from baseline expressed as RRatio. Secondary outcomes: responder rate, % free of seizures, change in seizure freq.

**Results**

Primary outcome

The reduction in seizures point was significantly greater in the 150-mg/day PGB and 600-mg/day PGB groups compared with placebo. The 150-mg/day and 600-mg/day PGB dosages were both significantly more effective than placebo in reducing the RRatio [−11.5 (p = 0.0007) and −31.4 (p ≤ 0.0001), respectively, vs. 0.9]. These RRatio values correspond to seizure-frequency reductions from baseline of 20.6, and 47.8% for 150 mg/day, and 600mg/day, respectively, and a seizure-frequency increase of 1.8% with placebo. Difference in the treatment means [95% confidence interval (CI)] compared with the placebo group was −12.4 (−20.5; −4.3) in the 150-mg/day PGB group and −32.3 (−40.6; −24.0) in the 600-mg/day PGB group. The 600-mg/day PGB group was statistically superior to the 150-mg/day PGB group (p ≤ 0.0001).

Secondary outcomes

Responder rate

The responder rate was significantly greater in the 600-mg/day PGB group (43.5%) than in the placebo group (6.2%) (p ≤ 0.001). In the 150-mg/day PGB group, the difference from placebo approached significance (14.1%; p=0.087). Responder rate for the 600-mg/day PGB group was statistically superior to the 150-mg/day PGB group (p ≤ 0.001).

Median percentage reduction

A median percentage reduction was seen in all partial seizures of 16.5% in the 150-mg/day PGB group and 42.8% in the 600-mg/day PGB group, and an increase of 1.3% in the placebo group.

Seizure free

During the last 28 days of treatment, 12% of patients in the 600-mg/day PGB group were free of seizures, as were 7% in the 150-mg/day PGB group and just 1% in the placebo group (p = 0.002 and p = 0.065 vs. placebo, respectively).

Subgroup analysis

The analysis of median percentage change in seizure frequency according to seizure typewas consistent with the analysis of all partial seizures combined.
Yes. PGB, 150mg/day and 600mg/day is effective as add-on therapy in patients with partial seizures.

### Safety and adverse effects

Frequency of serious treatment-emergent adverse events were higher in the PGB treatment groups.

### Does the study answer the question?

Yes. PGB, 150mg/day and 600mg/day is effective as add-on therapy in patients with partial seizures.

### Effect due to factor in study?

Yes. The study was well conducted and the sample size was derived from a power calculation which was based on results from other trials.

### Consistency of results with other studies?

The study comprised subjects who suffered from partial seizures.

### Internal Validity

Barcs G; Walker EB; Elger CE; Scaramelli A; Stefan H; Sturm Y; Moore A; Flesch G; Kramer L; D’Souza J;

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

Ref ID 4701

Funding Novartis

### Study Type

Randomised Controlled Trial

### Number of participant

Total 694 enrolled, 173 placebo, in OXC: 169 for 600mg/day, 178 for 1200mg/day, 174 for 2400 mg/day

### Inclusion/Exclusion Criteria

#### Inclusion:

Partial seizures classified as simple, complex, or partial seizures evolving to secondarily generalised seizures (ILEA 1981 and 1989)

Men or women aged 15-65 years

A average of ≥4 partial seizures per month during the 8 week baseline period while maintained on 1-2 concomitant AEDs

#### Exclusion criteria:

Women who were nursing/pregnant or trying to conceived

History of generalised status epilepticus in 2 years preceding trial

Seizures of metabolic, neoplastic, or infectious origin

Non-compliance

A cardiovascular, respiratory, hepatic, renal, gastrointestinal, haematologic, oncologic, psychiatric or progressive neurologic disorder

Attempted suicide, substance abuse, hypersensitivity to CBZ

Clinically significant laboratory abnormalities

History of OXC treatment

History of MAOI treatment within a 15 day period before inclusion

Concomitant treatment by ethosuximide and felbamate, or oestrogen therapy, or other hormonal contraceptive therapy
### Patient Characteristics

<table>
<thead>
<tr>
<th>Placebo</th>
<th>OXC 600mg/day</th>
<th>OXC 200mg/day</th>
<th>OXC 2400mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (%)</td>
<td>51.2</td>
<td>45.2</td>
<td>56.3</td>
</tr>
<tr>
<td>Mean age, yr(range)</td>
<td>34.6(15-65)</td>
<td>33.8(16-64)</td>
<td>35.2(15-66)</td>
</tr>
<tr>
<td>Mean weight kg(range)</td>
<td>73.1(44-139)</td>
<td>70.5(45-135)</td>
<td>70.9(44-131)</td>
</tr>
<tr>
<td>Median 28 days baseline Seizure frequency:</td>
<td>9.6</td>
<td>9.8</td>
<td>10.0</td>
</tr>
<tr>
<td>Median 28 days baseline secondary generalised Seizure frequency:</td>
<td>3.5 (n=49)</td>
<td>2.0 (n=68)</td>
<td>2.4 (n=60)</td>
</tr>
</tbody>
</table>

### Recruitmen

International, multi-centre study.

### Setting

International, multi-centre study.

### Interventions/Test/Factor being investigated

OXC 600mg/d 1200mg/day, 2400mg/day or placebo

### Comparisons

Adjunctive therapy: Adding OXC 600mg/d 1200mg/day, 2400mg/day or placebo

### Length of Study/Follow-up

Total 38 weeks: 8 weeks baseline, 2 weeks titration, 24 weeks maintenance, 2 weeks tapering off. Patients had the option to join an open label study.

### Outcome measures studied

Primary: % reduction in seizure frequency/28 days during the double blind treatment phase relative to the baseline phase
Secondary: 50% or greater reduction in seizure frequency in the double blind treatment phase relative to the baseline phase

### Results

#### Proportion of seizure free participants

<table>
<thead>
<tr>
<th>OXC 600mg/day</th>
<th>OXC 1200mg/day</th>
<th>OXC 2400mg/day</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>5/168 (3%)</td>
<td>18/177 (10%)</td>
<td>38/174 (22%)</td>
<td>1/173 (0.6%)</td>
</tr>
</tbody>
</table>

P value: all statistically significant vs placebo

#### Proportion of participants experiencing at least a 50% reduction in seizure frequency (i.e. responders)

<table>
<thead>
<tr>
<th>OXC 600mg/day</th>
<th>OXC 1200mg/day</th>
<th>OXC 2400mg/day</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>20/168 (26.8%)</td>
<td>64/177 (41.2%)</td>
<td>116/174 (50.0%)</td>
<td>15/173 (12.7%)</td>
</tr>
</tbody>
</table>

P value: all statistically significant vs placebo

#### The proportion of participants having treatment withdrawn due to unsatisfactory treatment effect

<table>
<thead>
<tr>
<th>OXC 600mg/day</th>
<th>OXC 1200mg/day</th>
<th>OXC 2400mg/day</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/168 (0.6%)</td>
<td>20/168 (11.9%)</td>
<td>64/177 (36.2%)</td>
<td>116/174 (66.7%)</td>
</tr>
</tbody>
</table>

P value:

#### Incidence of adverse events >10%

<table>
<thead>
<tr>
<th>OXC 600mg/day</th>
<th>OXC 1200mg/day</th>
<th>OXC 2400mg/day</th>
<th>Total</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=168</td>
<td>n=177</td>
<td>n=174</td>
<td>n=519</td>
<td>n=173</td>
</tr>
</tbody>
</table>

29 July 2010 Page 7 of 306

**Safety and adverse effects**
A large number of patients withdrawn due to adverse events. Protocol amendment was made to allow reduction to 1800mg in the 1400mg/day group.

**Does the study answer the question?**
OXC is safe and effective as adjunctive therapy in patients with uncontrolled partial seizures. 600mg/day is the minimum effective dose, effectiveness increases with dose. The fixed and rapid titration to high doses is associated with increased risk of adverse events.

**Effect due to factor in study?**
There was an overall 295/694 (42.5%) dropout rate. The dropout rate for the 2400mg arm was 128/174 (73.6%).

**Consistency of results with other studies?**
None noted

**Internal Validity**
Ben-Menachem E; Biton V; Jatuzis D; Bou-Khalil B; Doty P; Rudd GD;

**Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures**
Ref ID 1615 2007

**Study Type** Randomised Controlled Trial

**Number of participant**
n=421 (n=97 in placebo group, n=107 in lacosamide 200mg per day group, n=108 in lacosamide 400mg per day, n=106 in lacosamide 600mg per day)

**Inclusion/Exclusion Criteria**
Inclusion criteria: partial-onset seizures for at least the last 2 years despite prior therapy with at least 2 AEDs. During the 8-week baseline period, patients must have had at least 4 partial onset seizures per 28 days on average, with no seizure-free period longer than 21 days. In the 4 weeks before enrollment and during the baseline period, patients must have been on a stable dosage regimen of 1 or 2 AEDs. Exclusion criteria: Female patients if pregnant, breast-feeding, or of childbearing potential; received lacosamide in a previous trial or had participated in any other investigational drug or experimental device trial within the last 2 months; history of chronic alcohol or drug abuse within the previous 2 years; any medical or psychiatric condition that might jeopardize the patient’s health or compromise the patient’s ability to participate in this trial.

**Patient Characteristics**
Demographic and baseline characteristics of patients analyzed for safety

<table>
<thead>
<tr>
<th>600 mg/day Characteristic</th>
<th>Placebo (n=97)</th>
<th>LCM 200 mg/day (n=107)</th>
<th>LCM 400 mg/day (n=108)</th>
<th>LCM 600 mg/day (n=106)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, year Mean ± SD</td>
<td>10.53 ± 11.11</td>
<td>39.9 ± 11.71</td>
<td>41.2 ± 11.61</td>
<td>39.4 ± 11.11</td>
</tr>
<tr>
<td>Range</td>
<td>19 – 66</td>
<td>18 – 65</td>
<td>18 – 68</td>
<td>18 – 68</td>
</tr>
</tbody>
</table>

29 July 2010 Page 8 of 306
Four different doses of lacosamide (200, 400 or 600mg per day) as adjunctive therapy with currently used AEDs.

**Interventions/ Test/Factor being investigated**

Four different doses of lacosamide (200, 400 or 600mg per day) as adjunctive therapy with currently used AEDs.

**Comparisons**

The comparison is between lacosamide in four doses and placebo as adjunctive therapy to currently used AEDs.

**Length of Study/ Follow-up**

26 weeks: 8 weeks baseline period, 6 week titration and 12 week maintenance period.

**Outcome measures studied**

Primary outcome: change in seizure frequency (1) reduction in seizure frequency (2) responder rate. Secondary outcomes: seizure freq, seizure free days, CGI, QOLIE-31

**Results**

Primary outcomes

Median percent reduction in seizure frequency from baseline to maintenance. The median % reduction in seizure frequency from baseline to maintenance was 10% in the placebo, 26% in the lacosamide 200 mg/day, 39% in the 400 mg/day, and 40% in the 600 mg/day treatment groups. Statistically significant reductions in seizure frequency over placebo were observed in the lacosamide 400 mg/day (28.4%; \( p = 0.0023 \)) and 600 mg/day (21.3%; \( p = 0.0084 \)) treatment groups. For the lacosamide 200 mg/day treatment group, the reduction in seizure frequency over placebo was 14.6\% (\( p = 0.1010 \)), indicating a difference that did not reach statistical significance.

Response rates

The proportion of patients with at least a 50% reduction in seizure frequency during maintenance for lacosamide 400 mg/day (41.1\%; \( p = 0.0038 \)) and 600 mg/day (38.1\%; \( p = 0.0141 \)) was statistically significant when compared to placebo (21.9\%). For the lacosamide 200 mg/day treatment group, the 50% responder rate was 32.7\% (\( p = 0.0899 \)), indicating a difference that did not reach statistical significance.

Secondary outcomes

Seizure free rates

Seven patients were seizure-free throughout the 12-week maintenance period, all were randomized to lacosamide; 1 patient in the lacosamide 200 mg/day group, 5 in the 400 mg/day group, and 1 in the 600 mg/day group. At the end of the maintenance period, the median change from baseline in the percentage of seizure-free days was 3% for patients randomized to placebo, 6% for patients randomized to lacosamide 200 mg/day, 12% for 400 mg/day, and 12% for 600 mg/day. Statistically significant differences in the percentage of seizure-free days over placebo were observed in the
lacosamide 400 mg/day (p=0.0036) and 600 mg/day (p = 0.0004) groups.

Quality of life
Patients in the lacosamide 400 mg/day group experienced more improvement in quality of life than patients in the other treatment groups, as assessed by median changes in QOLIE-31 overall score from baseline, with an improvement of 2.7 points compared to an overall score of −1.3 points in the placebo group.

Clinical Global Impression of Change (CGIC)
The CGIC analysis showed an improvement ("very much improved"or "much improved") from baseline to maintenance in a greater percentage of patients in the lacosamide 200mg/day (35%), 400 mg/day (40%), and 600 mg/day (38%) treatment groups compared to the placebo group (25%).

Adverse events

| Treatment-emergent adverse events (%) occurring in at least 10% of patients in any treatment group |
|-----------------------------------------------|---------------|---------------|---------------|---------------|
| 600mg/d Lacosamide Total                      | Placebo       | LCM 200mg/d   | LCM 400mg/d   | LCM           |
| Adverse event                                 | (n = 97)      | (n = 107)     | (n = 108)     | (n = 106)     |
| Any event                                     | 68 (70)       | 85 (79)       | 87 (81)       | 98 (92)       |
| Dizziness (55)                                | 10 (10)       | 26 (24)       | 28 (26)       | 58            |
| Headache (13)                                 | 9 (9)         | 12 (11)       | 26 (24)       | 14            |
| Nausea (18)                                   | 9 (9)         | 11 (10)       | 16 (15)       | 19            |
| Fatigue (20)                                  | 5 (5)         | 11 (10)       | 13 (12)       | 21            |
| Ataxia (23)                                   | 3 (3)         | 4 (4)         | 14 (13)       | 24            |
| Vision abnormal (20)                          | 5 (5)         | 4 (4)         | 12 (11)       | 21            |
| Vomiting (12)                                 | 3 (3)         | 11 (10)       | 13 (12)       | 13            |
| Diplopia (14)                                 | 2 (2)         | 4 (4)         | 12 (11)       | 15            |
| Somnolence (9)                                | 6 (6)         | 8 (7)         | 13 (12)       | 10            |
| URI (6)                                       | 11 (11)       | 12 (11)       | 13 (12)       | 6             |
| Accident NOS (5)                              | 12 (12)       | 15 (14)       | 6 (6)         | 5             |
| Nystagmus (10)                                | 5 (5)         | 3 (3)         | 5 (5)         | 11            |

aPatients reporting the same adverse event more than once are counted once per adverse event and randomized dose.

NOS, not otherwise specified; URI, upper respiratory infection.

Of the 418 patients who received at least one dose of trial medication, 69 (17%) discontinued from the trial during the treatment period because of TEAEs; 5 patients randomized to placebo, and 12, 20, and 32 patients randomized to lacosamide 200, 400, and 600 mg/day, respectively.

The most frequently reported SAEs were dizziness and convulsions (3 patients each), as well as vomiting, accident not otherwise specified, nystagmus, nausea, and aggravated convulsions (2 patients each).

Safety and adverse effects
Does the study answer the question?
Effect due to factor in study?
Yes. Lacosamide, at doses of 400 mg/day and 600 mg/day, produced a statistically significant reduction in seizure frequency for patients with partial-onset seizures, with or without secondary generalization, when added to 1 or 2 concomitant AEDs.
Yes. The study was powered sufficiently well to detect differences between lacosamide groups and placebo.
Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

Ref ID 4741 2000

Study Type Randomised Controlled Trial

Funding Grant from UCB S.A. Pharma Sector, Braine l’Alleud, Belgium

Number of participant A total of 286 patients (placebo, n = 105; Levetiracetam 3000mg/d (LEV), n = 181) entered the add-on phase, and 86 patients (placebo, n = 17; LEV, n = 69) were eligible for the monotherapy phase.

Inclusion/Exclusion Criteria Included: Men and women aged 16 to 70 years with seizures refractory to one AED; women had to be using contraception. Excluded: hx of status, progressive disease,CVA or CV disease; diabetes, impaired hepatic or renal function, drug or alcohol abuse, psychiatric disorder, CNS drugs, digitalis, glucosides or coumarins

Patient Characteristics 286 enrolled patients (ITT population)

Recruitment Unknown

Setting 47 institutions throughout Europe

Interventions/ Test/ Factor being investigated To evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in selected patients with refractory partial seizures

Comparisons Comparison is made between treatment and placebo

Length of Study/ Follow-up 60 weeks

Outcome measures studied Primary: Percentage of patients who completed the monotherapy phase relative to the number of patients randomized to receive the study medication Secondary:Seizure frequency, reported as the number of partial seizures per week; the responder rate.

Results A total of 286 patients (placebo, n = 105; LEV, n = 181) entered the add-on phase, and 86 patients (placebo, n = 17; LEV, n = 69) were eligible for the monotherapy phase. Thirty-six of 181 patients (19.9%) who received LEV completed the entire study compared with only 10 of 105 patients (9.5%) in the placebo group (p = 0.029). The odds of completing the study on LEV were 2.36 times (95% confidence interval, 1.08, 5.57) higher than on placebo. The responder rate during the add-on phase was significantly higher in the LEV group compared with the placebo group (42.1% vs. 16.7%, respectively; p < 0.001). In the LEV monotherapy group, the median percent reduction in partial seizure frequency compared with baseline was 73.8% (p = 0.037), with a responder rate of 59.2%. Nine patients (18.4%) remained seizure-free on LEV monotherapy
Conversion to LEV monotherapy (1500 mg twice daily) is effective and well tolerated in patients a small group of patients with refractory partial seizures who responded to 3000 mg/d LEV as add-on therapy.

Internal Validity
Small study population completed study

Consistency of results with other studies?
See GRADE

Directly applicable to guideline population?
See GRADE

Safety and adverse effects
The incidence of adverse events in the add on phase was comparable between treatment groups (placebo 53%; LEV 55%). Asthenia, infection and somnolence had an incidence >5%.

Does the study answer the question?
Conversion to LEV monotherapy (1500 mg twice daily) is effective and well tolerated in patients a small group of patients with refractory partial seizures who responded to 3000 mg/d LEV as add-on therapy.

Effect due to factor in study?
The ultimate patient population is small and this drug needs to be studied further.

Funding
Not reported, 1 co author from Johnson Pharmaceutical

Study Type
Randomised Controlled Trial

Number of participant
Total 56, 28 topiramate, 28 placebo

Inclusion/Exclusion Criteria
Inclusion criteria:
- Healthy men and women aged 18 to 65 with history of partial seizures which had not responded to treatment with one or two AEDs
- Had secondary generalised seizures
- Presence of lateralised epileptiform pattern consistent with a diagnosis of localised related epilepsy documented by EEG within the past 5 years
- Women should be post menopausal, or surgically rendered incapable of having children, or used an acceptable method of birth control
- At least 8 partial seizures during the 8 week baseline period while maintained on therapeutic doses and plasma levels of one or two appropriate AEDs. Seizure free period must not be longer than 3 weeks, and only one such period permitted.

Exclusion criteria:
- Treatable cause of seizure
- Progressive neurologic disorder
- Significant laboratory abnormalities,
- History of alcohol or drug abuse, serious psychiatric disorders, nephrolithiasis,
- History of poor compliance

Patient Characteristics
Both groups
Male: 84%
Mean age, year: 37.2
Mean weight: 75.2
Number of AEDs:
One: 38%
Two: 62%

Median baseline monthly seizure: 14.2 for TPM, 11.4 for placebo

Recruitment
Multicentre trial, Sweden, Norway, Denmark, Germany

Setting
Multicentre - Sweden, Norway, Denmark, Germany

Ben-Menachem E; Henriksen O; Dam M; Mikkelsen M; Schmidt D; Reid S; Reife R; Kramer L; Pledger G; Karim R;

Ref ID 4748
1996
Interventions/ Test/ Factor being investigated: TPM or placebo as adjunctive therapy

Comparisons: Adjunctive therapy: TPM vs placebo

Length of Study/ Follow-up: 8 weeks baseline period, 13 week double blinded period – 5 week titration and 8 week maintenance

Outcome measures studied:
- Primary: % reduction in monthly seizure rate vs baseline
- Secondary: % of treatment responders (≥50% reduction in seizure rate), reduction in generalised seizures, the investigator’s global rating, the patient’s rating of study medication.

NO serious AE or laboratory changes reported. The present study established the risk/benefit profile of treatment of TPM in refractory epilepsy.

Interventions/ Test/ Factor being investigated (Contd.):

Comparisons: Adjunctive therapy: TPM vs placebo

Length of Study/ Follow-up: 8 weeks baseline period, 13 week double blinded period – 5 week titration and 8 week maintenance

Outcome measures studied:
- Primary: % reduction in monthly seizure rate vs baseline
- Secondary: % of treatment responders (≥50% reduction in seizure rate), reduction in generalised seizures, the investigator’s global rating, the patient’s rating of study medication.

Results:

Proportion of seizure free (GENERALISED seizure) participants (100% reduction vs baseline)

<table>
<thead>
<tr>
<th>Group</th>
<th>Seizure Free (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPM</td>
<td>6/11 (46%)</td>
</tr>
<tr>
<td>Placebo</td>
<td>2/13 (18%)</td>
</tr>
</tbody>
</table>

P no reported

Proportion of participants experiencing at least a 50% reduction in seizure frequency (i.e. responders)

<table>
<thead>
<tr>
<th>Group</th>
<th>% Reduction (50%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPM</td>
<td>12/28 (43%)</td>
</tr>
<tr>
<td>Placebo</td>
<td>0/28 (0%)</td>
</tr>
</tbody>
</table>

P=0.001

Proportion of participants experiencing at least a 50% reduction in GENERALISED seizure frequency (i.e. responders)

<table>
<thead>
<tr>
<th>Group</th>
<th>% Reduction (50%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPM</td>
<td>9/11 (69%)</td>
</tr>
<tr>
<td>Placebo</td>
<td>3/13 (27%)</td>
</tr>
</tbody>
</table>

P no reported

The proportion of participants having treatment withdrawn due to adverse event:

<table>
<thead>
<tr>
<th>Group</th>
<th>% Withdrawn</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPM</td>
<td>6/28 (21%)</td>
</tr>
<tr>
<td>Placebo</td>
<td>0/28 (0%)</td>
</tr>
</tbody>
</table>

P not reported

Incidence of adverse events >10%

<table>
<thead>
<tr>
<th>Event</th>
<th>Placebo</th>
<th>TPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>10/28 (36%)</td>
<td>22/28 (79%)</td>
</tr>
<tr>
<td>Headache</td>
<td>10/28 (36%)</td>
<td>6/28 (21%)</td>
</tr>
<tr>
<td>Concentration impaired</td>
<td>0/28</td>
<td>7/28 (25%)</td>
</tr>
<tr>
<td>Weight loss</td>
<td>0/28</td>
<td>7/28 (25%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1/28 (4%)</td>
<td>6/28 (21%)</td>
</tr>
<tr>
<td>Paraesthesia</td>
<td>1/28 (4%)</td>
<td>5/28 (18%)</td>
</tr>
</tbody>
</table>

(study only reported adverse events which affected ≥15% of patients in either treatment arm)

Adverse events occurring in 10-14% were abdominal pain, anorexia, ataxia, diplopia, dry mouth, tremor (TPM group); accidental injury, diarrhoea, dyspepsia, insomnia and nystagmus in the (placebo group); respiratory infection (both groups)

Safety and adverse effects:

No death or serious AE reported.

Does the study answer the question?

NO serious AE or laboratory changes reported. The present study established the risk/benefit profile of treatment of TPM in refractory epilepsy.

Effect due to factor in study?

Uncertain. Method of randomisation allocation, concealment and blinding not described. Sample size may not be large enough to detect significant differences in some effects.

Baseline characteristics not reported for each group

Consistency of results with other studies?

Median monthly baseline seizure rate higher in treatment group.
Directly applicable to guideline population? unsure

Internal Validity

Beydoun A;Uthman BM;Kugler AR;Greiner MJ;Knapp LE;Garofalo EA;Study Group;

Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy

Ref ID 4277 2005

Study Type Randomised Controlled Trial Funding Supported by Pfizer inc.

Number of participant N=313 randomised. Placebo n=98; BID n=103 and TID n=111.

Inclusion/Exclusion Criteria

Inclusion: patients had to experience a minimum of six partial-onset seizures during a prospective 8 week baseline period, with no 28-day seizure-free period, while maintained on stable doses of one to three AEDs. Patients also had to have failed two or more AEDs at maximally tolerated doses.

Exclusions: No pregnant or lactating women and women were to be using a reliable method of contraception. Patients with a treatable cause of their seizures were excluded, as were those with absence seizures, Lennox-Gastaut syndrome, or a progressive neurologic, psychiatric or systemic disorder. Patients with clinically relevant disease were excluded. Patients with a history of status epilepticus, illicit drug use or alcohol abuse within the previous year, progressive abnormalities on neuroimaging, or noteworthy abnormalities on a chest radiograph or those treated with any investigational drug within 30 days prior to screening or concomitantly treated with Gabapentin were excluded.

Patient Characteristics

All patients had medically refractory epilepsy, with a mean baseline frequency per 28 days ranging from 21.3 to 25.1 across the 3 treatment groups. The mean patient age at diagnosis was 16.6 years for the placebo, 13.0 years for the BID and 11.9 years for the TID treatment groups.

Recruitment Not reported

Setting Not clear

Interventions/ Test/ Factor being investigated Comparisons

Pregabalin 600mg/day BID (twice a day), Pregabalin 600mg/day TID (three times a day) versus placebo

Length of Study/ Follow-up Outcome measures studied

12 weeks treatment period. Reduction in seizure frequency during the double-blind period, responder rate (≥50 reduction in seizures) and median percentage change in seizure frequency compared to baseline.

Results

Both TID and BID were more efficacious than placebo in reducing the frequency of partial-onset seizures (p<0.0001). The percentage reduction in seizure frequency from baseline was 53.0% for the TID and 44.3% for the BID groups compared to an increase of 1.2% for placebo.

Responder rates between pregabalin and placebo (9%) for both TID (49%; p<0.001) and BID (43%; p< 0.001) groups. BID and TID were not significantly different from one another.

The median percentage seizure frequency reductions were greater for patients receiving pregabalin (48.1% for TID and 35.6% for BID) than those to placebo (0.8%).

BID (n=%) (D= discontinuation): Dizziness n=43 (D=7), somnolence n=31 (D=6), ataxia n=17(D=3), weight gain n=21(D=1), amyllophia n=10 (D=2), asthenia n=14 (D=2), Diplopia n=10 (D=3), and thinking abnormal n=9 (D=2).

TID: Dizziness n=42 (D=7), somnolence n=26 (D=4), ataxia n=30 (D=7), amyllophia n=19 (D=1), weight gain n=17(D=0) and asthenia n=13 (D=1), diplopia n=15 (D=1)
Pregabalin is efficacious as adjunctive therapy in the treatment of patients with partial seizures.

Safety and adverse effects

19% for the pregabalin TID and 26% from the BID group due to AEs.

Does the study answer the question?

Pregabalin is efficacious as adjunctive therapy in the treatment of patients with partial seizures.

Effect due to factor in study?

Yes.

Consistency of results with other studies?

Relevant population.

Directly applicable to guideline population?

Yes.

Internal Validity

Randomisation details not given.

Bill PA;Vigonius U;Pohlmann H;Guerreiro CA;Kochen S;Saffer D;Moore A;

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy

Ref ID 4726 1997

Study Type Randomised Controlled Trial Funding International Adult Oxcarbazepine/Phenytoin Trial Group and Novartis Pharma

Number of participant 287 total: 143 to OXC and 144 to PHT

Inclusion/Exclusion Criteria

Inclusion: Ages 16-65 years with newly diagnosed epilepsy with two seizures separated by at least 48 hours within 6 months before trial
Exclusion: No AED drug except for emergency treatment; Pregnancy risk, status, psychiatric illness or mental retardation, progressive neurological disorder, alcoholism, drug abuse or significant organic disease.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>OXC (n=143)</th>
<th>PHT (n=144)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean; range)</td>
<td>27.1(16-63) yrs</td>
<td>26.6(15-91) yrs</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>82/61</td>
<td>92/52</td>
</tr>
<tr>
<td>Race (Cauc/B/Other)</td>
<td>72/22/49</td>
<td>68/23/53</td>
</tr>
<tr>
<td>Body wt.</td>
<td>63.6 (41-104) kg</td>
<td>64.9 (43-101) kg</td>
</tr>
</tbody>
</table>

Recruitment

Unknown

Setting

Argentina, Brazil, Mexico and South Africa

Interventions/ Test/ Factor being investigated

Use of oxcarbazepine vs. phenytoin as monotherapy in newly diagnosed epilepsy patients

Comparisons

oxcarbazepine vs. phenytoin

Length of Study/ Follow-up

A flexible titration period of 8 weeks followed by 48 weeks of maintenance treatment

Outcome measures studied

The primary efficacy variable was the proportion of seizure free patients who had at least one seizure assessment during the maintenance period. Secondary outcomes: Treatment group differences in time and rate of premature discontinuation
Results

<table>
<thead>
<tr>
<th></th>
<th>OXC (n=118)</th>
<th>PHT (n=119)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure frequency per week: Mean/median</td>
<td>0.08/0</td>
<td>0.06/0</td>
<td>p=0.72</td>
</tr>
<tr>
<td>Total number of seizures mean/median</td>
<td>3.57/0</td>
<td>2.13/0</td>
<td></td>
</tr>
</tbody>
</table>

Number of patients with:
- No seizures: 70 vs 69
- 1 seizure: 17 vs 20
- 2-15 seizures: 26 vs 26
- 16-50 seizures: 3 vs 4
- More than 50 seizures: 2 vs 0

Five patients receiving OXC and 16 patients receiving PHT treatment were withdrawn due to adverse experiences. There was a statistically significant difference between groups in favour of the OXC treatment (p=0.02). There was no significant treatment difference due to premature discontinuations (p=0.63). Physicians and patients' overall assessment of tolerability on a 4 point scale, favoured the OXC treatment (p=0.032 for physicians and p=0.026 for patients).

Safety and adverse effects

- 5 patients in the OXC group and 16 in the PHT group discontinued for tolerability reasons. The most common side effects were somnolence, headache, dizziness, nausea, rash.

Does the study answer the question?

This trial provides support for the efficacy and safety of OXC as first line treatment in adults with PS.

Effect due to factor in study?

Yes

Consistency of results with other studies?

See GRADE

Directly applicable to guideline population?

See GRADE

Internal Validity

Binnie CD;Debets RM;Engelsman M;Meijer JW;Meinardi H;Overweg J;Peck AW;Van WA;Yuen WC;

Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy

Ref ID 4756

Study Type Randomised Controlled Trial

Funding Not reported. However, one of the authors was from the Wellcome Research Laboratories, Beckenham, UK.

Number of participant

34 patients were recruited to the randomised within-patient, crossover designed study.

Inclusion/Exclusion Criteria

Inclusion criteria: age 16 to 65 years, confident diagnosis of epilepsy, partial seizures, seizure frequency at least 4 per month, seizures resistant to drugs of first choice, co-medication unchanged for previous 3 months and unlikely to be changed during study.

Exclusion criteria: severe psychiatric, mental, neurological or haematological disease; status epilepticus in the preceding 6 months; use of investigative AEDs; pregnancy.

Patient Characteristics

Summary statistics n=30

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>16-51</td>
<td></td>
</tr>
<tr>
<td>Mean (+/- SD)</td>
<td>37.1(10.26)</td>
<td></td>
</tr>
<tr>
<td>Males/Females</td>
<td>22/8</td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>175(8)</td>
<td></td>
</tr>
</tbody>
</table>

29 July 2010 Page 16 of 306
Weight (kg) Mean (+/-SD)                                       70.7 (12.1) 
Age of onset epilepsy Mean (+/- SD)                           14.3(10.7) 
Duration of seizures Mean (+/- SD)                           22.8(11.0) 
No. of uncontrolled seizure types 
1                   9 
2                   16 
3                   4 
4                   1 

Recruitment
Epilepsy out-patient clinics x 3 in Netherlands.

Setting
Instituut voor Epilepsiebestrijding, Netherlands.

Interventions/ Test/ Factor being investigated
Lamotrigine (vs. placebo) adjunctive to currently used AEDs. 
Target dose 200mg, 100mg or 75 mg based on currently used AEDs. For the first week half the target dose was given. Dose doubled at end of first week. Reduced for side effects. 12 weeks treatment with lamotrigine and 12 weeks with placebo.

Comparisons
Lamotrigine vs. placebo adjunctive to currently used AEDs.

Length of Study/ Follow-up
Total of 44 weeks. 
Baseline = 8 weeks. 
Treatment period 1 = 12 weeks. 
Washout period 1 = 6 weeks. 
Treatment period 2 = 12 weeks. 
Washout period 2 = 6 weeks.

Outcome measures studied
Primary outcome was seizure frequency defined as the total count of all seizures. No secondary outcomes defined although adverse events were reported.

Results
The journal article reports that there was a significant treatment effect in favour of lamotrigine (P>0.02). The median percentage reduction in seizure count attributable to lamotrigine was 17% with a confidence interval of 0-30%. 19 (63%) patients had fewer seizures on lamotrigine compared to 9 (30%) who had fewer seizures on placebo and 2(7%) who had same number of seizures on each.

No other summary statistics are reported. One table presents a seizure count for each of the 30 patients when they have been treated with lamotrigine and placebo. Summing these from the table the total no. of seizures when on lamotrigine for all 30 patients is 1242 compared to 1647 on placebo (One patient had 444 seizures on lamotrigine and 697 on placebo).

A total of 39 adverse experiences were reported in 29 patients. Nine of these were classified as serious. Only 2 of these occurred on lamotrigine. One was a maculopapular rash appeared to be drug related and resolved after withdrawal. The other was depression. The latter had been previously reported by the same patient when on placebo.

Safety and adverse effects
There were no differences in adverse experiences between lamotrigine and placebo periods. The plasma concentrations of concomitantly administered AEDs were not affected by lamotrigine treatment.

Does the study answer the question?
To some extent yes. The authors conclude that lamotrigine produced a clinically modest but statistically significant reduction in seizure counts in patients with poorly controlled partial seizures. However, no sample size calculation was performed and the power of the study to detect a significant difference is unknown. The study did however employ a complex procedure of targeting plasma lamotrigine levels by means of an unblinded observer. Its use avoided the problems of underdosing or intoxication which would otherwise probably have resulted from the effects of co-medication on lamotrigine metabolism. It therefore enabled subsequent studies to employ a simpler design with lamotrigine dosing determined by co-medication.

Effect due to factor in study?
No. The authors conclude that lamotrigine produced a clinically modest but statistically significant reduction in seizure counts in patients with poorly controlled partial seizures. However, no sample size calculation was performed and the power of the study to detect a significant difference is unknown.
The patient population is directly comparable with the that of this guideline since patients in this study were required to have seizures which must include partial seizures together possibly with other types. Indirectness (?) (see comments on validity)

Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures

Ref ID 4286

Study Type Randomised Controlled Trial

Number of participant n=351 randomized (n=120 placebo, n=57 in ZNS 100mg/day group, n=56 in ZNS 300mg/day group and n=118 in the ZNS 500mg/day).

Inclusion/Exclusion Criteria Inclusion criteria: at least 12 years old with partial seizures with or without secondary generalization unsatisfactorily controlled despite a stable regimen of one to three AEDs. Exclusion: history of nonepileptic seizures, alcoholism, drug abuse, or significant drug sensitivity were excluded,as were those with progressive neurologic disease.

Patient Characteristics Patient demographics and baseline characteristics (safety population)

<table>
<thead>
<tr>
<th>mg/day</th>
<th>Placebo (n = 120)</th>
<th>ZNS 100 mg/day (n = 56)</th>
<th>ZNS 300 mg/day (n = 55)</th>
<th>ZNS 500 mg/day (n = 118)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender: no (%)</td>
<td>Male (68) (56.7)</td>
<td>30 (53.6)</td>
<td>27 (49.1)</td>
<td>53</td>
</tr>
<tr>
<td>Age at screening (yr)</td>
<td>Mean 36.5</td>
<td>36.1</td>
<td>32.9</td>
<td>36.1</td>
</tr>
<tr>
<td>Range 12–77</td>
<td></td>
<td>12–65</td>
<td>12–73</td>
<td></td>
</tr>
<tr>
<td>Time since epilepsy onset (mo)</td>
<td>Median 254.0</td>
<td>279.5</td>
<td>188.0</td>
<td></td>
</tr>
<tr>
<td>Range 227.0</td>
<td></td>
<td>5–672</td>
<td>7–670</td>
<td></td>
</tr>
<tr>
<td>Seizure start date: median (range) (yr)</td>
<td>CP seizure 20.0 (0–48)</td>
<td>16.0 (0–56)</td>
<td>14.0 (3–55)</td>
<td>16.0</td>
</tr>
<tr>
<td>(1–64)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SP+CP seizures 19.5 (0–48)</td>
<td>16.0 (0–56)</td>
<td>13.5 (0–55)</td>
<td>16.0</td>
<td></td>
</tr>
<tr>
<td>(1–64)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All seizures 21.0 (1–48)</td>
<td>22.5 (0–56)</td>
<td>14.0 (0–55)</td>
<td>17.0</td>
<td></td>
</tr>
<tr>
<td>(1–64)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Historic SP frequency/28 days Mean (SD) 10.9 (44.5)</td>
<td>9.2 (24.7)</td>
<td>12.5 (32.0)</td>
<td>9.5</td>
<td></td>
</tr>
<tr>
<td>(33.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range) 0.0 (0–459)</td>
<td>0.0 (0–139)</td>
<td>3.0 (0–212)</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>Historic CP frequency/28 days Mean (SD) 12.5 (22.0)</td>
<td>11.8 (2.1)</td>
<td>9.6 (13.0)</td>
<td>12.7</td>
<td></td>
</tr>
<tr>
<td>(20.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range) 5.7 (0–153)</td>
<td>6.3 (0–121)</td>
<td>2.9 (0–56)</td>
<td>6.2</td>
<td></td>
</tr>
<tr>
<td>Historic SG frequency/28 days Mean (SD) 2.7 (9.5)</td>
<td>2.7 (5.5)</td>
<td>2.4 (6.5)</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>(8.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range) 0.0 (0–81)</td>
<td>0.0 (0–27)</td>
<td>0.0 (0–45)</td>
<td>0.0</td>
<td></td>
</tr>
</tbody>
</table>
Concomitant AEDs: N (%)  

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>22</td>
<td>68</td>
<td>26</td>
</tr>
<tr>
<td>(0–64)</td>
<td>0</td>
<td>17</td>
<td>21</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>15</td>
<td>27</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>27.1</td>
<td>30.4</td>
<td>49.1</td>
<td>23.6</td>
</tr>
<tr>
<td></td>
<td>32</td>
<td>50</td>
<td>34</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>(1.7)</td>
<td>1.8</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

AEDs, antiepileptic drugs; CP, complex partial; SG, secondarily generalized; SP, simple partial; SD, standard deviation; ZNS, zonisamide.

Although seven patients were reported as taking more than three AEDs, these were not considered protocol violators, as the fourth medication was used only as rescue therapy.

Recruitment  
Not reported.

Setting  
54 centres in Europe (n=49) and S.Africa (n=5)

Interventions/Test/Factor being investigated  
Zonisamide (ZNS) in three doses: 100mg, 300mg and 500mg per day as adjunctive therapy with currently used AEDs.

Comparisons  
The comparison is between ZNS in three different doses (100mg, 300mg and 500mg per day) and placebo as adjunctive therapy.

Length of Study/Follow-up  
36 weeks: 12 week baseline, 6 week titration and 18 week fixed dose.

Outcome measures studied  
Primary outcome: a) median % change in frequency of complex partial seizures and b) response rate. Secondary: % change in all partial seizures and all seizures and corresponding response rates.

Results  
Primary outcome

Primary efficacy-analysis population (all patients in the ITT population with partial seizure frequency data collected during the fixed dose phase)

Median reduction in complex partial (CP) seizures
ZNS, 500 mg/day, produced a significantly greater median reduction in CP seizure frequency from baseline than did placebo [51.2% (n = 86 subjects included in the analysis) vs. 16.3% (n = 89)]. The difference between the two groups was 31.2% (95% CI, 15.7–44.6; p < 0.0001).

Response rates
The proportion of responders for CP seizures was significantly higher (p < 0.001) in the ZNS, 500 mg/day, group compared with placebo (52.3% vs. 21.3%). Odds ratio (95% CI) for the ZNS, 500 mg/day, group relative to placebo was 4.07 (1.94–8.56).

Secondary outcomes
Median reduction in simple partial (SP) and complex partial (CP) seizures

For all seizures and for SP+CP seizures, median baseline frequencies were broadly similar across treatment groups. The median percentage reduction in all seizure frequency from baseline was significantly greater than that with placebo [18.1% (n=112) for both ZNS, 500 mg/day [51.3% (n = 101); p < 0.0001] and 300 mg/day [41.8% (n = 45); p = 0.0005]. The median reduction in SP+CP seizure frequency from baseline also was significantly greater for both ZNS, 500 mg/day [50.6% (n = 99); p < 0.0001], and 300 mg/day [46.4% (n = 42); p = 0.0007] than for placebo [19.4% (n = 109)]. The median reduction in the frequency of all seizures and SP+CP seizures with ZNS, 100 mg/day, was not statistically different from placebo.

Response rates
For all seizures, the proportion of responders was higher in each ZNS group (500 mg, 52.5%; 300 mg, 42.2%; 100 mg, 29.8%) than for placebo (17.9%).
difference was significant (p < 0.001) for the ZNS, 500 mg/day, group compared with placebo; the odds ratio (95% CI) for the ZNS, 500 mg/day group relative to placebo was 4.63 (2.28–9.39). For SP+CP seizures, the proportion of responders also was higher in each ZNS group (500 mg, 50.5%; 300 mg, 42.9%; 100 mg, 28.8%) than in the placebo group (20.2%). Again, the treatment difference was significant (p < 0.001) for the ZNS, 500 mg/day, group compared with placebo; the odds ratio (95% CI) for the ZNS, 500 mg/day, group relative to placebo was 4.25 (2.01–8.95).

Adverse events

Adverse events (%) reported by ≥10% of patients during the titration phase and during the fixed-dose assessment phase (safety population)

<table>
<thead>
<tr>
<th>mg/day</th>
<th>Placebo</th>
<th>100 mg/day</th>
<th>300 mg/day</th>
<th>500 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titr. phase</td>
<td>(n = 120)</td>
<td>(n = 56)</td>
<td>(n = 55)</td>
<td>(n = 118)</td>
</tr>
<tr>
<td>Any AE</td>
<td>60 (50.0)</td>
<td>32 (57.1)</td>
<td>34 (61.8)</td>
<td>73 (61.9)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3 (2.5)</td>
<td>1 (1.8)</td>
<td>4 (7.3)</td>
<td>14 (11.9)</td>
</tr>
<tr>
<td>Headache</td>
<td>8 (6.7)</td>
<td>4 (7.1)</td>
<td>7 (12.7)</td>
<td>8 (6.8)</td>
</tr>
<tr>
<td>Nausea</td>
<td>7 (5.8)</td>
<td>2 (3.6)</td>
<td>6 (10.9)</td>
<td>9 (7.6)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>3 (2.5)</td>
<td>3 (5.4)</td>
<td>2 (3.6)</td>
<td>17 (14.4)</td>
</tr>
<tr>
<td>Fixed-dose assessment phase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any AE</td>
<td>58 (48.3)</td>
<td>29 (51.8)</td>
<td>23 (41.8)</td>
<td>59 (50.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>15 (12.5)</td>
<td>6 (10.7)</td>
<td>6 (10.9)</td>
<td>5 (4.2)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>3 (2.5)</td>
<td>6 (10.7)</td>
<td>1 (1.8)</td>
<td>3 (2.5)</td>
</tr>
</tbody>
</table>

The incidence of withdrawals due to AEs was higher for the 300-mg/day and 500-mg/day groups (18.2% and 27.1%, respectively) than for the 100-mg/day and placebo groups (1.8% and 10.0%, respectively). The higher incidence of AEs leading to withdrawal in the 500-mg/day group compared with other groups was mainly because of more events of dizziness, difficulty concentrating, nausea, and somnolence during the titration phase.

Safety and adverse effects

There was a higher incidence of AEs leading to withdrawal in the 500-mg/day group compared with other groups. This was mainly because of more events of dizziness, difficulty concentrating, nausea, and somnolence during the titration phase.

Does the study answer the question?

Yes. This is a well conducted study and it concludes that zonisamide provides dose-dependent, effective and generally well-tolerated adjunctive therapy in patients with partial seizures.

Effect due to factor in study?

Yes. The study is sufficiently powered to detect significant differences in seizure frequency between treatment groups and placebo.

Consistency of results with other studies?

All patients in the study had a diagnosis of refractory partial seizures.

Directly applicable to guideline population?

All patients in the study had a diagnosis of refractory partial seizures.

Internal Validity

Brodie MJ;Perucca E;Ryvlin P;Ben-Menachem E;Meencke HJ;Levetiracetam Monotherapy Study Group.;

Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.[see comment]

Ref ID 287 2007 Feb 6

Study Type Randomised Controlled Trial

Funding UCB SA

Number of participant n=285 in the LEV arm and n=291 in the CBZ-CR group.
Inclusion/Exclusion Criteria

Inclusion criteria: aged >=16 years, newly diagnosed partial or generalized seizures with clear focal origin or tonic-clonic seizures without clear focal origin if >= 2 seizures separated by >=48 hrs during the past year and >=1 seizure during the previous 3 months.

Exclusion criteria: pseudoseizures, seizures in clusters, and clinical or electroencephalographic findings suggestive of idiopathic generalized epilepsy.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>LEV</th>
<th>CBZ-CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>285</td>
<td>291</td>
</tr>
<tr>
<td>Age, years Mean (SD)</td>
<td>39.8 (16.6)</td>
<td>39.0 (15.8)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male n (%)</td>
<td>146 (51.2)</td>
<td>171 (58.8)</td>
</tr>
<tr>
<td>(58.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female n (%)</td>
<td>139 (48.8)</td>
<td>171 (58.8)</td>
</tr>
<tr>
<td>(41.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White n (%)</td>
<td>262 (91.9)</td>
<td>268 (92.1)</td>
</tr>
<tr>
<td>(91.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black n (%)</td>
<td>5 (1.8)</td>
<td>10 (3.4)</td>
</tr>
<tr>
<td>(3.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian n (%)</td>
<td>1 (0.4)</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td>(0.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other n (%)</td>
<td>17 (6.0)</td>
<td>9 (3.1)</td>
</tr>
<tr>
<td>(6.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height, cm Mean (SD)</td>
<td>170.0 (9.7)</td>
<td>171.1 (9.7)</td>
</tr>
<tr>
<td>Weight, kg Mean (SD)</td>
<td>73.7 (16.8)</td>
<td>73.6 (15.2)</td>
</tr>
<tr>
<td>BMI, kg/m2 Mean (SD)</td>
<td>25.5 (5.2)</td>
<td>25.1 (4.6)</td>
</tr>
<tr>
<td>No. of seizures in past year Median</td>
<td>4.0</td>
<td>2.0</td>
</tr>
<tr>
<td>No. of seizures in past 3 months Median</td>
<td>2.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Epilepsy duration, years Median</td>
<td>34.7</td>
<td>31.9</td>
</tr>
<tr>
<td>Age at onset, years Median</td>
<td>11.0</td>
<td>9.0</td>
</tr>
<tr>
<td>Time since last seizure, days Median</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Recruitment

Unknown.

Setting

85 centres in Europe and in South Africa.

Interventions/ Test/ Factor being investigated

Levetiracetam (LEV) 1000mg to 3000mg/day vs. Carbamazepine (CBZ-CR) 400mg to 1200mg/day

Comparisons

Comparison is between LEV and CBZ-CR in this non-inferiority trial, which aims to show that FEV has at least a similar benefit-risk balance to CBZ-CR.

Length of Study/ Follow-up

For the purposes of the primary outcome follow-up was 30 weeks (1 week screening, 2 weeks titration, 1 week stabilization and 26 weeks evaluation period). Patients who remained seizure free for 6 months entered an additional 26-week maintenance period.

Outcome measures studied

Primary outcome was proportion of study subjects in each arm who were seizure-free at 6 month, using per protocol (PP) population. Secondary outcome was proportion of patients seizure free at 6 months using ITT population. Also, adverse events.

Results

Primary outcome: In the PP population 73.0% (173/237) of patients in the LEV group and 72.8% (171/235) in the CBZ-CR group were seizure free for >=6 months. Adjusted absolute difference (95% two-sided CI) = 0.2% (95% CI -7.8% to 8.2%)

Secondary outcome: Seizure free at 6 months in ITT population LEV=66.7% and CBZ-CR 66.7%. No significant difference between the two groups in proportion seizure free at 12 months. Patients reporting >=3 seizures in the 3 months before
study start were less likely to achieve seizure free at 6 months than those experiencing <=2 seizures prior to study. (LEV 63.8% and CBZ-CR 62.9%) vs. (LEV 81.8% and CBZ-CR 79.7%).

Adverse events: A similar proportion of patients in the LEV (79.6%) and CBZ-CR groups (80.8%) experienced at least one AE during the treatment period with most events being of mild or moderate intensity. Depression and insomnia were more common in the LEV group and back pain more common in the CBZ-CR group (p<0.05). 14.4% discontinued in the LEV group because of AEs compared to 19.2% in the CBZ-CR group.

Safety and adverse effects
Significantly more patients in the LEV group experienced depression (6.3% vs. 2.1%) and insomnia (6.0% vs. 2.4%) than in the CBZ-CR group.

Does the study answer the question?
Yes. Levetiracetam and controlled-release carbamazepine produced equivalent seizure freedom rates in newly diagnosed epilepsy.

Effect due to factor in study?
Yes. This study was powered to detect noninferiority between populations using two proportions.

Consistency of results with other studies?
This study includes a population of newly diagnosed epilepsy patients.

Internal Validity

Callaghan N; Kenny RA; O'Neill B; Crowley M; Goggin T;
A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy

Ref ID: 4629

Number of participant
181 recruited. 102 had generalised seizures, 79 had partial seizures. Generalised tonic clonic seizures: 28 in the carbamazepine group; 37 in the phenytoin group; 37 in the valproate group.

Inclusion/Exclusion Criteria
Inclusion criteria:
Previously untreated; Recently diagnosed; General or partial seizures; Minimum of 2 seizures over six months period before referral for assessment;

Patient Characteristics
Patients with generalised tonic clonic seizures (without focal features):
Carbamazepine vs phenytoin vs valproate:
Sex: male: 13 vs 21 vs 20; female: 15 vs 16 vs 17;
Age (year) range (mean): 4-72 (26) vs 7-69 (26) vs 5-71 (23);
Duration of seizures prior to treatment months range (median):
0-132 (18) vs 3-156 (9) vs 0-120 (9);
Duration of treatment months range (median): 3-44 (15) vs 3-42 (18) vs 3-44 (24);
Total no of seizures since the onset of and range (median):
2-1277 (4) vs 2-900 vs 2-720 (3).

Patients with partial seizures with or without secondary generalised attacks:
Carbamazepine vs phenytoin vs valproate:
Sex: male: 15 vs 12 vs 14; female: 16 vs 9 vs 13;
Age (yr) range (mean): 8-75 (28) vs 7-64 vs 6-68 (25);
Duration prior to treatment months range (median): 0-180 (12) vs 6-168 (24) vs 3-36 (12);
Duration of treatment months range (median): 3-42 (14) vs 3-47 (24) vs 3-48 (24);
Total no. of seizures since the onset of attacks range (median):
2-1095 (6) vs 3-300 (6) vs 2-732 (26).

Recruitment
Not reported.

Setting
Cork, Ireland.

Interventions/ Test/
Factor being investigated
Assessments at seizure clinic of response to treatment and side effects documented and sample of blood taken to estimate serum AED levels.

The participants were instructed to take the drug twice daily. If they did not respond to the first preference of drug the dose of that drug was decreased by 200mg decrements of sodium valproate and carbamazepine and by 100mg phenytoin at two weekly intervals and then second preference drug was allocated from randomisation list.

CBZ was prescribed in a dosage of 600mg daily for adults and 5-10mg/kg body weight for children; phenytoin in a dose of 300mg daily for adults and 5-10mg/kg body weight for children; sodium valproate in a dose of 600mg daily for adults and 5-10mg/kg body weight for children.

Comparisons
Carbamazepine versus phenytoin vs sodium valproate.

Length of Study/ Follow-up
Patients are seen at one month after prescription then intervals of one to three months, depending on how they responded to treatment.

Follow up ranged from 3 to 9 weeks.

Outcome measures studied
Response to treatment: excellent control - complete freedom from seizures; good control - greater than 50% reduction in seizure frequency; poor control no response or less than 50% reduction in seizure frequency.

Results
Response in patients with generalised seizures:

Phenytoin vs carbamazepine vs valproate: Control (number (%)):
Excellent control (complete freedom from seizures): 27 (73%) vs 11 (39%) vs 22 (59%). Total 60 (59%).
Good control (greater than 50% reduction in seizure frequency): 3 (8%) vs 10 (36%) vs 7 (19%). Total 20 (20%).
Poor control (no response or less than 50% reduction in seizure frequency): 7 (19%) vs 7 (25%) vs 8 (22%). Total 22 (21%).
Phenytoin vs carbamazepine - excellent control, p<0.01.

Overall patients with primary generalised attacks: 71% achieved excellent or good control.

Overall response in patients with partial seizures with or without secondary generalised attacks:

Phenytoin vs carbamazepine vs valproate: Control (number (%)):
Excellent control: 12 (57.1%) vs 11 (33.5%) vs 12 (44.4%). Total 35 (44.3%).
Good control: 4 (19%) vs 12 (38.7%) vs 9 (33.3%). Total 25 (31.6%).
Poor control: 5 (23.8%) vs 8 (25.8%) vs 6 (22.2%). Total 19 (24%).
[partial also subdivided for partial complex and simple partial].

When compared response in patients with generalised seizures and those with partial seizures, with or without secondary generalised attacks, the overall response was better in patients with generalised seizures (p<0.05).

Withdrawal of treatment: 26 patients, 8 taking carbamazepine, 7 valproate and 11 phenytoin. 4 relapsed, 1 taking carbamazepine, 2 taking phenytoin and one taking sodium valproate. Not mentioned whether these were generalised or partial seizure types.
Safety and adverse effects

12 patients dropped out. 10 with generalised seizures and 2 with partial seizures.

Of these 5 with generalised took phenytoin, 3 carbamazepine and 2 sodium valproate.

One with partial seizures was taking phenytoin, one carbamazepine.

Does the study answer the question?

Yes.

Authors conclusion was that sodium valproate, carbamazepine and phenytoin are effective in the control of generalised and partial seizures, and that all three drugs can be prescribed as anti-convulsant of first choice. Irrespective of the drug prescribed, partial seizures were less responsive to treatment.

Effect due to factor in study?

Unsure as no blinding and no power calculation given.

Consistency of results with other studies?

Yes.

Internal Validity

Cereghino JJ; Biton V; bou-Khalil B; Dreifuss F; Gauer L J; Leppik I;

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

Ref ID 4740 2000

Study Type Randomised Controlled Trial

Funding UCB Pharma.

Number of participant

95 in the placebo group, 98 in the levetiracetam 1000mg/day group and 101 in the levetiracetam 3000mg/day group.

Inclusion/Exclusion Criteria

Inclusion criteria: age 16 to 70, uncontrolled partial seizures for >=2 years, min of 12 seizures in last 12 wks, min of 2 per 4 wks in baseline period, taking >=2 AEDs.

Exclusion criteria: pregnancy, comorbidities, use of investigational AED in last 4 wks, history of drug abuse, or renal or hepatic impairment.

Patient Characteristics

<table>
<thead>
<tr>
<th>Placebo</th>
<th>Lev 1000mg/d</th>
<th>3000mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>98</td>
<td>101</td>
</tr>
</tbody>
</table>

Male/female

50/45

62/36

66/35

Race

White

81

82

88

Black

7

10

9

Other

7

6

4

Age mean (SD) 38(11) 38(11) 38(11)

Weight kg mean (SD) 77.3(17.9) 79.4(19.1) 80.3(16.7)

Median weekly partial seizure frequency 1.77 2.53 2.08

Concomitant AEDs

1

2

>2

25

67

3

35

57

6

36

59

6

Recruitment

Unknown.

Setting

41 study sites in North America

Interventions/Test/Factor being investigated

Levetiracetam 1000mg and 3000mg per day compared to placebo.
Comparison is between levetiracetam (1000mg and 3000 per day doses) and placebo as adjunctive therapy with currently used AEDs.

Length of Study/ Follow-up

38 weeks: 12-week, single-blind placebo baseline period, a 4-week double-blind drug titration period; a 14 week double-blind treatment period; and an 8 week double-blind study medication withdrawal period.

Outcome measures studied

Primary efficacy variable was the mean number of partial seizures per week over the entire 14-week evaluation period. Secondary outcomes were median percent reduction compared to baseline, responder rate, and number of seizure-free patients.

Results

Primary outcome (14 wk treatment period)

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Lev 1000mg/d</th>
<th>3000mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Least squares mean (LSM) number of seizures per wk (SE).</td>
<td>1.366(-0.053)</td>
<td>1.131 (0.050)</td>
<td>1.041(0.049)</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median % reduction vs. placebo</td>
<td>20.9*</td>
<td>27.7*</td>
<td></td>
</tr>
<tr>
<td>Median % reduction vs baseline</td>
<td>6.8</td>
<td>32.5*</td>
<td>37.1*</td>
</tr>
<tr>
<td>50% responder rate</td>
<td>10.0</td>
<td>33.0*</td>
<td>39.8*</td>
</tr>
</tbody>
</table>

*p<0.001

Sub group analysis

Median percent reduction in seizure frequency from baseline by seizure subtype

<table>
<thead>
<tr>
<th>Seizure 1a (p value)</th>
<th>34.4</th>
<th>54.7(NS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>44.8(NS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizure 1b (p value)</td>
<td>6.4</td>
<td>34.2(0.003)</td>
</tr>
<tr>
<td>45.6(&lt;0.001)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizure 1c (p value)</td>
<td>24.4</td>
<td>84.7(0.018)</td>
</tr>
</tbody>
</table>

Adverse events

At least one, % of pts | 88.4 | 88.8 | 89.1

Safety and adverse effects

Very few Aes were severe: (<=4%). 5/95 (5.3%) of placebo group withdrew for AE reasons; 6/98 in the lev 1000mg/d group; 7/101 6.9% in the lev 3000mg/d group. Treatment -emergent AEs (>10%) with incidences higher than placebo were infection, headache, somonolence, dizziness, asthenia, rhinitis, and flu syndrome.

Internal Validity

Chadwick D;

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group
Study Type: Randomised Controlled Trial

Number of participant: Carbamazepine, n=230. Vigabatrin, n=229. Total = 459 enrolled.

Inclusion/Exclusion Criteria: Patients with newly diagnosed epilepsy, ages 12-65 and had at least 2 seizures in the previous 12 months (simple or complex partial seizures with or without secondary generalisation).

The occurrence of generalised seizures types as an exclusion criterion.

Patient Characteristics: Male: 122 (54%) in carbamazepine and 117 (53%) in vigabatrin.

Mean age (sd): 36(16) in carbamazepine and 35(15) in vigabatrin

Recruitment: Recruited from 44 centres after approval of local ethics committee - not stated how recruitment was done.

Setting: 44 multinational centres - recruitment: 1993-1996

Interventions/ Test/ Factor being investigated: Vigabatrin vs Carbamazepine (mono-therapies). All were divided into twice daily dosing.

Comparisons: Comparison were made between active treatments. The control - carbamazepine was the accepted first line therapy for newly diagnosed individuals with partial epilepsy in Europe.

Length of Study/ Follow-up: 52 weeks. After that, patients on vigabatrin continued on an open follow up study.

Outcome measures studied: Primary: time to treatment failure (withdrawal due to lack of efficacy or adverse events). Secondary: efficacy (time to 6 month remission and time to 1st seizure after initial dose stabilisation); adverse events (incidence & severity)

Results: 

Time to treatment failure (withdrawal): ITT analysis hazard ratio: 0.83, 95% CI 0.57 to 1.20, hazard ratio adjusted for covariates (centre, reciprocal of seizure frequency at baseline, duration of epilepsy, age, number of secondary generalised seizures): 0.75, 95% CI 0.52 to 1.10. Per protocol analysis (n=400), adjusted hazard ratio: 0.74 95% CI 0.50 to 1.12.

Time to withdrawal due to lack of efficacy: Adjusted hazard ratio 2.37 95% CI 1.09 to 5.18, p=0.0298 (23 in vigabatrin and 9 in carbamazepine)

Number of patients with 6 month remission by end of study: 107/220 in vigabatrin, 116/226 in carbamazepine. Hazard ratio (unadjusted): 1.20 95% CI 0.93 to 1.57, adjusted hazard ratio: 1.15 (0.88 to 1.55)

Time to first seizure after dose stabilisation: adjusted and unadjusted hazard ratio: 1.58 95% CI 1.09 to 5.18, p=0.0298

Time to withdrawal due to adverse events: adjusted hazard ratio 0.63 95% CI 0.43 to 0.94, unadjusted hazard ratio: 0.70 95% CI 0.47 to 1.03

Time to first seizure after randomisation: adjusted and unadjusted hazard ratio: 1.57 95% CI 1.23 to 2.02, p=0.0003.

Number and percentage of patients with adverse events:

Central nervous system (total): Carbamazepine - 144 (63%) Vigabatrin - 141 (62%)

Amnesia: Carbamazepine - 17 (7%) Vigabatrin - 6 (7%)

Drowsiness: Carbamazepine - 63 (28%) Vigabatrin - 49 (21%)

Fatigue: Carbamazepine - 50 (22%) Vigabatrin - 45 (20%)

Headache: Carbamazepine - 48 (21%) Vigabatrin - 47 (21%)

Psychiatry (total): Carbamazepine - 34 (15%) Vigabatrin - 58 (25%) p<0.05

Agitation: Carbamazepine - 13 (6%) Vigabatrin - 16 (7%)

Depression: Carbamazepine - 7 (3%) Vigabatrin - 15 (7%)
Carbamazepine showed better efficacy (time to 1st seizure after randomisation, and time to 1st seizure after dose increase) and fewer skin or appendages adverse events in the carbamazepine group. More patients with weight increase in the vigabatrin group.

**Safety and adverse effects**

195 (85%) of patients on carbamazepine and 191 (84%) on vigabatrin had an adverse event. 26 (11%) on vigabatrin and 21 (9%) in carbamazepine had serious adverse events. There were three deaths - 1 carbamazepine and 2 vigabatrin.

No clinically important haematological and biochemical parameters were noted, but there was an increase in alkaline phosphatase and decreases in uric acid and bilirubin concentrations and decrease in white blood cell counts in the carbamazepine patients.

Carbamazepine showed better efficacy (time to 1st seizure after randomisation, and time to 1st seizure after dose stabilisation and withdrawal due to lack of efficacy).

There were significantly more psychiatric and skin or appendages adverse events in the carbamazepine group more patients with weight increase in the vigabatrin group.

**Does the study answer the question?**

Internal Validity

Chadwick DW; Anhut H; Greiner MJ; Alexander J; Murray GH; Garofalo EA; Pierce MW;

A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77

Ref ID 4767 1998

Study Type Randomised Controlled Trial

Funding Parke Davis

Number of participant 292 patients were randomised: 74 to carbamazepine (CBZ) 600 mg; 72 to Gabapentin (GBP) 300 mg; 72 to GBP 900 mg and 74 to GBP 1200 mg.

Inclusion/Exclusion Criteria

Inclusion: newly diagnosed untreated partial epilepsy; at least 12 years old and weighing between 40-110 kg; women of childbearing age using contraception

Exclusions: idiopathic generalized Epilepsy; hx of status; progressive encephalopathy; medical or psychiatric condition that could affect study outcome

Patient Characteristics

<table>
<thead>
<tr>
<th>Gender</th>
<th>Carbamazepine (n=72)</th>
<th>Gabapentin (GBP) 300 mg (n=72)</th>
<th>Gabapentin (GBP) 900 mg (n=74)</th>
<th>Gabapentin (GBP) 1200 mg (n=74)</th>
<th>CBZ 600 (n=72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>56%</td>
<td>49%</td>
<td>55%</td>
<td>55%</td>
<td>55%</td>
</tr>
<tr>
<td>Women</td>
<td>44%</td>
<td>51%</td>
<td>45%</td>
<td>45%</td>
<td></td>
</tr>
<tr>
<td>Mean Age, y</td>
<td>37 (17.3)</td>
<td>34 (16.0)</td>
<td>37 (16.9)</td>
<td>34 (16.4)</td>
<td></td>
</tr>
<tr>
<td>Duration of epilepsy, m</td>
<td>1.0 (2.2)</td>
<td>0.0 (1.0)</td>
<td>1.5 (4.5)</td>
<td>1.3 (2.3)</td>
<td></td>
</tr>
</tbody>
</table>

Recruitment Unknown

Setting Multicentre - Europe, Australia, S. Africa, Canada

29 July 2010 Page 27 of 306
Gabapentin monotherapy for newly diagnosed partial seizures

GBP doses of 300 mg vs. 900 mg and 1800 mg/day vs. CBZ 600 mg/day

24 week evaluation phase

Primary efficacy variable was time to exit event.

GBP at 900 or 1800 mg/day is effective and safe as monotherapy for patients with newly diagnosed partial epilepsy.

<table>
<thead>
<tr>
<th>Interventions/ Test/ Factor being investigated</th>
<th>Gabapentin monotherapy for newly diagnosed partial seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparisons</td>
<td>GBP doses of 300 mg vs. 900 mg and 1800 mg/day vs. CBZ 600 mg/day</td>
</tr>
<tr>
<td>Length of Study/ Follow-up</td>
<td>24 week evaluation phase</td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>Primary efficacy variable was time to exit event.</td>
</tr>
</tbody>
</table>

Results

<table>
<thead>
<tr>
<th>600mg/d</th>
<th>GBP 300 mg/d</th>
<th>GBP 900 mg/d</th>
<th>GBP1800 mg/d</th>
<th>CBZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=72</td>
<td>18(25%)</td>
<td>28(38.9%)</td>
<td>28(37.8%)</td>
<td>27(36.5%)</td>
</tr>
<tr>
<td>Completion rate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exit event rate</td>
<td>45(62.5%)</td>
<td>29(40.3%)</td>
<td>32(43.2%)</td>
<td>22(29.7%)</td>
</tr>
<tr>
<td>AE withdrawal rate</td>
<td>0(0.0%)</td>
<td>3(4.2%)</td>
<td>10(13.5%)</td>
<td>18(24.3%)</td>
</tr>
<tr>
<td>Exit + AE withdrawal rate</td>
<td>45(62.5%)</td>
<td>32(44.4%)</td>
<td>42(56.8%)</td>
<td>40(54.1%)</td>
</tr>
</tbody>
</table>

Safety and adverse effects

No unexpected new adverse events emerged with GBP monotherapy

Does the study answer the question?

GBP at 900 or 1800 mg/day is effective and safe as monotherapy for patients with newly diagnosed partial epilepsy.

Effect due to factor in study?

Yes

Consistency of results with other studies?

See GRADE

Directly applicable to guideline population?

See GRADE

Internal Validity

Multi centre study

Christe W; Kramer G; Vigonius U; Pohlmann H; Steinhoff BJ; Brodie MJ; Moore A;

A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy

Ref ID 4770

Number of participant

249 in total, 128 in oxcarbazepine, 121 in sodium valporate

Inclusion/Exclusion Criteria

Inclusion: aged 15 to 65 years, newly diagnosed epilepsy with PS or GTCS, at least 2 seizures at least 48 hours apart in previous 6 months, no previous AED except for emergency treatment in previous 3 weeks

Exclusion: pregnancy or risk of becoming pregnant, history of status epilepticus, severe psychiatric illness or severe mental retardation, progressive neurological disorder, alcoholism or drug abuse, significant other organic disease

Patient Characteristics

In the oxcarbazepine group the mean age was 32.45 years (range 15 to 65 years), 60 out of 128 were male. The mean weight was 69.9 kg (range 42 to 119 kg). 76 patients had partial seizures with or without secondary generalised seizures and 52 had generalised seizures without partial onset.

In the sodium valporate group the mean age was 32.47 years (range 15 to 64 years), 67 out of 121 were male. The mean weight was 70.2 kg (range 44 to 115 kg). 78 patients had partial seizures with or without secondary generalised seizures and 43 had generalised seizures without partial onset.

29 July 2010
### Recruitment
Between November 1990 and first quarter 1995

### Setting
Europe, Brazil, South Africa

### Interventions/ Test/
Factor being investigated
300mg oxcarbazepine

### Comparisons
300 mg sodium valporate

### Length of Study/
Follow-up
No follow up reported

### Outcome measures studied
Number of patients who were seizure free, side effects, withdrawal

### Results
The trial was conducted in Belgium, Brazil, France, Germany, Netherlands, South Africa, Spain, UK.

The trial was split into two periods, an 8 week titration and 48 week maintenance period. No concomitant AEDs were allowed. During the titration period patients received 300 mg oxcarbazepine or sodium valporate, this was gradually increased depending upon response, there was no fixed titration schedule. After 8 weeks patients were on daily doses of 900 to 2400 mg oxcarbazepine or sodium valporate, this dose was continued for the maintenance period. However this dose could be changed according to response.

214 patients reached the maintenance period, of these 212 had at least 1 seizure assessment during the maintenance period and were therefore included in the results.

#### Number of patients who were seizure free:
- In the oxcarbazepine group 60 out of 106 were seizure free compared to 57 out of 106 in the sodium valporate group.
- In the oxcarbazepine group 46% of patients with partial seizures (with or without secondary generalised seizures) were seizure free compared to 48% of patients with partial seizures (with or without secondary generalised seizures) in the sodium valporate group.
- In the oxcarbazepine group 72% of patients with generalised seizures (without partial onset) were seizure free compared to 62% of patients with generalised seizures (without partial onset) in the sodium valporate group.

#### Withdrawal:
A total of 52 patients in the oxcarbazepine group withdrew compared to 41 in the sodium valporate group. In the oxcarbazepine group 15 patients withdrew due to adverse events compared to 10 in the sodium valporate group.

In the oxcarbazepine group 6 withdrew due to allergic reaction, 1 due to pregnancy, 1 due to nausea, 1 due to drowsiness, 5 due to other adverse experiences, 14 due to non-compliance, 6 due to unsatisfactory therapeutic effect, 4 due to lost to follow up, 7 due to protocol violation, 3 due to administrative reasons, 2 due to concomitant illness and 1 due to death.

In the sodium valporate group 4 withdrew due to hair loss, 2 due to pregnancy, 2 due to nausea, 5 due to other adverse experiences, 7 due to non-compliance, 6 due to unsatisfactory therapeutic effect, 7 due to lost to follow up, 3 due to protocol violation, 5 due to administrative reasons, 2 due to concomitant illness, and 1 due to abnormal laboratory results.

#### Side effects:
In the oxcarbazepine group 115 out of 128 had at least 1 adverse event compared to 106 out of 121 in the sodium valporate group.

In the oxcarbazepine group 115 out of 128 had at least 1 adverse event compared to 106 out of 121 in the sodium valporate group. In the oxcarbazepine group 15 patients withdrew due to adverse events compared to 10 in the sodium valporate group.

There was no significant difference in the number of patients becoming seizure free, withdrew or had at least 1 adverse event between the oxcarbazepine group and the sodium valporate group.
Effect due to factor in study?
Consistency of results with other studies?
Directly applicable to guideline population?

Internal Validity

Cramer JA; Arrigo C; Van HG; Gauer LJ; Cereghino JJ;

Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group

Ref ID 4763

Study Type Randomised Controlled Trial
Funding Please see database entry for Cereghino study for details of methods and results of RCT.

Number of participant
This publication reports only on the analysis of QoL data from a previously reported RCT (Cereghino et al, 2000, RID= 210, Ref Man ID 4740). Please see database entry for Cereghino study for details of methods and results of RCT.

Inclusion/Exclusion Criteria
Please see database entry for Cereghino study for details of methods and results of RCT.

Patient Characteristics
Baseline characteristics for patients for whom quality of life data available.

<table>
<thead>
<tr>
<th>3000mg</th>
<th>Placebo</th>
<th>LEV 1000mg</th>
<th>LEV</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=81)</td>
<td>(n=80)</td>
<td>(n=85)</td>
<td></td>
</tr>
<tr>
<td>Age (mean years)</td>
<td>38.5(11.3)</td>
<td>39.1(11.3)</td>
<td>38.5(10.2)</td>
</tr>
<tr>
<td>Gender (% male)</td>
<td>54.3%</td>
<td>61.3%</td>
<td>64.7%</td>
</tr>
<tr>
<td>Age at epilepsy onset (mean years)</td>
<td>13.9(11.9)</td>
<td>15.3(12.7)</td>
<td>13.6(10.8)</td>
</tr>
<tr>
<td>Duration of epilepsy (mean years)</td>
<td>24.6(12.0)</td>
<td>23.8(12.7)</td>
<td>24.9(12.1)</td>
</tr>
<tr>
<td>No. of AEDs (%)</td>
<td>One</td>
<td>29.6</td>
<td>36.3</td>
</tr>
<tr>
<td></td>
<td>Two</td>
<td>69.2</td>
<td>60.0</td>
</tr>
<tr>
<td></td>
<td>Three or more</td>
<td>1.2</td>
<td>3.7</td>
</tr>
<tr>
<td>Mean no. of partial-onset seizures per week at baseline</td>
<td>5.6(18.79)</td>
<td>7.55(13.99)</td>
<td>5.15(15.58)</td>
</tr>
<tr>
<td>Seizure type (%)</td>
<td>SPS or CPS</td>
<td>64.2</td>
<td>65.0</td>
</tr>
<tr>
<td></td>
<td>SPS or CPS + PSSG</td>
<td>35.8</td>
<td>31.3</td>
</tr>
<tr>
<td></td>
<td>PSSG</td>
<td>0.0</td>
<td>3.7</td>
</tr>
</tbody>
</table>

Recruitment
Please see database entry for Cereghino study for details of methods and results of RCT.

Setting

Interventions/ Test/ Factor being investigated
Please see database entry for Cereghino study for details of methods and results of RCT.

Comparisons
Please see database entry for Cereghino study for details of methods and results of RCT.

Length of Study/ Follow-up
Health related quality of life (HRQoL) was assessed at end of baseline period and at end of treatment (18 weeks between the two time points).
HRQoL as measured by the QOLIE-31 (quality of life in epilepsy), a self administered questionnaire. It includes 7 subscales: Seizure Worry, Overall QOL, Emotional Well-Being, Energy-Fatigue, Cognitive Functioning, and the Health Status item.

Results

Mean values of QOLIE-31 at follow-up assessment

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>LEV 1000mg</th>
<th>LEV 3000mg</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure Worry</td>
<td>55.9</td>
<td>65.8</td>
<td>65.7</td>
<td>0.0003</td>
</tr>
<tr>
<td>Overall QOL</td>
<td>62.7</td>
<td>67.3</td>
<td>67.6</td>
<td>0.04</td>
</tr>
<tr>
<td>Emotional Well-Being</td>
<td>67.2</td>
<td>69.7</td>
<td>67.4</td>
<td>0.41</td>
</tr>
<tr>
<td>Energy-Fatigue</td>
<td>52.7</td>
<td>54.4</td>
<td>55.2</td>
<td>0.62</td>
</tr>
<tr>
<td>Cognitive Functioning</td>
<td>60.0</td>
<td>64.6</td>
<td>66.6</td>
<td>0.01</td>
</tr>
<tr>
<td>Medication Effects</td>
<td>61.7</td>
<td>66.1</td>
<td>69.6</td>
<td>0.10</td>
</tr>
<tr>
<td>Social Function</td>
<td>55.6</td>
<td>58.6</td>
<td>59.9</td>
<td>0.36</td>
</tr>
<tr>
<td>Health Status</td>
<td>65.2</td>
<td>66.6</td>
<td>67.9</td>
<td>0.64</td>
</tr>
<tr>
<td>Total Score</td>
<td>59.4</td>
<td>63.4</td>
<td>64.1</td>
<td>0.0009</td>
</tr>
</tbody>
</table>

*p-value for difference between treatment groups on adjusted mean values at follow-up assessment (with baseline as covariate).

There were statistically significant changes among responders in all subscale scores (all p<0.0006 to p<0.0001).

Safety and adverse effects

Please see database entry for Cereghino study for details of methods and results of RCT.

Does the study answer the question?

The clinical trial was not powered for an HRQOL outcome. Thus, the QOLIE-31 analyses were exploratory.

Effect due to factor in study?

Please see database entry for Cereghino study for details of methods and results of RCT.

Consistency of results with other studies?

Please see database entry for Cereghino study for details of methods and results of RCT.

Directly applicable to guideline population?

Please see database entry for Cereghino study for details of methods and results of RCT.

Internal Validity

Duchowny M; Pellock JM; Graf WD; Billard C; Gilman J; Casale E; Womble G; Risner M; Manasco P;

A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group

Ref ID 4611 1999

Study Type Randomised Controlled Trial Funding GlaxoWellcome Research and Development

Number of participant

199 patients randomized: 98 patients lamotrigine group and 101 placebo

Inclusion/Exclusion Criteria

Inclusion: 2-16 years in US or 2-12 years in France, weighed at least 10 kg, had diagnosis of partial seizures and were incompletely controlled on AED.

Exclusion: Previous been exposed to lamotrigine; were using corticosteroid therapy for asthma; had intracerebral, structural lesions or history of status within previous 12 weeks; hx of medical noncompliance, drug abuse, psychiatric disorders or progressive neurological disease or had chronic cardiac, renal or hepatic condition, pregnancy or were awaiting surgery for epilepsy

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Lamotrigine (n=98)</th>
<th>Placebo (n=101)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;6</td>
<td>27</td>
<td>30</td>
</tr>
<tr>
<td>6-12</td>
<td>58</td>
<td>62</td>
</tr>
<tr>
<td>&gt;12</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>47/51</td>
<td>56/45</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>78</td>
<td>85</td>
</tr>
</tbody>
</table>

29 July 2010Page 31 of 306
<table>
<thead>
<tr>
<th>Race</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black</td>
<td>14</td>
<td>7</td>
</tr>
<tr>
<td>Other</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>36.1 +/- 19.4</td>
<td>32.5 +/- 19.1</td>
</tr>
<tr>
<td>Height, m</td>
<td>1.31 +/- 0.22</td>
<td>1.26 +/- 0.23</td>
</tr>
</tbody>
</table>

**Recruitment**
Not described

**Setting**
40 study sites in US and France

**Interventions/Test/Factor being investigated**
Efficacy and safety of lamotrigine when added to the current AED regimen in children and adolescents with partial seizures

**Comparisons**
Treatment (lamotrigine) and placebo

**Length of Study/Follow-up**
8 week baseline and 18 week trial periods

**Outcome measures studied**
Primary: Percentage change in seizure frequency between the 8 week baseline stage of the study and either the entire 18 week treatment stage or the 12 week period of maintenance dosing. Secondary: Percent reductions

**Results**
The median percentage changes from baseline in seizure counts with lamotrigine and placebo for weeks 1-18 were 36.1% vs. 6.7% respectively (p=0.008) and for weeks 7-18, 44.0% vs. 12.8% respectively (p=0.012). The frequency of secondarily generalized seizures was also significantly reduced from baseline. The median percentage changes from baseline in seizure counts with lamotrigine and placebo for weeks 1-18 were 53.0% vs. 8.6% respectively (p=0.003) and for weeks 7-18, 66.7% vs. 11.2% respectively (p=0.013). The percentage of patients who achieved at least a 50% reduction in the frequency of all partial seizures during weeks 1-18 was 42% with lamotrigine compared with 16% placebo (p<0.001) and during weeks 7-18 was 45% with lamotrigine compared with 25% with placebo (p=0.004). The percentage of patients who achieved at least a 50% reduction in the frequency of partial seizures with secondary generalization during weeks 1-18 was 53% with lamotrigine compared with 26% placebo (p<0.015) and during weeks 7-18 was 457% with lamotrigine compared with 30% with placebo (p=0.0023).

**Safety and adverse effects**
The most commonly reported adverse events in the lamotrigine treated patients were vomiting, somnolence, and infection; the frequency of these and other adverse events was similar to that in the placebo treated group with the exception of ataxia, dizziness, tremor and nausea which were more frequent and statistically significant (less than or equal to 0.05) in the lamotrigine treated group. Two patients were hospitalized for skin rash, which resolved after discontinuation of lamotrigine.

**Does the study answer the question?**
Lamotrigine was effective for adjunctive treatment of partial seizures in children and demonstrated an acceptable safety profile.

**Effect due to factor in study?**
Yes

**Consistency of results with other studies?**
See GRADE

**Directly applicable to guideline population?**
See GRADE

**Internal Validity**
Multi-centre

Elger CE; Brodie MJ; Anhut H; Lee CM; Barrett JA;

Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study

**Ref ID** 4161

**Study Type** Randomised Controlled Trial

**Funding** Not reported.

29 July 2010 Page 32 of 306
Pregabalin            Pregabalin                                                                           flexible dose  ... (ml/min)Mean (SD)                                     107.2 (28.9)            109.4 (33.8)           108.0 (31.7)

Flexible dose PGB (150-600mg PGB titrated to clinical response and adverse events in 150mg increments) and fixed dose PGB (300mg daily).

Inclusion criteria: aged 18 years or older, weight at least 50 kg, diagnosis of epilepsy with partial seizures, and not previously received pregabalin. They must have experienced at least 4 partial seizures during the 6-week baseline period with no 28-day period free of partial seizures, and to be currently receiving between 1 and 3 AEDs.

Exclusion criteria: seizures with a treatable cause, absence seizures, Lennox–Gastaut syndrome, or status epilepticus within the previous year.

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Placebo (n = 73)</th>
<th>Pregabalin flexible dose 150–600 mg/day (n = 131)</th>
<th>Pregabalin fixed dose 600 mg/day (n = 137)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in yr</td>
<td>40.3 (12.5)</td>
<td>40.0 (13.5)</td>
<td>41.1 (12.2)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>71 (97.3)</td>
<td>128 (97.7)</td>
<td>133 (97.1)</td>
</tr>
<tr>
<td>Black</td>
<td>0</td>
<td>0</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (2.7)</td>
<td>3 (2.3)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>37 (50.7)</td>
<td>64 (48.9)</td>
<td>69 (50.4)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>72.6 (15.6)</td>
<td>74.0 (17.4)</td>
<td>75.1 (16.3)</td>
</tr>
<tr>
<td>Estimated creatinine clearance (ml/min)</td>
<td>107.2 (28.9)</td>
<td>109.4 (33.8)</td>
<td>108.0 (31.7)</td>
</tr>
</tbody>
</table>

Number of participant n=341 (n=131 in PGB 150-600mg/day pregabalin (flexible dose), n=137 in the PGB 300mg/day fixed dose, and n=73 in the placebo group.)

Inclusion/Exclusion Criteria

Recruitment

Unknown.

Setting

53 centres worldwide

Interventions/ Test/ Factor being investigated

Flexible dose PGB (150-600mg PGB titrated to clinical response and adverse events in 150mg increments) and fixed dose PGB (300mg daily).

Comparisons

Comparisons are between two regimens of PGB and placebo as add-on therapy to currently used AEDs.

Length of Study/ Follow-up

18 weeks: a 6 week baseline phase and a 12 week treatment period.

Outcome measures studied

The primary efficacy measure was a reduction in the 28-day seizure rate. Secondary outcomes: responder rate, % pts seizure free, % completing study, reduction in proportion of sec. gen. tonic-clonic seizures.

Results

Primary outcome

Both pregabalin treatment regimens were significantly more effective than placebo in reducing the frequency of all partial seizures. Mean RRatios for the pregabalin flexible-dose group (~21.5, p = 0.0091) and the pregabalin fixed-dose group (~32.7, p = 0.0001) were both significantly lower than for the placebo group (~5.6), indicating a greater reduction in seizure frequency.

The corresponding percentage reduction in seizure frequency between baseline and treatment was 35.4% for the pregabalin flexible-dose group, and 49.3% for the pregabalin fixed-dose group compared with 10.6% for the placebo group (Fig. 2, left y-axis). Differences in the treatment means (95% confidence intervals) compared with the placebo group were ~15.8 (~27.4, ~4.3) for the pregabalin flexible-dose (150–600 mg/day) group, and ~27.0 (~38.5, ~15.6) for the pregabalin fixed-dose group. The pregabalin fixed-dose group was significantly superior to the pregabalin flexible-dose (150–600 mg/day) group (p = 0.0337), with a mean RRatio treatment difference of ~11.2 (~20.8, ~1.6).

Secondary outcomes
Responders rate
The responder rate (≥50% reduction) was significantly greater in both the pregabalin flexible-dose group (31.3%, \(p=0.001\)) and the pregabalin fixed-dose group (45.3%, \(p=0.001\)) compared with the placebo group (11.0%). The responder rate for the pregabalin fixed-dose group was also significantly higher than the rate in the pregabalin flexible-dose group (\(p=0.016\)).

Free of seizures
During the last 28 days of treatment, 16 (12.2%) patients in the pregabalin flexible-dose group, 17 (12.4%) in the pregabalin fixed-dose group, and 6 (8.2%) in the placebo group were completely free of seizures.

Completing study
Significantly more patients in the pregabalin flexible dose group (76.3%) completed the trial than did patients in the fixed-dose group (58.4%; \(p = 0.0019\)).

Reduction in secondary generalized tonic-clonic seizures
Compared with the placebo group (33%, \(n = 27\)), a higher proportion of patients in both the pregabalin flexible-dose group (53%, \(n = 28\)) and pregabalin fixed dose group (68%, \(n = 45\)) exhibited a decrease in the proportion of SGTC seizures by 28-day seizure rates for all partial seizures with the difference between the pregabalin fixed dose and placebo reaching statistical significance (\(p = 0.015\)).

Adverse events

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Frequency of adverse event</th>
<th>Pregabalin dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>fixed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>flexible dose</td>
</tr>
<tr>
<td>mg/day</td>
<td>Placebo 150–600 mg/day</td>
<td>600</td>
</tr>
<tr>
<td>Adverse event</td>
<td>(n = 73)</td>
<td>(n = 131)</td>
</tr>
<tr>
<td>(n = 137)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall adverse events (%)</td>
<td>63.0</td>
<td>86.3</td>
</tr>
<tr>
<td>Frequency of most common adverse events (%)</td>
<td></td>
<td>87.6</td>
</tr>
<tr>
<td>Dizziness</td>
<td>8.2</td>
<td>24.4</td>
</tr>
<tr>
<td>Ataxia</td>
<td>4.1</td>
<td>9.2</td>
</tr>
<tr>
<td>Weight gain</td>
<td>6.8</td>
<td>19.1</td>
</tr>
<tr>
<td>Asthenia</td>
<td>13.7</td>
<td>16.8</td>
</tr>
<tr>
<td>Somnolence</td>
<td>8.2</td>
<td>19.1</td>
</tr>
<tr>
<td>Vertigo</td>
<td>2.7</td>
<td>10.7</td>
</tr>
<tr>
<td>Diplopia</td>
<td>1.4</td>
<td>6.1</td>
</tr>
<tr>
<td>Amblyopia (blurred vision)</td>
<td>1.4</td>
<td>2.3</td>
</tr>
<tr>
<td>Headache</td>
<td>11.0</td>
<td>13.7</td>
</tr>
</tbody>
</table>

Withdrawal due to an adverse event was 33% in the pregabalin fixed-dose group followed by the pregabalin flexible-dose group (12%), and placebo group (7%).

Consistency of results with other studies?
Yes. The sample size was derived from a power calculation which was based on previous pregabalin trials.

Safety and adverse effects
Yes. Pregabalin administered either as fixed (600 mg/day), or as flexible (150–600 mg/day) dose, was effective as add-on therapy for partial seizures with or without secondary generalization. Lower incidence of adverse events and discontinuations were achieved in patients receiving a flexible dose.

Directly applicable to guideline population?
The study population comprised patients who all had suffered from partial seizures.
Internal Validity

Elterman RD; Glauser TA; Wyllie E; Reife R; Wu SC; Pledger G;

A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children.

Topiramate YP Study Group

Ref ID 4608

Study Type Randomised Controlled Trial

Funding R.W. Johnson Pharmaceutical Research Institute

Number of participant 41 patients in topiramate treatment and 45 patients in placebo group

Inclusion/Exclusion Criteria

Inclusion: Ages 1-16 years, weighing more than 16 kg and had partial onset seizures. Six or more seizures during the baseline phase with at least one during each 4 week interval while maintained on at least one but not more than two AEDs. Exclusion: Progressive neurologic disease, status, Lennox-Gastaut, EKG abnormalities, significant medical disease, drug or alcohol abuse, psychiatric condition and use of drugs that increased risk of renal stones.

Patient Characteristics

Age range 2-16; mean age placebo (n=45) 9.0 +/- 3.4 and topiramate (n=41) 8.8 +/- 3.6. Male/female placebo (n=45) 25/20 and topiramate (n=41) 23/18; mean weight placebo (n=45) 35.1 +/- 16.3 and topiramate (n=41) 34.7 +/- 15.8.

Recruitment Not described

Setting 16 sites in the US and one in Costa Rico

Interventions/ Test/ Factor being investigated Use of topiramate as adjunctive therapy for partial onset seizures in children

Comparisons Topiramate versus placebo

Length of Study/ Follow-up 8 week baseline and 16 week treatment phase (8 week titration and 8 week stabilization)

Outcome measures studied The primary efficacy variable was percent reduction in average monthly partial seizure frequency during the double blind phase. Secondary variable included percent reduction in various seizure types and parental global evaluation of seizure activity.

Results Topiramate treated patients: greater median percent reduction from baseline in average monthly partial onset seizure rate than placebo (33.1% versus 10.5%, p=0.034); a greater proportion of responders (>50%, 39% vs. 20%, p=0.08) (>75%, 17% vs. 2%, p=0.019) and better parental global evaluations of concentration or attention (12% versus 2%).

Safety and adverse effects No patients withdrew due to adverse experiences. One topiramate treated patient had a serious treatment emergent event not related to the drug (dehydration)

Does the study answer the question? Topiramate appears to be safe and effective in the treatment of partial onset seizures in children.

Effect due to factor in study? Yes

Consistency of results with other studies? See GRADE

Directly applicable to guideline population? See GRADE

Internal Validity Multi-centre
Patient Characteristics

Characteristic | Group A (n=85) | Group B1 (n=60) | Group B2 (n=58)
--- | --- | --- | ---
Sex, n (%)* | | | |
Men | 35 (41) | 37 (62) | 32 (55)
Women | 50 (59) | 23 (38) | 26 (45)
Race, n (%) | | | |
White | 72 (85) | 50 (83) | 51 (88)
African-American | 3 (11) | 7 (12) | 4 (7)
Asian | 1 (1) | 1 (2) | 0 (0)
Other | 3 (4) | 2 (3) | 3 (5)
Age, y | | | |
Mean (SD) | 34.2 (11.4) | 35.8 (11.4) | 33.6 (11.2)
Range | 14–67 | 13–66 | 15–68
Age at seizure onset, y | | | |
Mean (SD) | 12.2 (12.2) | 12.0 (10.7) | 12.9 (11.7)
Weight, kg | | | |
Mean (SD) | 75.0 (18.4) | 81.2 (20.3) | 75.6 (18.7)
Range | 45–140 | 44–133 | 44–128
Median baseline seizure frequency | | | |
All partial-onset | 13.0 | 11.2 | 13.0
Complex partial | 7.0 | 6.2 | 8.0
Seizure characteristics, n (%) | | | |
Complex partial | 81 (95) | 57 (95) | 57 (98)
Simple partial | 4 (5) | 3 (5) | 1 (2)
Secondarily generalized tonic-clonic | 20 (24) | 14 (23) | 12 (21)

Recruitment
Not reported.

Setting
20 epilepsy centres in the United States.

Interventions/ Test/ Factor being investigated
Zonisamide in three different doses.

Comparisons
Zonisamide with a target dose of 400 mg/day in three different titration doses.

Length of Study/ Follow-up
24 weeks: 4 weeks baseline and 20 weeks treatment which includes titration.

Outcome measures studied
Primary outcome: median % reduction in seizure frequency from the baseline period. Primary comparison is Group A (placebo) and Groups B1 and B2 (receiving zonisamide 400mg/d). Secondary outcomes: comparison over different weeks. And others e.g. response.
Results

The primary population for each analysis was a “modified intent-to-treat” population, including all patients who received at least one dose of study drug during the time period (n = 170).

Primary outcome
Zonisamide at 400 mg/d yielded a median reduction in the frequency of all seizures of 40.5% from baseline for pooled patient groups B1 and B2 over weeks 8 through 12 (n = 98), compared with a median reduction of 9% for patients on placebo (n = 72, p = 0.009).

"Worst case" intent to treat population
The same efficacy outcome is presented using the "worst case" intent to treat population: all patients who were randomly assigned with imputation of seizure frequency beyond the dropout period (n = 203 randomised).

Zonisamide at 400 mg/d yielded a median reduction in the frequency of all seizures of 32.3% from baseline for pooled patient groups B1 and B2 over weeks 8 through 12, compared with a median reduction of 5.6% for patients on placebo (p = 0.016).

Other outcomes
43% (41/98) of patients on zonisamide 400 mg/d had a >=50% reduction in all seizures, a responder rate that was significantly higher than that observed for the placebo group (16/72, 22%) (p = 0.014).

Group A (placebo) patients crossed over to 400 mg/d zonisamide (weeks 17 through 20) had a median reduction of 40.1% in all seizures (p = 0.0003) and 55% in complex partial seizures, compared with their previous seizure rates on placebo (p = 0.0012).

Zonisamide 100 and 200 mg/d.
The median reduction in seizure frequency for the 100-mg/d group (B1, n = 56) was 24.7% for all seizures, compared with 8.3% for the placebo (group A, n = 80, p = 0.038). For complex partial seizures, there was a 33.3% reduction in group B1 compared with 8.6% for placebo (p = 0.0095). The reduction in seizure frequency for the 200-mg/d dosage (group B2, n = 55) was 20.4% for all seizures, compared with 4.0% for placebo (group A, n = 82, p = 0.003). The reduction in complex partial seizures for the 200-mg group (17.2%) did not differ significantly from the 9.5% reduction noted for the placebo group.

Adverse events

Treatment-emergent adverse events reported by >=10% of patients

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Weeks 1-5 Group A (placebo)</th>
<th>Weeks 1-12 Group B1 and B2 (100,200 and 400mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=85</td>
<td>n=118</td>
</tr>
<tr>
<td>Somnolence</td>
<td>13 (15.3)</td>
<td>18 (15.3)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>8 (9.4)</td>
<td>17 (14.4)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>13 (15.3)</td>
<td>17 (14.4)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>12 (14.1)</td>
<td>16 (13.6)</td>
</tr>
<tr>
<td>Nausea or vomiting</td>
<td>15 (17.6)</td>
<td>14 (11.9)</td>
</tr>
<tr>
<td>Ataxia</td>
<td>6 (7.1)</td>
<td>12 (10.2)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>12 (14.1)</td>
<td>11 (9.3)</td>
</tr>
<tr>
<td>Headache</td>
<td>11 (12.9)</td>
<td>11 (9.3)</td>
</tr>
</tbody>
</table>

Safety and adverse effects

Does the study answer the question?
Yes. Zonisamide is effective as an adjunctive agent for refractory partial-onset seizures. The minimal effective dosage was 100mg/d, but 400mg/d was the most effective dosage.

Effect due to factor in study?
Yes. The study had 85% power to detect a difference between groups in the primary outcome.

Consistency of results with other studies?

29 July 2010 Page 37 of 306
Internal Validity

The study enrolled patients with epilepsy who had refractory partial-onset seizures (complex partial or simple partial with or without secondary generalization to tonic-clonic seizures.) Directness of comparisons to the intervention group.

Faught E; Wilder BJ; Ramsay RE; Reife RA; Kramer LD; Pledger GW; Karim RM;
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group

Ref ID 4699

Study Type: Randomised Controlled Trial
Funding: Robert Wood Johnson

Number of participant: 181 were randomised: placebo (n=45), 200 mg/day (n=45), 400 mg/day (n=45), 600 mg/day (n=46)

Inclusion/Exclusion Criteria:
Inclusion: History of partial onset seizures with EEG verification; experienced 12 partial seizures during 12 week baseline period preceding the double blind study phase while maintained on therapeutic AEDs. Age 18-65. Exclusion: Progressive neurological disease, status, child-bearing potential, alcohol or drug abuse, psychiatric disorder, nephrolithiasis, noncompliance history, abnormal baseline lab tests.

Patient Characteristics:
Gender: Male 143, Female 38
Race: White 159, Black 21, Other 1
Age (yr)
Mean 36.9
Range 19-68

Recruitment: Unknown

Setting: Multicentre - USA

Interventions/ Test/ Factor being investigated: Comparison of three doses of topiramate (200, 400 and 600 mg) with the placebo.

Comparisons: Comparison of three doses of topiramate (200, 400 and 600 mg/day) and placebo as adjunctive therapy in patients with refractory partial onset epilepsy

Length of Study/ Follow-up: 12 week baseline and 16 week double blind phase divided into 4 week titration segment and a 12 week stabilization period

Outcome measures studied:
Primary: percent reduction in average monthly seizure rate in the double blind phase relative to the baseline phase.
Secondary: percent treatment responders (those with greater than or equal to 50% reduction in seizure rate)

Results:

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>200 mg</th>
<th>400 mg</th>
<th>600 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>% seizure reduction</td>
<td>Median</td>
<td>13.1</td>
<td>29.6</td>
<td>47.8</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
<td>0.051</td>
<td>0.007</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Treatment responders:
Number: 8/45, 12/45, 21/45, 21/46
Percent: 18%, 27%, 47%, 46%

Number withdrawn due to adverse events:
3/45 (7%), 2/45 (4%), 4/45 (9%), 6/46 (13%)

Although the table in the study says 45 in order to be 13% and match the data elsewhere in the study.

29 July 2010
Toprimate may be a promising AED for adjunctive therapy in refractory partial onset seizures

Safety and adverse effects
CNS events were the most common adverse events including dizziness, fatigue, abnormal thinking, somnolence, headache and ataxia. Discontinuations due to adverse events were: 7% placebo; 4% 200mg; 9% 400 mg and 13% 600 mg. No remarkable abnormal clinical lab findings

Does the study answer the question?
Toprimate may be a promising AED for adjunctive therapy in refractory partial onset seizures

Effect due to factor in study?
Yes

Consistency of results with other studies?
See GRADE

Directly applicable to guideline population?
See GRADE

Internal Validity
Multi centre

French JA; Kugler AR; Robbins JL; Knapp LE; Garofalo EA;

Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures

Ref ID 4589  2003

Study Type  Randomised Controlled Trial  Funding Pfizer. Inc.

Number of participant
n=455 randomized (n=100 in placebo group, n=88 in PGB 50mg/day group, n=88 in PGB 150mg/day group, n=90 in 300mg/day group and n=89 in 600mg/day group)

Inclusion/Exclusion Criteria
Inclusion criteria: aged 12 to 70 years, experienced at least three observable partial seizures in the month prior to screening and six partial seizures in the 8 weeks between screening and baseline; their disease was refractory to at least two AEDs at maximally tolerated doses; and currently receiving at least one but no more than three AEDs.
Exclusion criteria: seizures caused by an underlying medical illness, absence seizures, Lennox-Gastaut syndrome, and status epilepticus in the past year. Patients who had received gabapentin within a week of screening were also excluded. Patients with clinically relevant medical illness were excluded. Women were not pregnant or breastfeeding and were reliably using barrier or hormonal contraception.

Patient Characteristics

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>Placebo</th>
<th>Pregabalin dose (mg/d)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>50</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>n = 100</td>
<td>n = 88</td>
</tr>
<tr>
<td></td>
<td>n = 86</td>
<td>n = 90</td>
</tr>
<tr>
<td>Age, mean(SD) (11.1)</td>
<td>39.5 (12.6)</td>
<td>38.9 (11.0)</td>
</tr>
<tr>
<td>Women, n (%) (51.7)</td>
<td>48 (48.0)</td>
<td>49 (55.7)</td>
</tr>
<tr>
<td>Race, white, n (%) (83.1)</td>
<td>84 (84.0)</td>
<td>76 (86.4)</td>
</tr>
<tr>
<td>Weight, mean(SD), kg (21.6)</td>
<td>80 (19.7)</td>
<td>79 (19.4)</td>
</tr>
<tr>
<td>28-Day seizure rate Mean(SD) (26.9)</td>
<td>22.3 (42.1)</td>
<td>27.4 (50.2)</td>
</tr>
<tr>
<td>Epilepsy duration, mean(SD), y (13.7)</td>
<td>24 (10)</td>
<td>25 (11.8)</td>
</tr>
<tr>
<td>Partial seizures with secondary generalization n (%) (32.6)</td>
<td>26 (26.0)</td>
<td>33 (37.5)</td>
</tr>
<tr>
<td>28-Day seizure rate Mean (SD)</td>
<td>4.3 (9.4)</td>
<td>1.8 (2.4)</td>
</tr>
</tbody>
</table>

29 July 2010  Page 39 of 306
Concurrent AED, n (%)

<table>
<thead>
<tr>
<th>1 AED</th>
<th>2 AED</th>
<th>3 AED</th>
</tr>
</thead>
<tbody>
<tr>
<td>26 (26.0)</td>
<td>48 (48.0)</td>
<td>24 (24.0)</td>
</tr>
<tr>
<td>30 (34.1)</td>
<td>39 (44.3)</td>
<td>18 (20.5)</td>
</tr>
<tr>
<td>27 (31.4)</td>
<td>44 (51.2)</td>
<td>15 (17.4)</td>
</tr>
<tr>
<td>30 (33.3)</td>
<td>46 (51.1)</td>
<td>14 (15.6)</td>
</tr>
<tr>
<td>22</td>
<td>49</td>
<td>18</td>
</tr>
</tbody>
</table>

(24.7) (55.1) (20.2)

Recruitment

Not reported.

Setting

76 centres in the United States and Canada.

Interventions/ Test/ Factor being investigated

Pregabalin in doses of 50, 150, 300, and 600 mg/day.

Comparisons

Comparisons are made between all the above doses of PGB and placebo, as add-on therapy to currently used AEDs.

Length of Study/ Follow-up

20 weeks: 8 week baseline period and 12 week treatment period.

Outcome measures studied

The primary outcome was reduction in seizure frequency as measured by response ratio (Rratio). Efficacy was also assessed on basis of responder rate (>=50% reduction)

Results

Primary outcome

Seizure reduction

Seizure reduction for all partial seizures was lower in the pregabalin 150-, 300-, and 600-mg/d groups compared with the placebo group at endpoint (p <= 0.0001). There was a percentage reduction in seizure frequency between baseline and endpoint of 7% (placebo; n=100), 12% (50 mg/d; n=88), 34% (150 mg/d; n=86), 44% (300 mg/d; n=90), and 54% (600 mg/d; n=89). Seizure reduction for all partial seizures was lower in the pregabalin 150-, 300-, and 600-mg/d groups compared with the placebo group at endpoint (p<=0.0001). There was a percentage reduction in seizure frequency between baseline and endpoint of 7% (placebo; n=100), 12% (50 mg/d; n=88), 34% (150 mg/d; n=86), 44% (300 mg/d; n=90), and 54% (600 mg/d; n=89).

Secondary outcomes

Seizure reduction by responder (>=50% reduction)

The responder rate was greater than placebo in the pregabalin 150 (p=0.006), 300 (p=0.001), and 600 (p=0.001) mg/d groups and was also dose related. The analyses of RRatio (p<=0.0001) and responder rate (p<=0.001) indicate that pregabalin exhibits a dose-response relationship.

Reduction by seizure type

In the analysis of seizure type, the reductions in simple partial seizures, complex partial seizures, and seizures without generalization were similar to those observed for all partial seizures across dose groups, as measured by RRatio. Too few patients experienced partial seizures with generalization during the baseline and treatment periods to provide meaningful data. However, the number of partial-onset seizures with generalization decreased in the pregabalin 300- and 600-mg/d groups.

Adverse events

<table>
<thead>
<tr>
<th>Placebo</th>
<th>Pregabalin dose (mg/d)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>300</td>
<td>50</td>
</tr>
<tr>
<td>600</td>
<td>150</td>
</tr>
<tr>
<td>n=89</td>
<td>n=100</td>
</tr>
<tr>
<td>Any AE</td>
<td>74 (74.0)</td>
</tr>
<tr>
<td>Incidence</td>
<td>59 (67.0)</td>
</tr>
<tr>
<td>(88.8)</td>
<td>61 (70.9)</td>
</tr>
<tr>
<td>AEs of severe intensity</td>
<td>76 (84.4)</td>
</tr>
<tr>
<td>Incidence</td>
<td>7 (7.8)</td>
</tr>
<tr>
<td>(14.6)</td>
<td>13</td>
</tr>
<tr>
<td>Dizziness Incidence</td>
<td>9 (9.0)</td>
</tr>
<tr>
<td>(9.0)</td>
<td>8 (9.1)</td>
</tr>
<tr>
<td>14 (16.3)</td>
<td>28 (31.1)</td>
</tr>
<tr>
<td>38</td>
<td></td>
</tr>
</tbody>
</table>
Yes. Adjunctive therapy with pregabalin 150, 300, and 600 mg/d, given in twice-daily doses without titration, is significantly effective in the treatment of patients with partial seizures.

Safety and adverse effects

There is a dose-related increase in the incidence of discontinuation due to adverse events in the 600 and 300mg/day groups compared with placebo. Significant weight gain is a relatively common adverse effect.

Does the study answer the question?

Yes. Adjunctive therapy with pregabalin 150, 300, and 600 mg/d, given in twice-daily doses without titration, is significantly effective in the treatment of patients with partial seizures.

Effect due to factor in study?

Yes. The sample size was derived from a power calculation which was based on results from earlier trials of pregabalin.

Consistency of results with other studies?

This study population comprised patients with epilepsy all of whom suffered from partial seizures.

Internal Validity

French JA; Mosier M; Walker S; Sommerville K; Sussman N;

A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort

Ref ID 4752

Study Type Randomised Controlled Trial

Funding Marion Merrell Dow Inc.

Number of participant n=182 (n=90 in placebo group and n=92 in the vigabatrin group.)

Inclusion/Exclusion Criteria

Inclusion criteria: age 18 to 60 years with a diagnosis of complex partial seizures, with or without secondary generalization; seizures unsatisfactorily controlled with AEDs; at least six documented complex partial seizures during the last 8 weeks of a 12-week period; at least one, but not more than two AEDs; prior treatment with phenytoin or carbamazepine; must not have experienced a seizure-free interval of 28 days or more over the last 8 weeks; MRI, demonstrated an abnormal EEG.

Exclusion criteria: treatable seizure etiology (e.g., metabolic or neoplastic cause) or progressive neurologic disorders; experienced more than one episode of status
The 182 patients (80 men and 102 women) included in the analyses ranged in age from 18 to 60 years (mean, 34 years). The majority of patients (113, 62%) received two concurrent antiepilepsy drugs. No significant differences were observed between treatment groups for any baseline demographic or clinical characteristic or in the use of any concomitant antiseizure medication.

**Patient Characteristics**
The 182 patients (80 men and 102 women) included in the analyses ranged in age from 18 to 60 years (mean, 34 years). The majority of patients (113, 62%) received two concurrent antiepilepsy drugs. No significant differences were observed between treatment groups for any baseline demographic or clinical characteristic or in the use of any concomitant antiseizure medication.

**Recruitment**
Not reported.

**Setting**
Multiple centres in the United States.

**Interventions/ Test/ Factor being investigated**
Vigabatrin 3 g/day.

**Comparisons**
Comparison is between vigabatrin 3g/day and placebo as adjunctive therapy to currently used AEDs.

**Length of Study/ Follow-up**
28 weeks: 12 week evaluation period, 4 week titration phase and 12-week treatment phase.

**Outcome measures studied**
Primary outcome: monthly freq complex partial seizures plus partial seizures with secondary gen during the last 8 weeks of the treatment phase vs. the last 8 weeks of the baseline phase.
Secondary outcomes: response rate, freq seizures, global eval.

**Results**
Primary outcome
There was a significant lower frequency of seizures (complex seizures plus partial seizures with secondary generalization) during the last 8 weeks of the study for patients receiving vigabatrin than for those receiving placebo. The median monthly frequency was reduced by three seizures per 28 days in the vigabatrin group (baseline, 8.3; end of study, 5.3) versus 0.8 seizures per 28 days in the placebo group (baseline, 8.3; end of study, 7.5) (p = 0.0002).

Percent change in total seizure frequency

<table>
<thead>
<tr>
<th>Percent change in seizures</th>
<th>Placebo N (%)</th>
<th>Vigabatrin N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50% increase</td>
<td>14 (15.6)</td>
<td>4 (4.4)</td>
</tr>
<tr>
<td>1-50% increase</td>
<td>21 (23.3)</td>
<td>14 (15.2)</td>
</tr>
<tr>
<td>0-49% reduction</td>
<td>38 (42.2)</td>
<td>34 (36.9)</td>
</tr>
<tr>
<td>50-99% reduction</td>
<td>16 (17.8)</td>
<td>34 (36.9)</td>
</tr>
<tr>
<td>100% reduction</td>
<td>1(1.1)</td>
<td>6 (6.5)</td>
</tr>
</tbody>
</table>

Overall, median percent reduction in seizures (1B + 1C) was 7.5% for the placebo group, versus 39.5% in the vigabatrin group (p > 0.001).

Secondary outcomes
Therapeutic success (>=50% reduction) was attained in 40 of the vigabatrin patients (43%) compared with 17 of those treated with placebo (19%) (p < 0.001). An analysis of response by seizure type showed the frequency of complex partial seizures at the end of study was significantly lower for vigabatrin-treated patients. The median monthly rate of these seizures was reduced by 3.5 seizures in the vigabatrin group and by 1.0 seizure in the placebo group (5.0 seizures per 28 days on vigabatrin versus 7.0 seizures per 28 days on placebo at end of study; p < 0.001). The median monthly rate of partial seizures with secondary generalization was reduced by 1.5 seizures per 28 days in the vigabatrin group and was unaffected by placebo therapy (2.5 seizures per 28 days on vigabatrin versus 1.5 seizures per 28 days on placebo at end of study; p = 0.3881).

Percent change in seizures for IB and IC subtypes (complex partial seizures and
Yes. Vigabatrin is more effective than placebo as add-on therapy.

Adverse events
The most common treatment-related adverse events were drowsiness (vigabatrin group, 29.3%; placebo group, 13.3%), light-headedness (vigabatrin group, 21.7%; placebo group, 14.4%), headache (vigabatrin group, 21.7%; placebo group, 16.7%), fatigue (vigabatrin group, 19.6%; placebo group, 13.3%), and tremor (vigabatrin group, 13.0%; placebo group, 4.4%).

Nine patients (2 placebo [2%]; 7 vigabatrin [7.6%]) discontinued from the study because of adverse events. Other treatment-related events that occurred in 10% or more of patients in either group were depression, vision abnormalities, nystagmus, and paresthesia.

Safety and adverse effects
Depression was the only behavioural change reported consistently during vigabatrin treatment. One patient on vigabatrin committed suicide and another experienced a behaviour abnormality, consisting of hyperactivity, paranoia, and grandiose thoughts, which resolved when vigabatrin was discontinued.

Does the study answer the question?
Yes. Vigabatrin is more effective than placebo as add-on therapy.

Effect due to factor in study?
Unsure. No statistical power calculation performed.

Consistency of results with other studies?

Directly applicable to guideline population?
All patients in this study had complex partial seizures which were difficult to control with established AED therapy.

Internal Validity

Gilliam F; Vazquez B; Sackellares JC; Chang GY; Messenheimer J; Nyberg J; Risner ME; Rudd GD;

An active-control trial of lamotrigine monotherapy for partial seizures

Ref ID 4719

Study Type Randomised Controlled Trial

Funding Not reported.

Number of participant n=156 (n=76 in LTG group and n=80 in VPA group)

Inclusion/Exclusion Criteria Inclusion criteria: >=13 years, partial seizures with or without sec. gen. tonic-clonic seizures, unresponsive to at least one AED, at least four seizures every 4 weeks during the baseline phase, no more than 20 consecutive seizure-free days during baseline.

Patient Characteristics Intent to treat population patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>LTG n=76</th>
<th>VPA n=80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y, mean (range)</td>
<td>37(13-73)</td>
<td>36(14-71)</td>
</tr>
</tbody>
</table>
Weight, kg, mean (range)                 78(49-137) 70(43-121)
Sex, n(%)                              
Male                                   33(43) 32(40)
Race, n (%)                            
White                                  52(68) 55(69)
Black                                  8(11) 11(14)
Other                                  16(21) 14(17)
Baseline seizure frequency             
Median/28 days (range)                 9(1-737) 10(3-226)
Presenting seizure type* n(%)          
Simple partial                          31(41) 35(44)
Complex partial                        64(84) 71(89)
Sec. gen.                              38(50) 27(34)
No. previous AEDs, mean (range)        4.4(1-13) 4.6(1-14)
AED at baseline, n(%)                  
Carbamazepine                          48(63) 46(58)
Phenytoin                               28(37) 34(42)

Recruitment
Not reported.

Setting
36 centres in United States.

Interventions/ Test/ Factor being investigated
Lamotrigine (LTG) 150 to 250mg twice daily as monotherapy.

Comparisons
The comparison is between LTG and valproic acid (VPA: target low dose of 500mg twice daily).

Length of Study/ Follow-up
28 weeks: 8 week baseline phase and 20 weeks treatment phase.

Outcome measures studied
Primary: proportion of pts meeting escape criteria (1) doubling of avg monthly seizure rate, 2) doubling of highest consecutive 2-day seizure rate 3) new more severe seizure type, 4) clinically sig. prolongation of gen. tonic-clonic seizure.)

Results
Results of primary efficacy analyses
N(%) of completed patients

|                         | Total | Completed | time
|-------------------------|-------|-----------|------
|                         | monotherapy | Escaped | Withdrawn |
| Median time to escape, d |        |          |      |
| Per protocol analysis  |       |          |      |
| LTG                     | 50    | 28(56)*  | 22(44) | NA   | 168* |
| VPA                     | 64    | 13(20)   | 51(80) | NA   | 57   |
| Intent to treat analysis|       |          |      |
| LTG                     | 76    | 28(37)*  | 32(42) | 16(21) | NA   |
| VPA                     | 80    | 13(16)   | 55(69) | 12(15) | NA   |

*p<=0.005 versus VPA.

Adverse events

Intent to treat population: adverse experiences (AE)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Monotherapy period LTG</th>
<th>Monotherapy period VPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=43, n(%)</td>
<td>n=44, n(%)</td>
<td></td>
</tr>
<tr>
<td>Patients with &gt;=1 AE</td>
<td>26(60)</td>
<td>19(43)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3(7)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>3(7)</td>
<td>1(2)</td>
</tr>
<tr>
<td>Headache</td>
<td>3(7)</td>
<td>6(14)</td>
</tr>
</tbody>
</table>
Yes. Results show that lamotrigine therapy is effective in adults with partial seizures. The proportion of patients who successfully completed 12 weeks of LTG monotherapy was more than two and half times greater than the proportion of patients completing monotherapy treatment with a low dose of VPA.

Safety and adverse effects
The most common AEs during LTG monotherapy were vomiting, headache, dizziness, nausea, dyspepsia, and coordination abnormalities (7% to 9%).

Does the study answer the question?
Yes. Results show that lamotrigine therapy is effective in adults with partial seizures.

Effect due to factor in study?
No. The study did not perform a statistical power calculation. A low dose of valproic acid was chosen as the control.

Consistency of results with other studies?
All patients were diagnosed with partial seizures (simple partial, complex partial, or secondarily generalized).

Directly applicable to guideline population?
All patients were diagnosed with partial seizures (simple partial, complex partial, or secondarily generalized).

Internal Validity
Gil-Nagel A;Lopes-Lima J;Almeida L;Maia J;Soares-da-Silva P;Investigators Study Group.;

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures
Ref ID 5082 2009 Nov

Study Type Randomised Controlled Trial
Funding BIAL (Portela & Ca SA).

Number of participant
n=252. Placebo n=87; ESL 800mg n=85; ESL 1200mg n=80.

Inclusion/Exclusion Criteria
Inclusion:
aged 18 or over;
general good health, other than epilepsy;
diagnosed with simple or complex partial seizures (with or without secondary generalisation) for a minimum of 12 months prior to screening;
noticed at least four partial-onset seizures in the two 4-week periods prior to screening as well as during each of the two 4-week periods of the 8-week baseline period;
treated with one to two concomitant AEDs in a stable dose regimen for at least 2 months prior to screening.
Exclusion:
If at time specified had: an uncontrolled, relevant medical disorder;
visual field loss caused by vigabatrin use (at least 1 year);
Simple partial seizures without motor symptoms;
primary generalised epilepsy;
rapidly progressive neurological disorder;
status epilepticus;
cluster seizures (within 3 months);
history of seizures of psychogenic origin (within 2 years);
history of schizophrenia or suicide attempts;
a known hypersensitivity to CBZ or OXC, or chemically-related substances;
Receiving OXC, felbamate, or a benzodiazepine except when used chronically as an AED;
Pregnant or breastfeeding women.

Patient Characteristics
Mean age placebo 37.7 +/-12.07 vs ESL 800mg 36.8 +/-10.65 and ESL 1200mg 36 +/-11.43
Males: placebo 43 (49.4) vs ESL 800mg 35 (41.2); ESL 1200mg 35 (43.8).
Ethnic origin: hispanic 54 (62.1) vs 52 (61.2) vs 53 (66.3); Caucasian 33 (37.9) vs 32

29 July 2010 Page 45 of 306
Seizure types: simple partial, complex partial, secondary generalised epilepsy and unclassified.

Types of AEDs:
Carbamazepine, valproic acid, phenytoin, levetiracetam, topiramate, lamotrigine, phenobarbital, clobazam, primidone, clonazepam.

**Recruitment**
Not reported.

**Setting**
39 sites in Mexico, Portugal and Spain between Dec

**Interventions/ Test/ Factor being investigated**
Eslicarbazepine 800mg and 1200mg and placebo once daily.

**Comparisons**
Comparisons between two doses and placebo.

**Length of Study/ Follow-up**
No follow-up.

**Outcome measures studied**
Proportion with at least 50% reduction in seizure frequency, seizure freedom, seizure exacerbation; incidence of adverse events, withdrawal due to adverse events.

**Results**
Placebo vs eslicarbazepine 800mg vs eslicarbazepine 1200mg:

At least 50% reduction in seizure frequency (titration and maintenance): placebo 22.6%, 800mg 34.5%; 1200mg 37.7%

Proportion of seizure free (titration and maintenance): placebo 1.2%, 800mg 4.8%; 1200mg 3.9%

Exacerbation in seizure frequency >/=25% placebo 22.5; 800mg 16.7%, 1200mg 13%

Adverse events (over 10%) n (%):
- dizziness 9 (10.3) vs 16 (18.8) vs 24 (30)
- somnolence 8 (9.2) vs 11 (12.9) vs 11 (13.8)
- headache 10 (11.5) vs 5 (5.9) vs 8 (10)
- nausea 1 (1.1) vs 5 (5.9) vs 8 (10)

Withdrawal due to treatment emergent adverse events:
6 (6.9) vs 7 (9.2) vs 9 (11.3) from abnormal coordination, dizziness and nausea.

**Safety and adverse effects**
See results for adverse events over 10%
Serious TEAEs: placebo 0% vs 800mg 0% vs 1200mg 1.3% - the one case in the eslicarbazepine 1200mg group was cerebellar syndrome and led to study discontinuation.
No deaths.

**Does the study answer the question?**
Yes.

**Effect due to factor in study?**
Yes.

**Consistency of results with other studies?**
Direct.

**Directly applicable to guideline population?**
Direct.

**Internal Validity**
Glauser TA;Ayala R;Elterman RD;Mitchell WG;Van Orman CB;Gauer LJ;Lu Z;Study Group.;
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures.[see comment]
Study Type: Randomised Controlled Trial

Number of participant: n=198 (n=101 in the LEV group and n=97 in the placebo group)

Inclusion/Exclusion Criteria:
Inclusion criteria: children aged 4 to 16 years, inclusive, and weighing 13.5 to 80 kg (30 to 177 lb), partial seizures (including the subtypes of simple, complex, and partial seizures evolving to secondarily generalized seizures) that at the time of enrollment were inadequately controlled with one or two concomitant AEDs, diagnosis made at least 6 months before the screening visit, at least four partial seizures during the 4 weeks preceding the screening visit and at least four partial seizures during each 4-week interval of the 8-week baseline period.

Exclusion criteria: pregnant females; a treatable seizure etiology; epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease; seizures too close together to accurately count; status epilepticus that required hospitalization during the 3 months before the screening visit; history of or the presence of pseudoseizures; current diagnosis of Lennox-Gastaut syndrome; a cardiovascular, respiratory, hepatic, renal, gastrointestinal, hematologic, oncologic, psychiatric, or progressive neurologic disorder likely to have an impact on the outcome of the trial.

Patient Characteristics:
Demographic and baseline characteristics (intent-to-treat population)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Levetiracetam, n=101</th>
<th>Placebo, n=97</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Male</td>
<td>53.5</td>
<td>47.4</td>
</tr>
<tr>
<td>% White</td>
<td>73.3</td>
<td>67.0</td>
</tr>
<tr>
<td>Age, median (range), y</td>
<td>10.4 (4–17)</td>
<td>9.7 (3–17)</td>
</tr>
<tr>
<td>% Receiving concomitant AEDs (in &gt;10% of patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>34.7</td>
<td>38.1</td>
</tr>
<tr>
<td>Topiramate</td>
<td>28.7</td>
<td>32.0</td>
</tr>
<tr>
<td>Valproate</td>
<td>25.7</td>
<td>28.9</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>22.8</td>
<td>20.6</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>12.9</td>
<td>10.3</td>
</tr>
<tr>
<td>Partial seizure frequency, median (range)</td>
<td>4.7 (0–696)</td>
<td>5.3 (0-467)</td>
</tr>
</tbody>
</table>

Recruitment: Not reported.

Setting: 60 centres in the United States and Canada.

Interventions/ Test/ Factor being investigated: Levetiracetam up to 60mg/kg/day as adjunctive therapy to currently used AEDs.

Comparisons: The comparison is between levetiracetam up to 60mg/kg/day and placebo as adjunctive therapy to currently used AEDs.

Length of Study/ Follow-up: 22 weeks: 8 week baseline, 4 weeks titration and 10 weeks maintenance period.

Outcome measures studied: Primary outcome: partial seizure frequency (including simple, complex, and secondarily generalized partial seizures) per week during treatment period. Secondary outcomes: responder rates, % reduction in partial seizure freq, % reduction by cat (>25% etc)

Results:

Levetiracetam resulted in a reduction in partial-onset seizure frequency per week, and % reduction over placebo during the treatment period was 26.8% (p=0.0002; 95% CI 14% to 37.6%).
The median percentage reduction from baseline during the treatment period in weekly partial seizure frequency was higher in the levetiracetam group compared with the placebo group (43.3% vs 16.3%; Kruskal–Wallis, p=0.0001).

Secondary outcomes

Categorical summary of percent reduction
Reduction from baseline in partial seizure frequency during treatment favored levetiracetam over placebo (Mantel–Haenszel, \( p=0.001 \)), with 24.8% and 12.9% of levetiracetam-treated patients achieving reductions of 50% to less than 75% and 75% to less than 100%, compared with 14.4% and 4.1%, for placebo.

Absolute change in seizure frequency
The median absolute change from baseline in seizure frequency per week during the treatment period was -1.6 seizures/week in the levetiracetam group vs -0.7 seizures/week for placebo (Kruskal–Wallis, \( p=0.003 \)).

Adverse events

Incidence (%) of treatment-emergent adverse events by COSTART body system and by individual adverse event*

<table>
<thead>
<tr>
<th>COSTART body system†</th>
<th>Levetiracetam, % (n=101)</th>
<th>Placebo, % (n= 97)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a whole</td>
<td>58.4</td>
<td>64.9</td>
</tr>
<tr>
<td>Digestive</td>
<td>36.6</td>
<td>38.1</td>
</tr>
<tr>
<td>Hematologic and lymphatic</td>
<td>5.9</td>
<td>2.1</td>
</tr>
<tr>
<td>Metabolic and nutritional</td>
<td>4.0</td>
<td>10.3</td>
</tr>
<tr>
<td>Nervous</td>
<td>58.4</td>
<td>47.7</td>
</tr>
<tr>
<td>Respiratory</td>
<td>30.0</td>
<td>28.9</td>
</tr>
<tr>
<td>Skin and appendages</td>
<td>9.9</td>
<td>13.4</td>
</tr>
<tr>
<td>Special senses</td>
<td>12.9</td>
<td>9.3</td>
</tr>
<tr>
<td>Urogenital system</td>
<td>9.9</td>
<td>9.3</td>
</tr>
<tr>
<td>Specific adverse event</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>23</td>
<td>11</td>
</tr>
<tr>
<td>Accidental injury</td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>Vomiting</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>Anorexia</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Hostility</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>Cough increased</td>
<td>11</td>
<td>7</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Nervousness</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Asthenia</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Personality disorder</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Dizziness</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Emotional lability</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Pain</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Agitation</td>
<td>6</td>
<td>1</td>
</tr>
</tbody>
</table>

* Adverse events had to occur in at least 5% of levetiracetam-treated patients and be more frequent than in placebo patients.
† Investigator term describing each adverse event was coded to a body system and preferred term using the COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms) dictionary (version 5).

Five patients randomized to levetiracetam (5.0%) discontinued treatment because of an adverse event. Eight patients (7.9%) in the levetiracetam group and nine patients (9.3%) in the placebo group experienced a serious adverse event.

Most adverse events were mild to moderate.

Safety and adverse effects

Does the study answer the question?

Yes. The results demonstrated that levetiracetam was efficacious and well tolerated at a target dose of 60mg/kg/day when given as adjunctive therapy in pediatric patients with inadequately controlled partial seizures.
Effect due to factor in study? Yes. The study had sufficient power to detect a 20% difference in seizure reduction between the placebo and levetiracetam groups.

Consistency of results with other studies? Those enrolled in the trial were children aged 4 to 16 years with partial seizures including the subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures.

Internal Validity

False. The study had sufficient power to detect a 20% difference in seizure reduction between the placebo and levetiracetam groups.

Consistency of results with other studies? Those enrolled in the trial were children aged 4 to 16 years with partial seizures including the subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures.

Directly applicable to guideline population? Yes. The study had sufficient power to detect a 20% difference in seizure reduction between the placebo and levetiracetam groups.

Consistency of results with other studies? Those enrolled in the trial were children aged 4 to 16 years with partial seizures including the subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures.

Internal Validity

Glauser TA;Nigro M;Sachdeo R;Pasteris LA;Weinstein S;bou-Khalil B;Frank LM;Grinspan A;Guarino T;Betts D;Kerrigan J;Geoffroy G;Mandelbaum D;Jacobs T;Mesenbrink P;Kramer L;D’Souza J;

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group

Ref ID 4603

Study Type Randomised Controlled Trial

Funding Novartis Pharmaceuticals Corporation

Number of participant 267 patients were randomised; oxycarbazepine (OXC) = 138 and placebo = 129.

Inclusion/Exclusion Criteria Inclusion:8 partial seizures during the 56 day baseline phase, had serum sodium concentration of at least 130 mmol/l, positive EEG, no progressive lesion, no possibility of pregnancy. Exclusion: status 6 months preceding; noncompliance; a CV, respiratory, hepatic, renal, GI, haematological, oncologic, substance abuse, psychiatric or progressive neurologic disorder; participation in other trial of OXC

Patient Characteristics Sex

<table>
<thead>
<tr>
<th></th>
<th>OXC(n=138)</th>
<th>Placebo (n=129)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>51%(70)</td>
<td>55%(71)</td>
</tr>
<tr>
<td>Female</td>
<td>49%(68)</td>
<td>45%(58)</td>
</tr>
</tbody>
</table>

Race

<table>
<thead>
<tr>
<th></th>
<th>OXC(n=138)</th>
<th>Placebo (n=129)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>87%(120)</td>
<td>87%(112)</td>
</tr>
<tr>
<td>Other</td>
<td>13%(18)</td>
<td>13%(17)</td>
</tr>
</tbody>
</table>

Age, y mean (range)

<table>
<thead>
<tr>
<th></th>
<th>OXC(n=138)</th>
<th>Placebo (n=129)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11%(3-17)</td>
<td>11%(3-17)</td>
<td></td>
</tr>
</tbody>
</table>

Weight, kg mean (range)

<table>
<thead>
<tr>
<th></th>
<th>OXC(n=138)</th>
<th>Placebo (n=129)</th>
</tr>
</thead>
<tbody>
<tr>
<td>44%(16-130)</td>
<td>44%(16-89)</td>
<td></td>
</tr>
</tbody>
</table>

Recruitment Unknown

Setting Multi centre -47 centres

Interventions/ Test/ Factor being investigated Evaluate the safety and efficacy of OXC as adjunctive therapy in children 3-17 years of age with inadequately controlled partial seizures.

Comparisons OXC vs. placebo

Length of Study/ Follow-up 112 days

Outcome measures studied Primary: percentage of reduction from baseline in partial seizure frequency per 28 days during double blind treatment Secondary: response to treatment and change in other seizure types

Results Patients treated with OXC experienced a significantly greater median percent reduction from baseline in partial seizure frequency than patients treated with placebo (p=0.0001; 35% vs. 9% respectively). Forty one percent of patients treated with OXC experienced a 50% or greater reduction from baseline in partial seizure frequency per 28 days compared with 22% of patients treated with placebo (p=0.0005).

Safety and adverse effects Ninety one percent of the group treated with OXC and 82% of the group treated with placebo report one or more adverse event; vomiting, somnolence, dizziness and nausea occurred more frequently in the group treated with OXC (twofold or greater)
OXC adjunctive therapy is safe, effective and well tolerated in children with partial seizures.

Does the study answer the question? Yes

Effect due to factor in study? Yes

Consistency of results with other studies? See GRADE

Directly applicable to guideline population? See GRADE

Internal Validity Multi-centre

Guberman A; Neto W; Gassmann-Mayer C;

Low-dose topiramate in adults with treatment-resistant partial-onset seizures

Ref ID 4747

Study Type Randomised Controlled Trial

Funding Industry: Johnson and Johnson Pharmaceutical

Number of participants 263 patients were enrolled. 171 were in Topiramate groups, and 92 to placebo.

Inclusion/Exclusion Criteria Age 18 to 65 years old, weigh >45 kg, had at least 3 partial-onset seizures, with or without secondary generalisation within the 4 week baseline. These seizures could not be clustered, patients had to be receiving Carbamazepine with and without another AED in stable doses for at least 30 days before entering the baseline phase. Women had to be postmenopausal or incapable of childbearing; women of childbearing potential had to be practising a medically acceptable methods of birth control.

Exclusion criteria: treatable cause of seizures, progressive neurological disorder, or primary generalised seizure. Documented history of status epilepticus during the past 3 months were also excluded.

Patient Characteristics Age, mean (range): Placebo: 36(18-67), Topiramate: 37 (18-64)

Female (%): Placebo: 50%, Topiramate: 54%

Time since diagnosis, year, median (range): Placebo: 18 year (0.4 -42), Topiramate: 19 year (0.2 to 54)

Carbamazepine dose, median (range): Placebo: 1200mg/day (200-1800), Topiramate: 100mg/day (100-2400)

Number of AEDS on baseline (1AED/2AED): Placebo: 42%/58%, Topiramate: 45%/55%

Baseline seizure type (simple partial/complex partial/secondary generalised):

Placebo: 29%/74%/39%, Topiramate: 27%/77%/32%

Monthly seizure frequency, median (range):

Partial onset: Placebo: 7 (2-462), Topiramate: 7 (2-184)

Secondary generalised: Placebo: 0 (0-27), Topiramate: 0 (0-37)

Number of patients with secondary generalised seizures:: Placebo: 36 Topiramate: 55

Recruitment Not stated

Setting Multicentre trial, mainly European centres

Interventions/Test/ Factor being investigated g/day, dose administered twice daily. In one group Topiramate was titrated to 200 mg/day over 8 weeks (25mg/day starting dose, with a 25mg/week increment) and in the other it was done over 4 weeks (50 mg/day starting dose with 50mg/week increment)

Comparisons Active treatment vs. placebo addition to stabilised AED regimen

Length of Study/Follow-up 12 weeks plus 4 weeks baseline.
Outcome measures studied

Primary outcome measure: median % reduction from baseline in monthly partial onset seizure frequency for the combine Topiramate groups vs. placebo
Secondary outcome measure: percent of patients who were treatment responders (50% seizure reduction)

Results

Proportion of seizure free participants:

Week 1-12 (double blind period):
Placebo: 51 (2%) All topiramate: 168 (6%)**

Week 9-12 (Maintenance period):
Placebo: 79 (8%) All topiramate: 30/150 (20%)**

Proportion of patients experiencing at least a 50% reduction in seizure frequency (i.e. responders):

Week 1-12 (double blind period):
Placebo: 22/91 (24%) Topiramate 25/25: 33/85 (39%)* Topiramate 50/50: 42/83**
All topiramate: 75/168 (45%)**

Week 9-12 (Maintenance period):
Placebo: 29/88 (33%) Topiramate 25/25: 49/76 (64%)** Topiramate 50/50: 38/74 (51%)* All topiramate: 87/150 (58%)**

Week 1-2 (early titration period):
Placebo: 27/91 (30%) Topiramate 25/25: 30/85 (35%) Topiramate 50/50: 40/84 (48%)
All topiramate: 70/169 (41%)
*p<0.05, **p=0.001

Double blind phase:

Proportion of patients experiencing at least a 50% reduction in seizure frequency (secondary generalised) frequency (i.e. responders):
Placebo: 12/36 (34%) All topiramate: 27/55 (50%) p=0.05

Proportion of participants having treatment withdrawn due to adverse events:
Placebo: 2/92 (2%) Topiramate 25/25: 7/85 (8%) Topiramate 50/50: 6/86 (7%) All topiramate: 13/171 (8%)

Adverse events (≥ 10% incidence):

Somnolence:
Placebo: 8/92 (9%) TPM25/25: 13/85 (15%) TPM50/50: 12/86 (14%) All topiramate: 25/171 (15%)

Paraeesthesia:
Placebo: 2/92 (2%) TPM25/25: 6/85 (7%) TPM50/50: 9/86 (10%) All topiramate: 15/171 (9%)

Nervousness:
Placebo: 2/92 (2%) TPM25/25: 9/85 (11%) TPM50/50: 6/86 (7%) All topiramate: 15/171 (9%)

Anorexia:
Placebo: 6/92 (7%) TPM25/25: 7/85 (8%) TPM50/50: 9/86 (10%) All topiramate: 16/171 (9%)

Safety and adverse effects

In the TPM group, 45% of discontinuations occurred within the first 3 weeks - during the titration period.

There were no significant difference between the two topiramate groups in terms of incidence of adverse events, time to onset of adverse events resulting in study discontinuation and in cumulative incidence rate of study drug discontinuations due to adverse events.

Mean body weight reduction was 1.9kg (2.6% of baseline) in topiramate group vs 0.1kg (1%) in placebo patients. Weight loss was occurred within the first two weeks and stabilised there after. One patient discontinued because of weight reduction.

Among adults with treatment resistant partial onset seizures, significantly more patients treated with topiramate (200mg/day) were treatment responders (at least 50% reduction in seizures) for partial seizures and secondary generalised seizures compared to patients receiving placebo.

Effect due to factor in study?

The study did not report sample size calculation and power.
### Internal Validity

All patients in this study had treatment resistant partial onset seizures. Topiramate dose used was low - target maintenance dose was 200mg

### Patient Characteristics

<table>
<thead>
<tr>
<th>Interventions/Test/Factor being investigated</th>
<th>Comparisons</th>
<th>Length of Study/Follow-up</th>
<th>Outcome measures studied</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>oxcarbazepine versus phenytoin.</td>
<td>Between treatments.</td>
<td>No follow up reported.</td>
<td>Number of patients who were seizure free, side effects, withdrawal</td>
<td>The trial was split into two periods, an 8 week titration and 48 week maintenance period. No concomitant AEDs were allowed. During the titration period patients received 150 mg oxcarbazepine or 50 mg phenytoin, this was gradually increased depending upon response, there was no fixed titration schedule. After 8 weeks patients were on daily doses of 450 to 2400 mg</td>
</tr>
</tbody>
</table>

### Study Type

Randomised Controlled Trial

### Number of participants

193 in total, 97 in oxcarbazepine, 96 in phenytoin

### Funding

None reported

### Inclusion/Exclusion Criteria

Inclusion: aged 5 to 18 years, newly diagnosed epilepsy with PS or GTCS, at least 2 seizures at least 48 hours apart in previous 6 months, no previous AED except for emergency treatment in previous 3 weeks

Exclusion: pregnancy or risk of becoming pregnant, history of status epilepticus, severe psychiatric illness or severe mental retardation, progressive neurological disorder, alcoholism or drug abuse, significant other organic disease

### Recruitment

Between 1991 and first quarter 1995

### Setting

Brazil and Argentina

### Study Type

Randomised Controlled Trial

### Number of participants

193 in total, 97 in oxcarbazepine, 96 in phenytoin

### Funding

None reported

### Inclusion/Exclusion Criteria

Inclusion: aged 5 to 18 years, newly diagnosed epilepsy with PS or GTCS, at least 2 seizures at least 48 hours apart in previous 6 months, no previous AED except for emergency treatment in previous 3 weeks

Exclusion: pregnancy or risk of becoming pregnant, history of status epilepticus, severe psychiatric illness or severe mental retardation, progressive neurological disorder, alcoholism or drug abuse, significant other organic disease

### Patient Characteristics

In the oxcarbazepine group the mean age was 10.22 years (range 5 to 17 years), 41 out of 97 were male. 80 were Caucasian, 11 were black, 6 were of other race. The mean weight was 36.4 kg (range 16 to 72 kg). 73 patients had partial seizures with or without secondary generalised seizures, 22 had generalised seizures without partial onset and 2 had no main type of seizure. 18 patients had localization-related idiopathic syndrome, 7 had localization-related symptomatic syndrome, 46 had localization-related cryptogenic syndrome, 11 had generalised idiopathic syndrome, 6 had generalised cryptogenic or symptomatic syndrome, 2 had generalised symptomatic syndrome, 6 had other syndromes and 1 was not classified.

In the phenytoin group the mean age was 10.85 years (range 6 to 17 years), 50 out of 96 were male. 80 were Caucasian, 6 were black, 10 were of other race. The mean weight was 40.7 kg (range 21 to 96 kg). 78 patients had partial seizures with or without secondary generalised seizures, 17 had generalised seizures without partial onset and 1 had no main type of seizure. 20 patients had localization-related idiopathic syndrome, 5 had localization-related symptomatic syndrome, 50 had localization-related cryptogenic syndrome, 11 had generalised idiopathic syndrome, 5 had generalised cryptogenic or symptomatic syndrome, 1 had had generalised symptomatic syndrome, and 4 had other syndromes.

### Results

The trial was split into two periods, an 8 week titration and 48 week maintenance period. No concomitant AEDs were allowed. During the titration period patients received 150 mg oxcarbazepine or 50 mg phenytoin, this was gradually increased depending upon response, there was no fixed titration schedule. After 8 weeks patients were on daily doses of 450 to 2400 mg
oxcarbazepine or 150 to 800 mg phenytoin, this dose was continued for the maintenance period. However this dose could be changed according to response.

161 patients reached the maintenance period, of these 158 had at least 1 seizure assessment during the maintenance period and were therefore included in the results

Number of patients who were seizure free:
In the oxcarbazepine group 49 out of 81 were seizure free compared to 46 out of 77 in the phenytoin group

In the oxcarbazepine group 60% of patients with partial seizures (with or without secondary generalised seizures) were seizure free compared to 62% of patients with partial seizures (with or without secondary generalised seizures) in the phenytoin group

In the oxcarbazepine group 59% of patients with generalised seizures (without partial onset) were seizure free compared to 54% of patients with generalised seizures (without partial onset) in the phenytoin group

Withdrawal:
In total 24 patients withdrew from the oxcarbazepine group compared to 34 in the phenytoin group.

In the oxcarbazepine group 8 patients withdrew due lost to follow up, 2 due to adverse events, 6 due to non-compliance, 4 due to unsatisfactory therapeutic effect, 3 due to protocol violation and 1 due to concomitant illness

In the phenytoin group 9 patients withdrew due lost to follow up, 14 due to adverse events, 5 due to non-compliance, 3 due to unsatisfactory therapeutic effect, 2 due to protocol violation and 1 due to discontinuations at baseline

Side effects:
In the oxcarbazepine group 79 out of 96 had at least 1 adverse event compared to 84 out of 94 in the phenytoin group

In the oxcarbazepine group 79 out of 96 had at least 1 adverse event compared to 84 out of 94 in the phenytoin group. In the oxcarbazepine group 2 patients withdrew due to adverse events compared to 14 in the phenytoin group.

There was no significant difference in the number of patients becoming seizure free between the oxcarbazepine group and the phenytoin group. More patients in the phenytoin group experienced side effects and more patients withdrew from the phenytoin group due to adverse events compared to the oxcarbazepine group.

No details of allocation concealment.

Had to impute the figures for partial seizures as partial and generalised.

Internal Validity

Halasz P;Kalviainen R;Mazurkiewicz-Beldzinska M;Rosenow F;Doty P;Hebert D;Sullivan T;

Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial

Ref ID 1034

Study Type Randomised Controlled Trial

Funding UCB Group, Research Triangle Park, NC, USA, sponsored and funded the trial.

Number of participant n=485 (n=163 in placebo group, n=163 in lacosamide 200mg/d group and n=159 in lacosamide 400mg/d group).
Inclusion/Exclusion Criteria

Inclusion criteria: age 16 to 70 years, diagnosis of partial-onset seizures with or without secondary generalizations, seizures for at least 2 years, therapy with at least two AEDs, at least four partial-onset seizures per 28 days on average, no seizure-free period longer than 21 days during the 8 week period prior to enrollment.

Exclusion criteria: pregnant, breast-feeding or childbearing potential, history of alcohol or drug abuse, medical condition that might jeopardize the trial.

Patient Characteristics

Demographic characteristics of patients receiving trial medication (safety set)

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>200 mg/day</th>
<th>Lacosamide 400mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=485</td>
<td>n=163</td>
<td>n=163</td>
<td>n=159</td>
</tr>
<tr>
<td>Age, year Mean ± SD</td>
<td>38.5 ± 10.93</td>
<td>36.9 ± 11.70</td>
<td>37.9 ± 12.96</td>
</tr>
<tr>
<td>Range 16–70</td>
<td>17–63</td>
<td>16–66</td>
<td>16–70</td>
</tr>
<tr>
<td>Sex, n (%) Male (51.5)</td>
<td>91 (55.8)</td>
<td>90 (55.2)</td>
<td>69 (43.4)</td>
</tr>
<tr>
<td>Female (48.5)</td>
<td>72 (44.2)</td>
<td>73 (44.8)</td>
<td>90 (56.6)</td>
</tr>
<tr>
<td>Race, n (%) Caucasian (99.2)</td>
<td>162 (99.4)</td>
<td>162 (99.4)</td>
<td>157 (98.7)</td>
</tr>
<tr>
<td>Black (0.2)</td>
<td>0 (0)</td>
<td>1 (0.6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Asian (0.6)</td>
<td>1 (0.6)</td>
<td>0 (0)</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>Weight, kg (mean ± SD)</td>
<td>74.7 ± 17.06</td>
<td>74.9 ± 16.93</td>
<td>72.2 ± 16.90</td>
</tr>
<tr>
<td>BMI, kg/m2 (mean ± SD)</td>
<td>25.9 ± 5.01</td>
<td>25.2 ± 4.79</td>
<td>25.3 ± 5.09</td>
</tr>
<tr>
<td>Mean time since diagnosis, year (mean ± SD)</td>
<td>21.1 ± 12.23</td>
<td>22.9 ± 12.30</td>
<td>22.8 ± 13.15</td>
</tr>
<tr>
<td>Seizure classification, n (%) Simple partial-onset seizures</td>
<td>61 (37.4)</td>
<td>67 (41.1)</td>
<td>58 (36.5)</td>
</tr>
<tr>
<td>Complex partial-onset seizures (87.8)</td>
<td>138 (84.7)</td>
<td>142 (87.1)</td>
<td>146 (91.8)</td>
</tr>
<tr>
<td>Partial-onset seizures with secondary generalization (78.8)</td>
<td>130 (79.8)</td>
<td>125 (76.7)</td>
<td>127 (79.9)</td>
</tr>
</tbody>
</table>

A total of 87% of patients were taking at least two AEDs, with 37% of these taking three AEDs in addition to their assigned trial medication.

Recruitment

Not reported.

Setting

75 sites worldwide inc. UK.

Interventions/ Test/ Factor being investigated

Lacosamide 200mg/day and lacosamide 400mg/day as adjunctive therapy.

Comparisons

The comparisons are between the lacosamide doses (200mg and 400mg) and placebo.

Length of Study/ Follow-up

24 weeks: 8 week baseline, 4 week titration and 12 week maintenance period.

Outcome measures studied

Primary outcome: seizure freq (ITT pop) 1) change in seizure freq per 28 days from baseline to maintenance phase 2) 50% responder rate per 28 days. Secondary: % change in seizure freq per 28 days and seizure-free for those completing maintenance phase.
Results

Primary outcome

Median percent reduction (ITT population) per 28 days
The median percent reduction in seizure frequency per 28 days from baseline to the maintenance period was 20.5% for placebo, 35.3% for lacosamide 200 mg/day (p=0.02, diff from placebo), and 36.4% for lacosamide 400 mg/day (p=0.03, diff from placebo).

Responder rate (ITT population)
The 50% responder rate for lacosamide 400 mg/day (40.5%) was statistically significant (p = 0.01) over placebo (25.8%). Although not statistically significant (p = 0.07), the 50% responder rate for lacosamide 200 mg/day (35.0%) was numerically higher than placebo.

Secondary outcomes

Seizure-free days (those completing the maintenance period)

Among patients completing the maintenance period, 5 (3.6%) of 137 patients in the lacosamide 200 mg/day group and 3 (2.4%) of 123 patients in the lacosamide 400 mg/day group were seizure-free throughout the 12-week maintenance period compared with 3 (2.1%) of 143 in the placebo group. A statistically significant increase of 5% in the percentage of seizure-free days over placebo during the maintenance period was observed for lacosamide 400 mg/day (p = 0.01; 95% CI 1.5, 8.5).

Adverse events

Incidence of treatment-emergent adverse events occurring in at least 5% of patients in any treatment group during the treatment period (titration plus maintenance periods)

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Placebo n=163</th>
<th>200mg/d n=163</th>
<th>Lacosamide 400mg/d n=159</th>
<th>Total n=322</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n(%)</td>
<td>n(%)</td>
<td>n(%)</td>
<td>n(%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>8 (4.9)</td>
<td>17 (10.4)</td>
<td>25 (15.7)</td>
<td>42 (13.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>12 (7.4)</td>
<td>18 (11.0)</td>
<td>13 (8.2)</td>
<td>31 (9.6)</td>
</tr>
<tr>
<td>Diplopia</td>
<td>2 (1.2)</td>
<td>13 (8.0)</td>
<td>16 (10.1)</td>
<td>29 (9.0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (1.2)</td>
<td>9 (5.5)</td>
<td>13 (8.2)</td>
<td>22 (6.8)</td>
</tr>
<tr>
<td>Vertigo</td>
<td>3 (1.8)</td>
<td>11 (6.7)</td>
<td>10 (6.3)</td>
<td>21 (6.5)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>6 (3.7)</td>
<td>8 (4.9)</td>
<td>10 (6.3)</td>
<td>18 (5.6)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>6 (3.7)</td>
<td>8 (4.9)</td>
<td>10 (6.3)</td>
<td>18 (5.6)</td>
</tr>
<tr>
<td>Coordination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abnormal</td>
<td>1 (0.6)</td>
<td>7 (4.3)</td>
<td>10 (6.3)</td>
<td>17 (5.3)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3 (1.8)</td>
<td>5 (3.1)</td>
<td>9 (5.7)</td>
<td>14 (4.3)</td>
</tr>
</tbody>
</table>

Overall, 42 patients (8.7%) discontinued participation in the trial during the treatment period because of AEs: 8 patients (4.9%) randomized to placebo, 10 (6.1%) to lacosamide 200 mg/day, and 24 (15.1%) to 400 mg/day.

The overall percentage of patients experiencing serious AEs (SAEs) during the treatment period was greater in the lacosamide treatment groups compared to placebo (3.7%, 8.0%, and 9.4% of patients in the placebo, lacosamide 200 mg/day, and 400 mg/day treatment groups, respectively).

Safety and adverse effects

Does the study answer the question?
Yes. This is a well conducted effectiveness study. Lacosamide 200 mg/day and 400 mg/day significantly reduced seizure frequency in patients with uncontrolled partial-onset seizures when added to one to three concomitant AEDs.

Effect due to factor in study?
Yes. The study was sufficiently well powered to detect differences between lacosamide and placebo.
Internal Validity

All patients enrolled in this study had a diagnosis of uncontrolled partial-onset seizures.

Patient Characteristics

<table>
<thead>
<tr>
<th>Intervention/Test/Factor being investigated</th>
<th>Double blind phase</th>
<th>Open label phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Placebo TGB</td>
<td>TGB</td>
</tr>
<tr>
<td>Men</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Women</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Age, y</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>40(14)</td>
<td>37(9)</td>
</tr>
<tr>
<td>Full Scale IQ</td>
<td>Mean(SD)</td>
<td></td>
</tr>
<tr>
<td>Mean(SD)</td>
<td>88(20)</td>
<td>82(18)</td>
</tr>
</tbody>
</table>

Recruitment

Unknown

Setting

Finland

Interventions/Test/Factor being investigated

The long-term effects of tiagabine on cognition and EEG in 37 patients with partial epilepsy.

Comparisons

TGB vs. placebo in double blind phase; open label phase is TGB only

Length of Study/Follow-up

12 week baseline period during which cognitive testing and EEG were performed to all patients. 12 week fixed dose period after which second cognitive testing and EEG were performed. Further 6-12 months and 18-24 months open label with two more evaluation

Outcome measures studied

Primary: Cognitive function as measured in a battery of 10 neuropsychological tests and scored by a blinded neuropsychologist; EEG tracings

Results

There were no differential changes across the TGB and placebo groups from the end of the baseline to the end of the drug treatment period in any of the cognitive measures. There were also no changes in cognitive function during long term TGB treatment at higher doses after 6-12 months. There was no deterioration seen in the 18-24 month phase but there was improvement in the List learning test and in auditory reaction times. There was no new rhythmic slow-wave activity or other constant, new abnormalities on EEG during longer follow-up with successful treatment on higher doses after 6-12 months (mean 65.7 mg/day, range 30-80 mg/day) and after 18-24 months (mean dose 67.6 mg/day, range 24-80 mg/day).

Safety and adverse effects

Reported separately in multicentre evaluation of TGB by the Northern European tiagabine Study Group

Does the study answer the question?

In this study the neuropsychological and neurophysiological evaluation did not indicate any adverse effects of TGB.
A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group

Ref ID 4761

Study Type  Randomised Controlled Trial

Funding  Unknown

Number of participant
A total of 77 patients were randomised to treatment in each arm.

Inclusion/Exclusion Criteria
Inclusion: Male and female patients aged between 16 and 75 years with history of partial seizures refractory to one to three AEDs.
Exclusion: pseudo seizures, progressive CNS disease or serious medical disorder requiring frequent medication changes. Also, a hx of drug or alcohol abuse and poor compliance were reasons for exclusion.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>TGB, n=77</th>
<th>Placebo, n=77</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>36.4 (18.7-59.7)</td>
<td>36.0 (17.9-71.3)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>34 (44%)</td>
<td>30 (39%)</td>
</tr>
<tr>
<td>Male</td>
<td>43 (56%)</td>
<td>47 (61%)</td>
</tr>
<tr>
<td>Years with epilepsy</td>
<td>24.9 (2-52)</td>
<td>23.0 (1-49)</td>
</tr>
</tbody>
</table>

Study population was entirely Caucasian.

Recruitment  Unknown

Setting  Multicentre - Finland, UK, Denmark

Interventions/ Test/ Factor being investigated
A three-times daily regimen of tiagabine was evaluated as add-on therapy in 154 adult patients with refractory partial seizures.

Comparisons  Treatment with fixed dose vs. placebo

Length of Study/ Follow-up
4 week titration period; 12 week fixed dose period

Outcome measures studied
Primary: proportion of responders (50% or more reduction in 4 weekly seizure rate). Secondary. Median percentage reduction in the 4 weekly seizure rate and the number of seizure free days attained.

Results
During the 12-week fixed-dose period, there was a significant reduction in the median 4-weekly seizure rate for all partial seizures and simple partial seizures (P < 0.05 in each case). Furthermore, the proportion of patients with a reduction of 50% or more in all partial seizures was higher in the tiagabine group than in the placebo group (14 versus 6%), though the difference did not achieve statistical significance. The difference with respect to simple partial seizures was significant (21 versus 6%, P < 0.01). The percentage of patients achieving an increase of at least 50% in the proportion of days free of all partial seizures was significantly greater in the tiagabine group compared to placebo (14 versus 4%, P<0.01).

Safety and adverse effects
Tiagabine did not appear to influence the plasma concentrations of other concomitant antiepileptic drugs and was generally well tolerated, with most drug-related adverse events being mild or moderate in severity. The most common adverse events were...
The present study shows that tiagabine, at a dose of 10 mg administered three-times daily, which is at the lower end of the usual recommended dose range (30-50 mg/day, tiagabine base), is generally well tolerated and demonstrates efficacy for the treatment of refractory partial seizures.

Effect due to factor in study? Yes

Consistency of results with other studies? See GRADE

Directly applicable to guideline population? See Grade

Internal Validity Multi centre; high discontinuation rate in TGB

Koeppen D; Baruzzi A; Capozza M; Chauvel P; Courjon J; Favel P; Harmant J; Lorenz H; Oller FV; Procacci G; ;

Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study

Ref ID 4645

Number of Participant 129 patients began this cross over study

Inclusion/Exclusion Criteria

Inclusion: Patients with refractory epilepsy who were on basic antiepileptic medication
Exclusion: Not addressed

Patient Characteristics Age: 33 +/- 12
Gender
Male 56
Female 73

Recruitment Not discussed

Setting Five European centres

Interventions/ Test/ Factor being investigated Clobazam in therapy resistant patients with partial epilepsy

Comparisons Clobazam vs. placebo

Length of Study/ Follow-up 7 months

Outcome measures studied Primary: Difference in seizure reduction
Secondary: EEG signs, mood ratings and global impressions

Results

The difference in seizure reduction between clobazam and placebo was significant (p<0.05). Nineteen percent of patients receiving clobazam became seizure free during the maintenance dose period compared to none in the placebo group. EEG signs, mood ratings and global impressions also indicated therapeutic effects of clobazam.

Withdrawal due to adverse events:
Clobazam: 0/129
Placebo: 3/129

Withdrawal due to lack of adverse events:
There is evidence of the therapeutic value of clobazam as adjunct medication in therapy resistant partial seizures.

Clobazam: 4/129
Placebo : 8/129

Safety and adverse effects
The most frequent adverse reactions to clobazam were drowsiness and dizziness.

Does the study answer the question?
There is evidence of the therapeutic value of clobazam as adjunct medication in therapy resistant partial seizures.

Effect due to factor in study?
Yes

Consistency of results with other studies?
See GRADE

Directly applicable to guideline population?
See GRADE

Internal Validity
Multi-centre

Korean Topiramate Study Group

Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group

Ref ID 4746

Study Type Randomised Controlled Trial Funding Janssen Korea Ltd.

Number of participant
n=91 in topiramate arm and n=86 in placebo arm.

Inclusion/Exclusion Criteria
Patients were eligible if: aged 16 to 65 years; well-established partial epilepsies; treatment with 1 or 2 AEDs; at least 2 seizures per 4 wks during 3 consecutive 4-wk periods. Excluded if: history of pseudoseizures; systemic or neurologic disease; history of drug or alcohol abuse; history of noncompliance; use of drugs known to cause nephrolithiasis.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Topiramate (n=91)</th>
<th>Placebo (n=86)</th>
<th>Total (n=177)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>47</td>
<td>48</td>
<td>95</td>
</tr>
<tr>
<td>Women</td>
<td>44</td>
<td>38</td>
<td>81</td>
</tr>
<tr>
<td>Age Mean (+/-)</td>
<td>29.58(7.80)</td>
<td>29.77(8.71)</td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>63.7(10.9)</td>
<td>63(10.5)</td>
<td></td>
</tr>
<tr>
<td>Seizure types</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simple partial</td>
<td>11(12.1%)</td>
<td>5(5.8%)</td>
<td></td>
</tr>
<tr>
<td>Complex partial</td>
<td>70(76.9%)</td>
<td>72(83.7%)</td>
<td></td>
</tr>
<tr>
<td>Secondary gen tonic-clonic</td>
<td>31(34.1%)</td>
<td>39(45.4%)</td>
<td></td>
</tr>
<tr>
<td>Seizure freq (episodes per wk)</td>
<td>Median 5.6</td>
<td>5.6</td>
<td></td>
</tr>
</tbody>
</table>

Recruitment
Not reported.

Setting
8 clinical centers in Korea. No further info.

Interventions/ Test/ Factor being investigated
Topiramate vs. placebo as adjunctive therapy.
Comparisons made between topiramate and placebo when used in addition to one or two currently prescribed antiepileptic drugs.

Length of Study/ Follow-up

18 weeks post randomisation.

Outcome measures studied

Primary outcome: Median seizure frequency reduction rate (MSFRR)
Secondary outcomes: responder rate; seizure-free rate; global evaluations by patient and physician; adverse events (AEs).

Results

<table>
<thead>
<tr>
<th>Primary outcome</th>
<th>Topiramate (n=89)</th>
<th>Placebo (n=85)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median seizure freq (episodes per 4wks)</td>
<td>5.6</td>
<td>5.6</td>
<td></td>
</tr>
<tr>
<td>Baseline phase</td>
<td>0.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experimental phase</td>
<td>2.4</td>
<td>5.1</td>
<td>0.0001</td>
</tr>
<tr>
<td>MSFRR</td>
<td>51.3%</td>
<td>9.1%</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Secondary outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Topiramate (n=89)</th>
<th>Placebo (n=85)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responder rate</td>
<td>45(50.6%)</td>
<td>11(12.9%)</td>
<td>0.04</td>
</tr>
<tr>
<td>Global eval physician</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excellent or good</td>
<td>46(60.5%)</td>
<td>19(24.7%)</td>
<td></td>
</tr>
<tr>
<td>Global eval pts</td>
<td>50(65.8%)</td>
<td>19(24.7%)</td>
<td></td>
</tr>
<tr>
<td>Incidence of AEs</td>
<td>74(81.3%)</td>
<td>42(48.8%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Anorexia</td>
<td>19(20.9%)</td>
<td>5(5.8%)</td>
<td>0.003</td>
</tr>
<tr>
<td>Abd. Discomfort</td>
<td>19(20.9%)</td>
<td>2(2.3%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Dizziness</td>
<td>18(19.8%)</td>
<td>18(21%)</td>
<td>0.85</td>
</tr>
<tr>
<td>Somnolence</td>
<td>18(19.8%)</td>
<td>8(9.3%)</td>
<td>0.85</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>15(16.5%)</td>
<td>7(8.1%)</td>
<td>0.09</td>
</tr>
<tr>
<td>Headache</td>
<td>10(11%)</td>
<td>6(7.0%)</td>
<td>0.52</td>
</tr>
<tr>
<td>Amblyopia</td>
<td>10(11%)</td>
<td>4(4.7%)</td>
<td>0.12</td>
</tr>
</tbody>
</table>

Subgroup analysis

<table>
<thead>
<tr>
<th>Type of seizure</th>
<th>Median seizure frequency reduction rate (MSFRR)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPMS</td>
<td>Topiramate (n=9)</td>
<td>Placebo (n=4)</td>
</tr>
<tr>
<td></td>
<td>87.5</td>
<td>72.9</td>
</tr>
<tr>
<td>CPS</td>
<td>Topiramate (n=70)</td>
<td>Placebo (n=72)</td>
</tr>
<tr>
<td></td>
<td>49.4</td>
<td>-14.3</td>
</tr>
<tr>
<td>GTCS</td>
<td>Topiramate (n=28)</td>
<td>Placebo (n=35)</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>40.26</td>
</tr>
</tbody>
</table>

SPMS=simple partial motor seizure, CPS=complex partial seizure, GTCS=secondarily generalized tonic-clonic seizure.

Safety and adverse effects

The AEs more frequently found in the topiramate group compared with the placebo group were abdominal discomfort or pain, anorexia, weight loss, speech disturbance, psychomotor slowing, and somnolence, with abdominal discomfort or pain and anorexia being the most common AEs. Severe AEs are not common. Rapid dose escalation increases rate of AEs.

Does the study answer the question?

Yes.

Toprimate appears to be effective as add on therapy in medically intractable partial epilepsies. However, the incidence of adverse events is high.

Effect due to factor in study?

Yes, it appears that the overall effect seen in this study is due to the add-on effect of topiramate. However, there is insufficient reporting of randomisation methods and concealment of allocation.

Consistency of results with other studies?

The comparisons used here (topiramate vs. placebo as adjunctive therapy) are relevant to the question in this guideline as is the study population.

29 July 2010
Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy

Study Type: Randomised Controlled Trial

Funding: GlaxoSmithKline Research and Development.

Number of participant: n=132 in lamotrigine group and n=136 in levetiracetam group were randomised to treatment.

Inclusion/Exclusion Criteria:
- Inclusion criteria: age >=16; IQ >=80, confident diagnosis of epilepsy, two partial seizures in previous 6 months, monotherapy with carbamazepine or phenytoin or polytherapy that included carbamazepine or phenytoin and one other AED.
- Exclusion criteria: taking antidepressants or antipsychotics or clinically significant comorbidity that could prevent completion of questionnaires.

Patient Characteristics:

<table>
<thead>
<tr>
<th></th>
<th>Lamotrigine</th>
<th>Levetiracetam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Age (SD)</td>
<td>38.3(12.3)</td>
<td>39.1(11.6)</td>
</tr>
<tr>
<td>Female n(%)</td>
<td>63(48)</td>
<td>56(41)</td>
</tr>
<tr>
<td>Race n(%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>0(0)</td>
<td>2(1)</td>
</tr>
<tr>
<td>Black</td>
<td>22(17)</td>
<td>23(17)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>11(8)</td>
<td>11(8)</td>
</tr>
<tr>
<td>White</td>
<td>94(71)</td>
<td>99(73)</td>
</tr>
<tr>
<td>Other</td>
<td>5(4)</td>
<td>1(&lt;1)</td>
</tr>
<tr>
<td>Mean (SD) age at first seizure</td>
<td>22.2(14.3)</td>
<td>21.2(15.6)</td>
</tr>
<tr>
<td>Mean (SD) seizures in past 8 weeks</td>
<td>12.0(37.7)</td>
<td>18.6(51.8)</td>
</tr>
<tr>
<td>Epilepsy classification n(%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any seizure type</td>
<td>132(100)</td>
<td>136(100)</td>
</tr>
<tr>
<td>Simple partial</td>
<td>37(28)</td>
<td>52(38)</td>
</tr>
<tr>
<td>Complex partial</td>
<td>110(83)</td>
<td>97(71)</td>
</tr>
<tr>
<td>Partial evolving to secondarily generalized</td>
<td>63(48)</td>
<td>82(60)</td>
</tr>
<tr>
<td>Gen. tonic-clonic</td>
<td>9(7)</td>
<td>15(11)</td>
</tr>
</tbody>
</table>

Recruitment: Not reported.

Setting: 62 North American study sites.

Interventions/ Test/ Factor being investigated: Lamotrigine as adjunctive therapy is compared with levetiracetam as adjunctive therapy. Lamotrigine is the intervention drug and levetiracetam is the control group.

Comparisons: The comparison is between lamotrigine and the active treatment levetiracetam. Both are used in the trial as adjunctive therapy. Patients are already taking a stable dose of at least one AED.

Length of Study/ Follow-up: Approximately 22 weeks. Up to 2 weeks for the screening phase, 8 weeks for the drug escalation phase and 12 weeks maintenance phase.

Outcome measures studied: Primary measure is the change from baseline to end of maintenance phase in the Anger-Hostility subscale of the Profile of Mood States (POMS). Secondary outcomes included a no. of depression outcomes. Also seizure frequency and clinical global improvement.

Results:

<table>
<thead>
<tr>
<th></th>
<th>Lamotrigine</th>
<th>Levetiracetam</th>
</tr>
</thead>
</table>

29 July 2010
Yes. The study sets out to measure efficacy and quality of life from adjunctive treatment with lamotrigine. The authors ... improvement (CGI) scores at study end.

Safety and adverse effects

The most common adverse events were headache, dizziness and nausea. 11% of patients in the lamotrigine and 18% in the levetiracetam groups discontinued because of AEs.

Does the study answer the question?

Yes. The study sets out to measure efficacy and quality of life from adjunctive treatment with lamotrigine.

Effect due to factor in study?

No. For the primary outcome (change in Anger-Hostility subscale) it is unclear how clinically significant the changes are. The change from baseline to study end for the lamotrigine group was 2 points compared to -0.3 for the control group. The study was powered to detect a difference of 4 points (>=90% power) yet they acknowledge that the threshold for clinically meaningful change in this scale has not been defined.

Consistency of results with other studies?

Efficacy outcome (seizure frequency) and clinically global improvement (CGI) scores were not significantly different between the two groups at study end.

Directly applicable to guideline population?

This study enrolled a population which is similar to the patient population of interest in this guideline. Patients were only enrolled in the study if they had partial seizures.

Internal Validity

Lee BI; Yi S; Hong SB; Kim M; Lee SA; Lee SK; Shin D; Kim JM; Song HK; Heo K; Lowe W; Leon T;

Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trial

Ref ID 1032 2009

Study Type Randomised Controlled Trial

Funding Pfizer Inc.

Number of participant n=178 (n=119 in the PGB group and n=59 in the placebo group).

<table>
<thead>
<tr>
<th>(n=125)</th>
<th>(n=126)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline score Anger-Hostility Mean (SD)</td>
<td>10.6(9.0)</td>
<td>9.1(8.7)</td>
</tr>
<tr>
<td>Mean change (SD)</td>
<td>-2.0(8.2)</td>
<td>-0.3(8.4)</td>
</tr>
<tr>
<td>Seizure frequency Median % decrease</td>
<td>60</td>
<td>65</td>
</tr>
<tr>
<td>Pts showing any improvement in CGI- %</td>
<td>89</td>
<td>85</td>
</tr>
<tr>
<td>Adverse events % patients &gt;=1 event</td>
<td>82</td>
<td>85</td>
</tr>
<tr>
<td>AEs leading to discontinuation % patients</td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>Most common AEs as % of AEs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headaches</td>
<td>32</td>
<td>25</td>
</tr>
<tr>
<td>Dizziness</td>
<td>13</td>
<td>15</td>
</tr>
<tr>
<td>Nausea</td>
<td>11</td>
<td>10</td>
</tr>
</tbody>
</table>

No significant differences were observed for CGI scores at end of maintenance phase.

NR=Not reported. CGI=Clinical Global Improvement.
Inclusion/Exclusion Criteria

Inclusion criteria: aged $\geq$ 18 years and weighing $\geq$ 40 kg with a diagnosis of partial seizures (simple, complex, or SGTC); at least one AED at the maximally tolerable dose and had to be taking one to three AEDs. Additional inclusion criteria included a minimum of four seizures that had occurred over at least 2 days during a 6-week baseline period with no 28-day seizure-free period. Exclusion criteria: patients with absence seizures, Lennox-Gastaut syndrome, status epilepticus within the previous year, clinically relevant medical illness, electrocardiography (ECG) abnormalities, or significant psychiatric disorders.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Pregabalin</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=119</td>
<td>n=59</td>
</tr>
<tr>
<td>Sex: male (%)</td>
<td>52 (44)</td>
<td>34 (58)</td>
</tr>
<tr>
<td>Age (years): mean (SD)</td>
<td>33.3 (9.7)</td>
<td>35.1 (8.8)</td>
</tr>
<tr>
<td>Height (cm): mean (SD)</td>
<td>163.8 (8.1)</td>
<td>164.1 (8.2)</td>
</tr>
<tr>
<td>Weight (kg): mean (SD)</td>
<td>62.2 (10.4)</td>
<td>64.0 (12.9)</td>
</tr>
<tr>
<td>Duration of illness (year)</td>
<td>Mean (range)</td>
<td>16.5 (0.3–48.0)</td>
</tr>
<tr>
<td>Etiology of epilepsy</td>
<td>Symptomatic (%)</td>
<td>55 (46.2)</td>
</tr>
<tr>
<td></td>
<td>Cryptogenic (%)</td>
<td>64 (53.8)</td>
</tr>
<tr>
<td>Seizure types</td>
<td>Simple partial (%)</td>
<td>66 (55.5)</td>
</tr>
<tr>
<td></td>
<td>Complex partial (%)</td>
<td>93 (78.2)</td>
</tr>
<tr>
<td></td>
<td>SGTC (%)</td>
<td>49 (41.2)</td>
</tr>
<tr>
<td></td>
<td>Partial w/o generalization (%)</td>
<td>116 (97.5)</td>
</tr>
<tr>
<td>Concomitant AEDs (%)</td>
<td>One</td>
<td>8 (6.7)</td>
</tr>
<tr>
<td></td>
<td>Two</td>
<td>34 (28.6)</td>
</tr>
<tr>
<td></td>
<td>Three</td>
<td>76 (63.9)</td>
</tr>
<tr>
<td></td>
<td>Four</td>
<td>1 (0.8)</td>
</tr>
</tbody>
</table>

Seizure frequency per 28 days

<table>
<thead>
<tr>
<th></th>
<th>Mean (SD)</th>
<th>Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>13.2 (14.5)</td>
<td>6.7 (2.4–69.3)</td>
</tr>
<tr>
<td></td>
<td>13.2 (19.2)</td>
<td>5.2 (2.5–91.8)</td>
</tr>
</tbody>
</table>

Recruitment

Not reported.

Setting

9 centres in Korea.

Interventions/ Test/ Factor being investigated

Pregabalin in a flexible dose (up to 600mg/day).

Comparisons

Comparison is between PGB (flexible dose) and placebo as add-on therapy to currently used AEDs.

Length of Study/ Follow-up

19 weeks: 6-week baseline phase, 12-week treatment phase, and 1 week taper period.

Outcome measures studied

The primary efficacy outcome was seizure frequency change expressed as the response ratio (RRatio). Secondary outcomes: responder rate, PCH in 28 day seizure rate, % SGTC responders, QoL measures.

Results

Primary outcome

Response ratio

The RRatio least mean was -35.8 for the PGB group and -23.2 for the placebo group, corresponding to 52.7% and 37.7% seizure frequency reduction, respectively. The estimated treatment difference in RRatio between the two groups was -12.6 (95% CI: -22.7 to -2.5), which was statistically significant (p = 0.015).

Secondary analysis

Response rate by seizure type

RRatio defined by seizure types favoured PGB in all types of seizure; however, the result was statistically significant only in “complex partial seizures” and “partial seizure without generalization”. (Data presented only in figures.)

Secondary outcomes
<table>
<thead>
<tr>
<th></th>
<th>Pregabalin</th>
<th>Placebo</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Responder rate (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All seizures</td>
<td>55 (46.2)</td>
<td>19 (32.2)</td>
<td>p = 0.068b</td>
</tr>
<tr>
<td>SGTCs</td>
<td>28 (62.2)</td>
<td>20 (80.0)</td>
<td>p = 0.143b</td>
</tr>
<tr>
<td><strong>PCH in 28 days seizure rate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (median)</td>
<td>-38.3 (-48.2)</td>
<td>-20.3 (-32.4)</td>
<td>p = 0.012d</td>
</tr>
<tr>
<td>95% CI for median</td>
<td>-53.1 to -36.5</td>
<td>-44.1 to -11.9</td>
<td></td>
</tr>
<tr>
<td><strong>Seizure free rate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double-blind phase (%)</td>
<td>5 (4.2)</td>
<td>2 (3.4)</td>
<td>p = 1.00e</td>
</tr>
<tr>
<td>Any 28-day period (%)</td>
<td>51 (43)</td>
<td>22 (37)</td>
<td>p = 0.52e</td>
</tr>
<tr>
<td><strong>Change in number of SFD per 28 days</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RDB:BL (95% CI)*</td>
<td>1.09 (1.07 to 1.10)</td>
<td>1.05 (1.03 to 1.08)</td>
<td></td>
</tr>
<tr>
<td>RDB:BL of PGB/Placebo (95% CI)*</td>
<td>1.03 (1.01 to 1.06)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*SGTC, secondarily generalized tonic–clonic seizures; PCH, percent change; CI, confidence interval; SFD, seizure free days.

**Pregabalin vs Placebo**

<table>
<thead>
<tr>
<th></th>
<th>Pregabalin</th>
<th>Placebo</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HAD-A</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline score (SD)</td>
<td>8.23 (3.87)</td>
<td>8.41 (3.67)</td>
<td></td>
</tr>
<tr>
<td>Week-12 score (SD)</td>
<td>7.87 (3.96)</td>
<td>7.69 (3.97)</td>
<td></td>
</tr>
<tr>
<td><strong>ANOVA of week-12 score:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS mean (SE)</td>
<td>7.91 (0.32)</td>
<td>7.56 (0.44)</td>
<td></td>
</tr>
<tr>
<td>Difference in LS means (95% CI)</td>
<td>0.35 (-0.70 to 1.41)</td>
<td>0.507</td>
<td></td>
</tr>
<tr>
<td><strong>HAD-D</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline score (SD)</td>
<td>9.29 (3.65)</td>
<td>9.02 (3.85)</td>
<td></td>
</tr>
<tr>
<td>Week-12 score (SD)</td>
<td>8.82 (4.16)</td>
<td>7.69 (3.89)</td>
<td></td>
</tr>
<tr>
<td><strong>ANOVA of week-12 score:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS mean (SE)</td>
<td>8.71 (0.33)</td>
<td>7.79 (0.46)</td>
<td></td>
</tr>
<tr>
<td>Difference in LS means (95% CI)a</td>
<td>0.92 (-0.16 to 2.00)</td>
<td>0.095</td>
<td></td>
</tr>
<tr>
<td><strong>SIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline SIS (SD)</td>
<td>2.06 (2.09)</td>
<td>2.21 (2.36)</td>
<td></td>
</tr>
<tr>
<td>Endpoint SIS (SD)</td>
<td>1.67 (2.00)</td>
<td>2.22 (2.51)</td>
<td></td>
</tr>
<tr>
<td><strong>ANOVA of endpoint SIS:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS mean (SE)</td>
<td>1.62 (0.13)</td>
<td>2.07 (0.18)</td>
<td></td>
</tr>
<tr>
<td>Difference in endpoints SIS (95% CI)a</td>
<td>-0.45 (-0.87 to -0.02)</td>
<td>0.039</td>
<td></td>
</tr>
<tr>
<td><strong>QOLIE-31</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline score</td>
<td>48.0 (7.96)</td>
<td>49.0 (8.08)</td>
<td></td>
</tr>
<tr>
<td>Week-12 score</td>
<td>50.4 (8.45)</td>
<td>49.3 (8.31)</td>
<td></td>
</tr>
<tr>
<td><strong>ANOVA of week-12 score:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS mean (SE)</td>
<td>50.7 (0.73)</td>
<td>49.2 (1.01)</td>
<td></td>
</tr>
<tr>
<td>Difference in endpoints (95% CI)a</td>
<td>1.4 (-1.0 to 3.8)</td>
<td>0.245</td>
<td></td>
</tr>
</tbody>
</table>

95% CI: 95% confidence interval; HADS-A, hospital anxiety and depression scale-anxiety; HADS-D, hospital anxiety and depression scale-depression; SIS, sleep interference scale (scores) from Daily Sleep Interference Scale; QOLIE-31, quality of life in epilepsy-31 questions.

aDifference between the pregabalin group and the placebo group; except for QOLIE-31, negative value indicated a result favoring pregabalin.

### Adverse events

<table>
<thead>
<tr>
<th></th>
<th>Pregabalin</th>
<th>Placebo</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All causality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>46 (38.7)</td>
<td>6 (10.2)</td>
<td>p = 0.081</td>
</tr>
<tr>
<td>Somnolence</td>
<td>26 (21.8)</td>
<td>3 (5.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Treatment related</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>42 (35.3)</td>
<td>5 (8.5)</td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>26 (21.8)</td>
<td>3 (5.1)</td>
<td></td>
</tr>
</tbody>
</table>
Yes. PGB was effective as add-on treatment in an Asian population with refractory partial-onset seizures.

Internal Validity

Does the study answer the question?

Yes. PGB was effective as add-on treatment in an Asian population with refractory partial-onset seizures.

Effect due to factor in study?

Yes. Sample size was derived from a power calculation which was based on results from previous PGB studies.

Consistency of results with other studies?

All patients in this study had a diagnosis of partial seizures.

Directly applicable to guideline population?

All patients in this study had a diagnosis of partial seizures.

Safety and adverse effects

Weight gain was reported as AEs in 14 patients (11.8%) taking PGB compared with 2 patients (3.5%) of the PLC group; however, post hoc analysis indicated that a significant weight gain, defined as ">=7% of baseline body weight gain," was found in 29 patients (24.8%) of the PGB group and in only 2 patients (3.5%) of the placebo group.

Funding

Unknown

Study Type

Randomised Controlled Trial

Number of participant

102 total; 35 patients in Gabapentin (GBP) group and 44 in Vigabatrin (VGB) group.

Inclusion/Exclusion Criteria

Inclusion: Refractory partial epilepsy with no more than two AED monotherapy regimens.
Exclusion: status within 6 months before study; progressive CNS disease; psychosis; severe liver or renal disease; pregnancy or nursing; treatment with phenytoin, antipsychotic or antidepressant drugs or antacids at the time of inclusion.

Patient Characteristics

GBP (n=50) VGB (n=52)

<table>
<thead>
<tr>
<th>Gender</th>
<th>GBP (n=50)</th>
<th>VGB (n=52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>28(56%)</td>
<td>23(44%)</td>
</tr>
<tr>
<td>Women</td>
<td>22(44%)</td>
<td>29(56%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age, y</th>
<th>GBP (n=50)</th>
<th>VGB (n=52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range)</td>
<td>34.5(13-68)</td>
<td>33(14-56)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>GBP (n=50)</th>
<th>VGB (n=52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range)</td>
<td>77.5(53-135)</td>
<td>69.0(46-104)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of epilepsy, m</th>
<th>GBP (n=50)</th>
<th>VGB (n=52)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range)</td>
<td>3.5(0-36)</td>
<td>9.5(0-43)</td>
</tr>
</tbody>
</table>
The efficacy and safety of gabapentin and vigabatrin as first-line add-on treatment in patients with partial epilepsy was investigated. The study failed to exclude a 15% difference in efficacy between GBP and VGB; the low statistical power may have contributed to this due to premature discontinuation of recruitment. The results offer little guidance as to which drug to choose when monotherapy fails.

### Results

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>GBP (n=50)</th>
<th>VGB (n=52)</th>
<th>Estimated difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improvement rate</td>
<td>24%(48)</td>
<td>29%(56)</td>
<td>-0.08</td>
</tr>
<tr>
<td>(0.27;0.12)</td>
<td></td>
<td></td>
<td>[-]</td>
</tr>
<tr>
<td>Seizure reduction</td>
<td>27%(54)</td>
<td>34%(65)</td>
<td>-0.10</td>
</tr>
<tr>
<td>(0.29;0.09)</td>
<td></td>
<td></td>
<td>[-]</td>
</tr>
<tr>
<td>Responder rate</td>
<td>13%(26)</td>
<td>18%(35)</td>
<td>-0.11</td>
</tr>
<tr>
<td>(0.28;0.07)</td>
<td></td>
<td></td>
<td>[-]</td>
</tr>
</tbody>
</table>

Withdrawal due to adverse events: VGB 7/52; GBP 7/50.

### Safety and adverse effects

The recruitment was stopped when it became apparent that vigabatrin could induce visual field defects. One patient taking VGB developed agitated depression and one had weight gain. 38 (76%) of patients in the GBP group and 45 (86.5%) in the VGB group had one or more adverse events. The five most common adverse events were tiredness, dizziness, respiratory infection, headache and diarrhea.

### Consistency of results with other studies?

See GRADE

### Effect due to factor in study?

Not applicable

### Internal Validity

Reduced statistical power as study was stopped.

### References

Loiseau P;Yuen AW;Duche B;Menager T;rne-Bes MC;

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures

Ref ID 4716

Study Type Randomised Controlled Trial

Funding GlaxoSmithKline

Number of participant N=25

2 patients did not complete the trial (1 was withdrawn because of protocol violation (receiving another investigative drug) and 1 withdrew his consent after 1st treatment)
Inclusion/Exclusion Criteria

Inclusion: 16–65 years; confident diagnosis of epilepsy uncomplicated by suspected psychogenic attacks; partial seizures easily recognisable by patient/carer and classifiable by ICS; minimum of 4 partial seizures/month in each of previous 3 months and baseline period; AED unchanged for previous 3 months; seizures resistant to first-choice AEDs to therapeutic plasma concentrations.

Exclusion: severe organic or psychiatric disease; severe mental subnormalities; progressive neurological disease; abnormal values of laboratory screen considered to be of clinical significance and not attributable to enzyme induction; status epilepticus in previous 6 months or more than once in previous 2 years; use of other investigational drugs in previous 6 months; more than 2 AEDs; other chronic medication; abuse of alcohol or other substances; inability to fulfil protocol requirements; pregnancy, lactation or current risk of pregnancy.

Patient Characteristics

Mean Age
Total (n = 23): 34.2 years (SD 12.41);
LTG/placebo (n = 10): 38.1 years (SD 12.91);
Placebo/LTG (n = 13): 31.2 years (SD 11.62);
Age range
total (n = 23): 20–54 years;
LTG/placebo (n = 10): 21–54 years;
placebo/LTG (n = 13): 20–52 years

Gender
Total (n = 23): men = 12, women = 11;
LTG/placebo (n = 10): men = 5, women = 5;
placebo/LTG (n = 13): men = 7, women = 6

Duration of seizures (years):
total (n = 23): 17.4 years (SD 10.81);
LTG/placebo (n = 10): 17.0 years (SD 12.17);
placebo/LTG (n = 13): 17.8 years (SD 10.14)

Pretrial medication
No. of AEDs at entry:
One AED: total (n = 23): 8;
LTG/placebo (n = 10): 4;
placebo/LTG (n = 13): 4
Two AEDs: total (n = 23): 15;
LTG/placebo (n = 10): 6;
placebo/LTG (n = 13): 9

Ongoing concurrent medication
One patient was receiving thyroxine for hypothyroidism.
One concurrent (AED) (n = 8/23)
Two concurrent AEDs (n = 15/23)
Concurrent AEDs were: CBZ (n = 10/23); PHT (n = 10/23); PB (n = 11/23); VPA (n = 5/23); CLB (n = 2/23)

Co-morbidities
One patient had hypothyroidism

Recruitment
Not stated

Setting
Outpatient setting in European country (France)

Interventions/Test/Factor being investigated
LTG 150 or 300 mg/day

Comparisons
randomised double blind placebo-controlled crossover trial of LTG added on to existing AEDs
Comparing LTG to placebo

Length of Study/Follow-up
Trial lasted 28 weeks.

29 July 2010
Outcome measures studied

Efficacy parameters: countable seizures during each phase, number of days during which seizures occurred
Safety parameters: clinical and neurological examinations, adverse events, haematology, routine blood chemistry

Results

1/ CHANGE IN SEIZURE FREQUENCY; reported as the percentage reduction in total seizure counts for each patient. Percentage change expressed relative to the larger of the two treatment period totals

Intervention:
LTG/placebo sequence group: patient no. 1 (23.12% decrease on LTG); no. 3 (36.3% decrease on LTG); no. 6 (15.15% decrease on LTG); no. 7 (20.0% decrease on LTG); no. 10 (52.38% decrease on LTG); no. 11 (27.27% decrease on LTG); no. 18 (10.0% decrease on placebo); no. 20 (58.87% decrease on placebo); no. 23 (68.66% decrease on LTG); no. 34 (nochange)
Median change in seizure count on LTG: 29% (95% CI: −11 to 52%)
Placebo vs LTG (p < 0.05)

Comparator
Placebo/LTG sequence group: patient no. 2 (35.06% decrease on LTG); no. 4 (18.18% decrease on LTG); no. 5 (19.35% decrease on LTG); no. 8 (40.0% decrease on placebo); no. 9 (100% decrease on LTG); no. 12 (56.25% decrease on LTG); no. 15 (68.75% decrease on LTG); no. 16 (20.0% decrease on placebo); no. 17 (17.64 decrease on placebo); no. 19 (40.0% decrease on LTG); no. 21 (63.15% decrease on LTG); no. 22 (62.5% decrease on LTG); no. 33 (32.0% decrease on placebo)

2/ SEIZURE DAYS; Reported as the total number of seizure days

Intervention
15/23 participants showed an improvement whilst on LTG (n = 3/23 showed at least a 50% decrease in seizure frequency).
Placebo vs LTG (p < 0.05)

Comparator
Data not reported

Safety and adverse effects

3/ PHYSICIAN/PATIENT GLOBAL EVALUATION OF IMPROVEMENT/EFFICACY/TOLERABILITY; Physician reported global evaluation of improvement

Intervention
Number of patients considered better on LTG than placebo (10/23)
Number of patients where there was no change from baseline for either treatment (8/23)

Comparator
Number of patients considered better on placebo than LTG (5/23)

4/ PERCENTAGE RESPONDERS; >=50% reduction in seizures

Intervention
First-phase data LTG (n = 11): 2/11
End-phase data (n = 25): 8/25

Comparator
First-phase data placebo (n = 14): 1/14
End-phase data not reported

Safety and adverse effects

Adverse events

Intervention
Vertigo (n = 3/23) 13%, nervousness (n = 2/23) 9%, anomaly vascular (n = 1/23) 4%, acne (n = 1/23) 4%, oedema peripheral (n = 1/23) 4%, pain (n = 1/23) 4%, conjunctivitis (n = 1/23) 4%, asthenia (n = 1/23) 4%, dizziness (n = 1/23) 4%
All events were classified as not serious and there were no withdrawals because of AEs

Comparator
Nervousness (n = 1/23) 4%, somnolence (n = 1/23) 4%, stupor (n = 1/23) 4%, dry mouth (n = 1/23) 4%, headache (n = 1/23) 4%
All events were classified as not serious and there were no withdrawals because of AEs
Yes. This randomised double-blind placebo-controlled crossover trial assessed the efficacy and safety of LTG in a group of outpatients with therapy-resistant epilepsy. In the very resistant epileptic population represented in this study, the use of LTG for 8 weeks as add-on therapy was effective in reducing total seizure frequencies by more than 50% in 7 out of 23 patients. Fourteen patients experienced fewer simple and complex partial seizures, with 8 patients benefiting by more than a 50% decrease in seizure frequency. The drug was well tolerated over the 2 months treatment period. There were no changes in laboratory safety measures considered to be attributable to lamotrigine. It did not affect the plasma concentration of concomitant antiepileptic drugs.

Effect due to factor in study?
Yes.

Consistency of results with other studies?

Directly applicable to guideline population?
Population, intervention and comparator all relevant to the guideline. Doses used were within the limits of usual doses for the two groups.

Internal Validity
Matsuo F; Bergen D; Faught E; Messenheimer JA; Dren AT; Rudd GD; Lineberry CG;
Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group
Ref ID 4739 1993

Study Type Randomised Controlled Trial
Funding Unknown

Number of participant 216 total with 73 placebo, 71 lamotrigine 300mg/day; 72 lamotrigine 500 mg/day

Inclusion/Exclusion Criteria
Inclusion: Men or women, aged 18 to 65 years; simple or complex partial seizures refractory to treatment with up to three AEDs. Excluded: newly diagnosed (<32 weeks); primary generalized seizures; seizures due to drugs, alcohol, infection, neoplasia, demyelination, metabolic illness, or progressive neurological disorder; taken VPA.

weeks of
weeks of study entry; drug or alcohol abuse; severe psychiatric condition; IQ<50

weeks of study; drug or alcohol abuse; psychiatric condition; IQ <50; medical condition interfering with drug absorption;

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>Placebo</th>
<th>300mg/day</th>
<th>500 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=73</td>
<td>n=71</td>
<td>n=72</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>22(30%)</td>
<td>30(42%)</td>
<td>15(21%)</td>
</tr>
<tr>
<td>Female</td>
<td>51 (70%)</td>
<td>41(58%)</td>
<td>57(79%)</td>
</tr>
<tr>
<td>Mean age (yr)</td>
<td>34</td>
<td>33</td>
<td>32</td>
</tr>
<tr>
<td>Range</td>
<td>16-63</td>
<td>20-57</td>
<td>18-59</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>60</td>
<td>66</td>
<td>68</td>
</tr>
<tr>
<td>Black</td>
<td>9</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Mean duration(yr)</td>
<td>21.5</td>
<td>22.4</td>
<td>21.8</td>
</tr>
</tbody>
</table>

Recruitment
Unknown

Setting
US multicentre

Interventions/ Test/ Factor being investigated
Long term efficacy and safety of lamotrigine 300mg/day and 500 mg/day

Comparisons
Lamotrigine 300mg/day and 500mg/day and placebo

Length of Study/ Follow-up
39 week study with baseline period 12 weeks, a dose-titration and maintenance treatment period 24 weeks and a taper/follow up period 3 weeks.

Outcome measures studied
Primary: reduction in seizure frequency
Secondary: number of days on which a seizure of any type occurred (seizure days) and the investigator's global evaluation of the patients' clinical status

Results
Median seizure frequency decreased by 8% with placebo, 20% with 300 mg lamotrigine and 36% with 500 mg lamotrigine. This decrease was statistically significant only in the 500 group (p=0.004 weeks 1-12; p=0.031 weeks 13-24; p=0.007 weeks 1-24). Seizure frequency decreased by greater than or equal to 50% in one third of the 500 mg group and one fifth of the 300 mg group. The proportion of patients experiencing a greater than or equal to 26% reduction in seizure days was statistically significant (p<0.05) in the 500mg group only.

Safety and adverse effects
9% of patients on lamotrigine withdrew due to adverse events. There was a statistically significant difference in withdrawals due to adverse events between the 300mg group and the 500 mg group(p value not given). Five adverse events were serious - one in the 300 mg group and four in the 500 mg group.

Does the study answer the question?
Lamotrigine appears to be safe and effective as an adjunct therapy in refractory partial seizure patients.

Effect due to factor in study?
Yes

Consistency of results with other studies?
see GRADE

Directly applicable to guideline population?
See GRADE
**Internal Validity**

Multi centre; not ITT analysis

---

Matsuo F; Gay P; Madsen J; Tolman KG; Rollins DE; Risner ME; Lai AA;

**Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study**

Ref ID 4769

**Study Type**  
Randomised Controlled Trial

**Funding**  
Not reported.

**Number of participants**

n=12 (n=8 in lamotrigine group and n=4 in placebo group)

**Inclusion/Exclusion Criteria**

Male or female patients aged 18-65 years with epilepsy but otherwise in general good health with no major organ system dysfunction were eligible for the study. Female patients had to be postmenopausal or surgically sterilized. Patients must have experienced <=40 seizures (preferably partial seizures) during the month before study entry and must not have experienced status epilepticus for the 6 months before receiving study drug. Patients were allowed as many as three currently marketed AEDs and must have had stable (within 50%) therapeutic plasma AED concentrations, with no dosage or drug regimen changes within 2 weeks (4 weeks for barbiturates) before the baseline phase of this study. They were not allowed VPA for 8 weeks before study entry, any over-the-counter medication or alcohol for 1 week before receiving study drug, or any psychoactive drugs other than those used to treat their epilepsy for 2 weeks before receiving study drug or at any time before completion of the follow-up evaluations. Patients who had a history of hypersensitivity to drugs chemically related to LTG were excluded.

**Patient Characteristics**

Twelve white male patients. Mean age was 32 years (range 24-51 years); mean height was 179 cm (range 168-188 cm), and mean weight was 81 kg (range 50-1 26 kg). Treatment groups were similar with regard to age, height, and weight. Most patients in both groups had a history of uncontrolled partial seizures. The mean duration of seizure history was slightly longer for the LTG group (22 +/- 8 years) than for the control group (8 +/- 6 years).

**Recruitment**

Not reported.

**Setting**

Drug Research Center, Utah, North America.

**Interventions/ Test/ Factor being investigated**

Lamotrigine up to 700mg per day.

**Comparisons**

The comparison is between lamotrigine (LTG) and placebo as adjunctive therapy

**Length of Study/ Follow-up**

11 weeks: 2 weeks baseline, 6 weeks titration up to 700mg/day, 2 week tapered dose phas, and 1 week follow up phase.

**Outcome measures studied**

Not specified. Aim of study was to assess dose tolerability and safety of lamotrigine. Also, to determine the pharmacokinetic profile at doses >=500mg/day.

**Results**

Adverse events

Most commonly reported treatment-emergent AE occurring in at least 50% of patients in either treatment group

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>LTG (n=8) incidence (%)</th>
<th>Placebo (n=4) incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>5(63)</td>
<td>3(75)</td>
</tr>
<tr>
<td>Drowsiness</td>
<td>5(63)</td>
<td>2(50)</td>
</tr>
<tr>
<td>Fainting</td>
<td>4(50)</td>
<td>2(50)</td>
</tr>
<tr>
<td>Diplopia</td>
<td>4(50)</td>
<td>0</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>1(13)</td>
<td>2(50)</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>1(13)</td>
<td>2(50)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0</td>
<td>2(50)</td>
</tr>
</tbody>
</table>

---

Page 71 of 306
Unsure. This was mainly a study to examine the tolerability and safety of lamotrigine in large doses. It did not set out to measure the effectiveness of the drug.

Internal Validity

Does the study answer the question?

No. This was mainly a study to examine the tolerability and safety of lamotrigine in large doses. It did not set out to measure the effectiveness of the drug.

Consistency of results with other studies?

Most of the patients enrolled suffered from partial seizures

Safety and adverse effects

1 patient withdrawn from LTG treatment because of a skin rash.

Effect due to factor in study?

Directly applicable to guideline population?

Meador KJ; Loring DW; Huh K; Gallagher BB; King DW;

Comparative cognitive effects of anticonvulsants

Ref ID 4653 1990

Study Type Randomised Controlled Trial

Funding Ciba-Geigy Corporation

Number of participant 15 patients in three equal groups using a randomised triple crossover design

Inclusion/Exclusion Criteria

Inclusion: partial complex epilepsy
Exclusion: Not described

Patient Characteristics

9 men and 6 women; mean age of 39 years (range 19 to 62); mean education of 11 years (range 3-16); mean duration of epilepsy was 16 years (range 1 month to 45 years).

Recruitment Unknown

Setting Augusta, Georgia, USA

Interventions/ Test/ Factor being investigated

The neuropsychological effects of carbamazepine (CBZ), phenobarbital (PB) and phenytoin (PT)

Comparisons: Made re the neuropsychological effects of carbamazepine (CBZ), phenobarbital (PB) and phenytoin (PT)

Length of Study/ Follow-up

9 months; each crossover period was 3 months

Outcome measures studied

The neuropsychological tests included: Digit Span, Selective Reminding Test, Digit Symbol, Finger Tapping, Grooved Pegboard, Choice Reaction Time, P3 evoked potential and Profile of Mood States.

Results

Employing anticonvulsant blood levels and seizure frequencies as covariates, the only significant difference was for Digit Symbol. Phenobarbital was worse when co varied for % anticonvulsant blood level (P<0.03) or for seizure frequency (P<0.03).

Safety and adverse effects

None

Does the study answer the question?

This study shows that patients receiving CBZ, PB and PT have comparable neuropsychological performance on most measures.

Effect due to factor in study?

Due to small sample size this study should be repeated. However, the evaluation was very thorough.
### Consistency of results with other studies?
See GRADE

### Directly applicable to guideline population?
See GRADE

### Internal Validity
Small sample size; no control group

---

Messenheimer J; Ramsay RE; Willmore LJ; Leroy RF; Zielinski JJ; Mattson R; Pellock JM; Valakas AM; Womble G; Risner M;

Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial

**Ref ID 4755** 1994

**Study Type** Randomised Controlled Trial  
**Funding** Not mentioned in the study but HTA (2005) for adults says this was funded by GlaxoSmithKline.

**Number of participant**
Total n=98.
Ten were excluded from the efficacy analysis as they did not complete 12 weeks of the second leg of the crossover.
N=88; n=44 in each arm.

**Inclusion/Exclusion Criteria**

#### Inclusion criteria:
- 18-65 years old.
- Simple or partial seizures (CPS, with or without secondarily generalised seizures) - ILAE classification 1981.

#### Exclusion criteria:
- Newly diagnosed epilepsy (<32 weeks).
- Exhibiting pseudosuzies (nonepileptic seizures) or primary generalised seizures.
- Had seizures secondary to drugs, alcohol, infection, neoplasia, demyelination, metabolic illness, or progressive degenerative disease.
- Had experienced status epileptics within 24 weeks of baseline.
- Had a progressive neurological disorder that was not stable for at least 24 weeks before baseline.
- Had taken valproate within 2 weeks of baseline.
- Concomitant VPA treatment during study.
- Abuse of any prescription or nonprescription drug (including alcohol).
- Current consumption of any psychoactive drug.
- A severe psychiatric condition requiring hospitalisation.
- IQ<50.
- Any medical condition that would interfere with absorption, distribution, metabolism, or excretion of drugs.
- A history of noncompliance.
- A clinically significant chronic medical disorder involving the renal, hepatic, cardiac, vascular, hematopoietic, reticuloendothelial, endocrine, pulmonary, gastrointestinal, genitourinary, or ophthalmic system.
- Those of childbearing potential had to have a negative pregnancy test before study entry and using an approved contraceptive method and signed a statement of `intent to avoid pregnancy' before admission.

**Patient Characteristics**
Total n=88, 47% male and 53% female.
Mean age (years/range): 35, 18-64 years.
Race white n=79; black n=6; other n=3.
Mean duration of epilepsy (years): 23.1.
Mean age at onset (years): 12.
Median seizure frequency (months):
- Simple partial seizures, complex partial seizures, secondarily generalised seizures (n=88): 12.5
- Simple partial seizures, complex partial seizures (n=87): 12.5.
- Secondarily generalised seizures (n=27): 1.5.
- % of patients receiving 1 concomitant AED: 41.
- % of patients receiving 2 concomitant AEDs: 57.
- % of patients receiving 3 concomitant AEDs: 2.
CBZ: 76.
PHT: 45.

By treatment sequence:

LTG/PBO n=44: 48% males, 52% females.
Mean age (years/range): 35 (18-58).
Race: white n=37; black n=4; other n=3.
Median seizure frequency (months):
- simple partial seizures, complex partial seizures, secondarily generalised seizures (n=88): 13.3
- simple partial seizures, complex partial seizures (n=87): 12.5
- Secondarily generalised seizures (n=27): 2.5
% of patients receiving 1 concomitant AED: 45.
% of patients receiving 2 concomitant AEDs: 52.
% of patients receiving 3 concomitant AEDs: 2.

PBO/LTG n=44: 45% males, 55% females.
Mean age (years/range): 35 (18-64).
Race: white n=42; black n=2; other n=0.
Median seizure frequency (months):
- simple partial seizures, complex partial seizures, secondarily generalised seizures (n=88): 12.3
- simple partial seizures, complex partial seizures (n=87): 12.3
- Secondarily generalised seizures (n=27): 1.0
% of patients receiving 1 concomitant AED: 36.
% of patients receiving 2 concomitant AEDs: 61.
% of patients receiving 3 concomitant AEDs: 2.

Recruitment
Not stated.

Setting
US.

Interventions/ Test/ Factor being investigated Lamotrigine 400mg/day or less as adjunctive treatment in patients with refractory partial seizures.
Lamotrigine was taken in capsule form and taken b.i.d at ~12 hour intervals.
Starting dosage was 100mg/day (50mg b.i.d) for 3 days; followed by 200mg/day (100mg b.i.d) for the next four days.
Dosage was increased by 100mg increments at weekly intervals to a maximum of 400mg/day.

Comparisons
Treatment vs placebo.
Cross-over study.

Length of Study/ Follow-up
Total 43 weeks.
Baseline period: 8 weeks.
First treatment period (treatment A): 14 weeks.
Washout period: 4 weeks.
Second treatment period (treatment B): 14 weeks.
Follow-up period (observed): 3 weeks.

Outcome measures studied
Seizure frequency.
Seizure days.
Number withdrawn.
Adverse events.

Results
Statistical analyses found no evidence of a significant treatment-by-period interaction.

Proportion of resosponders (median seizure frequency reduction of 50% or higher compared to placebo during the lamotrigine maintenance period (percentage/range): 20% (13-27%).

ITT analysis of first leg compared LTG and placebo groups:
Median 29% reduction in seizures frequency with LTG compared to 4% reduction with placebo (p=0.0248).
The author concluded that the addition of twice-daily LTG to an existing AED regimen was safe, effective and well tolerated in the study population. The decrease in seizure frequency is only given for all patients and not for lamotrigine and placebo separately.

Safety and adverse effects

5% discontinued participation prematurely from the study due to adverse events compared to 1% of participants in the placebo group. One placebo patient and three LTG patients were withdrawn after exhibiting a rash. The other two left during LTG treatment after experiencing mild to moderate CNS-related symptoms (dizziness for one patient and ataxia, nausea, diplopia, dizziness, headache and somnolence for the second patient. All experiences resolved after LTG discontinuation.

LTG therapy was stopped and the patient withdrawn from the study in three cases (1 with vision abnormality, 2 with rash).

Does the study answer the question?

The author concluded that the addition of twice-daily LTG to an existing AED regimen was safe, effective and well tolerated in these medically refractory partial seizure patients. However, the decrease in seizure frequency is only given for all patients and not for lamotrigine and placebo separately.

Effect due to factor in study?

No power calculation was stated. Yes.

Consistency of results with other studies?

Yes.

Directly applicable to guideline population?

Direct. The dose used was within the limits of usual therapeutic dose.

Internal Validity

differences at baseline;

Mikkelsen B; Berggreen P; Joensen P; Kristensen O; Kohler O; Mikkelsen BO;

Clonazepam (Rivotril) and carbamazepine (Tegretol) in psychomotor epilepsy: a randomized multicenter trial

Ref ID 4654

Study Type Randomised Controlled Trial

Funding Unknown

Number of participants

36 patients: 19 on carbamazepine and 17 on clonazepam

Inclusion/Exclusion Criteria

Included: Previously untreated patients with recently diagnosed psychomotor epilepsy, irrespective of age and number of seizures. Excluded: Patients with progressive brain diseases, presenile dementia, liver and kidney disease and pregnant women.

Patient Characteristics

The median age of 36 patients was 22.3 years (range 6-72 years). The sex ratio of this group was 14/22, 39.61% (M/F).

Recruitment

Not described
Comparison of antiepileptic properties of carbamazepine (CBM or Tegretol) and clonazepam (CLP or Rivotril).

Number of withdrawals; time of withdrawal; number of seizures until time of withdrawal and side effects.

This study indicates clonazepam and carbamazepine to be equally effective in the treatment of newly diagnosed and previously untreated patients with psychomotor epilepsy.

There was no significant difference between the two treatments with regard to number of withdrawals; time of withdrawal; number of seizures until time of withdrawal and side effects (p<0.20). Irrespective of treatment there was a significant decrease in the median number of seizures per month (p<0.01), a decrease that was not significantly different in the two groups (p>0.10). The estimated percentage of patients without seizures during the 6 months of treatment was 49% on carbamazepine and 46% on clonazepam.

Except for a single patient on CBM all patients had one or more side effects during treatment. There were no significant differences between the two groups with regard to sedation, headache, dizziness, impaired memory, marital relations, irritability and other complaints (p<0.05).

This study indicates clonazepam and carbamazepine to be equally effective in the treatment of newly diagnosed and previously untreated patients with psychomotor epilepsy.

Yes

See GRADE

See GRADE

Small population; multi-centre

Lamotrigine extended-release as adjunctive therapy for partial seizures

Ref ID 4836

Study Type Randomised Controlled Trial

Funding GlaxoSmithKline Research and Development (GSK R&D).

Number of participant n=243 (n=121 in lamotrigine group and n=122 in placebo group)

Inclusion/Exclusion Criteria

Inclusion: age >12 years; confident diagnosis of epilepsy with partial seizures with or without secondary generalized seizures for >24 weeks before the baseline phase of the study; had at least eight partial seizures during that 8-week baseline phase with at least one partial seizure during each 4-week period; and were treated with a stable regimen of one or two AEDs for at least 4 weeks before starting the baseline phase.

Exclusion criteria: presence of primary generalized seizures, status epilepticus during or within 24 weeks before the start of the baseline phase, chronic treatment with three or more AEDs, current or previous use of lamotrigine, current use of felbamate or adherence to the ketogenic diet, and pregnancy.

Patient Characteristics

<table>
<thead>
<tr>
<th>Lamotrigine extended-release (n = 116)</th>
<th>Placebo (n = 120)</th>
</tr>
</thead>
</table>

29 July 2010 Page 76 of 306
Demographics
Male, n (%)                                                       54 (47)                              63 (53)
Race, n (%)
African American/African                                        3 (3)                                10 (8)
American Indian/Alaskan Native                                  4 (3)                                3 (3)
Asian: Central/South Asian                                      16 (14)                              9 (8)
Asian: East Asian                                               15 (13)                              14 (12)
Asian: Southeast Asian                                          0 (0)                                2 (2)
White: White/Caucasian/European                                 77 (67)                              83 (69)
Mean age, y (SD)                                                 35.8 (12.7)                          37.5 (14.4)
Age stratum, n (%)
<16 y                                                           5 (4)                                4 (3)
16 to 65 y                                                      108 (93)                             112 (93)
>65 y                                                           3 (3)                                4 (3)
Baseline clinical characteristics
Mean age at first seizure, y (SD)                               14.9 (12.2)                          16.4 (13.7)
Mean duration of epilepsy, y (SD)                               21.8 (13.2)                          22.1 (16.1)
Seizure type, n (%)
Simple                                                           54 (47)                              58 (48)
Complex                                                          83 (72)                              91 (76)
Partial with secondary generalization                           38 (33)                              42 (35)
Median (range) number of partial seizures/wk during baseline phase 2.3 (0.5–59.0) 2.1 (0.9–50.0)
Concomitant AED regimens, n (%)
Valproate with enzyme-inducing AEDs                             7 (6)                                24 (20)
Valproate alone or with non–enzyme-inducing AEDs               23 (20)                              19 (16)
Enzyme-inducing AEDs alone or with neutral AEDs                 59 (51)                              43 (36)
Neutral AEDs                                                     27 (23)                              34 (28)
Most common concomitant AEDs, n (%)
Carbamazepine                                                    50 (43)                              50 (42)
Valproic acid                                                    27 (23)                              42 (35)
Topiramate                                                       18 (16)                              17 (14)
Oxcarbazepine                                                   11 (9)                               22 (18)
Phenytoin                                                        16 (14)                              16 (13)
Levetiracetam                                                    15 (13)                              13 (11)

Recruitment
Not reported.

Setting
Study sites in N and S. America, Europe and Asia.

Interventions/ Test/ Factor being investigated
Comparisons
Lamotrigine XR (extended release) in 3 doses (200mg/day, 500mg/day and 300mg/day) depending on type of AED currently used.

Length of Study/ Follow-up
Outcome measures studied
Primary outcome: % change from baseline in weekly partial seizure frequency during maintenance phase. Secondary outcomes: % change during titration phase and maintenance alone, response rate, time to response, % improved.

Results
Primary outcome
All partial seizures. The median percent reduction from baseline in weekly frequency of partial seizures during double-blind treatment (escalation and maintenance phases) was higher with lamotrigine XR (46.1%) than placebo (24.2%) (median difference: 18.2%; p=0.0004).

Secondary outcomes
Response rate. The percentage of patients with >=50% reduction in partial seizure frequency during doubleblind treatment (escalation and maintenance phases) was significantly higher in the lamotrigine XR group (42.2%) than the placebo group (24.2%) (p=0.0037).
During maintenance, the percentage of patients who were seizure free was higher in the lamotrigine XR group (18.9%) than the placebo group (5.1%) (p= 0.0016).

The time to >=50% reduction in partial seizure frequency after 1 week of double-blind treatment was significantly shorter in the lamotrigine XR group than the placebo group (p= 0.0007). This treatment difference reached and subsequently maintained statistical significance at day 18 of the escalation phase (p= 0.0448).

Secondarily generalized seizures.
The median % reduction from baseline in weekly frequency of secondarily generalized seizures during doubleblind treatment was significantly higher in the lamotrigine XR group (55.2%) than the placebo group (3.2%) (median difference between groups: 38.0%; p=0.0036). Similar results were observed for the escalation phase and the maintenance phase.

The percentage of patients with >=50% reduction in partial seizure frequency during doubleblind treatment was significantly higher in the lamotrigine XR group (52.2%) than the placebo group (25.5%) (p=0.0292). Similar results were observed for the escalation phase and the maintenance phase.

Investigator assessment of clinical status.
The % of patients with improvement in investigator-rated clinical status during double-blind treatment was higher in the lamotrigine XR group than the placebo group for overall clinical status (60% vs 40%; p=0.0012) and for the individual items of seizure frequency. The % of patients with deterioration in investigator-rated clinical status during double-blind treatment was higher in the lamotrigine XR group than the placebo group for adverse events (21% vs 9%; p= 0.03).

Patient-rated status.
The % of patients reporting improvement in seizure control (mild, moderate, or marked) during double-blind treatment was higher in the lamotrigine XR group (72%) than the placebo group (48%; p=0.0001).

Adverse events

Adverse events reported in >5% of patients in either treatment group (safety population)

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Lamotrigine extended-release (n=118)</th>
<th>Placebo (n=121)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>20 (17)</td>
<td>18 (15)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>21 (18)</td>
<td>6 (5)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>3 (3)</td>
<td>13 (11)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>8 (7)</td>
<td>5 (4)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>8 (7)</td>
<td>5 (4)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4 (3)</td>
<td>7 (6)</td>
</tr>
<tr>
<td>Nausea</td>
<td>8 (7)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Asthenia</td>
<td>6 (5)</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Tremor</td>
<td>6 (5)</td>
<td>1 (&lt;1)</td>
</tr>
</tbody>
</table>

The most common adverse events were headache and dizziness.

Safety and adverse effects

Does the study answer the question?

Yes. Once-daily adjunctive lamotrigine XR compared with placebo effectively reduced partial seizure frequency.

Effect due to factor in study?

Yes. The study had 90% power to detect a difference between the treatment and placebo groups in the primary outcome.

Consistency of results with other studies?
The study was comprised of patients with a diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures.

Nieto-Barrera M; Brozmanova M; Capovilla G; Christe W; Pedersen B; Kane K; O’Neill F; Novotny E; Renfroe B; Yardi N; Nordli D; Ness S; Wang S; Weber T; Kurland CL; Yuen E; Eerdekens M; Venkatraman L; Nye JS; Ford L;

A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy

Ref ID 4723 2001

Study Type  | Randomised Controlled Trial  | Funding | Unknown
--- | --- | --- | ---
Number of participant | 417 lamotrigine and 201 carbamazepine |
Inclusion/Exclusion Criteria | Inclusion: Newly diagnosed, untreated partial epilepsy; 2 seizures in preceding 6 months  
Exclusion: Not discussed |
Patient Characteristics | Aged 2-83 years with median age 47 years in both groups and 53% female in both groups. Mean weight 19 kg in lamotrigine group and 20 kg in carbamazepine group |
Recruitment | Unknown |
Setting | Spain, Slovakia, Italy, Germany, Denmark, UK |
Interventions/Test/Factor being investigated | A comparison of monotherapy with lamotrigine or carbamazepine |
Comparisons | Lamotrigine vs. carbamazepine |
Length of Study/Follow-up | 24 weeks |
Outcome measures studied | Proportion of patients free of seizures during the last 16 weeks of treatment and proportion of patients who did not withdraw before the end of week 18 and were seizure free in the last 16 weeks of the study. |
Results | Efficacy was similar with both treatments (65% with lamotrigine, 73% with carbamazepine, p=0.085), i.e. patients who were seizure free during the last 16 weeks of treatment. More patients receiving lamotrigine completed the study (81%) compared with those receiving carbamazepine (77%). This was due to adverse events. |
Safety and adverse effects | The proportion of patients who experienced adverse events in the lamotrigine group was lower (218 patients, 52%) compared with the carbamazepine group (120, 60%). Somnolence was the only adverse event reported at an incidence of greater than 5%. Paediatric patients and elderly patients showed better tolerability to lamotrigine than to carbamazepine (5% vs. 7% and 20% vs. 50% respectively). |
Does the study answer the question? | Lamotrigine appears to be as effective as carbamazepine in patients with newly diagnosed partial epilepsy and also appears to be better tolerated. |
Effect due to factor in study? | Yes |
Consistency of results with other studies? | See GRADE |

29 July 2010  Page 79 of 306
Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures

Ref ID 5087  2010 Mar 2

Study Type  Randomised Controlled Trial  Funding  Johnson and Johnson Pharmaceuticals.

Number of participant  n=149; placebo n=37, topiramate 5mg/kg/day n=38; topiramate 15mg/kg/day n=37; topiramate 25mg/kg/day n=37.

Inclusion/Exclusion Criteria

Inclusion criteria:
- aged 1-24 months, inclusive, or at least 41 weeks of gestational age;
- weighing ≥3.5kg and <15.5kg, length ≥49cm;
- receiving regular enteral feeding;
- diagnosed with Partial onset seizures with or without secondary generalisation (at least 1 month before for infants older than 6 months, and at least 2 weeks before for infants aged 6 months or younger);
- CT or MRI scan to confirm absence of a progressive lesion (lesions of tuberous sclerosis and Sturge-Weber syndrome were allowed) and EKG with 'no abnormal, clinically significant' interpretations as made by the central reader;
- must have been receiving at least one concurrent marketed AEE other than topiramate for 1 month or more for infants older than 6 months and for more than 2 weeks for infants aged 6 months or younger;
- existing treatment was concluded by investigator to be inadequate in controlling seizures if infants, at optimised doses of AEDs had at least 1 seizure in the 4 weeks before screening;

Exclusion criteria:
- if could not take oral medications;
- had a surgically implanted and functioning vagus nerve stimulator;
- had epilepsy surgery within 3 months before screening;
- had febrile seizures, seizures due to an acute medical illness or non-epileptic seizures within 2 weeks before first day of screening;
- Had progressive neurologic disorders, uncontrolled medical illness, disturbances of autonomic function, inborn errors of metabolism and known hypersensitivity to topiramate.
- Status epilepticus (30 minutes of continuous motor seizures) in the 2 weeks before;
- infants who had received more than 4 courses of rescue treatments (such as diazepam) in the month before the first day of screening;
- infants using 3 or more concurrent AEDs.

Patient Characteristics

Placebo vs 5mg/kg/day vs 15mg/kg/day vs 25mg/kg/day:

Age mean (sd) months: 12 (5.9) vs 13 (7.6) vs 12 (6.2) vs 10 (5.2).

Males, n(%): 14 (38) vs 22 (58) vs 19 (51) vs 23 (62).

Race: white 26 (70) vs 25 (66) vs 19 (51) vs 21 (57); black or African American 1 (3) vs 1 (3) vs 1 (3) vs 2 (5); Asian 9 (24) vs 7 (18) vs 11 (30) vs 7 (19); other: 1 (3) vs 5 (13) vs 6 (16) vs 7 (19).

Recruitment

Not reported.

Setting

19 countries in Asia, EU, Latin America, US.

Interventions/ Test/ Factor being investigated

Topiramate 5mg/kg/day vs 15mg/kg/day vs 25mg/kg/day vs placebo.

Comparisons

Between treatments and between treatments and placebo.

Length of Study/ Follow-up

This study reports only the double-blind treatment phase but there was a 1 year open label extension and follow up visit 30 days after last treatment.

Outcome measures studied

Primary: % reduction in daily partial onset seizures rate.

Results

Placebo vs 5mg/kg/day vs 15mg/kg/day vs 25mg/kg/day:

At least 50% reduction in seizure frequency: 10/37 vs 9/38 vs 13/37 vs 15/37.
Withdrawal due to treatment emergent adverse events: placebo 5% vs topiramate 4%.

Safety and adverse effects

Incidence of TEAEs higher in the combination topiramate groups (81%) vs placebo group (51%). Incidences of anorexia and weight decrease in topiramate groups were dose related. Status epilepticus in 1 infant each on 5mg/kg/day and placebo. No incidence of death in double-blind phase, but occurred on an unknown date after early discontinuation of topiramate 5mg/kg/day and was considered to have a doubtful relationship with topiramate.

Does the study answer the question?

Yes

Effect due to factor in study?

Yes.

Consistency of results with other studies?

Direct.

Directly applicable to guideline population?

Direct.

Internal Validity

Peltola J;Coetzee C;Jimenez F;Litovchenko T;Ramaratnam S;Zaslavaskiy L;Lu ZS;Sykes DM;Levetiracetam XN;

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial

Ref ID 4837 2009 Mar

Study Type Randomised Controlled Trial Funding UCB, Inc and UCB Pharma, SA.

Number of participant n=188 (n=79 in both the placebo and the levetiracetam XR groups)

Inclusion/Exclusion Criteria

Inclusion criteria: 12–70 years of age, with recurrent partial-onset seizures despite receiving at least one but no more than three concomitant AEDs, weigh at least 50 kg and have a confirmed diagnosis of POS, whether or not secondarily generalized, for at least 6 months preceding the screening visit and refractory to pharmacotherapy with one to three AEDs. During the 8-week baseline period to have at least eight partial seizures, with or without secondary generalization, and at least two partial seizures in each 4-week interval of the baseline period. Female patients of childbearing potential needed to use a medically accepted contraceptive method.

Exclusion criteria: history of status epilepticus, seizure clusters, flurries of seizures, pseudoseizures, or status epilepticus within 3 months preceding the screening visit. Other exclusion criteria included neoplasia, progressive cerebral or neurodegenerative disease, presence of another clinical condition or clinically significant abnormal laboratory value likely to influence the course of the trial.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N = 79)</th>
<th>LEV XR (N = 79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) Mean ± SD</td>
<td>32.38 ± 12.60</td>
<td>33.97 ± 13.41</td>
</tr>
<tr>
<td>Gender Female, n</td>
<td>32</td>
<td>27</td>
</tr>
<tr>
<td>Male, n</td>
<td>47</td>
<td>52</td>
</tr>
<tr>
<td>Race White, n (%)</td>
<td>35 (44.3)</td>
<td>37 (46.8)</td>
</tr>
<tr>
<td>Hispanic, n (%)</td>
<td>15 (19.0)</td>
<td>15 (19.0)</td>
</tr>
<tr>
<td>Other, n (%)</td>
<td>2 (2.5)</td>
<td>0</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Mean ± SD                          67.80 ± 15.55                 70.21 ± 15.66
Min–max                             48.0–134.0                 50.0–118.0
BMI (kg/m2)                           24.6 ± 4.55                 24.76 ± 4.71
Min–max                               16.8–38.6                 17.6–47.1
Epilepsy duration at
randomization (years)               16.43 ± 11.93                13.11 ± 10.87
Min–max                                  0.7–53.5                 0.8–42.6
Age at epilepsy diagnosis (years)     15.95 ± 11.51                20.86 ± 15.18
Min–max                                  0.1–47.9                 0.3–61.5
Seizure count in the 8-week
baseline period (mean ± SD)            30.3 ± 52.6                39.7 ± 66.3
Partial-onset seizures                 30.6 ± 52.5                40.7 ± 66.0
All seizure types
Number of concomitant AEDs
at baseline, n (%)                     0                        1 (1.3)               0
                                       1                        17 (21.5)              27 (34.2)
                                       2                        38 (48.1)              36 (45.6)
                                       3                        22 (27.8)              12 (15.2)
                                       >3                       1 (1.3)                4 (5.1)

Recruitment
Not reported.

Setting
34 sites in seven countries.

Interventions/ Test/ Factor being investigated
Extended release levetiracetam (2 x 500mg per day) as adjunctive therapy to currently used AEDs.

Comparisons
Comparison is between levetiracetam XR and placebo as adjunctive therapy to currently used AEDs.

Length of Study/ Follow-up
20 weeks: 8 week baseline period and 12 weeks double blind treatment period.

Outcome measures studied
Primary outcome is frequency of partial-onset seizures per week over the treatment period.

Secondary outcomes: responders (>=50% reduction), seizure freedom, adverse events, laboratory tests, physical and neurologic examinations, vital signs

Results
Changes from baseline in partial-onset seizures
Median seizure frequency per week
ITT population (primary efficacy analyses)

<table>
<thead>
<tr>
<th></th>
<th>Placebo n=79</th>
<th>LEV XR n=79</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline (min–max)</td>
<td>2.11 (1.0–53.5)</td>
<td>1.80 (0.0–47.3)</td>
</tr>
<tr>
<td>Treatment period (min–max)</td>
<td>1.36 (0.0–33.9) n = 78</td>
<td>0.99 (0.0–29.1) n = 75</td>
</tr>
<tr>
<td>% Reduction from baseline (min–max)</td>
<td>33.40 (-199.0–100.0) n = 78</td>
<td>46.07 (210.5–100.0) n = 74</td>
</tr>
<tr>
<td>Log-transformed value: LSpacean ± SE</td>
<td>1.067 ± 0.052 (n = 78)</td>
<td>0.912 ± 0.053 (n = 75)</td>
</tr>
<tr>
<td>Two-sided 95% CI (LEV XR–placebo)</td>
<td>0.009–0.301</td>
<td>Reduction (%)</td>
</tr>
<tr>
<td>Two-sided 95% CI (% reduction)</td>
<td>0.9%–26.0%</td>
<td>p-value</td>
</tr>
</tbody>
</table>

Secondary outcomes
Responder rates
In the LEV XR group, 43% of patients (34 of 79) showed a reduction from baseline of at least 50% in partial-onset seizures compared with 29% (23 of 79) in the placebo group (odds ratio 1.84 (0.95–3.55, p = 0.07).
Yes. This is a well-conducted trial which was powered sufficiently to detect differences between the treatment groups. Once daily levetiracetam extended release was effective in patients with partial-onset seizures.

Seizure-free days
LEV XR group had a median of 5.43 (min–max 0.1–6.4) seizure-free days per week at baseline and 6.1 (min–max 0.0–7.0) over the entire treatment period (median change of 13.1%). The placebo group had a median of 5.38 (min–max 0.0–6.5) seizure-free days per week at baseline and 5.83 (min–max 0.0–7.0) over the treatment period (median difference of 8.01%).

Adverse events
Treatment-emergent adverse events reported by >=5% patients in either treatment group (safety population)

| Preferred Term | Placebo (N = 79) | LEV XR (N = 77) |
|----------------|------------------|----------------|---|
| Patients with at least one adverse event, n (%) | 43 (54.4) | 41 (53.2) |
| Somnolence, n (%) | 2 (2.5) | 6 (7.8) |
| Irritability, n (%) | 0 | 5 (6.5) |
| Headache, n (%) | 11 (13.9) | 5 (6.5) |
| Dizziness, n (%) | 2 (2.5) | 4 (5.2) |
| Influenza, n (%) | 3 (3.8) | 6 (7.8) |
| Nasopharyngitis, n (%) | 4 (5.1) | 5 (6.5) |
| Nausea, n (%) | 2 (2.5) | 4 (5.2) |

Effect due to factor in study?
Yes. The study had 90% power to detect a difference between the groups with regard to seizure frequency.

Consistency of results with other studies?
All patients in the study had a diagnosis of partial-onset seizures.

Internal Validity
Prevey ML; Delaney RC; Cramer JA; Cattanach L; Collins JF; Mattson RH;

Effect of valproate on cognitive functioning. Comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group

Ref ID 4817

Study Type Randomised Controlled Trial

Funding Not stated. Main study funded by Department of Veteran Affairs Medical Research Service, with additional support from Abbot Lab and Ciba-Geigy

Number of participants
26 patients from carbamazepine and 39 patients from valproate group

29 July 2010 Page 83 of 306
The impact of carbamazepine and valproate monotherapy on cognitive functioning is similar. Both drugs produce minimal negative effects compared to pre-treatment baseline performance.
Consistency of results with other studies?

Directly applicable to guideline population?

Uncertain. Selective group of patient. The main study was not included in the review.

Internal Validity

Privitera M; Fincham R; Penny J; Reife R; Kramer L; Pledger G; Karim R;

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group

Ref ID  4700  1996

Study Type  Randomised Controlled Trial  Funding  Robert Wood Johnson

Number of participant  190 total: 48 to 600 mg/day; 48 to 800 mg/day; 47 to 1000mg/day; 47 to placebo

Inclusion/Exclusion Criteria

Inclusion: History of partial onset seizures with EEG verification; experienced 12 partial seizures during 12 week baseline period preceding the double blind study phase while maintained on therapeutic AEDs. Age 18-65. Exclusion: Progressive neurological disease/status, child-bearing potential, alcohol or drug abuse, psychiatric disorder, nephrolithiasis, noncompliance history, abnormal baseline lab tests.

Patient Characteristics

Gender: Male 152  
Female 38

Race: White 170  
Black 16  
Other 4

Age (yr): Mean 35.5  
Range 18-68

Recruitment  Unknown

Setting  Multi-centre

Interventions/ Test/ Factor being investigated

Safety and efficacy of three dosages of topiramate (600, 800, and 1,000 mg/day) as adjunctive therapy

Comparisons

Three dosages of topiramate and placebo

Length of Study/ Follow-up

12 week baseline and 18 week double blind phase divided into 6 week titration segment and a 12 week stabilization period

Outcome measures studied

Primary: percent reduction in average monthly seizure rate in the double blind phase relative to the baseline phase.

Secondary: percent treatment responders (those with greater than or equal to 50% reduction in seizure rate);

Results

<table>
<thead>
<tr>
<th>% seizure reduction</th>
<th>Placebo</th>
<th>600 mg</th>
<th>800 mg</th>
<th>1000 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median</td>
<td>1.2</td>
<td>40.7</td>
<td>41.0</td>
<td>37.5</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Treatment responders (>50% reduction in seizure frequency)

<table>
<thead>
<tr>
<th>Number</th>
<th>Placebo</th>
<th>600 mg</th>
<th>800 mg</th>
<th>1000 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>4/47</td>
<td>21/48</td>
<td>19/48</td>
<td>18/47</td>
</tr>
<tr>
<td>Percent</td>
<td>8.5</td>
<td>43.8</td>
<td>39.6</td>
<td>38.3</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Safety and adverse effects

CNS events were the most common adverse events including dizziness, fatigability, somnolence, nystagmus, diplopia, confusion, thinking abnormal and headache. Discontinuations due to adverse events were: 2% (1/47) placebo; 21% (10/48) - 600mg; 10% (5/48) - 800 mg and 17% (8/47) - 1000 mg. No remarkable abnormal
Toprimate may be a promising AED for adjunctive therapy in refractory partial onset seizures and is highly efficacious and well tolerated.

**Internal Validity**

26% of total sample

**Does the study answer the question?**

Yes

**Effect due to factor in study?**

See GRADE

**Consistency of results with other studies?**

See GRADE

**Directly applicable to guideline population?**

See GRADE

**Clinical lab findings.**

There were 60 men and 27 women with ages ranging from 18-77 years (mean, 37.4). Twenty seven patients (31%) had generalized convulsive seizures, 18 (20.7%) had partial seizures that secondarily generalized and 37 (42.5%) had partial seizures only.

**Comparison of treatments is studied**

Comparison of Carbamazepine (CBZ) with phenytoin (PHT)

**Comparisons**

Comparison of Carbamazepine (CBZ) with phenytoin (PHT)

**Length of Study/ Follow-up**

Minimum of 6 months

**Outcome measures studied**

Primary: treatment failure defined as the continued occurrence of seizures despite doses of medications that produced toxic symptoms or an increase in seizure frequency with therapeutic plasma levels.

Secondary: major and minor side effects

**Results**

The incidence of major side effects (8 patients in each group - 22.9%), minor side effects, and complete seizure control (85%) was the same in both groups. A mild but significant elevation of WBC count was found before initiation of drug treatment in the patients presenting with generalized convulsive seizures. Sporadically, elevations in SGOT and LDH were seen; WBC counts below 4,000 were reported, but these were not clinically significant.

**Safety and adverse effects**

See trial report. Major adverse effects: erythematous maculopapular rash (4 patients on PHT and one patient taking CBZ); one patient with pruritus on CBZ; cognitive impairment (1 patient) and elevated liver enzymes (1 patient) and generalized headache (1 patient). Minor side effects: nystagmus was most common and a fine
CBZ was as effective as PHT in the control of partial and generalized convulsive seizures. Although the frequency of different side effects varies between the drugs, the overall rate of major and minor side effects was the same for CBZ and PHT.

**Does the study answer the question?**
CBZ was as effective as PHT in the control of partial and generalized convulsive seizures. Although the frequency of different side effects varies between the drugs, the overall rate of major and minor side effects was the same for CBZ and PHT.

**Effect due to factor in study?**
Small study should be repeated.

**Consistency of results with other studies?**
See GRADE

**Directly applicable to guideline population?**
See GRADE

**Internal Validity**
Small sample size

Rastogi P, Mehrotra TN, Agarwala RK; Singh VS;

Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy

Ref ID 4662 1991

**Study Type**
Randomised Controlled Trial

**Funding**
Unknown

**Number of participant**
94 - 49 received sodium valproate and 45 received phenytoin

**Inclusion/Exclusion Criteria**
Inclusion: Patients with at least 2 fits per month

**Patient Characteristics**
70 males and 24 females ranging in age from 8-52 years.

**Recruitment**
Not described

**Setting**
Epilepsy Clinic at SVBP Hospital, Meerut India

**Interventions/ Test/ Factor being investigated**
Sodium valproate 15 mg/kg/day in 3 divided doses with increments as needed; Phenyltoin in dose of 5 mg/kg/day as a single bedtime dose and increased as needed

**Comparisons**
Sodium valproate vs. phenytoin for control of seizures

**Length of Study/ Follow-up**
None reported.

**Outcome measures studied**
Seizure reduction: excellent (100% reduction), good (75-99% reduction), fair (50-74% reduction) and poor (less than 50% reduction).

**Results**

<table>
<thead>
<tr>
<th>Seizure Type</th>
<th>Patients (49)</th>
<th>Excellent</th>
<th>Good</th>
<th>Fair</th>
<th>Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonic Clonic</td>
<td>28</td>
<td>16(57%)</td>
<td>8(29%)</td>
<td>3(10%)</td>
<td>1(4%)</td>
</tr>
<tr>
<td>Tonic</td>
<td>5</td>
<td>2 (40%)</td>
<td>2(40%)</td>
<td>1(20%)</td>
<td>--</td>
</tr>
<tr>
<td>Myoclonic</td>
<td>2</td>
<td>--</td>
<td>2(100%)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Simple partial</td>
<td>8</td>
<td>5(62.5%)</td>
<td>2(25%)</td>
<td>1(12.5%)</td>
<td>--</td>
</tr>
<tr>
<td>Complex partial</td>
<td>3</td>
<td>--</td>
<td>1(33.3%)</td>
<td>--</td>
<td>2(66.7%)</td>
</tr>
<tr>
<td>Sec. gen. of Partial seizures</td>
<td>3</td>
<td>1(33.3%)</td>
<td>2(66.7%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Seizure Type</th>
<th>Patients (49)</th>
<th>Excellent</th>
<th>Good</th>
<th>Fair</th>
<th>Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonic Clonic</td>
<td>27</td>
<td>18(67%)</td>
<td>7(26%)</td>
<td>2(7%)</td>
<td>--</td>
</tr>
<tr>
<td>Tonic</td>
<td>5</td>
<td>3 (60%)</td>
<td>1(20%)</td>
<td>1(20%)</td>
<td>--</td>
</tr>
<tr>
<td>Simple partial</td>
<td>8</td>
<td>2(25%)</td>
<td>4(50%)</td>
<td>1(12.5%)</td>
<td>1(12.5%)</td>
</tr>
<tr>
<td>Complex partial</td>
<td>1</td>
<td>--</td>
<td>1(1005)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Sec. gen. of Partial seizures</td>
<td>4</td>
<td>--</td>
<td>1(25%)</td>
<td>3(75%)</td>
<td></td>
</tr>
</tbody>
</table>

29 July 2010 | Page 87 of 306
It appears that while sodium valproate and phenytoin were equally effective in controlling generalised epilepsy, valproate was a better drug for controlling partial seizures.

Safety and adverse effects
The most common side effects seen with valproate included GI disturbances (12%), drowsiness (6.12%), and weight gain (2.04%). Side effects with phena did not include gum hyperplasia (17.7%), nystagmus (13.33%), ataxia (2.2%), GI disturbances (4.44%) and drowsiness (4.44%).

Does the study answer the question?
It appears that while sodium valproate and phenytoin were equally effective in controlling generalised epilepsy, valproate was a better drug for controlling partial seizures.

Effect due to factor in study?
Yes

Consistency of results with other studies?
See GRADE

Directly applicable to guideline population?

Internal Validity
Sachdeo RC; Leroy RF; Krauss GL; Drake ME; Green PM; Leppik IE; Shu VS; Ringham GL; Sommerville KW;

Tigabine therapy for complex partial seizures. A dose-frequency study. The Tigabine Study Group
Ref ID 4737

Study Type
Randomised Controlled Trial

Funding
Abbott Laboratories, North Chicago Ill.

Number of participant
n=318 (n=107 in placebo group, n=106 in 16mg x 2 group and n=105 in 8mg x 4 group.)

Inclusion/Exclusion Criteria
Inclusion criteria: age 12 to 75 years, min body weight 45kg, not pregnant, diagnosis of a complex partial seizure (CPS) with or without secondary generalization, at least 6 CPSs in the 8 week period before screening, stable regimen of 1 to 3 marketed AEDs.
Exclusion criteria: pseudoseizures, any disease of the CNS, history of drug abuse or addition or severe psychiatric illness.

Patient Characteristics
Demographic and clinical characteristics of 318 randomized patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo n=107</th>
<th>16mg x 2 n=106</th>
<th>8mg x 4 n=105</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, F:M, %</td>
<td>50:50</td>
<td>39:61</td>
<td>43:57</td>
</tr>
<tr>
<td>Race, white: black; other %</td>
<td>86:7:7</td>
<td>84:9:7</td>
<td>90:5:6</td>
</tr>
<tr>
<td>Mean age (range), y (66)</td>
<td>35.3(13-71)</td>
<td>33.4(12-67)</td>
<td>32.6(12-66)</td>
</tr>
<tr>
<td>Mean weight (range) kg (133)</td>
<td>71(41-118)</td>
<td>76(37-162)</td>
<td>75(33-133)</td>
</tr>
<tr>
<td>Median period with epilepsy (range) y</td>
<td>24(2-62)</td>
<td>18(3-54)</td>
<td>22(1-45)</td>
</tr>
<tr>
<td>Mean No. of antiepilepsy drugs ever taken (range)</td>
<td>6.5(2-20)</td>
<td>6.0(1-14)</td>
<td>6.9(2-20)</td>
</tr>
</tbody>
</table>

Recruitment
Not reported.

Setting
26 clinical centres in the United States.

Interventions/ Test/ Factor being investigated
Tiagabine in two dose regimens 16mg given 2 times per day and 8mg given 4 times per day as adjunctive therapy.

Comparisons
The study compares tiagabine with placebo as adjunctive therapy to currently used AEDs.

Length of Study/ Follow-up
24 weeks: 8 week baseline period, 12 weeks treatment period and 4 weeks termination period.
Primary outcome is the change from the baseline to experimental period in the 4 week frequency of CPSs. Secondary outcomes: same analysis for simple partial and partial seizures with sec. generalization.

**Results**

Primary outcome

**Median reduction**

In the ITT population patients on 16mg x 2 per day had a median reduction in the 4 week CPS frequency of 1.6 seizure from the baseline of 8.4 (p=0.06 vs P=0.2 with placebo from a baseline of 8.0). In patients who were taking 8mg x 4 per day the median reduction was 1.2 from a baseline of 7.9 (p=0.02 vs the placebo group).

Response rates
A reduction of 50% or more was observed in 33 (31%) of the patients who were taking 16mg x 2, 28(27%) of those who were taking 8mg x 4, , and 10(10%) of those in the placebo group (p<=.001 for each of the tiagabine groups compared to placebo).

Secondary outcomes

**Median reduction in simple partial seizures**
The 4 week frequency of simple partial seizures decreased by a median of 1.4 and 2.1 seizures in the group of patients who received 16mg x 2 per day and 8mg x 4, respectively, while the 4 week frequency rose by 0.6 seizures in the placebo group (p=0.008 for the 8mg x group vs placebo).

Response rates
Significantly more patients in the 16mg x 2 group had 50% or more reductions in the frequency of simple partial seizures than in the placebo group: 37% vs 16% (p=0.03). For the 8mg x 4 group there was no significant difference (p=.21, 29% vs 16%).

**Median reduction in secondarily generalized tonic-clonic (SGTC) seizures**
Patients in the 16mg x 2 group, the 8mg x 4 group, and the placebo group experienced median decreases in SGTC seizures of 0.8, 0.7 and 0.3 respectively (p=0.69 vs 16mg x 2; p=0.48 vs 8mg x 4).

Response rates
The combined partial seizure frequencies declined by 50% or more in 28% of the group that received tiagabine 2 times per day and 23% of the group that was given tiagabine 4 times per day compared with 8% of the placebo group (p<0.001 and p<0.002, respectively).

**Adverse events**

Adverse events occurring significantly more often in tiagabine-treated patients than in placebo-treated patients*

<table>
<thead>
<tr>
<th>Treatment group, % of patients</th>
<th>Placebo</th>
<th>16mg x 2</th>
<th>8mg x 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events n=107</td>
<td>n=106</td>
<td>n=105</td>
<td></td>
</tr>
<tr>
<td>Nervousness</td>
<td>0.9</td>
<td>9.4*</td>
<td>10.5*</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2.8</td>
<td>9.4*</td>
<td>3.8</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0.9</td>
<td>7.5*</td>
<td>9.5*</td>
</tr>
<tr>
<td>Emotional lability</td>
<td>0.9</td>
<td>0.9</td>
<td>7.6*</td>
</tr>
<tr>
<td>Amnesia</td>
<td>0.9</td>
<td>6.6*</td>
<td>4.8</td>
</tr>
<tr>
<td>Other pain</td>
<td>2.8</td>
<td>9.4*</td>
<td>1.0</td>
</tr>
</tbody>
</table>

* P<=0.05 vs placebo

28 patients discontinued drug therapy because of adverse events during the titration and fixed-dose periods: 13(12%) in the group that received 16mg x 2, 8(8%) in the group that received 8mg x 4 and 7(7%) in the placebo group. Serious adverse events occurred in 6 patients (2 from each treatment group).

**Safety and adverse effects**

**Does the study answer the question?**

Yes. Adjunctive tiagabine therapy given as 32mg/day (16mg x 2 or 8mg x 4) reduced the frequency of partial seizures in patients whose conditions were refractory to treatment with other AEDs.
Effect due to factor in study? Unsure. This is a relatively large study but no power calculation was performed. It is not clear how much power this study had to detect differences between the treatment groups.

Consistency of results with other studies? All patients had to have a diagnosis of complex partial seizures to be included in this study.

Internal Validity

Sackellaes JC; Ramsay RE; Wilder BJ; Browne TR; Shellenberger MK;

Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures

Ref ID 996 2004 Jun

Study Type Randomised Controlled Trial Funding Dainippon Pharmaceutical Company and Elan Pharmaceuticals, Inc.

Number of participant n=152 (n=74 in the placebo group and n=78 in the treatment group)

Inclusion/Exclusion Criteria

Inclusion criteria: aged 17 to 65 years, an unequivocal history of partial seizures refractory to current AED therapy; at least four complex partial seizures per month; no more than eight generalized tonic, clonic, or tonic-clonic seizures per month. Receiving at least one, but no more than two standard AEDs. Exclusion criteria: history or evidence of progressive encephalopathy or a progressive structural lesion in the CNS; progressive ophthalmologic disease; or clinically significant cardiac, hematologic, hepatic, or renal disease.

Patient Characteristics

Patient demographic characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo</th>
<th>ZNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, no. (%)a</td>
<td>n = 74</td>
<td>n = 78</td>
</tr>
<tr>
<td>Male</td>
<td>43 (58.1)</td>
<td>58 (74.4)</td>
</tr>
<tr>
<td>Female</td>
<td>31 (41.9)</td>
<td>20 (25.6)</td>
</tr>
<tr>
<td>Race, no. (%)</td>
<td>n = 74</td>
<td>n = 78</td>
</tr>
<tr>
<td>Caucasian</td>
<td>64 (86.5)</td>
<td>68 (87.2)</td>
</tr>
<tr>
<td>African American</td>
<td>5 (6.8)</td>
<td>4 (5.1)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (6.8)</td>
<td>6 (7.7)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>n = 74</td>
<td>n = 78</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>36.4 ± 11.3</td>
<td>35.6 ± 12.1</td>
</tr>
<tr>
<td>Range</td>
<td>17.8–67.5</td>
<td>17.9–64.1</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>n = 74</td>
<td>n = 78</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>72.7 ± 16.1</td>
<td>74.6 ± 15.7</td>
</tr>
<tr>
<td>Range</td>
<td>41–120</td>
<td>44–114</td>
</tr>
<tr>
<td>Age at seizure onset (yr)c</td>
<td>n = 73</td>
<td>n = 77</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>16.5 ± 10.5</td>
<td>15.9 ± 12.5</td>
</tr>
<tr>
<td>Range</td>
<td>0.0–43.0</td>
<td>0.0–59.0</td>
</tr>
<tr>
<td>Baseline seizure frequency (seizures/mo) All partial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>74</td>
<td>78</td>
</tr>
<tr>
<td>Mean</td>
<td>20.3</td>
<td>25.6</td>
</tr>
<tr>
<td>Median (range)</td>
<td>9.6 (2.0–186.7)</td>
<td>9.1 (1.3–201.0)</td>
</tr>
<tr>
<td>Complex partial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>72</td>
<td>78</td>
</tr>
<tr>
<td>Mean</td>
<td>15.1</td>
<td>23.6</td>
</tr>
<tr>
<td>Median (range)</td>
<td>7.8 (0.3–119.2)</td>
<td>8.0 (0.7–201.0)</td>
</tr>
<tr>
<td>All seizures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>74</td>
<td>78</td>
</tr>
<tr>
<td>Mean</td>
<td>20.9</td>
<td>25.9</td>
</tr>
<tr>
<td>Median (range)</td>
<td>10.6 (2.0–190.7)</td>
<td>9.1 (1.3–201.0)</td>
</tr>
</tbody>
</table>

ZNS, zonisamide.
aSignificant difference observed between treatment groups (p < 0.05).

29 July 2010 Page 90 of 306
bOther included patients of Hispanic heritage.
cAge at seizure onset was unavailable for one patient in the placebo group and one patient in the ZNS group.

Recruitment

Not reported.

Setting

Four locations in the United States.

Interventions/ Test/ Factor being investigated

Zonisamide as adjunctive treatment to currently used AEDs.

Comparisons

Zonisamide compared to placebo as adjunctive therapy to currently used AEDs.

Length of Study/ Follow-up

24 weeks: 8 to 12 weeks baseline and 12 weeks treatment.

Outcome measures studied

Primary outcome: median percentage reduction in frequency in patients with all partial seizures between weeks 5 and 12 of the treatment phase, relative to baseline seizure frequency. Secondary outcomes: responder rate.

Results

Percentage reduction in seizure frequency and responder rates for the placebo and ZNS groups

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Seizure type</th>
<th>All partial</th>
<th>Complex partial</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in seizure frequency</td>
<td>n = 74</td>
<td>n = 72</td>
<td>n = 74</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>-4.7%</td>
<td>0.5%</td>
<td>-6.6%</td>
<td></td>
</tr>
<tr>
<td>ZNS</td>
<td>n = 78</td>
<td>n = 78</td>
<td>n = 78</td>
<td></td>
</tr>
<tr>
<td></td>
<td>28.9%</td>
<td>27.4%</td>
<td>25.5%</td>
<td></td>
</tr>
<tr>
<td>p Value</td>
<td>0.0009</td>
<td>0.0007</td>
<td>0.0005</td>
<td></td>
</tr>
<tr>
<td>Responder rate</td>
<td>n = 74</td>
<td>n = 72</td>
<td>n = 74</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>16.2%</td>
<td>13.9%</td>
<td>16.2%</td>
<td></td>
</tr>
<tr>
<td>ZNS</td>
<td>n = 78</td>
<td>n = 78</td>
<td>n = 78</td>
<td></td>
</tr>
<tr>
<td></td>
<td>26.9%</td>
<td>30.8%</td>
<td>28.2%</td>
<td></td>
</tr>
<tr>
<td>p Value</td>
<td>0.1141</td>
<td>0.0159</td>
<td>0.0796</td>
<td></td>
</tr>
</tbody>
</table>

Adverse events

Overall, treatment-emergent adverse events occurred with significantly greater incidence in the ZNS group compared with the placebo group (p < 0.05). In both treatment groups, adverse events were generally mild (17 of 78, 21.8% ZNS; 20 of 74, 27.0% placebo) or moderate (30 of 78, 38.5% ZNS; 17 of 74, 23.0% placebo) in severity. The most frequently reported adverse events associated with ZNS were somnolence, irritability, dizziness, nausea, and fatigue. 12 patients in the ZNS group and one patient in the placebo group withdrew because of adverse events.

ZNS, zonisamide.

Safety and adverse effects

Does the study answer the question?

Unsure. The study concludes that as adjunctive treatment, ZNS was generally well tolerated and significantly improved seizure control among patients with refractory partial seizures. The study however did not conduct a power calculation so it is not clear how much power the study had to detect a difference between the two groups.

Effect due to factor in study?

No. The study however did not conduct a power calculation so it is not clear how much power the study had to detect a difference between the two groups.
All patients had an unequivocal history of partial seizures.

Sander JW; Patsalos PN; Oxley JR; Hamilton MJ; Yuen WC;

A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy

Ref ID 4733 1990

Study Type Randomised Controlled Trial Funding Not reported.

Number of participant n=21 in this cross-over study.

Inclusion/Exclusion Criteria Not reported.

Patient Characteristics Patients were aged 23-42 years (mean = 34 years) and weighed 52-92 kg (mean = 73 kg). The 3 female patients who participated were not considered to be at risk of pregnancy.

All patients had severe refractory epilepsy, which was due to a structural lesion in 11; in 10 patients no cause had been found. The duration of epilepsy ranged from 8 to 40 years (mean = 25 years). Eighteen patients had partial and secondarily generalized seizures, and 3 had generalized seizures. All patients had at least 4 seizures/month for the 3 months prior to the study and all had had extensive treatment with carbamazepine (CBZ), phenytoin (PHT), phenobarbitone (or primidone; PRM) and sodium valproate (SVP) in monotherapy or in combinations.

Recruitment All patients were recruited from a residential centre for Epilepsy.

Setting A residential home for patients with epilepsy.

Interventions/ Test/ Factor being investigated Lamotrigine in two doses according to patients’ currently used AED.

Comparisons The comparison is between lamotrigine and placebo as adjunctive therapy in patients taking at least one AED.

Length of Study/ Follow-up 44 weeks: an 8-week baseline period, a 12 week treatment period, a 6 week washout period, another 12 week treatment period and a final 6 week washout period.

Outcome measures studied Not specified. Efficacy was evaluated using 2 measures: the overall seizure frequency and the number of seizure days, i.e. days on which at least 1 seizure of any type was reported.

Results Generalized and total of seizures in the 18 patients who completed the trial

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 0-4</th>
<th>Week 5-8</th>
<th>Week 9-12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gener. Total</td>
<td>Gener. Total</td>
<td>Gener. Total</td>
<td>Gener. Total</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>76</td>
<td>371</td>
<td>72</td>
<td>450</td>
</tr>
<tr>
<td>Placebo</td>
<td>66</td>
<td>344</td>
<td>53</td>
<td>298</td>
</tr>
</tbody>
</table>

Although a comparison between the LTG and placebo periods showed no significant difference in total seizure frequency, there was a marked decrease in the number of generalized seizures observed in the last 4 weeks of the active treatment period, when compared to the placebo treatment period and with baseline.

Adverse events.

Adverse effects and number of patients reporting

<table>
<thead>
<tr>
<th>Adverse effect</th>
<th>Placebo</th>
<th>Lamotrigine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ataxia</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Diplopia</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Drowsiness</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>
Safety and adverse effects
There was no significant difference between the adverse experiences during the placebo and active treatment phases.

Does the study answer the question?
Unsure. The study sample was small (n=21) and no tests of significance were reported. The study concludes that there appears to be a drug effect as there is a marked reduction in generalized tonic-clonic seizures in favour of lamotrigine in the last 4 weeks of the treatment period.

Effect due to factor in study?
No. The study sample is small and no power calculation was performed. It is not clear if the result reported could have been found by chance.

Consistency of results with other studies?
The study comprised patients with severe epilepsy who all had partial complex seizures with or without generalized seizures.

Internal Validity

Schachter SC; Leppik IE; Matsuo F; Messenheimer JA; Faught E; Moore EL;

Lamotrigine: a six-month, placebo-controlled, safety and tolerance study.

Ref ID 4775

Study Type Randomised Controlled Trial

Funding Borroughs Wellcome (one of the companies merged to form GSK)

Number of participant 446, 334 to LTG, 112 to placebo (3:1 ratio)

Inclusion/Exclusion Criteria

Inclusion criteria:
- Men and women 18-65 years old with a history of simple or complex partial seizures (with or without becoming generalised seizures classified according to the International Classification of Epileptic Seizures) that were refractory to treatment with a stable regimen or one to three AEDS (excluding VPA).
- At least one partial seizure in the 12 weeks proceeding to randomisation.
- Women of child bearing age that use and acceptable contraceptive method and not pregnant.

Exclusion criteria:
- Epilepsy is newly diagnosed (>32 weeks)
- Have a diagnoses of primary generalised seizures (including absence seizures) or psychogenic seizures
- Progressive neurologic disorder that was not stable for at least 24 weeks before baseline
- Seizures secondary to infection, neoplasia, demyelination, metabolic illness, progressive generative disease, or the active use of drug or alcohol
- Experienced status epilepticus within 24 weeks of baseline
- Received treatment with an investigational drug within 12 weeks of baseline
- Concomitant AED dose adjustments within 2 weeks of baseline (within 4 weeks for phenobarbital)
- Concomitant valproic acid (VPA) within 4 weeks of baseline and during the study period
- Serious side effects from present therapy
- Drug abuse or consumption of any psychoactive drugs
- Severe psychiatric condition requiring hospitalisation
- IQ<50
- A significant concomitant medical disorder, or any condition that interfere with the pharmacokinetik of drugs
- History of non compliance
Lamotrigine (N=334)               Placebo (N=112)          Male:                                          173(52%)        ...                   (13%)                               Phenobarbital                    (13%)                   (14%)

Lamotrigine twice daily (to 500 mg/day)PlaceboAll patients received 1-3 marketed AEDs (except VPA)Adjunctive: Comparisons ... 2 weeks) and follow upPrimary and secondary outcomes not specified. This was described as a “safety and tolerance study”

LTG doses
≤ 500mg/day are well tolerated as an add on therapy for a 6-month
treatment period in outpatients with refractory partial seizures.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Lamotrigine (N=334)</th>
<th>Placebo (N=112)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male:</td>
<td>173(52%)</td>
<td>63(56%)</td>
</tr>
<tr>
<td>Mean age:</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>Range:</td>
<td>18-64</td>
<td>18-64</td>
</tr>
<tr>
<td>Race:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>290(87%)</td>
<td>96(86%)</td>
</tr>
<tr>
<td>Black</td>
<td>33(10%)</td>
<td>10(9%)</td>
</tr>
<tr>
<td>Other</td>
<td>11(3%)</td>
<td>6(5%)</td>
</tr>
<tr>
<td>Duration of epilepsy (year)</td>
<td>21</td>
<td>21</td>
</tr>
<tr>
<td>Mean age of epilepsy onset (year)</td>
<td>12</td>
<td>11.5</td>
</tr>
</tbody>
</table>

Concomitant therapy

<table>
<thead>
<tr>
<th></th>
<th>Lamotrigine (N=334)</th>
<th>Placebo (N=112)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 concomitant AED</td>
<td>(43%)</td>
<td>(46%)</td>
</tr>
<tr>
<td>2 concomitant AEDs</td>
<td>(50%)</td>
<td>(50%)</td>
</tr>
<tr>
<td>3 concomitant AEDs</td>
<td>(7%)</td>
<td>(4%)</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>(75%)</td>
<td>(71%)</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>(38%)</td>
<td>(45%)</td>
</tr>
<tr>
<td>Primidone</td>
<td>(16%)</td>
<td>(13%)</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>(13%)</td>
<td>(14%)</td>
</tr>
</tbody>
</table>

Recruitment

Patients were recruited from 34 centres

Setting

Multicentre – 34 centres.

Interventions/ Test/ Factor being investigated

<table>
<thead>
<tr>
<th></th>
<th>Lamotrigine twice daily (to 500 mg/day)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients received 1-3 marketed AEDs (except VPA)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comparisons

Adjunctive: Comparisons between treatment and placebo added on to existing therapy

Length of Study/ Follow-up

Total 27 weeks – 24 weeks for maintenance and titration, 3 weeks for tapering off (over 2 weeks) and follow up

Outcome measures studied

Primary and secondary outcomes not specified. This was described as a “safety and tolerance study”

Results

Subjective Global Investigator Evaluation scale: 65% of patients in the LTG and 35% in the placebo group improved at week 24 as opposed to baseline.

The proportion of participants having treatment withdrawn due to adverse events:

LTG: 28/334 (8%)
Placebo: 9/112 (8%)

In incidence of adverse events>10%

<table>
<thead>
<tr>
<th></th>
<th>LTG</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness:</td>
<td>167/334(50%)</td>
<td>20/112(18%)</td>
</tr>
<tr>
<td>Diplopia:</td>
<td>110/334(33%)</td>
<td>12/112(11%)</td>
</tr>
<tr>
<td>Ataxia:</td>
<td>80/334(24%)</td>
<td>6/112(5%)</td>
</tr>
<tr>
<td>Blurred Vision:</td>
<td>77/334(23%)</td>
<td>10/112(9%)</td>
</tr>
<tr>
<td>Nausea:</td>
<td>73/334(22%)</td>
<td>17/112(15%)</td>
</tr>
<tr>
<td>Somnolence:...</td>
<td>47/334(14%)</td>
<td>8/112(7%)</td>
</tr>
<tr>
<td>Coordination abnormality:</td>
<td>40/334(12%)</td>
<td>7/112(8%)</td>
</tr>
<tr>
<td>Rash:</td>
<td>33/334(10%)</td>
<td>6/112(5%)</td>
</tr>
<tr>
<td>Dysepsia:...</td>
<td>33/334(10%)</td>
<td>6/112(5%)</td>
</tr>
<tr>
<td>Respiratory disorder:</td>
<td>23/334(7%)</td>
<td>15/112(13%)</td>
</tr>
</tbody>
</table>

Safety and adverse effects

Most (90%) adverse events are mild or moderate.
One patient had Stevens Johnson syndrome while on LTG at 400mg/day.
One case of sudden unexplained death in epilepsy in the placebo group during the dose tapering stage.
Patients in the LTG group who received CB exhibited more adverse events.

ECG, urinalysis, haematology and clinical chemistry: “unremarkable” results

Does the study answer the question?

LTG doses ≤ 500mg/day are well tolerated as an add on therapy for a 6-month treatment period in outpatients with refractory partial seizures.

Effect due to factor in study?

There are no significant factors affecting the overall evaluation.
The sample size would be too small to detect significant differences in rarer events.
Internal Validity

Consistency of results with other studies? Unsure. No indirectness noticed

Directly applicable to guideline population? Unsure. No indirectness noticed

Study Type Randomised Controlled Trial

Number of participant

N=41
n=20 in LTG/Placebo group
n=21 in Placebo/LTG group

Inclusion/Exclusion Criteria

Inclusion: aged 16–65 years; refractory partial seizures; receiving no more than two other standard AEDs; at least 4/month partial seizures in previous 3 months; absence of concomitant medication; no confounding medical or psychiatric disturbances; ability to keep seizure diary; provide informed consent
Exclusion: severe organic or psychiatric disease; severe mental subnormality or progressive neurological disease

Patient Characteristics

Aetiology of seizures:
Idiopathic/unknown:
total (n=19/41); LTG/placebo: (n=8/20); Placebo/LTG (n=11/21)
Symptomatic:
total (n=22/41); LTG/placebo (n=12/20); Placebo/LTG (n=10/21)

Age at onset (yrs)
Mean (SD): total 10.4 (9.6); LTG/placebo 10.5 (9.5); Placebo/LTG 10.4 (10)
Range: total 0-46; LTG/placebo 0-37; Placebo/LTG 0.5-46

History of status epilepticus
Yes: total n=5/41; LTG/placebo n=2/20; Placebo/LTG n=3/21
No: total n=35/41; LTG/placebo n=18/20; Placebo/LTG n=17/21
Unknown: total n=1/41; LTG/placebo n=0/20; Placebo/LTG n=1/21

Number of uncontrolled seizure types:
1: total n=16/41; LTG/placebo n=9/20; Placebo/LTG n=7/21
2: total n=15/41; LTG/placebo n=6/20; Placebo/LTG n=9/21
3: total n=9/41; LTG/placebo n=4/20; Placebo/LTG n=5/21
4: total n=1/41; LTG/placebo n=1/20; Placebo/LTG n=0/21

Number of AEDs being taken:
One concurrent AED:
total (n = 6/41); LTG/placebo: (n = 2/20); placebo/LTG: (n = 4/21).

Two concurrent AEDs:
total(n = 34/41); LTG/placebo (n = 18/20); placebo/LTG (n = 16/21)

Three concurrent AEDs:
total(n = 1/41); LTG/placebo (n = 0/20); placebo/LTG: (n = 1/21)

Baseline seizure frequency
Total baseline seizure frequency (3 months prettrial):
total (n = 41); mean = 84.3 (SD 97.2);
LTG/placebo (n = 20); mean = 100.7 (SD 107.3);
placebo/LTG (n = 21); mean = 68.8 (SD 86.2)

Recruitment
Not stated

Setting
4 centres throughout Australia

Schapel GJ;Beran RG;Vajda FJ;Berkovic SF;Mashford ML;Dunagan FM;Yuen WC;Davies G;

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures

Ref ID 4758

Funding GlaxoSmithKline

1993
Lamotrigine (150mg or 300mg) as add-on therapy in patients with partial seizures poorly controlled by established AEDs.

There was a 3-month retrospective baseline period to establish seizure frequency. Patients were given full dose of LTG by week 2 of the 12-week treatment period. Patients on enzyme-inducing concomitant AEDs only received 300 mg/day (Group 1), patients on enzyme-inducing concomitant AEDs and VPA received 150 mg/day (Group 2). This was followed by a 4-week washout period with dosage tapered in the first week and placebo given in the remaining 3 weeks. The same procedure was followed for phase 2 of the study.

Comparisons
Lamotrigine (150mg or 300mg daily) compared to placebo

Length of Study/Follow-up
12 weeks

Outcome measures studied
Total seizure count; number of participants experiencing specified percentage reductions in total seizure counts; seizure days; change in seizure frequency; physician/patient global evaluation of improvement/efficacy/tolerability

Results
There was a highly significant (p<0.001) decrease in total seizure counts on LTG compared with placebo. Overall, 22% of patients experienced at least a 50% reduction in the total numbers of all seizure types on LTG compared with none on placebo.

There was a significant (p<0.05) reduction in partial seizure counts on LTG compared with placebo. When total numbers of secondarily generalised seizures were compared the trend for a reduction in this seizure type did not reach significance (0.05<p<0.1).

Concomitant AED plasma concentrations were virtually unchanged.

There was a significant reduction in the number of seizure days on LTG (p<0.001)

Adverse events:
All patients reported at least 1 adverse event, all but one of the 321 reports were classified as "not serious". Confidence intervals indicate that patients on LTG more frequently reported dizziness than on placebo. There were also trends for diplopia and vision abnormality to be reported more frequently on LTG than placebo, but the CI included zero. One serious adverse event was reported for a patient who developed CSF leak after a skull fracture due to seizure which required surgical repair. This occurred when the patient was receiving placebo.

There was no evidence of any effect of LTG on blood pressure, heart rate or body weight.

Results from Banks and Beran (RMId 4715) - cognitive outcomes in subsample of 10 patients:
Neuropsychological assessment including the following tests (National Adult Reading Test for intellectual level, Stroop Colour Word Test for concentration and attention, Trail Making Tests A and B and Digit Symbol for General Cerebral Efficiency, Digit Span and Rey Complex Figure Test for Mnestic functions)
Parametric statistical methods were impossible to use because of differing format of scores across cells (scaled scores, percentiles, IQ scores...)

While the neuropsychological data collection for LTG is still in infancy, it was readily apparent that this medication has few, if any, of the sedating properties previously associated with the older generation AEDs, particularly phenobarbitone and phenytoin.

Safety and adverse effects
see results section

Does the study answer the question?
This study concludes that lamotrigine is an effective AED in the treatment of therapy-resistant partial seizures and is well tolerated when given in addition to up to 2 other established AEDs

Effect due to factor in study?
Yes
Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine

Ref ID 903

2002 Sep

Study Type Randomised Controlled Trial

Funding Unknown.

Number of participant n=52 (25 in lamotrigine group and 27 in gabapentin)

Inclusion/Exclusion Criteria

Inclusion criteria: suffering from partial seizures of not more than 2 years duration and on carbamazepine (CBZ) monotherapy, at least 4 seizures before being enrolled.

Patient Characteristics

For the group as a whole (n=52) characteristics were as follows: simple partial seizures n=17, complex partial seizures n=15 and secondarily generalized seizures n=20; age group 10 to 60 years; female n=27 and male n=25.

In the gabapentin group the average frequency of seizures at baseline was 6.26+/-3.86 and 5.04+/-.2.47 in the lamotrigine group. The time period was not reported nor was length of baseline reported.

Recruitment Not reported.

Setting India.

Interventions/ Test/ Factor being investigated Gabapentin and lamotrigine as adjunctive therapy to carbamazepine.

Comparisons Comparisons are made between gabapentin and lamotrigine as adjunctive therapy to carbamazepine.

Length of Study/ Follow-up Unknown. Length of baseline period and titration period not reported. It is unclear whether the add-on period included a titration phase.

Outcome measures studied The primary efficacy criteria for efficacy were PCB (percentage change in seizure frequency from baseline), responder rate and response ratio. Subgroup analysis of seizures was performed by type of seizures.

Results

Primary outcome.

The average frequency of seizures at baseline was 6.26+3.86 and 5.04+2.47 in the gabapentin group and lamotrigine group, respectively. This frequency decreased significantly (p<.001) after 12 weeks of add on therapy to 1.75+2.16 and 1.68+2.94. The PCB value was -72+34.92 and -76.22+29.68 in the gabapentin group and lamotrigine group, respectively. However, no significant difference was seen in seizure frequency and PCB values between these two groups after 12 weeks of add on therapy. An inadequate response i.e. less than 50% reduction in number of seizures was observed in 4 out of 27 cases (14.8%) in group I, while, one out of 25 cases (4.0%) in group II, after 12 weeks of add on therapy. The responder rates in the gabapentin group and lamotrigine group were 77.7% and 92%, respectively.

Subgroup analysis

The responder rate for SPS, CPS and partial seizures with secondarily generalization was 90.9% (10 of 11 cases), 75% (3 of 4 cases), 66.6% (8 of 12 cases) respectively in the gabapentin group, while corresponding value in the lamotrigine group was 100%(6 of 6 cases), 90.9% (10 of 11 cases), 87.5% (7 of 8 cases).
Adverse events

The most commonly occurring adverse events were dizziness, headache and drowsiness in both groups. However, skin hypersensitivity reaction only occurred in the lamotrigine group.

Safety and adverse effects
Skin rashes appear to be related to lamotrigine use only.

Effect due to factor in study?
No. No statistical power calculations were conducted.

Consistency of results with other studies?
The study population consisted of patients with partial seizures whose seizures were refractory to carbamazepine.

Internal Validity

Sharief M; Viteri C; Ben-Menachem E; Weber M; Reife R; Pledger G; Karim R;

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

Ref ID 4745 1996

Study Type Randomised Controlled Trial  Funding Unknown

Number of participant 24 patients placebo; 23 patients topiramate

Inclusion/Exclusion Criteria
Inclusion: 18-65 years; hx of partial seizures by EEG and good mental and physical health without progressive lesion; refractory on one or two AEDs; women of childbearing age using birth control
Exclusion: Seizure free three weeks during baseline period; hx of nephrolithiasis or allergy to carbonic anhydrase inhibitors or sulfonamide.

Patient Characteristics

<table>
<thead>
<tr>
<th>Gender</th>
<th>Placebo n=24</th>
<th>Topiramate n=23</th>
<th>Total n=47</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>19</td>
<td>21</td>
<td>40</td>
</tr>
<tr>
<td>Women</td>
<td>5</td>
<td>2</td>
<td>7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race</th>
<th>Placebo n=24</th>
<th>Topiramate n=23</th>
<th>Total n=47</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y Mean (SD)</td>
<td>32.6(11.1)</td>
<td>35.4(14.0)</td>
<td>34(12.6)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>24</td>
<td>23</td>
<td>47</td>
</tr>
<tr>
<td>Weight (kg) Mean (SD)</td>
<td>73.1+-12.3</td>
<td>74.9+-12.4</td>
<td>74+-12.2</td>
</tr>
</tbody>
</table>

Recruitment Unknown

Setting Sweden, Spain, UK and France

Interventions/ Test/ Factor being investigated Safety and efficacy of topiramate as adjunctive therapy

Comparisons Topiramate vs. placebo

29 July 2010
3 week titration and 8 week stabilization

Seizure type and frequency data and global evaluations of investigators and patients.

Results of this trial strongly suggest that topiramate 400 mg/day is effective and well tolerated in the treatment of refractory partial epilepsy.

**Internal Validity**

Multicentre and small sample

**Length of Study/Follow-up**

3 week titration and 8 week stabilization

**Outcome measures studied**

Seizure type and frequency data and global evaluations of investigators and patients.

**Results**

Median percent reduction from baseline in monthly seizure frequency during the double-blind phase was not significantly greater in the topiramate group than in the placebo group (41% vs. 1%; P = 0.065). There were a greater number of treatment responders in the topiramate groups (> or = 50% reduction in seizures; 35% vs. 8%; P = 0.033); better investigator (P = 0.002) and patient (P = 0.021) global assessments; and greater reductions in secondarily generalized seizures compared to placebo (P = 0.002).

Premature withdrawals from study due to adverse events: 1/24 in placebo group and 6/34 in topiramate group.

**Safety and adverse effects**

The most commonly reported topiramate treatment-emergent adverse events were somnolence, fatigue, abnormal vision, weight decrease, and anxiety. Most adverse events were mild or moderate in severity. Among 7 withdrawals due to limiting adverse events, 6 were CNS-related (in 5 topiramate-treated patients).

**Does the study answer the question?**

Results of this trial strongly suggest that topiramate 400 mg/day is effective and well tolerated in the treatment of refractory partial epilepsy.

**Effect due to factor in study?**

This is a small study and should be repeated

**Consistency of results with other studies?**

See GRADE

**Directly applicable to guideline population?**

See GRADE

**Safety and adverse effects**

The most commonly reported topiramate treatment-emergent adverse events were somnolence, fatigue, abnormal vision, weight decrease, and anxiety. Most adverse events were mild or moderate in severity. Among 7 withdrawals due to limiting adverse events, 6 were CNS-related (in 5 topiramate-treated patients).

Premature withdrawals from study due to adverse events: 1/24 in placebo group and 6/34 in topiramate group.

**Consistency of results with other studies?**

See GRADE

**Does the study answer the question?**

Results of this trial strongly suggest that topiramate 400 mg/day is effective and well tolerated in the treatment of refractory partial epilepsy.

This is a small study and should be repeated

**Directly applicable to guideline population?**

See GRADE

**Internal Validity**

Multicentre and small sample

Shorvon SD;Lowenthal A;Janz D;Bielen E;Loiseau P;

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

Ref ID 4742

**Study Type**

Randomised Controlled Trial

**Funding**

UCB Pharma funded. Statistical analysis support from UCB.

**Number of participant**

N=324, n=112 placebo, 106 in LEV1000mg/day and LEV2000mg/day

**Inclusion/Exclusion Criteria**

Inclusion criteria:
- Men and women with refractory epilepsy who had seizure that were only or predominantly partial, with or without secondary generalisation.
- 16-65 years old
- Seizures persisted at lest the previous 2 years despite treatment with <=2 other AEDs
- maintain a stable dose of up to 2 AEDs for at least 4 weeks before selection visit and throughout the study
- AT least 4 partial seizures during each 4 week intervals in the 8-or 12-week baseline period.
- Women of childbearing age with medically accepted contraception method or sterilised

Exclusion criteria:
- Renal insufficiency, progressive neurological disorders, serious psychiatric disorders
- Clinically significantly baseline laboratory abnormalities , current or recent history of substance abuse, questionable compliance with drug treatment or concomitant disorders that could hinder evaluation of efficacy or tolerability
Severe or progressive disease excluded with EEG, 12 lead ECG and either cranial CT or MRI scan.

### Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>LEV1000mg/d</th>
<th>LEV2000mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=112</td>
<td>N=106</td>
<td>N=106</td>
</tr>
<tr>
<td>Age, mean±SD(yrs):</td>
<td>37±12</td>
<td>36±10</td>
<td>37±12</td>
</tr>
<tr>
<td>Males:</td>
<td>55(49%)</td>
<td>51(48%)</td>
<td>51(48%)</td>
</tr>
<tr>
<td>Weight±SD:</td>
<td>71±15</td>
<td>72±17</td>
<td>72±17</td>
</tr>
<tr>
<td>Duration of epilepsy(yrs):</td>
<td>23.2±11.0</td>
<td>23.8±12.3</td>
<td>23.6±13.3</td>
</tr>
<tr>
<td>Idiopathic/cryptogenic:</td>
<td>64(57.1%)</td>
<td>59(55.7%)</td>
<td>60(56.6%)</td>
</tr>
<tr>
<td>Seizure type:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simple partial:</td>
<td>40(36%)</td>
<td>31(29%)</td>
<td>30(28%)</td>
</tr>
<tr>
<td>Complex partial:</td>
<td>93(83%)</td>
<td>84(79%)</td>
<td>93(88%)</td>
</tr>
<tr>
<td>Secondary generalised:</td>
<td>26(23%)</td>
<td>28(26%)</td>
<td>29(27%)</td>
</tr>
<tr>
<td>Others:</td>
<td>8(7%)</td>
<td>4(4%)</td>
<td>10(9%)</td>
</tr>
<tr>
<td>Median baseline seizures:</td>
<td>2.50</td>
<td>2.82</td>
<td>2.58</td>
</tr>
<tr>
<td>Number of concomitant AEDS:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:</td>
<td>18(16%)</td>
<td>23(22%)</td>
<td>19(18%)</td>
</tr>
<tr>
<td>2:</td>
<td>88(79%)</td>
<td>76(72%)</td>
<td>83(78%)</td>
</tr>
<tr>
<td>≥3:</td>
<td>6(5%)</td>
<td>7(7%)</td>
<td>4(4%)</td>
</tr>
</tbody>
</table>

### Recruitment

324 patients recruited from 61 European centres from 392 screened

### Setting

61 European centres

### Interventions/ Test/ Factor being investigated

Adjunctive therapy: LEV 100mg/day vs LEV 2000mg/day vs placebo added on to 1-2 stabilised AEDs

### Comparisons

Primary: Mean number of seizure per week
Secondary: Seizure type or subtype, proportion of patients experiencing ≥50% reduction in partial seizure frequency compared to baseline, number of seizure free patients

### Length of Study/ Follow-up

8-12 weeks baseline, 4 weeks titration plus 16 weeks double blinded maintenance doses (Total 28 weeks)

### Outcome measures studied

Proportion of patients experiencing ≥50% reduction in partial seizure frequency (responder rate):
- LEV 1000mg/day: 23/101 (22.8%) p=0.019 vs placebo
- LEV 2000mg/day: 30/95 (31.6%) p=<0.001 vs placebo
- Placebo: 11/106 (10.4%) p=0.004 vs treatment groups

Proportion of seizure free patients:
- LEV 1000mg/day: 5/101 (5.0%)
- LEV 2000mg/day: 2/95 (2.0%)
- Placebo: 1/106 (0.9%)

Withdrawal due to adverse events:
- LEV 1000mg/day: 8/106 (7.5%)
- LEV 2000mg/day: 15/106 (14.2%)
- Placebo: 6/112 (5.4%)

### Safety and adverse effects

Incidence of adverse events ≥10%:
- Placebo: 17(15.2%) 13(12.3%) 14(13.2%)
- LEV1000mg/day: 10(8.9%) 14(13.2%) 17(16.0%)
- LEV2000mg/day: 9(8.0%) 8(7.5%) 14(13.2%)

Seizure type or subtype, proportion of patients experiencing ≥50% reduction in partial seizure frequency compared to baseline, number of seizure free patients

Serious adverse events with probable relationship to drug was recorded in 13 patients, 3 in placebo, 2 in LEV1000mg/day and 15 in 2000mg/day groups.

Somnolence, asthenia and headache are more commonly reported among patients receiving LEV.

No clinically relevant changes in laboratory values.

29 July 2010
Treatment by LEV is superior compared to placebo as an add on therapy in patients with refractory seizures in terms of efficacy at 1000mg/day and 2000mg/day, without interactions with other AEDs. Adverse events were profile comparable to placebo.

Industry sponsored double blinded study. Randomisation allocation, concealment and blinding methods not clearly reported.

No indirectness observed. Baseline frequency of 4 seizures/4 week typical?

Double-blind study of Gabapentin in the treatment of partial seizures

43 patients (20 men and 23 women) had a mean age of 39 years (range 16-59) and mean duration range from 1 to 49 years (median 23 years). CBZ was received by 39 patients, clonazepam by 14, valproate by 8 and phenytoin by 3.

GBP as add on therapy
Placebo or 900 mg GBP or 1200 mg per day
Initial 3 month baseline; treatment for 3 months.

Percentage of change of seizure frequency in the treatment group as compared with baseline

A statistically significant difference in seizure frequency from the baseline to the treatment phase was noted between patients receiving placebo and GBP 1,200 mg (p=0.016). The difference between GBP dosage of 900 mg and placebo was not statistically significant. The difference between doses of 900mg and 1200mg were significant (p=0.032).

The adverse effects were minor and consisted mainly of transient drowsiness.
GBP appears to be effective in the treatment of partial epileptic seizures in a dosage-related manner.

This is a small study and should be repeated.

See GRADE.

See GRADE.

Small study

Steiner TJ; Dellaportas CI; Findley LJ; Gross M; Gibberd FB; Perkin GD; Park DM; Abbott R;

Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin 1999

Study Type Randomised Controlled Trial

Funding Wellcome Foundation Ltd.

Number of participant 181 patients with newly diagnosed untreated partial seizures or secondarily or primary generalised tonic-clonic seizures were randomised to two treatment groups. One group (n = 86) received LTG titrated over 6 weeks from a starting dose of 100 mg/day. The other (n = 95) received PHT titrated from 200 mg/day.

Inclusion/Exclusion Criteria

Inclusion: ages 14-75 after two or more partial, secondarily generalised or primary generalised tonic-clonic seizures in the previous 6 months Exclusion: absence seizures; previous AEDs; clinically significant abnormal lab values; other chronic medical disorders, severe mental subnormality; abuse of alcohol and pregnancy or risk of pregnancy.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>LTG, n=86</th>
<th>PHT, n=95</th>
<th>All, n=181</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female (%)</td>
<td>55/45</td>
<td>57/43</td>
<td>56/44</td>
</tr>
<tr>
<td>Age (yr) Median</td>
<td>28 (13-70)</td>
<td>27 (13-74)</td>
<td>28 (13-74)</td>
</tr>
<tr>
<td>Weight (kg) Median</td>
<td>68</td>
<td>68</td>
<td>68</td>
</tr>
<tr>
<td>Age at first seizure (yr) Median</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
</tbody>
</table>

Recruitment Unknown

Setting UK (authors from 6 settings)

Interventions/ Test/Factor being investigated Comparison of LTG with PHT monotherapy for efficacy and tolerability in previously untreated patients with newly diagnosed epilepsy

Comparison between lamotrigine and phenytoin.

Length of Study/Follow-up 6 week titration and a treatment phase for less than or equal to 48 weeks.

Outcome measures studied Primary: Percentages of patients remaining on treatment and seizure free and the numbers of seizures with each treatment during the last 24 and 40 weeks of the study. Secondary: time to first seizure and time to discontinuation.

Results The percentages of patients remaining on each treatment and seizure free during the last 24 and 40 weeks of the study, and times to first seizure after the first 6 weeks of treatment (dose-titration period), did not differ significantly between the treatment groups. Time to discontinuation, a composite index of efficacy and safety, likewise did not distinguish between treatments.

In last 24 weeks: for primary generalised tonic-clonic the proportion of seizure-free participants was 19 (44%) in the lamotrigine group vs 17 (34%) in the phenytoin.
LTG and PHT monotherapy were similarly effective against these seizure types in patients with newly diagnosed epilepsy. LTG was better tolerated, more frequently causing rash, but with a lower incidence of central nervous system side effects.

In last 40 weeks: for primary generalised tonic-clonic the proportion of seizure-free participants was 13 (30%) in the lamotrigine group vs 16 (32%). 95% CI for difference was -10.30%.

For primary generalised tonic-clonic the time to first seizure after the first 6 weeks of treatment was 1.5 (95% CI 0.7-3.2).

Adverse events led to discontinuation of 13 (15%) patients from LTG and 18 (19%) from PHT.

Adverse events affected more than 10% of patients:
   LTG:
   Asthenia: 14/86*
   Rash: 12/86
   Headache: 9/86
   Dizziness: 8/86
   Somnolence: 6/86*
   Ataxia: 0/86

   PHT:
   Asthenia: 28/95*
   Rash: 12/95
   Headache: 9/95
   Dizziness: 8/95
   Somnolence: 6/95*
   Ataxia: 0/95

   * P<0.05

A quality-of-life instrument, the SEALS inventory, favoured LTG. Patients taking PHT showed the biochemical changes expected of an enzyme-inducing drug, whereas those taking LTG did not.

Adverse events led to discontinuation of 13 (15%) patients from LTG and 18 (19%) from PHT. The adverse-event profile for LTG was dominated by skin rash [discontinuation of 10 (11.6%) patients compared with five (5.3%) from PHT] rather than central nervous system side effects: asthenia, somnolence, and ataxia were each significantly more frequent in the PHT group. The high rate of rash with LTG was probably due to the high starting dose and may be avoidable.

Safety and adverse effects

Does the study answer the question?
Yes

Effect due to factor in study?

Consistency of results with other studies?

Directly applicable to guideline population?
See GRADE

Internal Validity
Stolarek I; Blacklaw J; Forrest G; Brodie MJ;
Vigabatrin and lamotrigine in refractory epilepsy
Ref ID 4759

Study Type Randomised Controlled Trial
Funding Funding was not stated. The lamotrigine and placebo tablets were supplied by Wellcome Trust.
All reported a minimum of three seizures a month despite stable regimen of antiepileptic treatment. 9 and 13 patients took VIG and one or two other antiepileptic drugs respectively.

Recruitment
Not stated

Setting
Glasgow

Interventions/ Test/ Factor being investigated
Addition of placebo, lamotrigine 25mg, 50 mg and 100 mg to stabilised treatment regimen containing vigabatrin

Comparisons
Comparison was made between the treatment and active treatment (matched pairs used)

Length of Study/ Follow-up
The patients were followed up during treatments (week 0, 4, 8 and 12).

Outcome measures studied
This was not stated

Results
Proportion of patients with at least 50% reduction in seizure:
Phase I: 25 mg twice daily : 3/20(15%)
Phassee II: 50 mg twice daily : 7/20(35%)
Phase III: 100mg twice daily : 9/20 (45%)
Overall - 12 weeks: 4/20 (20%)
(p values not reported in paper)

Number of seizure free patients: 3, while on 100 mg twice daily lamotrigine. This was not reported for placebo or other treatment doses.

Withdrawal from study : 1/22 on placebo arm (due to adverse events)

Outcomes related to cognitive effects:
Mean VAS score for sedation, concentration, memory, and depression did not differ significantly after a month’s treatment of lamotrigine 100 mg twice daily vs placebo.(data not shown)

16/20 patients prefered the LTG treatment

There were no significant difference in the total number of requested or spontaneously reported side effects 6 for lamotrigine and 7 for placebo.

There were no difference in number of reported adverse events between the placebo and treatment arms.

There was no statistically difference in number of adverse events between the two treatment arms for this very small cross over RCT

Safety and adverse effects
Does the study answer the question?
Effect due to factor in study?
Consistency of results with other studies?
Directly applicable to guideline population?
Internal Validity

Tanganelli P;Regesta G;
The effects of VGB in the monotherapy of newly diagnosed subjects

**Vigabatrin vs. carbamazepine**
Initially for 4 months; crossover to the alternative drug was carried out for 4 months only in cases with persisting seizures or in the presence of intolerable side effects.

**Inclusion/Exclusion Criteria**
Inclusion: Age between 18 and 65 years; at least two untreated and unprovoked seizures, complex partial type in the previous 8 weeks.
Exclusion: history of alcohol or drug abuse; the presence of a brain tumour or progressive neurological disease; an IQ <90; the presence or history of psychiatric, cardiac, renal, hepatic or metabolic disease; pregnancy or the risk of pregnancy.

**Patient Characteristics**

<table>
<thead>
<tr>
<th></th>
<th>VBG</th>
<th>CBZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (y)</td>
<td>37.9</td>
<td>34.8</td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>1.5</td>
<td>1.4</td>
</tr>
<tr>
<td>Seizure frequency</td>
<td>9.1</td>
<td>7.4</td>
</tr>
</tbody>
</table>

**Recruitment**
Unknown

**Setting**
Italy

**Interventions/Test/Factor being investigated**
The effects of VGB in the monotherapy of newly diagnosed subjects

**Comparisons**
Vigabatrin vs. carbamazepine

**Length of Study/Follow-up**
Initially for 4 months; crossover to the alternative drug was carried out for 4 months only in cases with persisting seizures or in the presence of intolerable side effects.

**Outcome measures studied**
Primary: seizure frequency
Secondary: side effects, EEG, lab tests for serum levels and routine WBC and chemistries

**Results**
No significant difference (p values not given) between VGB and CBZ in control of seizures: 17/37 (45.9%) with VBZ and 20/39 (51.3%) with CBZ. Side effects were more frequent and severe with CBZ (41% vs. 21.6% in VGB).

**Safety and adverse effects**
Side effects were generally slight - drowsiness was the most common side effect but was not significantly different in the two groups (p=0.079). One patient in CBZ group dropped out due to a generalised rash.

**Does the study answer the question?**
VGB may be considered as a first line drug for epilepsy with CP seizures and as a valid alternative when other monotherapies are ineffective or poorly tolerated.

**Effect due to factor in study?**
The study should be repeated with a larger sample and with appropriate blinding and concealment.

**Consistency of results with other studies?**
See GRADE

**Directly applicable to guideline population?**
See GRADE

**Internal Validity**
No blinding or allocation concealment

**Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study**

Ref ID 4713 1986

**Study Type**
Randomised Controlled Trial

**Funding**
Not reported.
Mean age = 31, mean number of years duration of epilepsy = 18, females n=10, males n=13. All patients on two concurrent AEDs the majority receiving carbamazepine and phenobarbitol.

**Inclusion/Exclusion Criteria**

Inclusion criteria: (a) age 16-65 years; (b) epilepsy uncontrolled by conventional treatment, irrespective of seizure type; (c) minimum seizure frequency of one seizure a week, with a stable seizure frequency during the previous 6 months; (d) treatment with no more than two antiepileptic drugs, without major changes in drug therapy during the 2 months prior to entry; (e) routine hematology, blood chemistry, and urinalysis values within the expected ranges; (f) absence of psychiatric, cardiac, renal, hepatic, metabolic, or progressive neurological diseases; (g) no pregnancy or risk of pregnancy; (h) no history of poor compliance; and (i) written informed consent (patient or guardian).

Exclusion criteria: none listed.

**Patient Characteristics**

Mean age = 31, mean number of years duration of epilepsy = 18, females n=10, males n=13. All patients on two concurrent AEDs the majority receiving carbamazepine and phenobarbitol.

**Recruitment**

Not reported.

**Setting**

Outpatients at an epilepsy clinic in Italy.

**Interventions/ Test/ Factor being investigated**

Vigabatrin as add-on therapy.

**Comparisons**

The comparison is between vigabatrin as add-on therapy and placebo.

**Length of Study/ Follow-up**

14 weeks: two periods of 7 weeks, one period on placebo and the other on vigabatrin.

**Outcome measures studied**

Primary outcome: number of seizures a week in each 7-week period. Secondary outcomes: neurological outcomes and adverse events.

**Results**

Primary outcome

On average, the total number of seizures a week was significantly lower during the vigabatrin period than during the placebo period (2.2 +/- 2.6 vs. 3.8 +/- 3.7, respectively, means +/- SD, p < 0.01).

In terms of individual responses, 12 of the 20 patients (60%) experienced a decrease in seizure frequency of >50%, with 4 of the 12 showing a >75% decrease. For the remaining 8 patients, 3 showed a decrease between 25 and 50%, 1 showed a decrease of 0-25%, and 4 showed an increase in seizure frequency.

To evaluate the effect of treatment on seizure type, the data from the 17 patients with partial seizures were analyzed separately. Weekly seizure numbers in these patients were significantly lower during the vigabatrin period (2.0 +/- 2.4) than during the placebo period (3.7 +/- 3.8) (p < 0.01), with 10 of the 17 patients (62%) showing a >50% improvement in seizure control.

Adverse events

The most frequent emergent event was drowsiness, which developed in 7 patients on vigabatrin and in 1 patient on placebo. Nausea and vomiting were reported by 2 patients on vigabatrin; in at least 1 of them, in whom vomiting occurred after 28 days of 2 g/day vigabatrin and lasted for 3-4 days, the relationship to drug intake is uncertain.

Withdrawal due to adverse events:
Vigabatrin: 1/21
Placebo: 0/21

Safety and adverse effects

No serious adverse events.

**Does the study answer the question?**

Unsure. The study concludes that add-on treatment with vigabatrin is effective and well tolerated in adult patients with drug resistant epilepsy. However, the study sample size is small (n=20) and results can only be considered exploratory since no power calculation was performed.
Effect due to factor in study?

Unsure. The study concludes that add-on treatment with vigabatrin is effective and well tolerated in adult patients with drug resistant epilepsy. However, the study sample size is small (n=20) and results can only be considered exploratory since no power calculation was performed.

Consistency of results with other studies?

17 of the 20 patients who completed the study suffered from partial seizures and three had generalized seizures.

Internal Validity

Tassinari CA;Michelucci R;Chauvel P;Chodkiewicz J;Shorvon S;Henriksen O;Dam M;Reife R;Pledger G;Karim R;
Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy
Ref ID 4688
1996

Study Type Randomised Controlled Trial

Number of participant 60-30 in each arm

Inclusion/Exclusion Criteria

Inclusion criteria:
- 18-65 years with good mental and physical health and a documented history of partial seizures.
- EEG in the preceding 5 years to verify presence of lateralised epileptiform consistent with a diagnosis of partial epilepsy
- CT or MRI scan in the preceding 2 years to exclude potentially progressive neurologic diseases
- Received fixed regimen of one of two of the following AEDs: PHT, CBZ, VPA, PB, PRM. Clobazam or clonazepam permitted only in combination with either PHT, CBZ, PN or PRM.
- Women of child bearing age who are not nursing or pregnant and using birth control measures

Exclusion:
- Known to be allergic or hyper sensitive to carbonic anhydrase inhibitors or sulphonamides, or contraindicated to these
- History of nephrolithiasis
- At least 8 partial seizures while being maintained with therapeutic plasma levels of AED concentrations

Patient Characteristics

Men: 47/60 (68%)
White: 57/60 (95%)
Mean age: 32.9 years
Mean weight: 69.4kg
Mean height: 172.1cm
Median seizure rate: 16.8 (4-230) for TPM group, and 15.0 (4-925) for placebo group. 63% received CBZ in combination with PB, PHT, PRM or VPA.
Study reported that the demographics were comparable between the two groups

Recruitment

Recruited from 6 study sites

Setting

UK, Italy, France, Norway, Denmark

Interventions/Test/ Factor being investigated

TPM600mg or placebo

Comparisons

Adjunctive: TPM vs placebo

Length of Study/Follow-up

8 weeks baseline, plus 12 weeks treatment (including 4 week of titration)

Outcome measures studied

Not stated

Page 107 of 306
Results

Proportion of seizure free participants
TPM: 0/30
Placebo: 0/30
P value: NS

Proportion of participants experiencing at least a 50% reduction in seizure frequency
(i.e. responders)
TPM: 11/30 (47%)
Placebo: 3/30 (10%)
P value: 0.001

The proportion of participants having treatment withdrawn due to adverse events:
TPM: 4/30
Placebo: 1/30

Incidence of adverse events

<table>
<thead>
<tr>
<th></th>
<th>Placebo n=30, [%]</th>
<th>TPM n=30, [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache:</td>
<td>3[10]</td>
<td>6[27]</td>
</tr>
<tr>
<td>Somnolence:</td>
<td>4[13]</td>
<td>7[23]</td>
</tr>
<tr>
<td>Dizziness:</td>
<td>3[10]</td>
<td>7[23]</td>
</tr>
<tr>
<td>Fatigue:</td>
<td>3[10]</td>
<td>7[23]</td>
</tr>
<tr>
<td>Thinking abnormal:</td>
<td>0[0]</td>
<td>6[20]</td>
</tr>
<tr>
<td>Confusion:</td>
<td>0[0]</td>
<td>4[13]</td>
</tr>
<tr>
<td>Anxiety:</td>
<td>3[10]</td>
<td>3[10]</td>
</tr>
</tbody>
</table>

URTI= upper respiratory tract infections

Safety and adverse effects

There were no noteworthy laboratory value changes. The most frequently reported adverse events were CNS related. Most AEs were classified as mild or moderate severity.

Does the study answer the question?

TPM 600mg/day effective in the treatment of refractory partial onset seizures with or without secondarily generalised seizures

Effect due to factor in study?
The sample size is too small to detect significant differences for smaller differences

Consistency of results with other studies?

No indirectness ascertained.

Directly applicable to guideline population?

Internal Validity

Tsai JJ; Yen DJ; Hsih MS; Chen SS; Hiersemenzel R; Edrich P; Lai CW;

Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study

Ref ID 437

Study Type Randomised Controlled Trial

Funding Not reported.

Number of participant n=94 (n=47 in LEV group and n=47 in placebo group)
**Inclusion/Exclusion Criteria**

Inclusion criteria: diagnosed as having epilepsy for ≥6 months before the study. Partial seizures were treatment resistant in all cases, and, during an 8-week baseline period, all patients had at least four complex or secondarily generalized partial seizures (type IB or IC).

For ≥2 weeks before the study, patients had received a stable dosage of one to three AEDs (including benzodiazepines) other than LEV; all patients had been treated with at least two classic AEDs, either simultaneously or consecutively, before the study. Exclusion criteria: status epilepticus in the 3 months before the study, or if they had clusters of seizures that could not be reliably and regularly counted. A history or presence of pseudoseizures; a history of recurrent psychotic or major affective disorder; the presence of clinically significant acute or chronic illness.

**Patient Characteristics**

Summary of baseline demographic characteristics for the intention-to-treat population of 94 randomized patients

<table>
<thead>
<tr>
<th>Demographic characteristic</th>
<th>LEV (n = 47)</th>
<th>PLA (n = 47)</th>
<th>p Value (LEV vs. PLA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>32.8 (±10.5)</td>
<td>31.7 (±8.2)</td>
<td>0.564 c</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of males (%)</td>
<td>17 (36.2%)</td>
<td>25 (53.2%)</td>
<td>0.146 d</td>
</tr>
<tr>
<td>Number of females (%)</td>
<td>30 (63.8%)</td>
<td>22 (46.8%)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>47 (100%)</td>
<td>47 (100%)</td>
<td></td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>63.3 (±14.1)</td>
<td>64.7 (±12.6)</td>
<td>0.596 c</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>160.7 (±8.5)</td>
<td>164.1 (±7.9)</td>
<td>0.051 c</td>
</tr>
<tr>
<td>Body mass index (kg/m2)</td>
<td>24.4 (±5.0)</td>
<td>24.0 (±4.0)</td>
<td>0.620 c</td>
</tr>
<tr>
<td>Epilepsy history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of illness (yr)</td>
<td>18.6 (±8.5)</td>
<td>18.7 (±10.7)</td>
<td>0.968 c</td>
</tr>
<tr>
<td>Age at onset (yr)</td>
<td>14.3 (±8.5)</td>
<td>13.1 (±8.7)</td>
<td>0.499 c</td>
</tr>
<tr>
<td>Cause unknown</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Withdrawal seizures</td>
<td>13 (27.7%)</td>
<td>20 (42.6%)</td>
<td>0.194 d</td>
</tr>
<tr>
<td>Status epilepticus</td>
<td>4 (8.5%)</td>
<td>7 (14.9%)</td>
<td>0.523 d</td>
</tr>
<tr>
<td>Documentation of spikes or</td>
<td>6 (12.8%)</td>
<td>10 (21.3%)</td>
<td>0.411 d</td>
</tr>
<tr>
<td>Spike–waves on EEG</td>
<td>41 (87.2%)</td>
<td>45 (95.7%)</td>
<td>0.267 d</td>
</tr>
<tr>
<td>Baseline seizure frequency per week</td>
<td>4.0 (±14.1)</td>
<td>4.0 (±5.6)</td>
<td></td>
</tr>
<tr>
<td>Partial seizures Mean (SD)</td>
<td>1.6 (1.2–2.5)</td>
<td>2.0 (1.1–3.9)</td>
<td>0.378 e</td>
</tr>
<tr>
<td>Median (interquartile range)</td>
<td>4.0 (±14.1)</td>
<td>4.3 (±7.0)</td>
<td></td>
</tr>
<tr>
<td>Total seizures Mean (SD)</td>
<td>1.6 (1.2–2.5)</td>
<td>2.0 (1.1–3.9)</td>
<td>0.378 e</td>
</tr>
<tr>
<td>Number of concomitant AEDs taken by patients (overall study) [number (% of patients]</td>
<td>4.014 f</td>
<td>7 (14.9%)</td>
<td>11 (23.4%)</td>
</tr>
<tr>
<td>One</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two</td>
<td>19 (40.4%)</td>
<td>18 (38.3%)</td>
<td></td>
</tr>
<tr>
<td>Three</td>
<td>21 (44.7%)</td>
<td>16 (34.0%)</td>
<td></td>
</tr>
<tr>
<td>Four or more</td>
<td>0 (0.0)</td>
<td>2 (4.3%)</td>
<td></td>
</tr>
</tbody>
</table>

**Recruitment**

Not reported.

**Setting**

Five centres in Taiwan.

**Interventions/ Test/ Factor being investigated**

Levetiracetam up to 2000mg per day as adjunctive therapy with currently used AEDs.

**Comparisons**

The comparison is between levetiracetam (up to 2000mg per day) and placebo as adjunctive therapy to currently used AEDs.

**Length of Study/ Follow-up**

22 weeks: 8 week baseline period, 2 weeks titration and 12 week maintenance.
**Outcome measures studied**


**Results**

Summary of results for primary and secondary efficacy variables in the intention-to-treat population

<table>
<thead>
<tr>
<th>Variable</th>
<th>LEV (n = 47)</th>
<th>PLA (n = 47)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Least square mean</td>
<td>0.813</td>
<td>1.085</td>
<td></td>
</tr>
<tr>
<td>% reduction over placebo</td>
<td>23.8% (95% CI: 10.4% to 35.2%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Secondary efficacy variables

<table>
<thead>
<tr>
<th>Variable</th>
<th>LEV (n = 47)</th>
<th>PLA (n = 47)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute decrease from baseline</td>
<td>0.6 (−0.1 to 1.4)</td>
<td>0.3 (−0.2 to 0.7)</td>
<td>0.129</td>
</tr>
<tr>
<td>Percentage decrease from baseline</td>
<td>45.4 (−13.1 to 76.9)</td>
<td>15.6 (−5.7 to 41.4)</td>
<td>0.010</td>
</tr>
<tr>
<td>Responder rated</td>
<td>20/46 (43.5%)</td>
<td>5/47 (10.6%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Number (%) of patients free of seizures</td>
<td>4 (8.5%); [47]</td>
<td>0 (0.0%); [47]</td>
<td>0.117</td>
</tr>
<tr>
<td>Number of seizure-free days per 4 wke</td>
<td>24.2 (±3.3); [46]</td>
<td>21.4 (±6.3); [46]</td>
<td></td>
</tr>
<tr>
<td>Number (%) of patients in six ranked categories of % change from baseline in weekly seizure frequency:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;25% increase</td>
<td>7 (15.2%); [46]</td>
<td>8 (17.0%); [47]</td>
<td></td>
</tr>
<tr>
<td>25% increase to &lt;25% decrease</td>
<td>9 (19.6%); [46]</td>
<td>19 (40.4%); [47]</td>
<td></td>
</tr>
<tr>
<td>25% decrease to 50% decrease</td>
<td>10 (21.7%); [46]</td>
<td>15 (31.9%); [47]</td>
<td></td>
</tr>
<tr>
<td>50% decrease to &lt;75% decrease</td>
<td>7 (15.2%); [46]</td>
<td>4 (8.5%); [47]</td>
<td></td>
</tr>
<tr>
<td>75% decrease to &lt;100% decrease</td>
<td>9 (19.6%); [46]</td>
<td>1 (2.1%); [47]</td>
<td></td>
</tr>
<tr>
<td>100% decrease</td>
<td>4 (8.7%); [46]</td>
<td>0 (0.0%); [47]</td>
<td></td>
</tr>
</tbody>
</table>

### Total seizures

<table>
<thead>
<tr>
<th>Variable</th>
<th>LEV (n = 47)</th>
<th>PLA (n = 47)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Least square mean</td>
<td>0.819</td>
<td>1.095</td>
<td></td>
</tr>
<tr>
<td>% reduction over placebo</td>
<td>24.1% (95% CI: 10.6%–35.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absolute decrease from baseline</td>
<td>0.6 (−0.1–1.4)</td>
<td>0.3 (−0.2–0.7)</td>
<td></td>
</tr>
<tr>
<td>Percentage decrease from baseline</td>
<td>45.4 (−13.1–76.9)</td>
<td>15.6 (−5.7–39.1)</td>
<td></td>
</tr>
<tr>
<td>Number (%) of patients free of seizures</td>
<td>4 (8.5%); [47]</td>
<td>0 (0.0%); [47]</td>
<td></td>
</tr>
<tr>
<td>Number of seizure-free days per 4 wke</td>
<td>24.2 (±3.3); [46]</td>
<td>21.3 (±6.4); [46]</td>
<td></td>
</tr>
</tbody>
</table>

LEV, levetiracetam; NA, not applicable; PLA, placebo.

aValues in square brackets indicate numbers of evaluable patients.
bAbsolute decrease from baseline over the evaluation period; median and interquartile range.
cPercentage decrease from baseline over the evaluation period; median and interquartile range.
dProportion of patients with a ≥50% decrease from baseline in weekly seizure frequency.
eMean (± standard deviation).

**Adverse events**

Number (%) of patients with adverse events observed with an incidence of ≥5% during the evaluation period (data for the intention-to-treat population)

Adverse events considered at least possibly

All adverse events related to study medication by the
Yes. Adjunctive LEV therapy, \( \leq 1000 \text{mg twice daily} \), was significantly more effective than placebo in Taiwanese adults with treatment-resistant partial-onset seizures.

### Safety and adverse effects

**Does the study answer the question?**

Yes. Adjunctive LEV therapy, \( \leq 1000 \text{mg twice daily} \), was significantly more effective than placebo in Taiwanese adults with treatment-resistant partial-onset seizures.

**Effect due to factor in study?**

Yes. The study had a power of 80% to detect 20% superiority for LEV over placebo regarding logarithmically transformed weekly seizure frequency.

**Consistency of results with other studies?**

All patients had a diagnosis of partial-onset seizures with or without secondary generalization.

### Internal Validity

Turnbull DM; Howel D; Rawlins MD; Chadwick DW;

Which drug for the adult epileptic patient: phenytoin or valproate?

Ref ID 4672

**Number of participant**

140 in total sample with 70 in each arm, valproate and phenytoin respectively.

**Inclusion/Exclusion Criteria**

Inclusion: a history of two or more seizures in the previous three years; over age 16 and had received no previous anticonvulsant.

**Patient Characteristics**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Valproate (70 patients)</th>
<th>Phenytoin (70 patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>16-69 (30 median)</td>
<td>16-70 (30 median)</td>
</tr>
<tr>
<td>Female</td>
<td>36</td>
<td>31</td>
</tr>
<tr>
<td>Male</td>
<td>34</td>
<td>39</td>
</tr>
</tbody>
</table>

**Recruitment**

Unknown.

**Setting**

Dept of Neurology, Royal Victoria Infirmary.
Valproate vs. phenytoin in newly diagnosed adult patients with epilepsy.

PHT 100mg 3 times a day; VPA 200mg 3 times a day; if further seizures occurred medication was increased PHT depending on plasma concentration if less than 10mg/l the dose was increased by 50mg/day and if greater than 10mg/l it was increased by 25mg/day, doses were further increased until seizures stopped or adverse effects seen; valporate was increment of 1200mg/2100mg and 3000mg/day given in 3 divided doses regardless of serum concentration.

Comparison is made between two treatments< valporate vs. phenytoin

48 months.

Achievement of a two year remission and 'time to first seizure'.

<table>
<thead>
<tr>
<th>Interventions/ Test/ Factor being investigated</th>
<th>Valproate</th>
<th>Phenytoin</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>70</td>
<td>70</td>
</tr>
<tr>
<td>No achieving 2 year remission</td>
<td>36</td>
<td>31</td>
</tr>
<tr>
<td>No controlled for &lt;2 years</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>No continuing to have seizures</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>Idiosyncratic adverse effect requiring drug withdrawal</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Death</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Non-compliant or lost to follow-up</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

In patients with tonic clonic seizures 27 of 37 patients on valproate and 22 of 39 on phenytoin achieved 2 year remission.
In patients with partial seizures 9 of 31 patients on valproate and 9 of 31 on phenytoin achieved 2 year remission.

Sodium valproate and phenytoin in the treatment of tonic clonic or partial seizures showed no significant difference in the efficacy as regards time to two year remission. However patients with a clinical history of partial seizures did significantly less well than those with a history of tonic clonic seizures only (p<0.025) and to time to first seizure (p<0.001). There were not figures to report time to first seizure in evidence review.

Valporate dose related adverse effects: tremor, irritability and restlessness and alopecia. Phenytoin dose related adverse effects: nystagmus, ataxia, tremor, diplopia and mental change. Idiosyncratic effects of phenytoin: skin eruption, erythoderma and jaundice.

This study showed no major difference in efficacy between sodium valproate and phenytoin in adults with recent onset of epilepsy.

Yes

See GRADE

Gabapentin dose related adverse effects: tremor, irriability and restlessness and alopecia. Phenytoin dose related adverse effects: nystagmus, ataxia, tremor, diplopia and mental change. Idiosyncratic effects of phenytoin: skin eruption, erythoderma and jaundice.

This study showed no major difference in efficacy between sodium valproate and phenytoin in adults with recent onset of epilepsy.

Yes

See GRADE

UK Gabapentin Study Group.

Gabapentin in partial epilepsy.

Ref ID 4622 1990

Study Type Randomised Controlled Trial  
Funding Unknown

Number of participant 127 total; 61 Gabapentine and 66 placebo

29 July 2010  Page 112 of 306
Gabapentin as additional therapy in patients with drug resistant partial epilepsy

Gabapentin vs. placebo

12 weeks

Responder rate: percentage of patients in whom the number of partial seizures fell by at least 50% from baseline.

Response ratio: a calculation of percent change

Frequency of partial seizures was at least halved in 25% of patients treated with gabapentin compared with 9.8% treated with placebo (p=0.043). The median reduction in partial seizure frequency during 12 weeks treatment was 29.2% with gabapentin compared with 12.5% with placebo. The mean adjusted response ratio for gabapentin (-0.192) was significantly better than the ratio of -0.060 for placebo (p=0.0056) by analysis of variance.

Gabapentin: 62% of patients reported mostly mild or moderate adverse effects

Placebo: 41% of patients reported mostly mild or moderate adverse effects

Haematological and biochemical parameters monitored during treatment showed no significant trends for any parameter, compared with baseline for either gabapentin or placebo.

Gabapentin is an effective additional treatment for patients with partial epilepsy refractory to standard therapy.

Yes

See GRADE

See GRADE

Multicentre study

Ref ID 4621

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study.

Funding Park-Davis

Study Type Randomised Controlled Trial

Number of participant 306 patients total: 98 placebo, 53 received 600 mg gabapentin, 101 received 1200 mg gabapentin, 54 received 1800 mg gabapentin.

Inclusion/Exclusion Criteria Inclusion: Patients with documented partial seizures refractory to treatment with at least 4 partial seizures per month for 3 months prior to baseline while taking one or two AEDs at stable dosages. Age over 16 years. Use of reliable contraception if female in childbearing years.

Excluded: Patients with atypical absence seizures or nonepileptic seizures,
progressive structural lesion in the CNS; severe liver or kidney insufficiency; neutropenia; previous investigational drug use in the past 3-12 months.

**Patient Characteristics**

<table>
<thead>
<tr>
<th>Total N=306</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Mean</td>
</tr>
<tr>
<td>Range</td>
</tr>
<tr>
<td>Partial seizure frequency/28 days during baseline</td>
</tr>
<tr>
<td>Mean</td>
</tr>
</tbody>
</table>

**Recruitment**

Not described

**Setting**

15 centres in the US between May 1987 and November

**Interventions/ Test/ Factor being investigated**

To define the safety, efficacy and dose response characteristics of gabapentin administered as an add on therapy in patients with refractory partial seizures

**Comparisons**

Comparison is made between three doses of gabapentin (600 mg, 1200 mg and 1800 mg) and placebo.

**Length of Study/ Follow-up**

12 week baseline period; 12 week double blind phase

**Outcome measures studied**

Primary outcome: Number of seizures per 28 days
Secondary outcomes: Response ratio (RRatio); percent change in seizure frequency and responder rate.

**Results**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo</th>
<th>600 mg GBP</th>
<th>1200 mg GBP</th>
<th>1800 mg GBP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response ratio</td>
<td>-0.025</td>
<td>-0.151</td>
<td>-0.118</td>
<td>-0.233</td>
</tr>
<tr>
<td>Adjusted mean</td>
<td>0.022</td>
<td>0.037</td>
<td>0.027</td>
<td>0.034</td>
</tr>
<tr>
<td>SEM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p value compared to placebo</td>
<td>0.007</td>
<td>0.023</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Responder rate</td>
<td>8.4%</td>
<td>18.4%</td>
<td>17.6%</td>
<td>26.4%</td>
</tr>
<tr>
<td>(percent of patients with at least 50% reduction in seizure frequency from baseline to treatment)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p value compared to placebo</td>
<td>0.103</td>
<td>0.080</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>Median percent change in seizure frequency</td>
<td>-5.9</td>
<td>-24.3</td>
<td>-20.0</td>
<td>-31.9</td>
</tr>
</tbody>
</table>

**Safety and adverse effects**

The three most frequently occurring adverse events were somnolence, dizziness and ataxia, were not dose related and usually occurred within the first 15 to 20 days of therapy and resolved in 2 weeks or less for most patients.

**Does the study answer the question?**

Gabapentin's low inherent toxicity and its lack of drug interactions make it an ideal candidate for use as add on therapy in patients with refractory partial epilepsy.

**Effect due to factor in study?**

Yes

**Consistency of results with other studies?**

See GRADE

**Directly applicable to guideline population?**

See GRADE

**Internal Validity**

Multi-centre study

Uthman BM; Rowan AJ; Ahmann PA; Leppik IE; Schachter SC; Sommerville KW; Shu V;

29 July 2010
Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial

Ref ID 4760

Study Type Randomised Controlled Trial

Funding Abbott Laboratories; the study drugs were also provided by Abbott Laboratories.

Number of participant n=297 (n=91 in placebo group, n=61 in TGB 16mg/d, n=88 in 32mg/d, and n=57 in 56mg/d groups)

Inclusion/Exclusion Criteria

Inclusion criteria: (1) age between 12 and 77 years; (2) good health except for epilepsy; (3) occurrence of at least 6 CPS alone or in combination with any other seizure type in the 8 weeks preceding the screening visit (with each of the two 4-week segments containing at least 1 CPS); (4) electroencephalographic evidence of a unilateral or bilateral abnormality consistent with CPS; and (5) availability of at least 1 neuroimaging study of the brain to rule out the presence of any progressive lesions. Female patients could not be pregnant or lactating. The patient had to be receiving a stable regimen of 1 to 3 hepatic enzyme-inducing AEDs: phenytoin, carbamazepine, phenobarbital, or primidone.

Patient Characteristics

Demographic and Medical Characteristics of Patients With Complex Partial Seizures Randomized to Treatment (N=297)*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>F/M ratio, %</td>
<td>42:58</td>
</tr>
<tr>
<td>Mean age, y (range)</td>
<td>34.0 (12.0-77.0)†</td>
</tr>
<tr>
<td>Medical history, median (range)</td>
<td></td>
</tr>
<tr>
<td>History of epilepsy, y</td>
<td>22.9 (1.4-65.8)</td>
</tr>
<tr>
<td>No. of different AEDs ever taken</td>
<td>7.0 (2.0-20.0)</td>
</tr>
<tr>
<td>Concomitant AEDs, ‡ No. (%)</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>77 (26)</td>
</tr>
<tr>
<td>Combined with other AED</td>
<td>128 (43)</td>
</tr>
<tr>
<td>Phenytoin sodium</td>
<td></td>
</tr>
<tr>
<td>As monotherapy</td>
<td>25 (8)</td>
</tr>
<tr>
<td>Combined with other AED</td>
<td>69 (23)</td>
</tr>
<tr>
<td>Divalproex sodium§</td>
<td>79 (27)</td>
</tr>
<tr>
<td>Primidone</td>
<td>40 (13)</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>76 (26)</td>
</tr>
</tbody>
</table>

*There were no significant differences between treatment groups on any demographic or medical variable. †One patient in the study was 77 years old, 2 years over the protocol limit; he was enrolled because his health was excellent in other respects. ‡Patients had to be receiving a stable regimen of concomitant antiepileptic drugs (AEDs) for at least 8 weeks preceding the baseline phase. §Patients taking divalproex sodium could enter the study only if taking it in combination with another enzyme-inducing drug.

Recruitment

Unknown.

Setting

21 treatment sites in the United States.

Interventions/ Test/ Factor being investigated

Tiagabine in four daily doses: 16mg, 32mg or 56mg as adjunctive therapy to currently used AEDs.

Comparisons

The comparison is between the 3 doses of tiagabine and placebo as adjunctive therapy.

Length of Study/ Follow-up

32 weeks: a 12 week baseline phase, a four week titration phase and a 16 week maintenance period.

Outcome measures studied

Primary outcome: change in 4-week median complex partial seizures frequency from baseline phase to double-blind treatment phase. Secondary outcomes: proportions of patients having a 50% or greater reduction in CPS frequency. Also SPS and SGTCS.
Results

Change in Frequency of Complex Partial Seizures From Baseline to Double-blind Treatment Phase in Placebo- and Tiagabine-Treated Patients*

<table>
<thead>
<tr>
<th>Reduction</th>
<th>Median Change</th>
<th>P vs Placebo</th>
<th>Median % Change</th>
<th>P vs</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>-0.7</td>
<td>. .</td>
<td>-11</td>
<td>4 (4)</td>
<td></td>
</tr>
<tr>
<td>Tiagabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 mg/d</td>
<td>-0.8</td>
<td>.44</td>
<td>-13</td>
<td>5 (8)</td>
<td>.42</td>
</tr>
<tr>
<td>32 mg/d</td>
<td>-2.2</td>
<td>.03</td>
<td>-25†</td>
<td>17 (20)</td>
<td></td>
</tr>
<tr>
<td>.002</td>
<td>.002</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56 mg/d</td>
<td>-2.8</td>
<td>.03</td>
<td>-33‡</td>
<td>16 (29)</td>
<td></td>
</tr>
<tr>
<td>&lt;.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Counts include complex partial seizures occurring alone or in combination with other seizure types. Values for P vs placebo were calculated by weighted pairwise comparison, nonparametric. P values comparing the proportions of tiagabine-treated patients and placebo-treated patients experiencing 50% or greater reduction in seizure frequency were calculated using the Cochran-Mantel-Haenszel statistic. Median percent change was based on the percentages of seizure reduction from baseline in individual patients.

†P=.02. ‡P=.009.

Secondary outcomes

Change in frequency of simple partial seizures between baseline and double-blind treatment phase in placebo and tiagabine treated patients *

<table>
<thead>
<tr>
<th>Reduction</th>
<th>Median Change</th>
<th>P vs Placebo</th>
<th>Median % Change</th>
<th>P vs</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>0.9</td>
<td>. .</td>
<td>10.5</td>
<td>5 (9.8)</td>
<td></td>
</tr>
<tr>
<td>Tiagabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 mg/d</td>
<td>-2.3</td>
<td>.001</td>
<td>-23.7</td>
<td>11(28.2)</td>
<td>.03</td>
</tr>
<tr>
<td>32 mg/d</td>
<td>-1.7</td>
<td>.04</td>
<td>-12.4</td>
<td>17 (34.7)</td>
<td></td>
</tr>
<tr>
<td>.003</td>
<td>.003</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56 mg/d</td>
<td>-3.3</td>
<td>.003</td>
<td>-36.3</td>
<td>12 (36.4)</td>
<td></td>
</tr>
<tr>
<td>.005</td>
<td>.005</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32 and 56 mg/d, combined</td>
<td>-2.6</td>
<td>.004</td>
<td>-25.0</td>
<td>29 (35.4)</td>
<td></td>
</tr>
<tr>
<td>.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adverse events

Adverse Events for Which Significant Differences Between Tiagabine and Placebo Groups Were Observed*

<table>
<thead>
<tr>
<th>mg/d</th>
<th>Placebo Group</th>
<th>16 mg/d</th>
<th>32 mg/d</th>
<th>56 mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Event†</td>
<td>(n=91)</td>
<td>(n=61)</td>
<td>(n=88)</td>
<td>(n=57)</td>
</tr>
</tbody>
</table>

Dizziness [ .07 ]

Tremor [ .001 ]

29 July 2010   Page 116 of 306
A clear dose-response relationship was observed between tiagabine dose levels and reduction in CPS frequency, with higher doses of tiagabine (32 and 56 mg/d) resulting in a significantly greater decrease in 4-week seizure frequency than that observed in the placebo group.

8% of patients in the placebo terminated study prematurely because of adverse events. Percentages in other drug groups were 7% in 16mg/d group, 15% in 32mg/d group and 16% in 56mg/d group. Adverse events were serious in 6 patients (7%) in the placebo group, 2 (3%) in the tiagabine 16-mg group, 4 (4%) in the 32-mg group, and 4 (7%) in the 56-mg group.

Safety and adverse effects

Does the study answer the question?
Yes. A clear dose-response relationship was observed between tiagabine dose levels and reduction in CPS frequency, with higher doses of tiagabine (32 and 56 mg/d) resulting in a significantly greater decrease in 4-week seizure frequency than that observed in the placebo group.

Effect due to factor in study?
Yes. The study was sufficiently well powered to detect differences in seizure frequency between the groups.

Consistency of results with other studies?

Directly applicable to guideline population?
All patients had had at least 6 complex partial seizures in the 8 weeks preceding study enrollment.

Internal Validity

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures

Study Type Randomised Controlled Trial Funding UCB Pharma SA.

Number of participant n=206 (n=103 in the placebo group and n=103 in the LEV group)
Inclusion/Exclusion Criteria
Inclusion criteria: Chinese subjects aged 16 to 70 years with partial-onset seizures, with or without secondary generalization, diagnosed at least 6 months prior to the selection visit, present with treatment-resistant partial onset seizures and had to have experienced at least eight partial-onset seizures during the 8-week historical baseline period. Exclusion criteria: history of pseudoseizures or if they had status epilepticus in the 3 months before the study or clusters of seizures that could not be reliably and regularly counted, a history of recurrent psychotic or major affective disorder; alcohol or drug abuse within the previous year; or current cardiac, renal, hepatic dysfunction; questionable compliance with drug treatment; laboratory test abnormalities; and the use of central nervous system (CNS)-influencing medication (other than concomitant AED therapy), unless patients had been stabilized on such medication for more than 1 month before the trial.

Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao Z; Lv CZ;

Ref ID 4841 2009 Mar

29 July 2010 Page 117 of 306
Baseline demographic characteristics and history of epilepsy (intent-to-treat population)

Placebo (n=100)  LEV (n=102)

Age (years), mean (SD)  32.8 (11.9)  32.7 (13.4)
Range  16–64  15–70
Gender, male, n (%)  54 (54.0)  51 (50.0)
Weight (kg), mean (SD)  63.2 (13.6)  60.7 (11.6)
Age at onset of epilepsy (years), mean (SD)  15.2 (10.9)a  16.0 (11.0)
Duration of epilepsy (years), mean (SD)  17.3 (12.1)a  16.5 (12.7)
Seizure type at baseline, n (%)
Simple partial  30 (30.0)  30 (29.4)
Complex partial  61 (61.0)  57 (55.9)
Secondarily generalized  48 (48.0)  56 (54.9)
Primary generalized  2 (2.0)  1 (1.0)
Concomitant AEDs,b n (%)  
Carbamazepine  52 (52.0)  59 (57.8)
Valproate  30 (30.0)  31 (30.4)
Topiramate  25 (25.0)  29 (28.4)
Gabapentin  16 (16.0)  12 (11.8)
Phenytoin  9 (9.0)  9 (8.8)
Clonazepam  9 (9.0)  7 (6.9)
Phenobarbital  9 (9.0)  6 (5.9)
Lamotrigine  5 (5.0)  3 (2.9)

a n= 99.
b Used by >=5% of patients in either treatment group.

AED, antiepileptic drug; LEV, levetiracetam; SD, standard deviation.

Recruitment
Not reported.

Setting
Six centres in China.

Interventions/ Test/ Factor being investigated
Levetiracetam up to 3000mg per day as adjunctive therapy.

Comparisons
The comparison is between levetiracetam up to 3000mg per day and placebo as adjunctive therapy to currently used AEDs.

Length of Study/ Follow-up
24 weeks: 8 week baseline, 4 week titration and 12 week maintenance.

Outcome measures studied
Primary outcome: weekly frequency of partial-onset seizures over the 16 week treatment period. Secondary outcomes: weekly freq of all seizures, % reduction of in weekly freq partial onset and all seizures, responder rate, seizure freedom rates.

Results
Weekly frequency of partial-onset seizures during historical baseline and 16-week treatment periods, and absolute and percentage reduction from historical baseline in partial-onset seizure frequency over 16-week treatment period (intent-to-treat population)

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=100)</th>
<th>LEV (n=102)</th>
<th>p-</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Historical baseline weekly seizure frequency</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>1.75 (1.13–4.00)</td>
<td>1.81 (1.13–3.38)</td>
<td></td>
</tr>
<tr>
<td><strong>Treatment period weekly seizure frequency</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>1.74 (0.90–3.67)</td>
<td>0.85 (0.25–2.54)</td>
<td></td>
</tr>
<tr>
<td><strong>Transformed LSmean 1.23 0.92</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percentage reduction over placebo (95% CI) — &lt;0.001</td>
<td></td>
<td>26.8% (14.0–37.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Absolute reduction in weekly seizure frequency from historical baseline</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>0.29 (-1.25–0.81)</td>
<td>0.91 (0.02–1.75)</td>
<td></td>
</tr>
<tr>
<td><strong>Percentage reduction in weekly seizure frequency from historical baseline</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>13.7 (-38.8–50.4)</td>
<td>55.9 (0.9–87.6)</td>
<td></td>
</tr>
</tbody>
</table>

29 July 2010  Page 118 of 306
LEV was effective in Chinese patients with refractory partial onset seizures. The study appeared to be well conducted but no power calculation was performed. Cannot be confident about the effectiveness of LEV compared to placebo.

**Internal Validity**

Does the study answer the question?

LEV was effective in Chinese patients with refractory partial onset seizures. The study appeared to be well conducted but no power calculation was performed. Cannot be confident about the effectiveness of LEV compared to placebo.

Effect due to factor in study?

No. No power calculation was performed. Therefore, it is not clear if the difference in seizure reduction between LEV and placebo occurred by chance.

Consistency of results with other studies?

All patients had a diagnosis of partial-onset seizures.

**Safety and adverse effects**

Number (% of patients)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Placebo (n=103)</th>
<th>LEV (n=103)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least one TEAE</td>
<td>62 (60.2)</td>
<td>65 (63.1)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>18 (17.5)</td>
<td>18 (17.5)</td>
</tr>
<tr>
<td>Decreased platelet count</td>
<td>10 (9.7)</td>
<td>10 (9.7)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>14 (13.6)</td>
<td>8 (7.8)</td>
</tr>
<tr>
<td>Headache</td>
<td>9 (8.7)</td>
<td>4 (3.9)</td>
</tr>
</tbody>
</table>

LEV, levetiracetam; TEAE, treatment-emergent adverse event.

None of the patients in the LEV group discontinued medication due to an adverse event, compared with two patients (1.9%) in the placebo group. Serious adverse events were reported by three patients (2.9%) in LEV group (appendicitis, pregnancy, fracture) and two (1.9%) in the placebo group (schizophrenia, overdose). None of the serious adverse events was considered to be related to the study drug.

**Study Type**

Randomised Controlled Trial

29 July 2010

**Funding**

UCB pharmacy, Netherlands

**Ref ID**

4842

2009
**Number of participant**

56 patients. 28 in each arm.

**Inclusion/Exclusion Criteria**

Inclusion criteria:
- 16 to 70 years old
- Unequivocal history of partial seizures, with or without secondary generalisation
- Refractory to current antiepileptic therapy
- Experienced at least 4 seizures per month (averaged within the two preceding month) while on AEDs
- Received 1-2 of the following AEDs: phenytoin, carbamazepine, phenobarbital or primidone, valproate Topiramate, gabapentin, clonazepam, or lamotrigine for at least 10 weeks.
- Good physical health and capable of counting seizures
- Female patients should be post-menopause, had surgical sterilisation or an approved method of birth control
- Prior (if any) surgery for epilepsy failed to reduce frequency (≥ 6 months ago).

Exclusion criteria:
- Previous exposure to LEV
- History or evidence of progressive encephalopathy or structural lesion in the CNS, progressive degenerative neurological disorder, serious psychiatric disorder or mental retardation within the past 5 years.
- Pseudoseizures within the past year
- Uncountable seizures or history of convulsive status epilepticus within the past 5 years
- Clinically significant cardiac, haematologic hepatic, or renal disease or any conditions that might interfere with the pharmacokinetics of the drugs
- Serum creatinine >177 micromol/l or neutrophil counts < 2800/ml or platelet counts <100,000/ml

**Patient Characteristics**

**Demographics**
- LEV, n=28
  - Gender (male): 12 (42.9%)
  - Age, years, mean±SD: 32.8±11.2 (17-60)
  - Weight, kg, mean±SD: 58.4±14.6 (43-82)
  - Asian: 28 (100%)
- Placebo, n=28
  - Gender (male): 12 (45.9%)
  - Age, years, mean±SD: 32.5±11.2 (12-58)
  - Weight, kg, mean±SD: 58.1±14.6 (41-102)
  - Asian: 28 (100%)

**Epilepsy aetiology**
- Cause unknown: 23 (82.1%) 17 (60.7%)
- Age at onset: 18.6±9.4 (2-40) 16.3±11.2 (1-41)
- Duration of epilepsy: 14.1±9.4 (2-40) 16.1±12.5 (2-48)
- Baseline frequency of seizure: 4.9±7.3 (1-23.6) 5.6±5.4 (1-50)
- Seizure type:
  - Simple partial: 3 (10.7%) 8 (28.6%)
  - Complex partial: 18 (64.3%) 19 (67.9%)
  - Secondary generalised: 14 (50%) 15 (53.6%)

**Concomitant AED**
- Topiramate: 11 (39.3)% 10 (35.7)
- Carbamazepine: 11 (39.3) 9 (32.1)
- Valproic acid: 9 (32.1) 9 (32.1)
- Gabapentin: 5 (17.9) 9 (32.1)
- Barbiturates: 1 (3.6) 2 (7.1)
- Lamotrigine: 1 (3.6) 2 (7.1)
- Clonazepam: 3 (13.8) 1 (3.6)

**Recruitment**

Enrolled by the Epilepsy Centre over a period of 4 months. All patients screened were eligible.

**Setting**

China – Chongqing Medical University

**Interventions/ Test/ Factor being investigated**

Levetiracetam vs placebo

**Comparisons**

Adjunctive therapy: Levetiracetam vs placebo added on to existing therapy

**Length of Study/ Follow-up**

8 weeks baseline period.
- Treatment: 16 weeks – 4 week titration and 8 week maintenance
- Withdrawal: 4 weeks study of medication withdrawal
Primary outcome: weekly frequency of partial seizures (logarithmically transformed)
Secondary:
- Absolute and % reduction in frequency/week
- 50% responder rate
- Number and % of seizure free patients and number of seizure free days/4 weeks.

Results

Proportion of seizure free participants:
LEV: 3/28 (10.7)
Placebo: 2/28 (7.1%)
P= NS

Proportion of participants experiencing at least a 50% reduction in seizure frequency (i.e. responders)
LEV: 13/28 (46.4%)
Placebo: 11/28 (39.3%)
P= NS

The proportion of participants having treatment withdrawn because of adverse events:
LEV: 0/28 (0%)
Placebo: 0/28 (0%)
P= NS

The proportion of participants having treatment withdrawn because of lack of efficacy:
LEV: 0/28 (0%)
Placebo: 0/28 (0%)
P= NS

Incidence of adverse events more than 10% in each arm:

<table>
<thead>
<tr>
<th>Event</th>
<th>LEV 1200mg/day</th>
<th>LEV 1800mg/day</th>
<th>Placebo 1200mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT increases</td>
<td>4 (14.3%)</td>
<td>3 (10.7%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>AST increases</td>
<td>3 (10.7%)</td>
<td>2 (7.1%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Platelets decreases</td>
<td>10 (35.7%)</td>
<td>10 (35.7%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>WBC decreases</td>
<td>3 (10.7%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>3 (10.7%)</td>
<td>5 (17.9%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Dizziness (except vertigo)</td>
<td>3 (10.7%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Agitation</td>
<td>3 (10.7%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Safety and adverse effects
The most common treatment emergent adverse events were mild to moderate in severity.

Does the study answer the question?
Adjunctive therapy with LEV 3000 mg daily was well tolerated but not as effective as expected in controlling partial seizures. Considering the lower mean weight of the study population, the dosage of LEV3000 mg may contribute to the results.

Effect due to factor in study?
The sample size was not powered to detect a significant difference in the outcomes measured.

Consistency of results with other studies?
Uncertain – baseline frequency of epileptic episodes is a minimum of 4/month. Is this the typical frequency(severity)?

Internal Validity

Yamauchi T; Kaneko S; Yagi K; Sase S;

Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study

Ref ID 362 2006 Aug

Study Type Randomised Controlled Trial  Funding Not reported.

Number of participant n=209 (n=86 in gabapentin 1200mg/day, n=41 in gabapentin 1800mg/day and n=82 in placebo group)
Inclusion/Exclusion Criteria

Inclusion criteria: men and non-pregnant women, at least 16 years of age with partial seizures, inpatients or outpatients, weight 40–110 kg, on a stable dose of no more than two AEDs.

Exclusion criteria: evidence of unstable diseases, such as progressive diseases in the central nervous system, encephalopathy, or histological lesions as detected by magnetic resonance imaging or computed tomography scan conducted in the previous 2 years.

Patient Characteristics

Demographic and baseline disease characteristics†

<table>
<thead>
<tr>
<th>Enrolled patients</th>
<th>Placebo</th>
<th>Gabapentin (mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1800)</td>
<td>82</td>
<td>86</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>42 (51.2)</td>
<td>37 (43.0)</td>
</tr>
<tr>
<td>(53.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>40 (48.8)</td>
<td>49 (57.0)</td>
</tr>
<tr>
<td>(46.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>18–44</td>
<td>55</td>
<td>70</td>
</tr>
<tr>
<td>45–64</td>
<td>18</td>
<td>11</td>
</tr>
<tr>
<td>≥65</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>31.8 ± 11.3</td>
<td>31.3 ± 10.6</td>
</tr>
<tr>
<td>Bodyweight (kg) (mean ± SD)</td>
<td>59.3 ± 11.5</td>
<td>59.4 ± 11.1</td>
</tr>
<tr>
<td>Type of seizure (n/%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SP</td>
<td>44 (58.7)</td>
<td>44 (55.0)</td>
</tr>
<tr>
<td>(51.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP</td>
<td>67 (89.3)</td>
<td>66 (82.5)</td>
</tr>
<tr>
<td>(85.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SG</td>
<td>25 (33.3)</td>
<td>21 (26.3)</td>
</tr>
<tr>
<td>(37.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of epilepsy† (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>19.5</td>
<td>19.8</td>
</tr>
<tr>
<td>Range</td>
<td>2.1–47.0</td>
<td>4.0–42.0</td>
</tr>
<tr>
<td>(5.2–43.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline seizure (per 28 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>19.9</td>
<td>31.6</td>
</tr>
<tr>
<td>Median</td>
<td>9.7</td>
<td>11.2</td>
</tr>
<tr>
<td>Range</td>
<td>3.3–289.7</td>
<td>2.7–564.3</td>
</tr>
<tr>
<td>(2.9–101.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant AED, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One</td>
<td>16 (19.5)</td>
<td>12 (14.0)</td>
</tr>
<tr>
<td>(4.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two</td>
<td>66 (80.5)</td>
<td>74 (86.0)</td>
</tr>
<tr>
<td>(95.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Recruitment

Not reported.

Setting

54 sites in Japan.

Interventions/ Test/ Factor being investigated

Gabapentin 1200mg per day and 1800mg per day as adjunctive therapy to currently used AEDs.

Comparisons

The comparisons are between the two doses of gabapentin (1200mg and 1800mg) and placebo.

Length of Study/ Follow-up

32 weeks: 12 weeks baseline, 12 weeks treatment, 4 weeks phased withdrawal and 4 weeks observation period.
Outcome measures studied

Primary outcome: response ratio (RRatio). RRatio = (T – B)/(T + B), where T and B are the seizure frequencies during treatment and during baseline. RRatio = -1 (reduction) to +1.

Secondary outcomes: % change from baseline in seizure frequency.

Results

Efficacy results for the per-protocol set population

<table>
<thead>
<tr>
<th>Efficacy parameters</th>
<th>Placebo (n = 75)</th>
<th>Gabapentin 1200 mg/day (n = 80)</th>
<th>Gabapentin 1800 mg/day (n = 35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% change in partial seizures †</td>
<td>Mean</td>
<td>2.6</td>
<td>-17.8</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>-9.7</td>
<td>-21.2</td>
</tr>
<tr>
<td>Responder rate ‡, n (%)</td>
<td>5 (6.7)</td>
<td>13 (16.3)</td>
<td>7 (20.0)</td>
</tr>
<tr>
<td>Improvement in seizure frequency §, n (%)</td>
<td>Completely resolved</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Markedly improved (2.9)</td>
<td>0 (2.5)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Moderately improved (17.1)</td>
<td>5 (6.7)</td>
<td>11 (13.8)</td>
<td>6</td>
</tr>
<tr>
<td>Slightly improved (37.1)</td>
<td>17 (22.7)</td>
<td>22 (27.5)</td>
<td>13</td>
</tr>
<tr>
<td>No change (20.0)</td>
<td>23 (30.7)</td>
<td>29 (36.3)</td>
<td>7</td>
</tr>
<tr>
<td>Worse (22.9)</td>
<td>30 (40.0)</td>
<td>16 (20.0)</td>
<td>8</td>
</tr>
<tr>
<td>Improvement in seizure intensity/duration ¶, n (%)</td>
<td>Better (45.7)</td>
<td>25 (33.3)</td>
<td>36 (45.0)</td>
</tr>
<tr>
<td>No change (48.6)</td>
<td>40 (53.3)</td>
<td>39 (48.8)</td>
<td>17</td>
</tr>
<tr>
<td>Worse (9.3)</td>
<td>7 (9.3)</td>
<td>5 (6.3)</td>
<td>2 (5.7)</td>
</tr>
</tbody>
</table>

† Percent change in partial seizures (PCH) was calculated by the formula: PCH (%) = 100(T−B)/B, where T and B are the seizure frequencies during treatment and during baseline, respectively.

‡ The responder was defined as a patient with reduction in PCH >50%, meaning summed patients categorized into completely resolved, markedly improved and moderately improved with regard to improvement in seizure frequency rating.

§ Improvement in seizure frequency was classified into six categories by PCH: completely resolved (−100%), markedly improved (−99.9 to −75.0%), moderately improved (−74.9 to −50%), slightly improved (−49.9 to −25%), no change (−24.9 to 0%), and aggravated (>0.1%).

¶ Improvement in seizure intensity/duration was rated by summed scores at weeks 4, 8, and 12 compared to baseline (better,+1; no change, 0; worse, −1).

Safety and adverse effects

Adverse events

<table>
<thead>
<tr>
<th>Efficacy parameters</th>
<th>Placebo (n)</th>
<th>Gabapentin 1200 mg/day (n)</th>
<th>Gabapentin 1800 mg/day (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluated subjects</td>
<td>82</td>
<td>86</td>
<td>41</td>
</tr>
<tr>
<td>No. events</td>
<td>65</td>
<td>108</td>
<td>50</td>
</tr>
<tr>
<td>No. patients with events (%)</td>
<td>38 (46.3)</td>
<td>55 (64.0)</td>
<td>27 (65.9)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>17 (20.7)</td>
<td>44 (51.2)</td>
<td>18 (43.9)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>4 (4.9)</td>
<td>16 (18.6)</td>
<td>8 (19.5)</td>
</tr>
</tbody>
</table>

15 patients withdrew prematurely due to aggravation of seizures (3 in placebo), safety reasons (one placebo, four gabapentin 1200mg/day, 3 gabapentin 1800mg/day.)
Discontinuation rates due to adverse events or laboratory test abnormalities were 5.5% for gabapentin-treated patients (7/127) compared to 1.2% for placebo-treated patients (1/82). Serious treatment-related adverse events were reported for two gabapentin patients: ataxic gait, nystagmus, dizziness, ataxia and leg pains appeared in one patient receiving gabapentin 1200 mg/day, and seizures and dizziness appeared in another patient receiving gabapentin 1800 mg/day.

**Does the study answer the question?**
Yes. The study demonstrated that 1200 mg/day and 1800 mg/day gabapentin significantly reduced the frequency of refractory partial seizures compared to placebo and that there was a definite dose–response relationship for this effect.

**Effect due to factor in study?**
Yes. The sample size for the study was determined from the RRatio obtained in previous studies.

**Consistency of results with other studies?**
All patients enrolled in this study had refractory epilepsy with partial seizures.

**Internal Validity**
Yen DJ; Yu HY; Guo YC; Chen C; Yiu CH; Su MS;

A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy

**Ref ID** 4762

**Study Type** Randomised Controlled Trial

**Funding** Grant from Taipei Veterans General Hospital and Yen Tjing Ling Medical Foundation. Topiramate and placebo tablets provided by Jassen Cilag Taiwan.

**Number of participant**
Total: 46; 23 in each arm

**Inclusion/Exclusion Criteria**
Chinese adults aged 18 to 65 with a history of partial seizure that has not responded to adequate doses of AED treatment for 2 or more years. Diagnosis were supported with scalp electroencephalograms with nasopharangeal electrode and MRI or CT scans of the head. The seizure patterns and rates were recorded in diaries.

Exclusion criteria: intracranial tumour, severe hepatic or renal dysfunction, history of nephrolithiasis; pregnancy or breast feeding.

Patients who did not benefit from previous temporal lobotomy did were not excluded.

To quality for randomization, patients should have 4 or more complex partial seizures with or without secondary generalisation during the 8-week baseline period.

**Patient Characteristics**
Gender (male/female): topiramate: 6/17, placebo: 13/10
Age (years), mean, sd (range): topiramate: 31.4 sd 10.1 (18-54), placebo: 32.0 sd 8.7 (22-48)
Weight (kg), mean, sd (range): topiramate: 58.2 sd 12.7 (39.5 to 85), placebo: 60.4 sd 12.6 (34 to 83)
Seizure history (years), mean, sd (range): topiramate: 14.9 sd 10.9 (5 to 45), placebo: 18.9 sd 11.1 (2 to 39)
Seizure focus (temporal / non temporal lobe): topiramate: 21/2, placebo: 21/2
(Among the non temporal lobe origin, 2 were frontal, 1 centroparietal and 1 occipital)
Number of AEDs (1/2/3/4 or more): topiramate: 4/6/1/2, mean 2.48 sd 0.90, placebo: 1/7/11/4, mean 2.78 sd 0.80.
Specific AEDs used (carbamazepine/valproate/lemotrigine/phenytoin): topiramate: 19/11/5/2, placebo: 17/10/8/5. The other concomitant AEDs were phenobarbital (7 patients), clonazepam (4), vigabatrin (4), primidone (3), acetolamide (1)

**Recruitment**
Patients were recruited from the epilepsy outpatient clinic at Taipei Veterans General Hospital, Taiwan

29 July 2010
<table>
<thead>
<tr>
<th>Setting</th>
<th>Taipei, Taiwan from October 1997 to 1998</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interventions/ Test/ Factor being investigated</td>
<td>Topiramate vs placebo as adjuvant therapy to patients with at least one other stabilised AED</td>
</tr>
<tr>
<td>Comparisons</td>
<td>Treatment vs placebo</td>
</tr>
<tr>
<td>Length of Study/ Follow-up</td>
<td>14 weeks of treatment, plus 8 weeks of baseline follow up</td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>These were not clearly specified</td>
</tr>
<tr>
<td>Results</td>
<td>Proportion of patients experiencing at least 50% reduction in complex partial seizures: 11/23 in topiramate, 3/23 in placebo group (auras or simple partial seizures were not included in analysis)</td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>There were no significant changes in laboratory values during the study.</td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>Paper noted that most of the adverse events reported were mild and transient, occurring predominantly during the titration phase.</td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>Topiramate (at 300mg) was more effective than placebo as an adjunct therapy in reducing complex partial seizures among patients refractory to stabilised AED treatments</td>
</tr>
<tr>
<td>Directly applicable to guideline population?</td>
<td>Direct</td>
</tr>
</tbody>
</table>

The treatment effect was large (RR 3.67, 95% CI 1.32 to 11.34) but the confidence interval was wide due to the small sample size and there were uncertainty about the blinding of the analysis.
Grading: 1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias

Aldenkamp AP; Baker G; Mulder OG; Chadwick D; Cooper P; Doelman J; Duncan R; Gassmann-Mayer C; de Haan GJ; Hughson C; Hulsman J; Overweg J; Pledger G; Rentmeester TW; Riaz H; Wroe S;

A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures

Ref ID 4728 2000

Study Type Randomised Controlled Trial Funding Not reported.

Number of participant n=59 (n=29 in topiramate and n=30 in the valproate group)

Inclusion/Exclusion Criteria

Inclusion criteria: age between 18 and 60 years, minimum weight of 45 kg; localization-related epilepsy with partial-onset seizures, with or without secondary generalization; steady-state treatment with CBZ monotherapy for at least 28 days; and epilepsy uncontrolled on CBZ or requiring another AED for other reasons. Exclusion criteria: progressive cerebral lesion, degenerative disorder, malignancy, or history of malignancy in the past 5 years; cognitive impairment; females who do not practice reliable contraception; nonepileptic seizures; documented history with generalized status epilepticus in the past 3 months; unstable medical or psychiatric disease.

Patient Characteristics

Demographic and clinical characteristics of the intent-to-treat population

<table>
<thead>
<tr>
<th></th>
<th>Topiramate</th>
<th>Valproate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>34.7 (10.2)</td>
<td>39.4 (11.4)</td>
</tr>
<tr>
<td>Gender (% male)</td>
<td>63</td>
<td>52</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>75.9 (17.5)</td>
<td>76.2 (18.0)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>174.2 (13.0)</td>
<td>172.1 (10.4)</td>
</tr>
<tr>
<td>Duration of epilepsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>time since first</td>
<td></td>
<td></td>
</tr>
<tr>
<td>seizure (years)</td>
<td>18.3 (12.4)</td>
<td>22.7 (16.0)</td>
</tr>
<tr>
<td>Median baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>seizure rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(all seizures)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBZ average daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dose (baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medication) (mg/d)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>average dose during</td>
<td></td>
<td></td>
</tr>
<tr>
<td>maintenance (ug/d)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1070.8 (411.23)</td>
<td>1231.0 (409.79)</td>
</tr>
<tr>
<td></td>
<td>251.1 TPM (101.8)</td>
<td>1384 VPA (377.0)</td>
</tr>
</tbody>
</table>

Data shown are means (SD) unless specified otherwise.

Recruitment Not reported.

Setting Multicentre study in Netherlands.

Interventions/ Test/ Factor being investigated

Topiramate as add-on therapy

Comparisons

The comparison is between topiramate and valproate up to their maximum tolerated doses as adjunctive therapy to carbamazepine.

Length of Study/ Follow-up

22 weeks: 2 week baseline phase, 12 week titration phase and 8 week maintenance phase.

Outcome measures studied

The primary outcome measure is the difference between the treatments (TPM versus VPA) in change from baseline to end point and change from baseline to titration. That is, in cognitive tests: motor speed, mental speed, memory, and mood and well-being.
Results

Cognitive test results

Comparisons between baseline and end point for the two treatments.

In the memory tasks (4 tasks) there is a worsening of scores for topiramate in all tasks and improvement for valproate in all but one task. Only one of these tasks shows a statistically significant difference between the treatments (The Rey Auditory Verbal Learning Task, (p=0.02)).

Comparisons between baseline to titration for the two treatments

There was a tendency for worsening of memory performance for topiramate, with again one memory test, Recognition of Words, showing worsening of performance for both treatments, but significantly more for topiramate (p = 0.04).

Seizure reduction

The mean percentage reduction in the average monthly seizure rate for all seizure types during maintenance was 29.6% for topiramate and 22.1% for valproate; thus, the percentage reductions were comparable.

Safety and adverse effects

No adverse events data reported.

Does the study answer the question?

Yes. Although, it is of concern that only those administering the cognitive tests were blind to patient treatment: clinicians and patients were not.

Effect due to factor in study?

No. The sample size was chosen based on sample sizes from other studies which had used an information-processing task. This study assumed therefore that such a sample size would be sufficient to detect statistically significant differences of a magnitude that is generally reported in cognitive function studies.

Consistency of results with other studies?

All patients who were enrolled had localization-related epilepsy with partial-onset seizures.

Internal Validity

Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P;

eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

Ref ID 5077 2010 May

Study Type Randomised Controlled Trial

Number of participant n=395. Placebo n=100; esl 400mg n=96; esl 800mg n=101; esl 1200mg n=98.

Inclusion/Exclusion Criteria

aged 18 years or over; assessed in general good health; diagnosed with simple or complex partial-onset seizures (with or without secondary generalisation) for minimum of 12 months prior to screening; experienced at least 4 partial-onset seizures in the two 4-week periods before screening as well as during each of the two 4-week periods of the 8-week baseline period; treated with 1 to 3 concomitant AEDs in a stable dose regimen for at least 2 months prior to screening (vagus nerve stimulation considered an AED);

Exclusion criteria:

If at time specified they had:
an uncontrolled, relevant medical disorder;
visual field loss caused by vigabatrin use (at least 1 year); simple partial-onset seizures without motor symptoms;
primary generalised epilepsy;
rapidly progressive neurological disorder;

29 July 2010  Page 127 of 306
status epilepticus;
cluster seizures (within 3 months)
history of seizures of psychogenic origin (within 2 years)
a history of schizophrenia or suicide attempts;
a known hypersensitivity to carbamazepine or oxcarbazepine or chemically related substances.

**Patient Characteristics**

Placebo vs 400mg vs 800mg vs 1200mg

Mean age (s.d): 36.7 (12.2) vs 37.6 (11.2) vs 36.4 (12.6) vs 36.9 (11.6)
Males n (%): 52 (52) vs 39 (40.6) vs 51 (50.5) vs 52 (53.1)
Ethnic group: caucasian 84 (87) vs 87 (90.6) vs 91 (90.1) vs 81 (82.7); black 6 (6) vs 2 (2.1) vs 6 (5.9) vs 9 (9.2); Asian 0 vs 2 (2.1) vs 0 vs 5 (5.1); other 7 (7) vs 5 (5.2) vs 4 (4.0) vs 3 (3.1);
Seizure types at baseline: simple partial, complex partial, secondarily generalised and unclassified.
No. Of concomitant AEDs - up to 4.
Types of AEDs: carbamazepine, valproic acid, lamotrigine, clobazam, levetiracetam, phenytoin, phenobarbital, topiramate, clonazepam.

**Recruitment**

Not reported.

**Setting**

45 sites in 13 countries across world.

**Interventions/ Test/ Factor being investigated**

Eslicarbazepine 400mg, 800mg 1200mg.

**Comparisons**

Comparisons between dosages and placebo.

**Length of Study/ Follow-up**

Those who completed 14-week double-blind could enter an open-label extension treatment with ESL - not reported here.

**Outcome measures studied**

Primary efficacy: Seizure frequency.

**Results**

placebo vs 400mg vs 800mg vs 1200mg:
50% reduction in seizure frequency: 13% vs 17% vs 40% vs 37.1%.

Seizure freedom: 1% vs 1% vs 8% vs 4.1%.

Exacerbation of seizures (>25%): 30% vs 14% vs 18.6% - no details given for 400mg.

Incidence of adverse events n(%):
dizziness 10 (10%) vs 22 (22.9%) vs 30 (29.7%) vs 43 (43.9%);
somnolence 17 (17%) vs 15 (15.6%) vs 17 (16.8%) vs 21 (21.4%);
headache 9 (9%) vs 12 (12.5%) vs 15 (14.9%) vs 19 (19.4%);
nausea 4 (4%) vs 8 (8.3%) vs 12 (11.9%) vs 15 (15.3%);
diplopia 4 (4%) vs 8(8.3%) vs 15 (14.9%) vs 10 (10.2%);

TEAEs leading to discontinuation: 3 (3%) vs 12 (12.5%) vs 19 (18.8%) vs 26 (26.5%).

**Safety and adverse effects**

Serious TEAE 0% vs 4.2% vs 5.9% vs 2%, no deaths occurred.

**Does the study answer the question?**

Yes.

**Effect due to factor in study?**

Allocation and blinding methods unclear. Power calculation: 80% - sample size of 86 per treatment group and drop-out assumed at 15% so 400 required for enrollment. Drop-out was considerably higher than assumed and 400 were not enrolled.

**Consistency of results with other studies?**

Direct.

**Directly applicable to guideline population?**

Direct.
Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.[see comment]

Ref ID 358 2006 Aug 8

Study Type Randomised Controlled Trial Funding GlaxoSmithKline

Number of participant 193: 192 (96 patients randomised to each treatment group) were randomised and received at least one dose of study drug.

Inclusion/Exclusion Criteria

Inclusion criteria: Aged ≥ 18, confident diagnosis of epilepsy for ≥ 6mths, ≥ 1 and ≤ 8 partial or secondary gen. tonic-clonic seizures in past month, currently receiving carbazepine or phenytoin as monotherapy or one additional AED, no change of AED dose > 10% for at least 1 month before enrollment.

Exclusion criteria: none listed.

Patient Characteristics

<table>
<thead>
<tr>
<th>Lamotrigine</th>
<th>Topiramate</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=96</td>
<td>n=96</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>59 (61)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>72 (75)</td>
</tr>
<tr>
<td>Black</td>
<td>12 (13)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>11 (11)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Mean age, y (SD)</td>
<td>39.2 (14.1)</td>
</tr>
<tr>
<td>Mean age at first seizure, y (SD)</td>
<td>23.9 (15.6)</td>
</tr>
<tr>
<td>Seizure classification, n (%)</td>
<td></td>
</tr>
<tr>
<td>Simple partial</td>
<td>40 (42)</td>
</tr>
<tr>
<td>Complex partial</td>
<td>82 (85)</td>
</tr>
<tr>
<td>Partial evolving to secondarily generalized</td>
<td>52 (54)</td>
</tr>
<tr>
<td>Absence</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Myoclonic</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Tonic</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Generalized tonic–clonic</td>
<td>9 (9)</td>
</tr>
<tr>
<td>Atonic</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Unclassified</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Mean number of seizures/month (SD)</td>
<td>4.3 (4.2)</td>
</tr>
<tr>
<td>Antiepileptic medication, n (%)</td>
<td>Carbamazepine</td>
</tr>
</tbody>
</table>

Recruitment

Unknown.

Setting

Study sites in the United States and Canada.

Interventions/ Test/ Factor being investigated

Lamotrigine is compared with topiramate as adjunctive therapy in adult patients with partial seizures.

Comparisons

Comparison between lamotrigine and active comparator topiramate as adjunctive therapy.

Length of Study/ Follow-up

18 weeks: 2 weeks screening, 8 weeks titration and 8 weeks maintenance phase.

Outcome measures studied

Primary endpoint: change in a combined analysis of the standardized measures of cognition (COWA; Stroop Color-Word Interference; Digit Cancellation; Lafayette Grooved Pegboard, dominant hand; RAVLT, delayed recall; and symbol-Digit modalities test.)

Results

Primary outcome

Lamotrigine, n= 67  Topiramate, n = 57

<table>
<thead>
<tr>
<th>n</th>
<th>Mean (SD)</th>
<th>n</th>
<th>Mean (SD)</th>
<th>p</th>
</tr>
</thead>
</table>

29 July 2010 Page 129 of 306
Yes. The study concludes that the frequencies of cognitive adverse events and of premature withdrawals related to cognitive decline were higher with topiramate than with lamotrigine. This trend became nonsignificant during the maintenance phase (41% vs. 57%; p=0.054).

The percentage of patients with at least one adverse event during the study was 74% in the lamotrigine group and 83% in the topiramate group. The most common adverse events were headache (13% lamotrigine, 24% topiramate), dizziness (19% lamotrigine, 9% topiramate), fatigue (8% lamotrigine, 13% topiramate), and nausea (11% lamotrigine, 6% topiramate).

Adverse events led to premature withdrawal from the study in 21% of patients in the lamotrigine group and 25% in the topiramate group. The adverse events most frequently leading to premature withdrawal were vomiting (4% lamotrigine, 2% topiramate), dizziness (5% lamotrigine, 0% topiramate), nausea (3% lamotrigine, 0% topiramate), and memory impairment (0% lamotrigine, 3% topiramate).

Safety and adverse effects

Although adverse events were not serious, a fifth of patients in the lamotrigine group and a quarter of patients in the topiramate group discontinued treatment because of adverse events.

Does the study answer the question?

Yes. The study concludes that the frequencies of cognitive adverse events and of premature withdrawals related to cognitive decline were higher with topiramate than with lamotrigine.

Effect due to factor in study?

No. The study was powered (80%) to detect a significant difference of a 12-point reduction from baseline in the Stroop Color-Word Interference measure. The primary outcome however, was a combined score of six different measures including the Stroop measure.

Consistency of results with other studies?

The study population included patients suffering from mostly partial seizures. High maintenance dose of lamotrigine compared to medium dose in topiramate - indirectness of comparison.

Internal Validity

Bourgeois B; Leppik IE; Sackellares JC; Laxer K; Lesser R; Messenheimer JA; Kramer LD; Kamin M; Rosenberg A; Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures

Ref ID 4627 1993

Study Type Randomised Controlled Trial Funding Wallace Laboratories

Number of participant 30 patients in FBM arm and 34 in placebo arm

Inclusion/Exclusion Criteria

Inclusion: video/EEG confirmed partial onset seizures; frequency not exceeding an average of four complex partial onset seizures per day or more than one secondarily generalized seizure per day during the last 3 days of the surgical evaluation; interictal duration of greater than 2 hours; minimum average of one seizure per day for the last 3 days of the surgical evaluation; previous CT or MRI to confirm the absence of progressive lesion; age at least 18 and body weight at least 40 kg and ECG and CXR normal in previous year. Women of childbearing age were to be non-gravid, non-nursing and either incapable of conception or practicing birth control. Exclusion: status epilepticus in last 3 months, significant medical disorder with recent history of psychiatric disorder, poor compliance with prior AED therapy, serious AED complication in the past, change in benzodiazepine dosing during the surgical evaluation, drug or alcohol abuse.
The efficacy and safety of felbamate in patients with refractory partial onset seizures with or without generalization who had completed a hospital evaluation for epilepsy surgery was investigated. Secondary, the number of patients having a fourth seizure was reported. The results confirmed the anticonvulsant activity of felbamate and its ability to quickly and safely reduce the occurrence of frequent partial onset seizures.

### Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Felbamate</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (yr)</strong></td>
<td>n=30</td>
<td>n=34</td>
</tr>
<tr>
<td>Mean</td>
<td>33.3</td>
<td>33.3</td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>n=30</td>
<td>n=34</td>
</tr>
<tr>
<td>Mean</td>
<td>78.9</td>
<td>71.6</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td>n=30</td>
<td>n=34</td>
</tr>
<tr>
<td>Male</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td>Female</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td>n=30</td>
<td>n=34</td>
</tr>
<tr>
<td>White</td>
<td>30</td>
<td>32</td>
</tr>
<tr>
<td>Black</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

### Recruitment

During a 4-week outpatient baseline period, patients were identified who were appropriate for study participation.

### Setting

USA

### Interventions/Test/Factor being investigated

The efficacy and safety of felbamate were assessed in patients with refractory partial onset seizures with or without generalization who had completed a hospital evaluation for epilepsy surgery.

### Comparisons

Felbamate and placebo as an add-on therapy to the AED regimen existing at the completion of the surgical evaluation.

### Length of Study/Follow-up

8 hospital days and 21 outpatient days

### Outcome measures studied

The efficacy variable was the time to the fourth seizure. Secondary, the number of patients having a fourth seizure was reported.

### Results

Thirty patients were randomized to felbamate; of these, 13 completed the trial by having a fourth seizure, 15 completed 28 study days without a fourth seizure, and two dropped out due to adverse clinical events. Thirty-four patients were randomized to placebo; of these, 29 completed the trial by having a fourth seizure, four completed 28 study days without a fourth seizure and one withdrew consent. The primary efficacy analysis included 61 patients. The mean rank according to seizure frequency for placebo-treated patients was 35.4 compared to 25.8 for the felbamate-treated patients (p=0.028). In the secondary analysis, 13 (46.4%) of 28 patients in the felbamate group experienced a fourth seizure compared with 29 (87.9%) of 33 patients in the placebo group (p<0.001). In a "worst-case" analysis, with two felbamate patients who dropped out classified as having experienced a fourth seizure and one placebo patient who dropped out classified as a completer, 15 (50%) of 30 patients in the felbamate group experienced a fourth seizure compared with 29 (85.3%) of 34 patients in the placebo group (p=0.003).

### Safety and adverse effects

The most commonly occurring adverse experience in both groups was headache reported in 12 (40%) of FBM group and in 4 (12%) of the placebo group. The other commonly occurring adverse experiences in the felbamate group were insomnia and nausea (11 patients - 37%), dizziness (7 patients - 23%), fatigue, constipation and anorexia each in six (20%) of patients. Only one patient in the FBM group had adverse experiences (stupor and confusion) reported as severe; however these resolved without intervention and the patient continued in the study. Two patients in the felbamate group failed to complete the trial due to adverse experiences: one patient on the second treatment day due to agitation, insomnia and psychosis and the second patient on the third treatment day due to dizziness, unsteadiness, numb feet and hands, sleeplessness, upset stomach, nausea and general malaise. In both patients the adverse experiences were mild or moderate in severity and were not considered related to felbamate.

### Does the study answer the question?

The results confirmed the anticonvulsant activity of felbamate and its ability to quickly and safely reduce the occurrence of frequent partial onset seizures.

### Effect due to factor in study?

Yes
### Consistency of results with other studies?
See GRADE

### Directly applicable to guideline population?
See GRADE

### Internal Validity
Small study with short time period

---

**Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group**

**Study Type**
Randomised Controlled Trial

**Funding**
Supported by the Welcome foundation.

**Number of participant**
N= 260; n=131 lamotrigine and n=129 carbamazepine.

**Inclusion/Exclusion Criteria**
No specific inclusion and/or exclusion criteria.

**Patient Characteristics**
Patients 13 years and older with newly diagnosed epilepsy with partial seizures without secondary generalisation, and primary or secondary generalised tonic-clonic seizures. No patient had received previous treatment with an AED. Lamotrigine group had a median baseline seizure count of 4 (mean 36) versus 3 mean (mean 22) for the carbamazepine group.

**Recruitment**
Not reported.

**Setting**
8 centres in the UK.

**Interventions/ Test/ Factor being investigated**
Pharmacological interventions. Patients received increasing doses of identical 50mg lamotrigine or 200mg carbamazepine tablets. At the end of 4 weeks, all patients were taking 150mg lamotrigine or 600mg carbamazepine daily. During weeks 6-24 the daily dose could be increased by one tablet at each visit if seizures continued and no clinically relevant adverse events had been reported provided the drug concentration was in the lower half of the target range or lower.

**Comparisons**
Lamotrigine versus carbamazepine.

**Length of Study/ Follow-up**
For 48 weeks.

**Outcome measures studied**
time to first seizure and adverse events.

**Results**
No significant difference between the drugs in time to first seizure after 6 weeks treatment for the whole study population (hazard ratio 0.8, 95% CI 0.6-1.2), or for the subgroup with partial seizures with or without secondary generalisation or the subgroup with primary tonic-clonic seizures.

Percentage seizure-free (for primary generalised tonic-clonic seizures) at last 40 weeks:
- LTG: 37% - calculated as 22/60
- CBZ: 35% - calculated as 22/62

Percentage seizure-free (for primary generalised tonic-clonic seizures) at last 24 weeks:
- LTG: 47% - calculated as 28/60
- CBZ: 47% - calculated as 29/62

Percentage seizure-free (for partial seizures with or without generalisation) at last 40 weeks:
- LTG: 22%
CBZ: 31%

Percentage seizure-free (for partial seizures with or without generalisation) at last 24 weeks:
LTG: 35%
CBZ: 37%

Percentage seizure-free (all seizures) at last 40 weeks:
LTG: 26%
CBZ: 29%

Percentage seizure-free (all seizures) at last 24 weeks:
LTG: 39%
CBZ: 38%

A greater proportion of the LTG group completed the study compared to the CBZ group (65 vs. 51%, p=0.018).

Safety and adverse effects

Adverse events: Headache 30% LTG group vs. 25% CBZ group (95% CI -6 to 16); Astenia 21% LTG group vs. 29% CBZ group (95% -18 to 3); rash 19% LTG vs. 19% CBZ group (95% CI -10 to 9); nausea 15% LTG group vs. 12% CBZ group (95% CI -3 to 14); dizziness 12% LTG vs. 17% CBZ (95% CI -13 to 4); sleepiness 12% LTG group vs. 22% CBZ group (95% CI -19 to -1); and flu-like symptoms 11% LTG group vs. 8% for the CBZ group (95% CI -3 to 11). The only significant adverse event is sleepiness.

Nineteen patients withdrew from the LTG group (n=131) and 35 withdrew from the CBZ group (n=129).

Does the study answer the question?
Similar efficacy for both LTG and CBZ. LTG seems to be better tolerated.

Effect due to factor in study?
No.

Consistency of results with other studies?
Yes.

Directly applicable to guideline population?
Yes.

Internal Validity

Chmielewska B; Stelmasiak Z;

Clinical evaluation of Gabitril and Lamictal for drug-resistant epilepsy in adults

Ref ID 4731

Study Type Randomised Controlled Trial

Funding Not reported.

Number of participant LTG n=22 vs TGB n=26.

Inclusion/Exclusion Criteria
Inclusion criteria:
- adults, aged 16-60 years;
- CPS in accordance with ILAE classification;
- Refractory epilepsy during at least 1 year and 4 or above CPS/ 4 weeks during the last 3 months;
- Intake of max 2 concomitant AEDs;
- Able to record all seizures in a seizure diary throughout trial;

Exclusion criteria:
- Data of status epilepticus in last year;
- Any signs of serious somatic or psychiatric pathologies;
- Data of non-compliance during previous treatment.

29 July 2010 Page 133 of 306
### Internal Validity

- **Recruitment**: Not reported.
- **Setting**: Not reported.

### Results

- **Comparison**: LTG vs TGB:
  - At least 50% reduction in seizure frequency: 11/22 (50%): 11/26 (42.3%)
  - Seizure freedom: 2/22 (9.1%): 2/26 (7.7%)
  - Incidence of headache: 6/22 (27.3%): 8/26 (30.8%)
  - Incidence of fatigue: 5/22 (22.7%): 9/26 (34.6%)
  - Incidence of disturbed sleep: 4/22 (18.2%): 7/26 (26.9%)
  - Incidence of dizziness: 4/22 (18.2%): 6/26 (23.1%)
  - Incidence of nervousness: 5/22 (22.7%): 1/26 (3.8%)
  - Incidence of paresthesia: 3/22 (13.6%): 3/26 (11.5%)
  - Incidence of nausea: 2/22 (9.1%): 4/26 (15.4%)

- **Safety and adverse effects**: See results above.

- **Does the study answer the question?**: Yes.

- **Effect due to factor in study?**: No details of randomisation, allocation concealment and no blinding and small sample size so uncertainty in the overall effect due to intervention.

- **Consistency of results with other studies?**: Direct.

- **Directly applicable to guideline population?**: Direct.

### Patient Characteristics

- **LTG vs TGB:**
  - Male %: 59.01 vs 53.85
  - Age 25 (6.7) vs 27 (8.2)
  - Epilepsy duration year mean (sd): 10 (7.1) vs 11 (8.2)
  - Aetiology - unknown (%): 81 vs 85

### Inclusions/Exclusions

- **Inclusion criteria**: Seizures poorly controlled with the baseline AED defined as four or more CPS per month.

---

**Study Type**: Randomised Controlled Trial

**Funding**: Abbott Laboratories.

- **Number of participants**: CBZ+PHT n=101 vs CBZ+TGB n=105; PHT+CBZ n=76 vs PHT+TGB n=67.

---

**Ref ID**: 4697

**Date**: 29 July 2010
<table>
<thead>
<tr>
<th>Internal Validity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ref ID</td>
<td>4679</td>
</tr>
<tr>
<td>Study Type</td>
<td>Randomised Controlled Trial</td>
</tr>
<tr>
<td>Funding</td>
<td>Ciba-Geigy, ParkeDavis; Sanofi.</td>
</tr>
<tr>
<td>29 July 2010</td>
<td>Page 135 of 306</td>
</tr>
<tr>
<td>Number of participant</td>
<td>PHB n=10; PHT n=54; CBZ n=54; VPA n=49;</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Inclusion/Exclusion</td>
<td>Inclusion criteria:</td>
</tr>
<tr>
<td>Criteria</td>
<td>Aged 3-16 years;</td>
</tr>
<tr>
<td></td>
<td>At least 2 generalised tonic-clonic seizures or partial seizures with or without secondary generalisation or an episode of status epilepticus;</td>
</tr>
<tr>
<td></td>
<td>Received no previous AEDs.</td>
</tr>
<tr>
<td></td>
<td>Exclusion criteria:</td>
</tr>
<tr>
<td></td>
<td>Any other type of seizure eg myoclonic jerks, drop attacks, or febrile seizures, or clinical evidence of progressive neurological disease;</td>
</tr>
<tr>
<td>Patient Characteristics</td>
<td>PHB vs PHT vs CBZ vs VPA:</td>
</tr>
<tr>
<td></td>
<td>Median age 10.3 years. For each group median (interquartile range): 9.6 (4.7-11.3) vs 9.9 (6.8-11.8) vs 9.4 (5.4-12) vs 12 (9.8-13.5).</td>
</tr>
<tr>
<td></td>
<td>Males: 4 (40.5) vs 34 (63%) vs 30 (56%) vs 18 (37%)</td>
</tr>
<tr>
<td></td>
<td>Seizure type: GTC: 5 (50%) vs 24 (44%) vs 25 (44%) vs 24 (49%)</td>
</tr>
<tr>
<td></td>
<td>P+GTC: 5 (50%) vs 30 (56%) vs 29 (54%) vs 25 (51%)</td>
</tr>
<tr>
<td>Recruitment</td>
<td>At the Neurological outpatients dept of King's College London and the Paediatric neurology dept. Guy's hospital.</td>
</tr>
<tr>
<td>Setting</td>
<td>London.</td>
</tr>
<tr>
<td>Interventions/ Test/</td>
<td>Phenobarbitone vs phenytoin vs carbamazepine vs sodium valproate.</td>
</tr>
<tr>
<td>Factor being</td>
<td>Between treatments.</td>
</tr>
<tr>
<td>investigated</td>
<td></td>
</tr>
<tr>
<td>Comparisons</td>
<td></td>
</tr>
<tr>
<td>Length of Study/</td>
<td>1,2, 3 years. Median duration follow-up 44 months (range 3-88 months).</td>
</tr>
<tr>
<td>Follow-up</td>
<td></td>
</tr>
<tr>
<td>Outcome measures</td>
<td>Seizure freedom; withdrawal due to adverse events; incidence of adverse events.</td>
</tr>
<tr>
<td>studied</td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phenobarbitone versus phenytoin</td>
</tr>
<tr>
<td></td>
<td>Withdrawal due to adverse events: 6/10 (60%) vs 5/54 (9.3%)</td>
</tr>
<tr>
<td></td>
<td>Incidence of behavioural disorder: 5/10 (50%) vs 0/54 (0%)</td>
</tr>
<tr>
<td></td>
<td>Phenobarbitone versus sodium valproate</td>
</tr>
<tr>
<td></td>
<td>Withdrawal due to adverse events: 6/10 (60%) vs 2/49 (4.1%)</td>
</tr>
<tr>
<td></td>
<td>Incidence of behavioural disorder: 5/10 (50%) vs 1/49 (2%)</td>
</tr>
<tr>
<td></td>
<td>Phenytoin versus carbamazepine</td>
</tr>
<tr>
<td></td>
<td>Withdrawal due to adverse events: 5/54 (9.3%) vs 2/54 (3.7%)</td>
</tr>
<tr>
<td></td>
<td>Phenytoin versus sodium valproate</td>
</tr>
<tr>
<td></td>
<td>Withdrawal due to adverse events: 5/54 (9.3%) vs 2/49 (4.1%)</td>
</tr>
<tr>
<td></td>
<td>Carbamazepine versus sodium valproate</td>
</tr>
<tr>
<td></td>
<td>Withdrawal due to adverse events: 5/54 (9.3%) vs 2/49 (4.1%)</td>
</tr>
<tr>
<td>Safety and adverse</td>
<td>One child died of acute liver failure after overdose of valporate (suicide).</td>
</tr>
<tr>
<td>effects</td>
<td></td>
</tr>
<tr>
<td>Does the study</td>
<td>Yes.</td>
</tr>
<tr>
<td>answer the question?</td>
<td></td>
</tr>
<tr>
<td>Effect due to factor</td>
<td>Underpowered as they assumed 60 in each group to detect 80% power and the sample sizes were not this size in any group.</td>
</tr>
<tr>
<td>in study?</td>
<td></td>
</tr>
<tr>
<td>Consistency of</td>
<td></td>
</tr>
<tr>
<td>results with other</td>
<td></td>
</tr>
<tr>
<td>studies?</td>
<td></td>
</tr>
<tr>
<td>Directly applicable</td>
<td>Indirect - 53% of participants had partial and secondary generalized seizures.</td>
</tr>
<tr>
<td>to guideline population?</td>
<td></td>
</tr>
</tbody>
</table>
# Internal Validity

Dean C; Mosier M; Penry K;

Dose-Response Study of Vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures

Ref ID 4751 1999

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Randomised Controlled Trial</th>
<th>Funding</th>
<th>Marion Merrell Dow.</th>
</tr>
</thead>
</table>

| Number of participant | 174 patients: randomized to placebo = 45 pts, 1g/day = 45 pts, 3g/day = 43 pts, 6g/day = 41 pts. |

<table>
<thead>
<tr>
<th>Inclusion/Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion criteria: age 18 to 60, uncontrolled complex partial seizures or partial seizures with secondary generalization, receiving at least one but not more than two concomitant AEDs. Lack of adequate seizure control was defined as at least six seizures plus a seizure-free interval of &lt;28 days during the last 8 weeks of the pretreatment evaluation period. Previous adequate therapeutic trials with phenytoin (PHT) or carbamazepine (CBZ) were required. In addition, patients had a history of an abnormal EEG documenting focal abnormalities, including focal rhythmic, slow, sharps, or spikes. Exclusion criteria: treatable causes of seizures, such as metabolic or neoplastic causes or active infection; history of more than one episode of status epilepticus within the previous 6 months; progressive neurologic disorders, such as multiple sclerosis or brain tumors; surgery for epilepsy or brain tumor within the previous 6 or 12 months, respectively; history of alcoholism, drug addiction, major depression, or other serious psychiatric disorders; and clinically significant hepatic, renal, hematologic, endocrine, or gastrointestinal disease. Patients with a Verbal or Performance Intelligence Quotient (IQ) of 45 on the Wechsler Adult Intelligence Scale-Revised (WAIS-R) also were excluded.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>VGB</th>
<th>placebo</th>
<th>1g VGB</th>
<th>3g VGB</th>
<th>6g VGB</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=41</td>
<td></td>
<td>n=45</td>
<td>n=45</td>
<td>n=43</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td>Male n(%)</td>
<td>17(38)</td>
<td>19(42)</td>
<td>24(56)</td>
</tr>
<tr>
<td>Age (yr) Mean (SD)</td>
<td></td>
<td>35(11)</td>
<td>34(9)</td>
<td>34(9)</td>
<td></td>
</tr>
<tr>
<td>Weight (kg) Mean (SD)</td>
<td></td>
<td>69(15)</td>
<td>76(19)</td>
<td>72(17)</td>
<td></td>
</tr>
<tr>
<td>Number (% of concurrent AEDs)</td>
<td></td>
<td>One 19(42)</td>
<td>24(53)</td>
<td>23(53)</td>
<td></td>
</tr>
<tr>
<td>Two</td>
<td></td>
<td>26(58)</td>
<td>20(44)</td>
<td>20(47)</td>
<td></td>
</tr>
<tr>
<td>Three</td>
<td></td>
<td>0(0)</td>
<td>1(2)</td>
<td>0(0)</td>
<td></td>
</tr>
<tr>
<td>Onset age (yr) Mean (SD)</td>
<td></td>
<td>13(10)</td>
<td>10(8)</td>
<td>14(10)</td>
<td></td>
</tr>
<tr>
<td>Duration of epilepsy (yr) Mean (SD)</td>
<td></td>
<td>22(11)</td>
<td>24(9)</td>
<td>20(9)</td>
<td></td>
</tr>
<tr>
<td>Seizure frequency Median (range)</td>
<td></td>
<td>9(3-71)</td>
<td>8.5(3-786)</td>
<td>8(1-228)</td>
<td>9(2-45)</td>
</tr>
</tbody>
</table>

| Recruitment | Unknown. |

| Setting | 14 investigative sites in the United States. |

29 July 2010  Page 137 of 306
Interventions/ Test/ Factor being investigated

Comparison is between 3 doses of vigabratrin (VGB) (1, 3 or 6 g per day) and placebo as adjunctive therapy to currently used AEDs.

Comparisons

The comparisons are between three doses of VGB and placebo, on top of currently used AEDs.

Length of Study/ Follow-up

30 weeks: 12 weeks pretreatment period, 6 weeks titration and 12 weeks maintenance phase.

Outcome measures studied

Primary outcome: mean monthly frequency of complex partial seizures (1B) plus partial seizures secondarily generalized (1C) during the last 8 weeks of the study as compared with the last 8 weeks of the baseline phase. Secondary outcomes: response rates, response rates

Results

Primary outcome

<table>
<thead>
<tr>
<th>Treatment</th>
<th>No.</th>
<th>Seizure frequency (no/28 days)</th>
<th>Baseline median</th>
<th>End study median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>45</td>
<td>9.0 (95% CI)</td>
<td>(7.0, 10.5)</td>
<td>(6.0, 12.1)</td>
</tr>
<tr>
<td>1 g VGB</td>
<td>45</td>
<td>8.5 (95% CI)</td>
<td>(6.0, 12.3)</td>
<td>(4.1, 11.5)</td>
</tr>
<tr>
<td>3 g VGB</td>
<td>43</td>
<td>8.0 (95% CI)</td>
<td>(7.0, 10.5)</td>
<td>(2.5, 6.0)</td>
</tr>
<tr>
<td>6 g VGB</td>
<td>41</td>
<td>9.0 (95% CI)</td>
<td>(7.0, 14.5)</td>
<td>(3.3, 6.0)</td>
</tr>
</tbody>
</table>

Treatment comparisons

- p-values
  - Linear trend: 0.0001
  - Placebo versus 1 g VGB: 0.1263
  - Placebo versus 3 g VGB: 0.0001
  - Placebo versus 6 g VGB: 0.0001
  - 3 g VGB versus 6 g VGB: 0.8140

p Values from ANCOVA of the ranked end-study seizure frequencies using model that adjusted for treatment, investigative site, ranked baseline seizure frequency, and investigative Site-by-Treatment interaction. VGB, vigabatrin.

Secondary outcome: therapeutic success (>=50% reduction in seizure freq)

The percentages of therapeutic successes were 7% for placebo and 24, 51, and 54% for VGB daily doses of 1, 3, and 6 g, respectively.

The difference from placebo was significant for all VGB groups; however, the 6-g dose was not significantly different from the 3-g dose of VGB.

Adverse events

Treatment-related adverse events were reported by 77.8% of patients in the placebo group and by 82.6, 88.6, and 90.9% of patients taking VGB daily doses of 1, 3, and 6 g, respectively. Fatigue, drowsiness, and dizziness were the most common treatment-related adverse events. The incidence of severe adverse events increased with increasing dose of VGB, ranging from 2.2% for the placebo group to 8.7, 11.4, and 15.9% for patients taking 1, 3, and 6 g, respectively.

Safety and adverse effects

The incidence of severe adverse events increased with increasing dose of VGB.

Does the study answer the question?

Yes. VGB was significantly more effective than placebo as add-on therapy in reducing seizure frequency. VGB at 3 and 6 g/day produced the best efficacy; however, adverse events may limit the use of the 6-g/day dose in some patients.
Effect due to factor in study?
No. The study did not perform any power calculations to help determine sample size.

Consistency of results with other studies?

Directly applicable to guideline population?
The population is relevant because only patients with partial seizures were recruited.

Internal Validity

Dodrill CB; Arnett JL; Deaton R; Lenz GT; Sommerville KW;

Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood

Ref ID 4695

Study Type Randomised Controlled Trial
Funding Sponsored by Abbott Laboratories.

Number of participant
n=277 in this analysis (n=349 in the original RCT).

Inclusion/Exclusion Criteria
Inclusion criteria: adults with uncontrolled partial seizures who at study entry were on phenytoin (PHT) or carbamazepine (CBZ) alone. At least four complex partial seizures had to have occurred alone or in combination with other seizure types while receiving either CBZ or PHT monotherapy in the baseline period.

Patient Characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline CBZ group</th>
<th>Baseline PHT group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PHT added (n=71)</td>
<td>TGB added (n=82)</td>
</tr>
<tr>
<td>Years of age Mean</td>
<td>33.34</td>
<td>37.07</td>
</tr>
<tr>
<td>Age at seizure Mean</td>
<td>12.73</td>
<td>12.23</td>
</tr>
<tr>
<td>Age at onset S.D.</td>
<td>10.76</td>
<td>10.40</td>
</tr>
<tr>
<td>Gender F</td>
<td>47</td>
<td>45</td>
</tr>
<tr>
<td>Baseline complex partial seizure frequency (seizures 28 days)</td>
<td>N 70</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>Median 7</td>
<td>6</td>
</tr>
<tr>
<td>Baseline total partial seizure frequency (seizures 28 days)</td>
<td>N 70</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>Median 10</td>
<td>7</td>
</tr>
<tr>
<td>Baseline generalized tonic-clonic seizures (seizures 28 days)</td>
<td>N 23</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Median 2</td>
<td>2</td>
</tr>
</tbody>
</table>

Recruitment
Not reported.

Setting
Not reported.

Interventions/ Test/ Factor being investigated
In one part of the study tiagabine (TGB) was compared with phenytoin (PHT) in patients who were currently receiving carbamazepine (CBZ) at baseline.
In the second part of the study TGB was compared to CBZ in patients who were currently receiving PHT.

Comparisons
In part 1 of the study TGB is compared with PHT as add-on therapy to CBZ. In part 2 of the study CBZ is compared with TGB as add-on therapy to PHT.

Length of Study/ Follow-up
24 weeks: 8-week baseline period and 16-week double blind treatment period.

Outcome measures studied
Primary outcomes in original trial not known. This investigation reports on the neuropsychological portion of the study. All the patients were administered a battery of tests midway through the baseline period and again after 12 weeks of treatment.
Results

The study presents 4 large tables of results. 2 report scores for tests of abilities and scores for tests of adjustment and mood. for add-on therapies PHT and TGB in patients currently receiving CBZ. The other two tables report the same scores for add-on therapies CBZ and TGB in patients currently receiving PHT.

PHT vs TGB as add-on therapy in patients receiving CBZ
A statistical test comparing the average difference scores of the two add-on treatment groups was performed with each of the 37 variables related to tests of ability. No statistically significant differences between the add-on treatment groups were found. The same was true for the tests of adjustment and mood.

CBZ vs TGB as add-on therapy in patients receiving PHT
Two statistically significant differences were found in the measures of abilities with improvements with TGB versus worsening with CBZ on tests of verbal fluency and perceptual: motor speed. For measures of adjustment and mood, treatment with TGB resulted in poorer scores on measures of overall mood (Mood Rating Scale, total) and financial concern (WPSI Financial Status Scale) compared to treatment with CBZ.

Safety and adverse effects

None reported.

Does the study answer the question?

No. The study concludes that overall, add-on tiagabine showed few or no differences in comparison with Add-on carbamazepine and add-on phenytoin. However, this analysis was based on only 79% of the original RCT sample. And it is not clear from which groups the data is missing. Also, we must presume that these variables were secondary outcomes. The original study would have been powered to detect differences in different efficacy variable(s). Therefore this analysis can only be exploratory.

Effect due to factor in study?

No. It can only be presumed that the variables described in this study are secondary outcomes. The original study would have been powered to detect differences in different efficacy variable(s). Therefore this analysis can only be exploratory.

Consistency of results with other studies?

All patients in this study were included because they suffered from partial seizures.

Internal Validity

Dodrill CB; Arnett JL; Sommerville KW; Shu V;

Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy

Ref ID 4764 1997

Study Type Randomised Controlled Trial

Funding Supported by Abbot Laboratories.

Number of participant

In the main RCT 297 were randomised to placebo (n=91), tiagabine (TCB) 16mg/d (n=61), TCB 32mg/d (n=88) and TCB 56mg/d (n=57). Those included in this study were those who had had neuropsychological testing: placebo (n=57), TCB 16mg/d (n=34), TCB 32mg/d (n=39) and TCB 56mg/d (n=26).

Inclusion/Exclusion Criteria

In the main RCT the inclusion criteria were: at least six complex partial seizures during the prior 8 weeks.

Patient Characteristics

Mean (SD) age 35.62 (11.44)
Mean years of education 12.02 (2.92)
There were more men in the placebo group and 56mg TCB group (p<0.05)

Recruitment

Unknown.

Setting

21 centers in the United States.
This study compares placebo with 3 doses of tiagabine (16mg/d, 32mg/d and 56mg/d) as adjunctive treatment for complex partial seizures.

Comparisons are between placebo and 3 doses of TCB as adjunctive therapy to currently used AEDs.

Length of Study/ Follow-up

24 weeks: baseline period of 8 weeks and 4 week titration phase, followed by 12 week fixed dose phase.

Outcome measures studied

Not clearly stated. This study compared changes from baseline testing with the testing at the end of the drug treatment period of the combined higher dose (32 and 56mg) tiagabine groups compared with placebo group for all psychological tests (n=11).

Results

From 37 statistical comparisons, only 1 was statistically significant at the 0.05 level of confidence, and none was significant at the 0.01 level. The one statistically significant finding was on form F of the Benton Visual Retention Test where the placebo group improved somewhat (average change +0.78 items correct) and where the 32- and 56-mg groups were slightly worse (average change -0.08 items correct).

Safety and adverse effects

None reported.

Does the study answer the question?

No. Results showed no clinically important changes with the action of tiagabine on the test battery. However, the sample included in this study was not random.

Effect due to factor in study?

No. All results could have occurred by chance. No statistical power calculation was performed. And no primary outcome measure specified.

Consistency of results with other studies?

The study included only patients with complex partial seizures.

Internal Validity

Dodrill CB;Arnett JL;Sommerville KW;Sussman NM; Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy

Ref ID 4766

Study Type  Randomised Controlled Trial

Funding See data entry for study by French et al, Reference Manager ID 4752.

Number of participant n=182 in original trial (see data entry for study by French et al, Reference Manager ID 4752) QoL data available for vigabatrin n=83/92 (90%) and n=85/90(94%) in placebo group.

Inclusion/Exclusion Criteria See data entry for study by French et al, Reference Manager ID 4752.

Patient Characteristics See data entry for study by French et al, Reference Manager ID 4752.

Recruitment See data entry for study by French et al, Reference Manager ID 4752.

Setting

Interventions/ Test/ Factor being investigated

See data entry for study by French et al, Reference Manager ID 4752.

Comparisons See data entry for study by French et al, Reference Manager ID 4752.
### Internal Validity

**Dodrill CB; Arnett JL; Sommerville KW; Sussman NM;**

Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy

Ref ID 4765 1995

### Study Type

Randomised Controlled Trial

### Funding

Marion Merrell Power.

### Number of participant

CGB 1g/day n=45; VGB 3g/day n=43; VGB 6g/day n=41; placebo n=45.

### Inclusion/Exclusion Criteria

**Inclusion criteria:**
- Focal epilepsy whose complex partial seizures or partial seizures secondarily generalised were difficult to control;
- Each patient was receiving one or two marketed AEDs and no other experimental agents;

**Exclusion criteria:**
- History of progressive neurologic disorder;
- Frequent episodes of status epilepticus;
- WAIS-R verbal IQ or performance IQ<65;
- Ongoing or recent psychiatric disorder;
- Any other condition that may have affected study results.

### Patient Characteristics

Placebo; VGB 1g; VGB 3g; VGB 6g:
- Age mean (s.d, range): 33.88 (9.77, 20-60) vs 34.89 (8.38, 18-54) vs 34.26 (9.18, 18-53) vs 33.72 (9.66, 19-63).
- Females: 26 vs 19 vs 17 vs 15.

### Recruitment

From 14 major medical centers.

### Setting

USA.
Interventions/ Test/ Factor being investigated
Vigabatrin versus placebo.

Comparisons
Between treatment and placebo.

Length of Study/ Follow-up
Not reported.

Outcome measures studied
Cognitive and quality of life effects.

Results
Significant reduction for vigabatrin group x time interaction in dominant hand tapping frequency (motor speed and flexibility) (p=0.01) and for design learning task (memory) p=0.04. No significant differences in any other test including measures of mood or behaviour.

The following cognitive tests were tested in the study; Lafayette Pegboard, Stroop Test, Benton Visual Retention, Controlled Oral Word, Symbol Digit Modalities, Auditory Verbal Learning, Wonderlic Personnel Test, Digit Cancellation. Participants in vigabatrin group demonstrated significantly higher mean scores of Stroop Test (interference sec) (worse performance) and significantly lower scores in Digit Cancellation scale (worse performance) compared to placebo.

The following health related quality of life tests were tested in the study; Profile of Mood States (POMS) (including tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, confusion-bewildermement, total mood disturbance subscales), Washington Psychosocial Seizure Inventory (WPSI) (including family background, emotional adjustment, interpersonal adjustment, vocational adjustment, financial status, adjustment to seizures, medicine and med. Management, overall functioning, lie scale and rare items subscales), Mood rating scale and none was significantly significant associated with the use of vigabatrin or placebo.

Safety and adverse effects
Not reported.

Does the study answer the question?
Yes for cognitive outcomes and quality of life outcomes.

Effect due to factor in study?
No details of randomisation, allocation concealment or blinding so uncertainty if overall effect is due to the study intervention.

Consistency of results with other studies?
Direct.

Directly applicable to guideline population?
Direct.

Internal Validity

Elger C;Bialer M;Cramer JA;Maia J;Almeida L;Soares-da-Silva P;

Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures
Ref ID 4862

2007

Study Type Randomised Controlled Trial
Funding BIAL (Portela & C SA).

Number of participant
ESL once a day 50/143, ESL twice a day 46/143 and Placebo 47/143,

Inclusion/Exclusion Criteria
Inclusion criteria; adults 18-65 yrs with at least four partial onset seizures per month being treated with one or two of the following AEDs (phenytoin, valproic acid, primidone, phenobarbital, lamotrigine, gabapentin, topiramate, clonazepam in stable doses during at least 2 months prior to randomization. Exclusion criteria: vagus nerve stimulation, primarily generalized seizures, known progressive neurological

29 July 2010 Page 143 of 306
Adults aged 18-65 yrs, all White with at least four partial onset seizures per month being treated with one or two of the following AEDs (phenytoin, valproic acid, primidone, phenobarbital, lamotrigine, gabapentin, topiramate, clonazepam in stable doses during at least 2 months prior to randomization

Treatment with Eslicarbazepine acetate (ESL) once daily and twice daily. Comparison were made in the seizure frequency between the two treatment groups (ESL once and twice daily) and the placebo group. The two treatment groups were also compared to each other with regards to reduction in seizure frequency.

The 12 week treatment phase followed by a 1 week tapering off phase.

Primary outcome: % of patients with 50% or greater reduction in seizure frequency. Secondary outcomes were reduction in total seizure frequency at each 4 week period and the proportion of seizure free patients. Incidence of adverse effects.

During the 12 week treatment phase, the number of seizure free patients significantly increased in both ESL treatment groups compared to placebo. The proportion of seizure free participants were 10% for the group taking ESL once a day (400mg) and 4% for those taking twice a day (200mg) during the first 4 weeks. The following 4 weeks (weeks 5-8), there were 18% seizure free patients in the ESL group once a day group (800mg) and 13% in the ESL twice a day group (400mg). The last four weeks, the proportion of seizure free patients was 24% for both ESL groups (once and twice daily, 1200mg and 600 mg). The proportion of seizure free patients in placebo was 11% for the first 8 weeks and 9% for the following four weeks.

A significantly higher proportion of patients were found with 50% or more reduction in seizure frequency between the ESL group once a day and the placebo (54% versus 28%, p=0.008). No significant difference was found on the 50% or more reduction in seizure frequency between the ESL group twice a day and the placebo (41% versus 28%, p=0.12).

None adverse event was prevalent over 10% in the sample. The number of patients reporting adverse events were similar in the three treatment groups.

A higher proportion of seizure free patients found in the ESL treatment group taking once daily compared to placebo. A significantly higher proportion of patients received ESL once daily had 50% or more reduction in seizure frequency compared to placebo. No significant differences in reduction of seizure frequency were found between the ESL group twice daily and the placebo.

Randomization procedure, allocation concealment and blindness were poorly reported. Preconsideration of statistical power of the study. Potential limitations on the study design are likely to lower confidence in the estimate of effect.
Internal Validity

Elger C; Halasz P; Maia J; Almeida L; Soares-da-Silva P; Investigators Study Group;

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study

Ref ID 4863

2009

Study Type Randomised Controlled Trial

Funding BIAL

Number of participant sample size was 402/468 (82%); placebo n=102; ESL 400mg n=100; ESL 800mg n=98; ESL 1200mg n=102

Inclusion/Exclusion Criteria inclusion criteria: adults >=18 yrs with simple or complex partial seizures with or without secondary generalization for at least 12 months before screening, receiving one or two AEDs (in a stable dose) for at least 2 months before screening, had at least four partial onset seizures in the two 4 week periods of the baseline phase with no seizure free interval >=21 consecutive days, had a negative pregnancy test, not breastfeeding, agreed to use acceptable contraception. Exclusion criteria: patients with only simple partial seizures without motor symptoms, with primarily generalized epilepsy, with a known rapid progressive neurologic disorder, with status epilepticus or cluster seizures within 3 months before screening, with seizures of psychogenic origin within the last 2 yrs, with a history of schizophrenia or suicide attempts, with an uncontrolled, relevant medical disorder, with a second or third degree atroventricular blockade not corrected with a pacemaker, with relevant clinical laboratory abnormalities (liver enzymes at least two times the upper limit of normal or sodium <130 mmol/L or white blood cell count <3,000 cells/mm3, or creatinine clearance <50 ml/min), with poor compliance, with a history of drug or alcohol abuse within the previous 2 yrs, patients with a known hypersensitivity to carbamazepine and oxcarbazepine, patients taking or had taken felbamate within 1 month before screening.

Patient Characteristics Patient population was consisted of adults >=18 yrs (mean age 39 yrs, range 18-76 yrs) with simple or complex partial seizures with or without secondary generalization for at least 12 months before screening receiving adjunctive therapy (AEDs). They were 100% Caucasian, 51% female.

Recruitment Not clearly reported.

Setting 40 centers in 11 countries.

Interventions/ Test/ Factor being investigated Eslicarbazepine acetate in three doses; 400mg, 800mg and 1200mg.

Comparisons comparison were made between the treatments (ESL 400mg, 800mg and 1200mg) and the placebo group.

Length of Study/ Follow-up 4 weeks tapering off period.

Outcome measures studied Primary outcome; seizure frequency/ 4 weeks. Secondary outcomes; % patients with >=50% reduction in seizure frequency, relative reduction in seizure frequency, number of days with seizure, seizure free patients, % patients with >=25% seizure exacerbation

Results The proportion of patients with at least a 50% reduction in seizure frequency was significantly higher in the ESL 1200mg group (43%, p=0.0009) and the ESL 800mg (34%, p=0.0395) than in the placebo (20%). The median relative reduction in seizure frequency during the 12 maintenance period was higher in the ESL 800mg (36%) and 1200mg (45%) than in the ESL 400mg (26%) and placebo (16%).

A significantly higher proportion of patients in the ESL 1200 mg group (8%, P<0.05) achieved seizure freedom compared to patients in the 800mg group (4%, n.s.), in the 400mg group (2%, n.s.) and placebo (2%). 22% of patients in the placebo group showed exacerbation in seizure frequency than in any of the other ESL groups (<=12% in all groups).
Safety and adverse effects
The overall incidence of adverse effects increased with increasing dose of ESL. Prevalence >10% of Aes; 14.3% and 13.7% showed dizziness in ESL 800mg and ESL 1200mg respectively. 10.8% of patients in the ESL 1200mg group had headache and diplopia.

Does the study answer the question?
Yes. Treatment with ESL 800mg and ESL 1200mg as adjunctive therapies demonstrated higher relative and >50% reduction in seizure frequency compared to ESL 400mg and placebo (for adults with refractory partial onset seizures). Safety analysis was performed.

Effect due to factor in study?
Overall the study was well conducted. The power of the study was adequate to demonstrate an effect of the study intervention. The main pitfalls of the study were the absence of report on allocation concealment. The study design and the methodology adopted in relation to data collection and outcome measures used was appropriate to test the efficacy of ELS as an intervention.

Consistency of results with other studies?
Direct.

Internal Validity
Fakhoury TA; Hammer AE; Vuong A; Messenheimer JA;
Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy
Ref ID 671 2004 Aug

Study Type Randomised Controlled Trial
Funding GlaxosmithKline.

Number of participant
LTG n=98 vs CBZ n=46;
LTG n=105 vs VPA 53.

Inclusion/Exclusion Criteria
Inclusion criteria:
Aged 16 or over;
Diagnosed with epilepsy and experiencing any seizure type classified by International Classification of Seizures;
Treated with one AED for a minimum of 4 weeks prior to screening and had experienced at least 2 seizures during the 8 weeks before screening;
A clinical determined appropriate candidates for add-on therapy with lamotrigine, carbamazepine or valproate; and possible candidates for conversion to monotheapy with lamotrigine, carbamazepine, or valproate;
Females only eligible if had negative urine or serum pregnancy test at screening and agreed to use acceptable contraceptive methods during the study or were incapable of bearing children.
Exclusion criteria:
Treated with more than one AED at screening or if they were being treated with phenobarbital or primidone that could not be withdrawn over an 8-week period.

Patient Characteristics
LTG vs CBZ; LTG vs VPA:
mean age (s.d): 41 (14.8) vs 40.3 (12.9); 38.3 (13.3) vs 39 (12.7);
number of females: 58 (59%) vs 25 (54%); 59 (56%) vs 33 (62%);
mean no. Of seizure during 2 months prior to screening: 14.2 (37.6) vs 17.7 (50.1);
6.2 (11) vs 8.3 (14.3);
Seizure type during 2 months prior to screening n(%):
- simple partial: 25 (26%) vs 15 (33%); 35 (33%) vs 15 (28%);
- complex partial: 56 (57%) vs 32 (70%); 65 (62%) vs 38 (72%);
- partial with secondary generalisation : 39 (40%)vs 14 (30%); 30 (29%) vs 19 (36%)
- other:24 (24%) vs 10 (22%); 20 (19%) vs 11 (22%)

Recruitment
Not reported.

Setting
US. Part of a larger study in 17 countries.
| Interventions/ Test/ Factor being investigated | Lamotrigine versus carbamazepine. Lamotrigine versus sodium valproate. |
| Comparisons | Between treatments. 2 study arms. |
| Length of Study/ Follow-up | Not reported. |
| Outcome measures studied | % of patients receiving sustainable monotherapy with study medication; % seizure fee or had >50% reduction in seizure frequency during monotherapy phase (weeks 21, 28); time to treatment failure; incidence of adverse events. |

**Results**

LTG vs VPA:

Withdrawal due to adverse effects: 14/105 (13.3%) vs 11/53 (20.8%)
Incidence of dizziness: 16/105 (15.2%) vs 6/53 (11.3%)
Incidence of somnolence: 11/105 (10.5%) vs 7/53 (13.2%)
Incidence of tremor: 5/105 (4.8%) vs 11/53 (20.8%)
Incidence of nausea: 6/105 (5.7%) vs 7/53 (13.2%)
Incidence of alopecia: 1/105 (1%) vs 6/53 (11.3%)
Incidence of blurred vision: 11/105 (10.5%) vs 1/53 (1.9%)
Incidence of headache: 3/43 (7%) vs 6/44 (13.6%)

We have a blinded study for LTG vs CBZ so data not used from this study for that comparison as this is an unblinded study.

**Safety and adverse effects**

See above results.

**Does the study answer the question?**

Yes.

**Effect due to factor in study?**

No power calculation and poor methodology so uncertainty in the overall effect due to study intervention.

**Consistency of results with other studies?**

Some indirect there was 20% who were 'other' seizure types in the LTG vs VPA group and over 20% in the LTG vs CBZ group.

**Directly applicable to guideline population?**

Grunewald RA; Thompson PJ; Corcoran R; Corden Z; Jackson GD; Duncan JS;

Effects of vigabatrin on partial seizures and cognitive function

Ref ID 4686 1994

**Study Type** Randomised Controlled Trial

**Funding** Marion Merrell Dow.

**Number of participant** n=45 (n=22 in vigabatrin n=23 in placebo group)

**Inclusion/Exclusion Criteria**

Inclusion criteria: patients with partial seizures refractory to optimal antiepileptic drug treatment, ability to keep an accurate seizure diary.

**Patient Characteristics**

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>Vigabatrin n=22</th>
<th>Placebo n=23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range)</td>
<td>29(17-59)</td>
<td>27(16-55)</td>
</tr>
<tr>
<td>Age at onset median (range)</td>
<td>11(2-34)</td>
<td>10(1-22)</td>
</tr>
</tbody>
</table>

Twenty one women and 24 men, age range 15 to 61 years. N=35 had simple partial seizures, n=44 complex partial seizures, and 14 secondary generalised seizures. On study entry 26 patients were receiving monotherapy; Eighteen were taking two and
one three antiepileptic drugs.

Not reported.

Setting

Outpatient setting. UK.

Interventions/ Test/ Factor being investigated

Vigabatrin up to 1.5g twice daily as adjunctive therapy.

Comparisons

Vigabatrin is compared to placebo as adjunctive therapy to currently used AEDs.

Length of Study/ Follow-up

28 weeks: 8 weeks baseline and 20 weeks treatment.

Outcome measures studied

Primary and secondary outcomes not specified. Seizure frequency and psychological tests.

Results

Seizure control

Seizure frequency at baseline and during double blind treatment

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th></th>
<th>Weeks 12 to 20</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SPS</td>
<td>CPS</td>
<td>SPS</td>
</tr>
<tr>
<td>Placebo group:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>2</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Back transformed mean</td>
<td>4.37</td>
<td>8.55</td>
<td>0.58</td>
</tr>
<tr>
<td>Range</td>
<td>0.55</td>
<td>0.124</td>
<td>0.13</td>
</tr>
<tr>
<td>Vigabatrin group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>4</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Back transformed mean</td>
<td>5.46</td>
<td>9.72</td>
<td>0.51</td>
</tr>
<tr>
<td>Range</td>
<td>0.91</td>
<td>0.38</td>
<td>0.17</td>
</tr>
</tbody>
</table>

* p=0.009, ** p=0.001. Data include median numbers of each type of seizure recorded during eight week periods (median), antilogarithm of mean of logarithmically transformed seizure data (back transformed mean) and range. SPS=simple partial seizures, CPS= complex partial seizures; SGS=secondary generalised.

Adverse events

Two patients allocated vigabatrin developed severe depressive symptoms and withdrew within four weeks of starting treatment. In both, symptoms improved within four weeks of vigabatrin.

<table>
<thead>
<tr>
<th></th>
<th>Placebo n=23</th>
<th>Vigabatrin n=22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight gain</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Headache</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Constipation</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Mild depression</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>double vision</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Tremor</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Impaired memory</td>
<td>0</td>
<td>2</td>
</tr>
</tbody>
</table>

The only difference that approached statistical significance was constipation (p=0.07)

Neuropsychological assessment.

Vigabatrin treatment was associated with a significant reduction in dominant hand tapping frequency (mean baseline tapping rate 85.6 in placebo group, 77.0 in treatment group, rising to 92 at the end of the double blind period in the placebo group but falling to 72.1 in the vigabatrin treated group; group x time interaction
The study concludes that there was a >50% improvement in the control of complex partial seizures in 45% of patients during the double blind period of 20 weeks of treatment, and a statistically significant improvement in overall complex partial seizure frequency compared with the placebo control group. However, the study is small, no primary efficacy outcome has been specified, and is not powered to detect differences between the two groups. The results should only be considered exploratory.

Safety and adverse effects

Two patient discontinued vigabatrin because of depression.

Does the study answer the question?

The study concludes that there was a >50% improvement in the control of complex partial seizures in 45% of patients during the double blind period of 20 weeks of treatment, and a statistically significant improvement in overall complex partial seizure frequency compared with the placebo control group. However, the study is small, no primary efficacy outcome has been specified, and is not powered to detect differences between the two groups. The results should only be considered exploratory.

Effect due to factor in study?

No. The study is small, no primary efficacy outcome has been specified, and the study did not perform a power calculation. The results should only be considered exploratory.

Consistency of results with other studies?

All patients had partial seizures (simple partial, complex partial seizures, and secondary generalised seizures.)

Internal Validity

Jawad S; Richens A; Goodwin G; Yuen WC;

Controlled trial of lamotrigine (Lamictal) for refractory partial seizures

Ref ID 4757 1989

Study Type Randomised Controlled Trial

Funding not mentioned.

Number of participant 24 participants (cross over).

Inclusion/Exclusion Criteria

Inclusion: patients with drug-resistant seizures, aged 16–60 years, epilepsy uncomplicated by psychogenic attacks, partial seizures with or without secondary generalisation and seizures recognisable by a patient or relative, at least 4 partial seizures per month in the previous 3 months, no abnormal laboratory values of clinical significance, no more than 2 standard AEDs, stable AEDs for the previous 3 months and unlikely to change during study, compliant with treatment and able to record seizures and Aes, women not at risk of pregnancy

Exclusion:
- suffering from severe organic or psychiatric illness; progressive neurological disease;
- and with tests revealing possible abnormality of bone marrow, liver or renal function other than those attributable to concomitant AEDs
- taking any chronic drugs other than AEDs or oral contraceptive; alcohol abuse;
- pregnancy, lactation or current exposure to risk of pregnancy
- mental retardation
- evidence of previous serious non-compliance

Patient Characteristics

Type of epilepsy: Refractory

Type of seizures: Partial onset

Mean age/age range:

Total (n = 21): 37.3 years (SD 13.2);
LTG/placebo (n = 10): 38.9 years (SD 12.81);
Placebo/LTG (n = 11): 35.9 years (SD 13.94);
Total (n = 21): 19–65 years;

LTG/placebo (n = 10): 23–64 years;
Placebo/LTG (n = 11): 19–65 years

29 July 2010
Gender
Total (n = 21): men = 12, women = 9
LTG/placebo (n = 10): men = 5, women = 5
Placebo/LTG (n = 11): men = 7, women = 8

Age at onset of seizures
Mean age at onset: total (n = 21): 9.7 years (SD 7.6)
LTG/placebo (n = 10): 12.6 years (SD 9.6)
Placebo/LTG (n = 11): 7.2 years (SD 4.3)

Mean duration of seizures:
Total (n = 21): 27.6 years (SD 15.2)
LTG/placebo (n = 10): 26.3 years (SD 16.0)
Placebo/LTG (n = 11): 28.7 years (SD 15.2)

Recruitment
Patients attending the epilepsy Unit of the University of Wales College of Medicine.

Setting
University of Wales College of Medicine.

Interventions/ Test/ Factor being investigated
Lamotrigine

Comparisons
Treatment and placebo.

Length of Study/ Follow-up
44 weeks in total.
8 weeks baseline phase.
12 weeks treatment period 1.
6 weeks washout period.
12 weeks treatment period 2.
6 weeks washout 2.

Outcome measures studied
>50% reduction in seizure frequency, withdrawal due to adverse events, improvement in seizure days.

Results
1 out of the 3 patients who withdraw was due to experience of adverse events. He had ataxia, tiredness, dyspnea, and diplopia. The patient died 18 days later of carcinoma involving the liver - not believed to be attributable to LTG.
12/21 patients with partial seizures only had > 50% reduction in seizure frequency with LTG.

Withdrawal due to adverse events: LTG 1/21 vs PCB 0/21.

Safety and adverse effects
Experience of adverse events is reported as rates of occurrence and not as proportion of patients with that experience. The five most frequently reported adverse events were tiredness, diplopia, drowsiness, ataxia and headache.

Does the study answer the question?
Uncertain. The methodology adopted was not a randomized clinical trial in order to test the efficacy of lamotrigine over the placebo.

Effect due to factor in study?
The study design was poor, as no randomization procedure and allocation concealment are reported. Uncertain about the overall effect was due to the medication (lamotrigine) used.

Consistency of results with other studies?
Indirect.

Directly applicable to guideline population?
Indirect.

Internal Validity
Loiseau P; Hardenberg JP; Pestre M; Guyot M; Schechter PJ; Tell GP;

Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy
12/19 patients were female, 7/19 males aged from 10-58 years. The duration of epileptic disorders ranged from 2-40 years (mean +/- sd, 13.4 +/-8.34 years). 17/19 had complex partial seizures, 8/19 had secondary generalization, 2/19 had generalized tonic or tonic clonic seizures.

Comparison is made on the seizure frequencies between vigabatrin and placebo groups.

An initial 5 week observation phase with constant doses of AEDs, following 2 periods of 10 weeks each in which vigabatrin/placebo were administered and a final 5 week single blind period in which placebo was administered as add on therapy.

>50% reduction in seizure frequency, adverse events, patient preference for drug/placebo.

11/19 patients experienced a >50% reduction in seizure frequency (results are presented for the whole group of 19 patients).

Withdrawal due to adverse events among partial epilepsy patients:
VIG: 1/19
Placebo: 1/19

9/19 patients reported adverse events during treatment with vigabatrin, 10/19 in placebo period. Three patients withdrew due to adverse events.

Yes, within the limitations of the study to clearly describe its randomization procedure and its blindness. The main conclusion was that using 3gr/day vigabatrin as add on therapy was shown to reduce the weekly seizure frequency in 11 out of 19 patients by >50%.

It is not certain that the effect observed in the study was due to the intervention as the report of the methodology adopted was not clear and there was no prior consideration of sample size based on the statistical power of the study.

Funding not mentioned.

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Randomised Controlled Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participant</td>
<td>N=19 (crossover study)</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>Inclusion criteria: complex partial seizures or primary generalized epilepsy, a total frequency of at least one/week, despite treatment with no more than 3 standard AEDs, age 10-60 yrs, constant doses of AED during 5 weeks prior to study entry and informed consent. Excluded criteria: history or evidence of a progressive neurological disorder, serious medical disorders other than epilepsy (liver disease, renal dysfunction, cardiac disease, abnormal haematology results or allergic disease), pregnancy or risk of pregnancy.</td>
</tr>
<tr>
<td>Patient Characteristics</td>
<td>12/19 patients were female, 7/19 males aged from 10-58 years. The duration of epileptic disorders ranged from 2-40 years (mean +/- sd, 13.4 +/-8.34 years). 17/19 had complex partial seizures, 8/19 had secondary generalization, 2/19 had generalized tonic or tonic clonic seizures.</td>
</tr>
<tr>
<td>Recruitment</td>
<td>Not addressed.</td>
</tr>
<tr>
<td>Setting</td>
<td>Not addressed.</td>
</tr>
<tr>
<td>Interventions/ Test/ Factor being investigated</td>
<td>vigabatrin as an add on to a standard therapy in therapy resistant epileptic patients.</td>
</tr>
<tr>
<td>Comparisons</td>
<td>Comparison is made on the seizure frequencies between vigabatrin and placebo groups.</td>
</tr>
<tr>
<td>Length of Study/ Follow-up</td>
<td>An initial 5 week observation phase with constant doses of AEDs, following 2 periods of 10 weeks each in which vigabatrin/placebo were administered and a final 5 week single blind period in which placebo was administered as add on therapy.</td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>&gt;50% reduction in seizure frequency, adverse events, patient preference for drug/placebo.</td>
</tr>
<tr>
<td>Results</td>
<td>11/19 patients experienced a &gt;50% reduction in seizure frequency (results are presented for the whole group of 19 patients).</td>
</tr>
<tr>
<td>Safety and adverse effects</td>
<td>9/19 patients reported adverse events during treatment with vigabatrin, 10/19 in placebo period. Three patients withdrew due to adverse events.</td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>Yes, within the limitations of the study to clearly describe its randomization procedure and its blindness. The main conclusion was that using 3gr/day vigabatrin as add on therapy was shown to reduce the weekly seizure frequency in 11 out of 19 patients by &gt;50%.</td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>It is not certain that the effect observed in the study was due to the intervention as the report of the methodology adopted was not clear and there was no prior consideration of sample size based on the statistical power of the study.</td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>Direct.</td>
</tr>
<tr>
<td>Directly applicable to guideline population?</td>
<td>Direct.</td>
</tr>
</tbody>
</table>
A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial

Ref ID 1496 2007

Study Type Randomised Controlled Trial

Funding Commissioned and sponsored by NHS R&D Health Technology Assessment Programme. Also supported by pharmaceutical companies with drugs in the study (approx 20% of the total costs of study).

Number of participant

Arm A: Total n=1721. CBZ n=378; GBP n=377; LTG n=378; OXC n=210; TPM n=378.

Arm B: total n=716. VPA n=239; TPM n=239; VPS n=238.

Inclusion/Exclusion Criteria

Inclusion criteria: History of 2 or more clinically definite unprovoked epileptic seizures in the previous year and if treatment with a single AED represented the best therapeutic option.Patients with newly diagnosed epilepsy, those who had failed previous monotherapy (providing that did not include one of the drugs present in the randomisation) and patients in remission of epilepsy, who had relapsed after a withdrawal of treatment.

Exclusion criteria: If patient or clinician felt treatment was contraindicated, if all seizures had been acute symptomatic seizures (including febrile seizures), they were aged 4 years or younger or if there was a history of progressive neurological disease.

Patient Characteristics CBZ vs GBP vs LTG vs OXC vs TPM:

Males: 55% vs 55% vs 53% vs 55%

Treatment history, n(%):

Untreated: 309 (81.8) vgs 306 (81.2) vs 308 (81.5) vs 181 (86.2) vs 308 (81.5);

Monotherapy (not optimally treated): 60 (15.9) vs 60 (15.9) vs 61 (16.1) vs 25 (11.9) vs 60 (15.9);

Recent seizures after remission: 9 (2.4) vs 11 (2.9) vs 9 (2.4) vs 4 (1.9) vs 10 (2.7);

Epilepsy syndrome, n(%):

Idiopathic partial 4 (1.1) vs s5 (1.3) vs 6 (1.6) s 3 (1.4) vs 6 (1.6);

Symptomatic or cryptogenic partial: 338 (89.4) vs 333 (88.6) vs 330 (88) vs 180 (85.7) vs 322 (85.4);

Idiopathic generalised: 3 (0.8) vs 3 (0.8) vs 4 (1.1) vs 5 (2.4) vs 7 (1.9);

Other syndrome: 2 (0.5) vs 0 (0) vs 0 (0) vs 1 (0.5) vs 1 (0.3);

Unclassified: 31 (8.2) vs 35 (9.3) vs 35 (9.3) vs 21 (10) vs 41 (10.9)

Recruitment

Patients presenting to participating clinicians were cued for entry if met inclusion criteria.

Setting Multicentre study hospital outpatient clinics UK.

Interventions/ Test/ Factor being investigated

At start of study information was recorded including patient demographics, presence of a history of learning disability or developmental delay, prior neurological history including head injury, stroke, intracerebral infection and acute symptomatic seizures, and a history of epilepsy in a first-degree family member. Clinicians were asked to classify seizures and epilepsy syndromes according to ILAE classifications or at least differentiate between focal or generalised onset seizures. Where there was uncertainty patients were recorded as having unclassified convulsive or other unclassified seizures. Any EEG or brain imaging results at time of randomisation were recorded.

Clinicians involved in the study were asked to choose either CBZ or VPA as the most appropriate treatment for an individual patient. When CBZ was chosen the patient entered arm A and were then allocated to either CBZ, GBP, LTG, OXC, or TPM in ration of 1:1:1:1 (OXC was included in randomisation only after 1st June 2001). If VPA was chosen patients entered arm B and were randomised to either VPA, LTG or TPM in ratio n of 1:1:1.
Drug was randomised but drug, dosage and preparation were those used typically by the clinician.

Comparisons

Arm A: carbamazepine versus gabapentin versus lamotrigine versus oxcarbazepine versus topiramate.

Length of Study/ Follow-up

Follow-up at 3, 6, 12 months and at successively yearly intervals from randomisation. First randomisation was Jan 1999 and continued to randomise until 31st August 2004. Patients were followed up at least until the end of the study (31st August 2005).

Outcome measures studied

Primary clinical outcomes:
Time from randomisation to treatment failure. Time from randomisation to the achievement of a 1-year period of remission of seizures. Quality of life.

Results

Carbamazepine versus lamotrigine:
Seizure freedom: 125/347 vs 103/356
Withdrawal due to adverse events: 96/368 vs 60/370
Withdrawal due to lack of efficacy: 29/368 (7.9%) vs 29/368 (7.9%)
Time to exit/withdrawal of allocated treatment due to adverse events: HR 0.62 (0.46 to 0.83)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 1.17 (0.84 to 1.84)

Carbamazepine versus Gabapentin:
Seizure freedom: 125/347 (36%) vs 81/337 (24%)
Withdrawal due to adverse events: 114/442 (25.8%) vs 75/512 (14.6%)
Withdrawal due to lack of efficacy: 29/368 (7.9%) vs 91/366 (24.9%)
Time to exit/withdrawal of allocated treatment due to adverse events: HR 0.60 (0.44 to 0.81)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 2.45 (1.81 to 3.32)

Carbamazepine versus topiramate:
Time to exit/withdrawal of allocated treatment due to adverse events: HR 0.99 (0.77 to 1.30)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 1.43 (1.03 to 1.98)

Carbamazepine versus oxcarbazepine:
Time to exit/withdrawal of allocated treatment due to adverse events: HR 0.85 (0.59 to 1.24)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 1.33 (0.82 to 2.15)

Gabapentin versus lamotrigine:
Time to exit/withdrawal of allocated treatment due to adverse events: HR 1.04 (0.75 to 1.44)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 0.48 (0.36 to 0.64)

Gabapentin versus topiramate:
Time to exit/withdrawal of allocated treatment due to adverse events: HR 1.66 (1.24 to 2.24)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 0.58 (0.44 to 0.77)

Lamotrigine versus topiramate:
Time to exit/withdrawal of allocated treatment due to adverse events: HR 1.60 (1.20 to 2.15)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 1.22 (0.89 to 1.67)

Gabapentin versus oxcarbazepine:
Time to exit/withdrawal of allocated treatment due to adverse events: HR 1.36 (0.90 to 2.05)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 0.43 (0.29 to 0.64)

Lamotrigine versus oxcarbazepine:
Safety and adverse effects

Does the study answer the question?
Yes.

Effect due to factor in study?
Unblinded and no details of allocation concealment but it is a very large pragmatic trial. Therefore some uncertainty over whether overall effect is due to the study interventions or not.

Consistency of results with other studies?

Directly applicable to guideline population?
Mixed population but over 80% had partial seizures.

Internal Validity

McKee PJ; Blacklaw J; Friel E; Thompson GG; Gillham RA; Brodie MJ;

Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?

Ref ID 4693 1993

Study Type Randomised Controlled Trial  Funding Marrion merrell dow.

Number of participant n=24 crossover study.

Inclusion/Exclusion Criteria Not specified.

Patient Characteristics Aged 17-53 years; 16 women; 8 men; Refractory epilepsy; 14 had complex partial seizures secondary generalised; 8 had complex partial seizures alone; 2 had generalised tonic-clonic seizures. Average of at least 2 generalised or one partial seizure a week during 3 months prior to recruitment. 11 were on monotheapy (9 carbamazepine, 1 phenytoin, 1 valproate) and 13 were on two AEDs (10 carbamazepine, 6 primidone, 4 valproate, 4 phenytoin, 2 phenobarbital.

Recruitment Patients at the Western Infirmary Glasgow.

Setting Hospital, Glasgow.

Interventions/ Test/ Factor being investigated

Comparisons Adjunctive vigabatrin versus placebo.

Length of Study/ Follow-up 30 weeks.

Time to exit/withdrawal of allocated treatment due to adverse events: HR 1.21 (0.81 to 1.81)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 0.99 (0.63 to 1.54)

Topiramate versus oxcarbazepine:
Time to exit/withdrawal of allocated treatment due to adverse events: HR 0.98 (0.67 to 1.44)
Time to exit/withdrawal of allocated treatment due to lack of efficacy: HR 0.82 (0.53 to 1.28)

See results above.
Outcomes measures studied

>50% reduction in seizure frequency vgb compared to placebo; withdrawal due to adverse events; incidence of adverse events.

Results

>50% reduction in seizure frequency:

All seizures (n=19)
- Phase 1: 9
- Phase 2: 6
- Overall: 8

Partial seizures (n=17)
- Phase 1: 7
- Phase 2: 6
- Overall: 8

GTCs (n=12)
- Phase 1: 3
- Phase 2: 3
- Overall: 3

Does not give results for vigabatrin and placebo separately. Phase 1 was VGB/placebo 1g twice daily for 6 weeks; phase 2 was VGB/placebo 1.5g twice daily for 6 weeks.

Withdrawal due to adverse events: VGB 1/24 vs placebo 0/24.

Safety and adverse effects

Incidence of adverse events:
- VGB (2g, 3g) vs placebo (2g, 3g):
  - Tiredness: 7, 3 vs 0, 1;
  - Dizziness: 3, 0 vs 1, 1.

Does the study answer the question?

Author's conclusions: VGB is useful adjuvant therapy for treatment of partial seizures. There may be a ceiling to effective dosage. This demands individual dose titration for each patient.

Effect due to factor in study?

No. Very small crossover study with few details of randomisation, blinding or allocation concealment.

Consistency of results with other studies?

Direct.

Directly applicable to guideline population?

Direct.

Internal Validity

Meador KJ; Loring DW; Hulihan JF; Kamin M; Karim R; CAPSS-027 S;

Differential cognitive and behavioral effects of topiramate and valproate

Ref ID 602

2003

Study Type Randomised Controlled Trial

Funding Ortho McNeil Pharmaceutical KJM

Number of participant

n=76 randomised (n=34 in the topiramate group, n=29 in the valproate group and n=13 in the placebo group).

Inclusion/Exclusion Criteria

Inclusion criteria: 16 to 55 years, IQ >70, three partial-onset seizures during a 28-day baseline phase, not pregnant, CT or MRI to confirm absence of a progressive cerebral lesion. AED other than CBZ had to be discontinued 28 days before the baseline visit.

Exclusion criteria: nonepileptic seizures; treatable cause of seizures; progressive neurologic disorders; status epilepticus within past 3 months; history of major medical disease within past 2 years or malignancy within past 5 years. Patients previously treated with TPM were also excluded.
### Patient Characteristics

<table>
<thead>
<tr>
<th>Comparisons</th>
<th>ITT</th>
<th>TPM Completers,*</th>
<th>VPA Completers,*</th>
<th>ITT</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, %</td>
<td>35</td>
<td>37</td>
<td>52</td>
<td>60</td>
<td>43</td>
</tr>
<tr>
<td>Age, y, mean (range)</td>
<td>41 (22–66)</td>
<td>41 (22–61)</td>
<td>37 (17–52)</td>
<td>37 (17–51)</td>
<td>40 (25–57)</td>
</tr>
<tr>
<td>Baseline monthly seizure rate, median (range)</td>
<td>6.6 (2–154)</td>
<td>7.7 (2–154)</td>
<td>8.9 (0–63)</td>
<td>8.9 (2–61)</td>
<td>7.9 (2–225)</td>
</tr>
</tbody>
</table>

### Recruitment

Not reported.

### Setting

24 centres.

### Interventions/ Test/ Factor being investigated

Topiramate 400mg/d compared to valproate 2,250mg/day and placebo as adjunctive therapy. 24 weeks: 4 week baseline, 8 week titration phase and 12 week maintenance phase.

### Comparisons

Topiramate 400mg/d compared to valproate 2,250mg/day and placebo as adjunctive therapy.

### Length of Study/ Follow-up

24 weeks: 4 week baseline, 8 week titration phase and 12 week maintenance phase.

### Outcome measures studied

Recruitment difficulty led to termination of the study before enrolling the number of patients required to evaluate the primary seizure reduction efficacy variable. Neuropsychological and quality of life outcomes are presented.

### Results

Neuropsychological test results Changes from baseline to the end of the maintenance period were significant (ANCOVA) in 4 of 24 (17%) measures (SDMT, COWA, Stroop–word, and Stroop–color). Negative effects for topiramate vs placebo were observed for four variables; negative effects for valproate vs placebo were observed for one variable. Patients receiving topiramate performed worse than valproate treated patients on two variables (SDMT and COWA) after 20 weeks of treatment. SDMT=Symbol Digit Modalities Test, COWA=Controlled Oral Word Association Test.

### Adverse events

Cognitive complaints

<table>
<thead>
<tr>
<th></th>
<th>TPM n=34</th>
<th>VPA n=29</th>
<th>Placebo n=13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memory difficulty</td>
<td>6 (18)</td>
<td>5 (17)</td>
<td>0</td>
</tr>
<tr>
<td>Speech difficulty</td>
<td>4 (12)</td>
<td>2 (7)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Concentration/attention difficulty</td>
<td>3 (9)</td>
<td>3 (10)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Psychomotor slowing</td>
<td>3 (9)</td>
<td>1 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Depression</td>
<td>6 (18)</td>
<td>4 (14)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Confusion</td>
<td>2 (6)</td>
<td>1 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Language problems</td>
<td>2 (6)</td>
<td>2 (7)</td>
<td>2 (15)</td>
</tr>
<tr>
<td>Other cognitive problems</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 (3)</td>
<td>1 (3)</td>
<td>0</td>
</tr>
</tbody>
</table>

Values are n (%).

### Safety and adverse effects

Unknown.

### Does the study answer the question?

No. The study was terminated due to recruitment difficulties before enrolling the number of patients required to evaluate the primary seizure reduction efficacy variable. Only a subset of patients enrolled performed the neuropsychological tests.

### Effect due to factor in study?

No. The study was terminated due to recruitment difficulties before enrolling the number of patients required to evaluate the primary seizure reduction efficacy variable. Only a subset of patients enrolled performed the neuropsychological tests.

29 July 2010
Internal Validity

Consistency of results with other studies? Directly applicable to guideline population?

Patients had partial-onset seizures during the baseline phase.

Schachter SC; Vazquez B; Fisher RS; Laxer KD; Montouris GD; Combs-Cantrell DT; Faught E; Willmore LJ; Morris GL; Ojemann L; Bennett D; Mesenbrink P; D'Souza J; Kramer L;

Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures

Ref ID 4707 1999

Study Type Randomised Controlled Trial Funding Sponsored by Ciba-Geigy Corporation (Novartis Pharmaceutical Corporation)

Number of participant OXC n=51; Placebo n=51.

Inclusion/Exclusion Criteria

Inclusion criteria:
- Completed an evaluation for epilepsy surgery;
- 2-10 partial seizures within 48 hours of randomisation, including at least one complex partial seizure and no more than two partial seizures evolving to secondarily generalised seizures (minimum between-seizure duration of 30 minutes);
- Aged 11 to 65 years;
- Weight over 45kg;
- No AEDs within 48 hours of randomisation (except for lorazepam up to 8mg/day);
- Normal routine clinical laboratory values;
- Subtherapeutic plasma concentrations of AEDs prior to randomisation;
- CT scan or MRI within the past 5 years that excluded a progressive cerebral lesion;
- Normal electrocardiogram (EC);
- Capability of satisfying protocol requirements;
- Ability to provide informed consent;
- Women of childbearing potential enrolled only if they were not pregnant and were not lactating and if using a barrier method of contraception.

Exclusion criteria: history of status epilepticus in 3 months preceding randomisation;
- Ingestion of benzodiazepines or barbiturates within 15 days of hospitalisation (other than lorazepam);
- Cardiac, hepatic, endocrine, gastrointestinal, renal, hematologic, oncologic, or progressive neurologic disorders;
- Seizures of metabolic, neoplastic or active infectious origin;
- Second or third degree atioventricular block if not adequately treated with a cardiac pacemakers;
- Nonspecific seizures within 2 years of randomisation;
- Major psychiatric disorder or medicaitons that could affect trial participation;
- Suspected substance or alcohol abuse within 6 months of randomisation;
- Participation in another investigational drug trial within 30 days of randomisation;
- Use of calcium channel blockers or monoamine oxidase inhibitors;
- Hypersensitivity to oxcarbazepine or its metabolites, lorazepam or carbamazepine;
- Treatment with felbamate within 30 days of randomisation;
- History of oxcarbazepine therapy;
- History of noncompliance.

Patient Characteristics

Type of epilepsy Refractory
Type of seizures Partial onset
Aged 11 to 62 years (mean age: 33 years)

Recruitment Patients who were to undergo presurgical evaluations.

29 July 2010 Page 157 of 306
Oxcarbazepine versus placebo. Between treatment and placebo comparison. Not reported. Patients could enter an open-label extension trial.
Primary: time to meeting one of the exit criteria. Secondary % of patients who met one of the exit criteria.

Results
Proportion of seizure free: 13/51 vs 1/51 were seizure free for entire 10 day phase;
Withdrawal due to adverse events: 2/51 vs 0/51.
Incidence of headache: 10/51 vs 10/51
Incidence of dizziness: 9/51 vs 6/51
Incidence of somnolence: 8/51 vs 0/51
Incidence of nausea: 10/51 vs 3/51
Incidence of vomiting: 5/51 vs 2/51
Incidence of pruritus: 9/51 vs 4/51
Incidence of diplopia: 6/51 vs 0/51
Incidence of fatigue: 5/51 vs 1/51

Safety and adverse effects
Does the study answer the question?
Yes.

Effect due to factor in study?
Power: 47 in each group should complete the study for power of 85% and 48 and 49 completed the study. There was no details of allocation concealment and the study was only 10 days long so uncertainty in overall effect due to study intervention.

Consistency of results with other studies?
Direct.

Directly applicable to guideline population?
Direct.

Internal Validity

Sun MZ; Deckers CL; Liu YX; Wang W;
Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy
Ref ID 5091 2009 Mar

Study Type Randomised Controlled Trial

Number of participant n=136.
VPA: n=68 vs PRM n=68.

Inclusion/Exclusion Criteria
Inclusion criteria:
8 years and older;
diagnosis of partial epilepsy;
well-defined types of seizures;
patients not becoming seizure free on CBZ as their first antiepileptic drugs with a seizure frequency of at least 2 seizures per month during the retrospective baseline period of 3 months;
Exclusion criteria:
not satisfying the inclusion criteria;
VPA vs Primidone:
Males/females: 44:24 vs 45:23;
Average age (years): 22.3 (8-58) vs 22.9 (8-50);
Monthly seizure frequency: 6.2 (2-60) vs 6.8 (2-45);
Seizure types: CPSY, SGTCS, SPS.

Recruitment
Neurologists from two hospitals identified eligible patients.

Setting
Shanxi medical university, China.

Interventions/ Test/
Factor being investigated
Sodium valproate versus primidone.

Comparisons
Comparisons between treatments.

Length of Study/
Follow-up
No follow-up.

Outcome measures studied
Seizure frequency. Adverse events.

Results
VPA vs PRM:
At least 50% reduction in seizure frequency: 35/68 (51%) vs 23/68 (34%), risk difference 17% relative risk 1.52 (1.01 -2.28).
Seizure reduction (100%): 18/68 (26%) vs 11/68 (16%) risk difference 10% RR 1.64 (95% CI 0.84-3.20).
Withdrawn due to adverse effects: 3 vs 7.

Safety and adverse effects
None reported.

Does the study answer the question?
Yes.

Effect due to factor in study?
No - poor methodology.

Consistency of results with other studies?
Direct.

Internal Validity
Zamponi N;Cardinali C;
Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children
Ref ID 4607
1999

Study Type Randomised Controlled Trial
Funding Not reported.

Number of participant VGB n=38, CBZ n=32.
**Inclusion/Exclusion Criteria**
- Inclusion criteria: newly diagnosed partial epilepsy

**Patient Characteristics**
- VGB group: 21 boys, 17 girls mean age 7 years 4 months (range 6 months to 10 years 3 months). In 35 cases epilepsy had occurred less than 1 month earlier.
- CBZ group: 17 boys and 15 girls, mean age 9 years 5 months (range 3 years to 13 years 2 months).

**Recruitment**
- Not reported.

**Setting**
- Neuropsychiatric dept, pediatric hospital, Italy.

**Interventions/ Test/ Factor being investigated**
- Vigabatrin 50-60mg/kg/day or carbamazepine controlled release 15 to 20mg/kg per day.

**Comparisons**
- Vigabatrin versus carbamazepine controlled release.

**Length of Study/ Follow-up**
- 2 years (at 1,3,6,12,18,24 months).

**Outcome measures studied**
- Withdrawal due to adverse events; adverse events.

**Results**
- States how many relapsed but not clear how many were seizure free to begin with.
- VGB vs CBZ:
  - Withdrawal due to adverse events 1/38 vs 1/32.
  - Irritability/excitability: 0 vs 6 (15.7%) vs 0
  - Weight gain: 3 (9.3%) vs 10 (26.3%)
  - Excessive sedation: 6 (18.7%) vs 0
  - Urticarial rash: 6 (18.7%) vs 0

**Safety and adverse effects**
- See above results for adverse events and withdrawal due to adverse events.

**Does the study answer the question?**
- No, it is unclear and only reports adverse events clearly.

**Effect due to factor in study?**
- No. Only 70 patients, no power calculation and few details on methodology. Open study.

**Consistency of results with other studies?**
- Mixed population as some had the drug as first line and others had it as refractory treatment, although said all were newly diagnosed.

**Directly applicable to guideline population?**
- Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures

**Zhou B; Zhang Q; Tian L; Xiao J; Stefan H; Zhou D;**

**Ref ID** 169
**Study Type** Randomised Controlled Trial
**Funding** Not reported.

**Number of participant** n=28 (n=14 in the LEV group and n=14 in the placebo group)
Inclusion/Exclusion Criteria
Inclusion criteria: adult patients (aged 16–70 years), partial-onset seizures (simple or complex partial with or without secondary generation, poorly controlled by at least one first-line AED at the time of the study, a minimum of eight seizures during the 8-week baseline period with a minimum of two seizures during each 4-week period. Participants were not seriously intellectually disabled (IQ>=80), and could read and comprehend the questions.
Exclusion criteria: patients with progressive neurological disorders, severe internal organ diseases, pregnancy, alcohol addiction, or drug abuse.

Patient Characteristics
Demographics of the LEV and placebo groups

<table>
<thead>
<tr>
<th>Demographic</th>
<th>LEV group</th>
<th>Placebo group</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N = 13)</td>
<td>(N = 11)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>28.2 ± 11.1</td>
<td>31.3 ± 9.8</td>
</tr>
<tr>
<td>Gender (% male)</td>
<td>53.8%</td>
<td>54.5%</td>
</tr>
<tr>
<td>Age at epilepsy onset (years)</td>
<td>18.5 ± 10.1</td>
<td>14.6 ± 7.5</td>
</tr>
<tr>
<td>Duration of epilepsy (years)</td>
<td>8.7 ± 6.4</td>
<td>16.5 ± 7.2</td>
</tr>
<tr>
<td>Seizure frequency at baseline (No. of seizures/week)</td>
<td>6.55 ± 10.79</td>
<td>6.15 ± 11.20</td>
</tr>
<tr>
<td>Education (years)</td>
<td>8.4 ± 3.9</td>
<td>8.2 ± 3.4</td>
</tr>
<tr>
<td>Number of antiepileptic drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4 (30.7%)</td>
<td>3 (27.3%)</td>
</tr>
<tr>
<td>2</td>
<td>9 (69.3%)</td>
<td>8 (72.7%)</td>
</tr>
</tbody>
</table>

Note. Values are expressed as means ± SD, percentages (%), or number (No).

Recruitment
Not reported.

Setting
Outpatients - Epilepsy Clinic West China Hospital

Interventions/ Test/ Factor being investigated
Levetiracetam up to 1500mg twice daily adjunctive to currently used AEDs.

Comparisons
The comparison is between levetiracetam as adjunctive therapy and placebo.

Length of Study/ Follow-up
24 weeks: 8-week baseline period, 4 week titration phase and 12 week max dose phase.

Outcome measures studied
Primary/secondary outcomes not specified. Study measured seizure frequency for the double blind period. It measured neuropsychological and quality of life outcomes after an extended 24 week open label phase. Seizure rates will be reported here.

Results
Seizure frequency at end of double blind period
One patient (7.7%) in the LEV group was seizure-free. Six patients (46.2%) in the LEV group achieved >75% reduction in seizure frequency, compared with one patient (9.1%) in the placebo group. Five patients (38.5%) in the LEV group had no response, compared with nine patients (81.8%) in the placebo group. Thus, a total of eight patients in the LEV group (61.5%) had >50% reduction in seizure frequency (described as responders in some studies), compared with two patients (18.2%) in the control group (P < 0.05).

Adverse events not reported.

Safety and adverse effects
Not reported.

Does the study answer the question?
No. The study concludes that it has provided further evidence that levetiracetam as adjunctive therapy reduces seizure frequency. However, this is a small study and might not be able to confidently provide evidence of effectiveness.

Effect due to factor in study?
No. This is a small exploratory study and does not have the power to provide evidence about effectiveness of the study drug.

Consistency of results with other studies?

29 July 2010
Internal Validity

All patients who were enrolled were diagnosed with partial-onset seizures.

**Question:** Which AEDs are clinically effective and cost-effective for people with idiopathic generalised epilepsy?
Grading: 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

Ref ID 157

Study Type Randomised Controlled Trial

Funding UCB Pharma SA.

Number of participant N = 62 to LEV and n = 60 to placebo. ITT population was n=61 for LEV and n=60 for placebo.

Inclusion/Exclusion Criteria

Inclusions: if patients had myoclonic seizures on ≥ 8 days during the study baseline period and were receiving a stable dose of one AED for ≥ 4 weeks before the study entry. Exclusion: nonepileptic seizures within the previous year, signs suggestive of a progressive brain lesion; history of parital-onset seizures; status epilepticus within the previous 3 months; previous or current treatment with LEV; current use of vigabatrin or tiagabine; or current use of felbamate with less than 18 months exposure.

Patient Characteristics

Male and female patients aged 12 to 65 years inclusive with a diagnosis of IGE with myoclonic seizures according to the ILAE classification of epileptic seizures were eligible. Diagnosis was based on clinical and EEG features consistent with IGE, absence of evidence of brain lesions, and diagnosis of JME, juvenile absence epilepsy (JAE), or epilepsy with generalised tonic-clonic seizures on awakening, in accordance with ILAE classification of epileptic syndromes. Most patients (75%) had a history of taking AEDs other than the one currently prescribed. The most common concomitant AEDs were valproic acid (57.9%) and lamotrigine (26.4%). During the baseline period, the averages (median/mean) for myoclonic seizures days/week and for all seizure days/week for the whole trial population were 1.7/2.5 and 2.2/2.8. All subjects had refractory IGE and experienced myoclonic seizures. Majority had Juvenile Myoclonic Epilepsy JME (88.5% in the LEV group and 98.3% in the placebo group).

Recruitment Not clear.

Setting Secondary care.

Interventions/ Test/ Factor being investigated Levetiracetam versus placebo.

Comparisons Levetiracetam versus placebo.

Length of Study/ Follow-up Efficacy outcomes were measured up to 16 week treatment. Adverse events were also reported in the conversion period (22 weeks).

Outcome measures studied Primary efficacy variable was ≥ 50% reduction in myoclonic seizure days/week during the treatment period. Secondary were: responder rates for seizure days/week for all seizure types; median % reduction from baseline; and rates of seizure freedom.

Results Per protocol analysis: During the 16 week treatment, 35/60 (58.3%) for the LEV group and 14/60 (23.3%) for the placebo group reported at least a 50% reduction from baseline in the number of myoclonic seizure days/week (OR=4.77, 95% CI: 2.12 to 10.77, p<0.001). During the 16 week treatment 10/60 patients (16.7%) receiving LEV were myoclonic seizure free compared to 2/60 on placebo (3.3%; p=0.03); 8/ 60 patients (13.3%) on LEV and 0/60 on placebo (0.0%) were free from any seizure subtype (p=0.006). During the 12 week evaluation period 15/60 (25.0%) receiving LEV and 3/60 receiving placebo (5.0%) were myoclonic seizure free (p=0.004); 13/60 patients receiving LEV (21.7%) and 1/60 receiving placebo (1.7%) were free from any seizure subtype (p<0.001).

Health-related quality of life

29 July 2010 Page 163 of 306
The largest improvements (LEV group) were reported in health status (8.1) and seizure worry subscales (8.0). More patients receiving LEV than placebo reported improvement in their overall HRQoL (88.3% versus 60.4%).

ITT analysis: 10/62 (16.1%) in levetiracetam and 2/60 (3.3%) were myoclonic seizure free during up-titration and evaluation period. 8/62 (12.9%) in levetiracetam and 0/60 were seizure free (any seizure subtype) during up-titration and evaluation period. 85/62 (56.5%) in levetiracetam group and 14/60 (23.3%) in placebo experienced at least 50% reduction in myoclonic seizure frequency (up-titration and evaluation period).

During the evaluation period 15/62 (24.2%) in levetiracetam group and 3/60 (5%) in placebo were free from myoclonic seizures and 13/62 (21%) in levetiracetam and 1/60 (1.7%) in placebo were seizure free from any seizure subtype. The incidence of headache was 13/62 (21%) in levetiracetam group and 14/60 (23/3%) in placebo.

The incidence of somnolence was higher in levetiracetam group (6/62) compared to placebo (1/60). A higher proportion of participants in levetiracetam group had experienced improvement in their health related quality of life (53/62) compared to placebo (36/60).

Safety and adverse effects

Somnolence was reported in the LEV group during the up-titration (6/60; 10.0%), but not in the evaluation period. It also occurred in 5 patients (10.6%) from the placebo group during conversion to LEV.

Four patients (3 on LEV) discontinued study medication due to adverse events.

Does the study answer the question?

LEV appears to be an effective and well-tolerated adjunctive treatment for patients with previously uncontrolled IGE with myoclonic seizures.

Effect due to factor in study?

Overall very well conducted study. However, is pharma funded.

Consistency of results with other studies?

Directly applicable to guideline population?

Direct population and intervention.

Internal Validity
Patient Characteristics

Levetiracetam vs placebo:

Mean age (years): 26.9 (s.d=11.2) vs 30.6 (s.d=12.1);
Sex (male/female): 34 (42.5%)/46 (57.5%) vs 39 (46.4%)/45 (53.5%);
Ethnicity (white/nonwhite): 57 (71.3%)/23 (28.7%) vs 64 (76.2%)/20 (23.8%); Mean GTC seizure frequency per week (combined baseline): 1.27 (s.d=2.46) vs 1.20 (s.d=1.90);
Epilepsy syndrome:
- localisation-related - idiopathic 0 vs 1 (1.2%);
- generalised - idiopathic:
  childhood absence epilepsy: 3 (3.8%) vs 4 (4.8%);
  Juvenile absence epilepsy: 8 (10%) vs 11 (13.1%);
  Juvenile myoclonic epilepsy: 24 (3%) vs 30 (35.7%);
Epilepsy with GTC seizures on awakening: 22 (27.5%) vs 27 (32.1%);
Other idiopathic generalised epilepsies: 18 (22.5%) vs 10 (11.9%);
Epilepsy syndrome unknown: 5 (6.3%) vs 2 (2.4%);

Seizure type:
- partial seizures: 3 (3.8) vs 2 (2.4%);
- generalised seizures: 80 (100%) vs 84 (100%);
  - absence seizures 31 (38.8%) vs 47 (56%);
  - atypical absence seizures: 1 (1.3%) vs 1 (1.2%);
  - myoclonic seizures: 27 (33.8%) vs 35 (41.7%);
  - clonic seizures: 0 (0) vs 1 (1.2%);
  - tonic seizures 1 (1.3%) vs 5 (6%);
  - tonic-clonic seizures: 80 (100%) vs 84 (100%);

Concomitant AEDs used by >=10% of patients during treatment period:
- valproate: 45 (53.2%) vs 44 (52.4%);
- Lamotrigine: 22 (27.8%) vs 23 (27.4%);
- Carbamazepine: 17 (21.5%) vs 14 (16.7%);
Topiramate: 11 (13.9%) vs 8 (9.5%);  
Phenytoin: 6 (7.6%) vs 11 (13.1%);

**Recruitment**
Not reported.

**Setting**
50 Centers (Europe, N. America, Mexico, Aus, NZ).

**Interventions/ Test/ Factor being investigated**
Patients had a 4 week historical baseline period and a 4 week prospective single-blind placebo baseline period before randomisation to double blind period.

Levetiracetam dose 3000mg/day for adults and 60mg/kg/day for pediatric patients and adolescents aged <16 years and weighing <50kg.

4 week double-blind titration period followed by a 20 week evaluation period.

Offer made after the study to continue with open-label levetiracetam therapy as part of long-term follow-up study. Or they could discontinue over 4 weeks followed by a 2 week period without study medication. Maximum duration of study was 34 weeks.

**Comparisons**
Levetiracetam versus placebo.

**Length of Study/ Follow-up**
Could go onto open label follow-up trial; max 34 weeks not reported here.

**Outcome measures studied**
% reduction in GTC seizure frequency from baseline; % reduction in seizure days per week (all seizures) from baseline; responder rates - GTC seizure frequency per week and seizure days per week (all seizures);

**Results**
Responder rates:
ITT analysis; levetiracetam n=80 and placebo n=84.
% of patients demonstrating >=50% reduction in GTC seizure frequency per week between the combined baseline and treatment:57/80 in levetiracetam vs 38/84 in placebo.

Seizure-free:
During the evaluation period the % remaining free of GTC seizures: 27/80 (34.2%) in levetiracetam vs 9/84 (10.7%) in placebo, p< 0.001.

During the titration and evaluation period, % of patients remaining free of all seizures:19/80 in levetiracetam vs 6/84 in placebo, p<0.009.

Incidence of adverse events:
- incidence of nasopharyngitis; 11/80 (13.8%) in levetiracetam and 4/84 (4.8%) in placebo
- incidence of headache; levetiracetam 8/80 (10%) and 10/84 (11.9%) in placebo
- incidence of fatigue; levetiracetam 8/80 (10%) and 7/84 (8.3%) in placebo

QOLIE-31-P questionnaire: completed by 50 patients in levetiracetam group and 60 in the placebo group at end of baseline and by 47 and 56 at end of evaluation period or at early discontinuation.

38.3% reported important improvement in overall QoL since start of study treatment compared to 28.6% of those in the placebo group.

Global evaluation scores improved (investigators and patients): levetiracetam group 29.5% (58/73) and 77.6% (52/67) vs placebo group 57.1% (45/79) and 64 % (48/75).

**Safety and adverse effects**
No evidence of seizure exacerbation found with levetiracetam.

In treatment period (up-titration and evaluation) less patients in the levetiracetam group than placebo experienced a x25% increase in GTC seizure frequency/week 8/79 (10.1%) vs 13/84 (15.5%) and all seizures days/weeks: 6/79 (7.6%) vs 20/84 (23.8%).

One (1.3%) in levetiracetam vs 5 (4.8%) in the placebo group discontinued due to adverse events.

Most common adverse events - incidence:
levetiracetam n=79 vs placebo n=84:

Nasopharyngitis; 11/79 (13.9%) vs 4/84 (4.8%);
The authors concluded that adjunctive levetiracetam is an effective and well-tolerated antiepileptic drug for treating generalised tonic-clonic seizures in patients with idiopathic generalised epilepsies.

**Effect due to factor in study?**
Yes.

**Consistency of results with other studies?**
Yes.

**Directly applicable to guideline population?**
Direct.

**Internal Validity**

Glauser TA; Cnaan A; Shinnar S; Hirtz DG; Dlugos D; Masur D; Clark PO; Capparelli EV; Adamson PC;

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy1

Funding
National Institutes of Health (NS045911, 5 U10 HD037249, 1 UL1 RR026314 and P30 HD26979).

Number of participant
N= 453 children, n ethosuximide=156, n lamotrigine=149, n valproic acid=148 (451 were included in the safety analysis and 446 in the efficacy analysis).

Inclusion/Exclusion Criteria
Inclusion criteria: children between 2.3-13 years who had childhood absence epilepsy of new onset that was clinically diagnosed according to the International League Against Epilepsy classification of epilepsy syndromes (including frequent clinical absence seizures and reported normal development, had bilateral synchronous, symmetric spike waves (2.7 to 5 Hz) on a normal background with at least one electrographically reported seizure lasting 3 seconds or more on a 1-hour, awake video EEG, weighted 10 kg or more, had a body mass index below the 99th percentile, had a normal complete blood count and normal levels of serum alanine aminotransferase, serum aspartate aminotransferase, and bilirubin. The girls had to be premenarchal.

Exclusion criteria: had received antiseizure medication for more than 7 days before randomization, had a history of nonfebrile seizures other than absence seizures (e.g. afebrile generalized tonic-clonic or myoclonic seizures), had a history consistent with juvenile absence epilepsy or juvenile myoclonic epilepsy (e.g. generalized tonic-clonic or myoclonic seizures), had a history of a severe dermatologic reaction to medication, or had a history of major psychiatric disease, autistic-spectrum disorder, or any clinically significant medical condition.

Patient Characteristics
the median age of cohort was 7 years 5 months; 17 (4%) children were under 4 years of age, 184 (41%) were 8 to less than 12 years of age, and 10 (2%) were 12 to 13 years of age. No significant differences were found in the three groups on the following baseline characteristics: gender, ethnicity, race, BMI>90th percentile.

Recruitment
Not reported.

Setting
32 sites across United States.
ethosuximide, valproic acid and lamotrigine as AEDs in childhood absence epilepsy.

1) Ethosuximide versus Lamotrigine
2) Valproic acid versus Ethosuximide
3) Valproic acid versus Lamotrigine

Treatment for 16-20 weeks (end of trial); subjects without seizures at their last follow up visit continued to receive medication in double blind fashion for up to 2 more years.

1) Experience of adverse events (>10%) 2) Attentional dysfunction (for children 4 years or older).

Yes. Ethosuximide is associated with fewer adverse events compared to valproic acid and lamotrigine. Significantly more participants in valproic acid had attentional dysfunction compared to participants in ethosuximide and lamotrigine.

Internal Validity

Interventions/ Test/ Factor being investigated

Comparisons

1) Ethosuximide versus Lamotrigine
2) Valproic acid versus Ethosuximide
3) Valproic acid versus Lamotrigine

Length of Study/ Follow-up

Outcome measures studied

Results

1) Experience of adverse events: fatigue (ethosuximide 15/156 (10%), lamotrigine 13/149 (9%), valproic acid 18/148 (12%), headache (ethosuximide 19/156 (12%), lamotrigine 12/149 (8%), valproic acid 12/148 (8%), sleep problem (ethosuximide 10/156 (6%), lamotrigine 5/149 (3%), valproic acid 14/148 (10%)), nausea, vomiting or both (ethosuximide 23/156 (15%), lamotrigine 2/149 (1%), valproic acid 10/148 (7%)), stomach upset (ethosuximide 16/156 (10%), lamotrigine 4/149 (3%), valproic acid 8/148 (5%), hyperactivity (ethosuximide 14/156 (9%), lamotrigine 10/149 (7%), valproic acid 15/148 (10%)), hostility (ethosuximide 4/156 (3%), lamotrigine 10/149 (7%), valproic acid 18/148 (12%)), personality change (ethosuximide 4/156 (3%), lamotrigine 9/149 (6%), valproic acid 16/148 (11%)).

2) Attentional dysfunction: Secondary analysis in a subgroup of 104 participants in lamotrigine group and 106 in valproic acid group. CPT confidence index=0.60 (ethosuximide 35/106 (33%), lamotrigine 25/104 (24%), valproic acid 52/106 (49%)). Ethosuximide versus Lamotrigine; odds ratio (95% CI) 1.56 (0.85-2.85), P<0.001 Valproic acid versus Ethosuximide; odds ratio (95% CI) 1.95 (1.12-3.41), P=0.03 Valproic acid versus Lamotrigine; odds ratio (95% CI) 3.04 (1.69-5.49), P<0.001

Safety and adverse effects

See results in Q2.

Does the study answer the question?

Yes. Ethosuximide is associated with fewer adverse events compared to valproic acid and lamotrigine. Significantly more participants in valproic acid had attentional dysfunction compared to participants in ethosuximide and lamotrigine.

Effect due to factor in study?

Yes. It is a well conducted double blind RCT with a reasonable sample size for the study to have enough statistical power to estimate the effect.

Consistency of results with other studies?

Direct.

Directly applicable to guideline population?

Direct.
Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison

Ref ID 252 2007 Jun

Study Type Randomised Controlled Trial

Funding Not reported.

Number of participants
- Topiramate n=19;
- Valproate n=9.

Inclusion/Exclusion Criteria

Inclusion criteria:
- adolescents/adults;
- 12-65 years old;
- >/=25kg;
- confirmed diagnosis of juvenile myoclonic epilepsy;
- Diagnostic criteria included myoclonic jerks, seizure onset at 8-26 years of age and coexistent generalised tonic-clonic seizures with generalised epileptiform abnormalities on EEG consistent with JME;
- Have active epilepsy in the form of myoclonus or >/=1 primary generalised tonic-clonic seizure in the 3 months before study entry;
- topiramate or valproate could be initiated as monotherapy as an adjunct to another AED (not topiramate or valproate) that was then withdrawn, as clinically indicated, to achieve topiramate or valproate monotherapy;
- females of child-bearing potential had to be premenopausal, physically incapable of bearing children or practicing an acceptable method of contraception;

Exclusion criteria:
- previous discontinuation of topiramate or valproate due to an adverse event;
- abnormal cranial CT or MRI scan;
- dementia or mental retardation;
- progressive myoclonic epilepsy;
- clinically unstable medical conditions;
- history of nephrolithiasis;
- SCOT and/or SGPT levels greater than 2 times the upper limit of the normal range;
- co-therapy with a carbonic anhydrase inhibitor or barbiturate AED;
- and use of an experimental medication or device within 30 days of study entry.

Patient Characteristics

Topiramate versus valproate:
- Age: 15 (9-42) vs 16 (12-34);
- Gender, female: 13 (68%) vs 4 (445);
- Weight (kg): 66 (32-116) vs 72 (55-109);
- Baseline seizure type:
  - myoclonic 14 (74%) vs 9 (100%);
  - PGTCS 12 (63%) vs 4 (44%);
  - absence 2 (11%) vs 2 (22%);

Baseline AED:
- None 12 (63%) vs 4 (44%);
- Carbamazepine 3 (16%) vs 0;
- Oxcarbazepine 1 (5%) vs 0;
- Phenytoin 1 (5%) vs 2 (22%);
- Lamotrigine 1 (5%) vs 1 (11%);
- Valproate 1 (5%) vs 1 (11%);
- Ethosuximide 0 vs 1 (11%);

Recruitment
- Not reported.

Setting
- Not reported.
Target topiramate dosage was 3-4mg/kg/day (max 9mg/kg/day) for patients 12-16 years old and 200mg/day (maximum 600mg/day) for patients over 16 years of age; Valproate target dosages were 10mg/kg/day in patients 12-16 years of age and 750mg/day in those over 16 years (overall maximum 60mg/kg/day). Topiramate was provided in 25 or 100mg TOPAMAX tablets; valproate was provided as 125, 250 or 500mg depakote tablets;

Topiramate versus valproate.

Comparisons

Topiramate versus sodium valproate.

Not reported.

Length of Study/Follow-up

Reduction in seizures; evaluations of improvement; toxicity and neurotoxicity scores.

Outcome measures studied

Results

Topiramate vs valproate seizure reduction from baseline:

ITT:

Myoclonic:
50% to 75% reduction in seizures: 0 vs 1/9 (11%);
75% to <100% reduction in seizures: 3/14 (21%) vs 1/9 (11%);
100% reduction in seizures: 9/14 (64%) VS 7/9 (78%);

PGTCS:
50% to <75% reduction in seizures: 1/12 (8%) vs 0;
100% reduction in seizures: 10/12 (83%) vs 3/4 (75%);
No seizures in preceding 12 weeks: 8 (42%) vs 4 (44%);

Study completers:

Myoclonic:
50% to <75% reduction in seizures: 0 vs 1/7 (25%);
75 to 100% reduction in seizures: 3/11 (27%) vs 0;
100% reduction in seizures: 7/11 (64%) vs 6/7 (86%);

PGTCS:
50 to <75%: 1/10 (10%) vs 0;
100%: 8/10 (80%) vs 3/4 (75%);
No seizures in preceding 12 weeks: 8 (67%) vs 4 (57%).

Participants withdrawn due to adverse events in topiramate group: 2 (11%) because of inadequate seizure control and 1 (5%) due to patient choice. 2 (11%) of patients were lost to follow-up. One (11%) valproate patient discontinued due to adverse events and one (11%) discontinued for other reasons.

Systemic toxicity were higher in the valproate-treated patients. Neurotoxicity scores did not substantially differ between treatment groups.

Most common adverse events occurring in two or more patients during randomised treatment:

Topiramate vs valproate:

headache: 5/19 (26%) vs 1/9 (11%)
concentration/attention difficulty: 3/19 (16%) vs 1/9 (11%);
fatigue: 2/19 (11%) vs 3/9 (33%);
aloeopia: 2/9 (11%) vs 3/9 (33%);
dizziness: 2/19 (11%) vs 1/9 (11%);
weight loss: 2/19 (11%) vs 0;
paresthesia: 2/19 (11%) vs 0;
psychomotor slowing: 2/19 (11%) vs 0;
somnolence: 2/19 (11%) vs 0;
nausea: 1/19 (5%) vs 3/9 (33%);
weight gain: 0 vs 2/9 (22%);
apetite increase: 0 vs 2/9 (22%);
insomnia: 0 vs 2/9 (22%);
abnormal vision: 0 vs 2/9 (22%).
Author concludes that topiramate may be an effective, well-tolerated alternative to valproate which warrants validation by a double-blind trial.

There is no power calculation and the numbers are small with variations in the groups.

Internal Validity
Variation in the groups by seizure type and number

Marson AG; Appleton R; Baker GA; Chadwick DW; Doughty J; Eaton B; Gamble C; Jacoby A; Shackley P; Smith DF; Tudur-Smith C; Vanoil A; Williamson PR;

A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial

Ref ID 1496

Study Type Randomised Controlled Trial

Funding Commissioned and sponsored by NHS R&D Health Technology Assessment Programme. Also supported by pharmaceutical companies with drugs in the study (approx 20% of the total costs of study).

Number of participant

Arm A: Total n=1721. CBZ n=378; GBP n=377; LTG n=378; OXC n=210; TPM n=378.

Arm B: total n=716. VPA n=239; TPM n=239; VPS n=238.

Inclusion/Exclusion Criteria

Inclusion criteria: History of 2 or more clinically definite unprovoked epileptic seizures in the previous year and if treatment with a single AED represented the best therapeutic option. Patients with newly diagnosed epilepsy, those who had failed previous monotherapy (providing that did not include one of the drugs present in the randomisation) and patients in remission of epilepsy, who had relapsed after a withdrawal of treatment. Exclusion criteria: If patient or clinician felt treatment was contra-indicated, if all seizures had been acute symptomatic seizures (including febrile seizures), they were aged 4 years or younger or if there was a history of progressive neurological disease.

Patient Characteristics

Arm B:
Mean age +/- SD (years): Total: 22.5 +/- 14; LTG 22.8 +/- 14.3; TPM 22.3 +/- 13.3; VPA: 22.5 +/- 14.5.
Gender: male vs female: LTG: 142 (59%) vs 97 (41%); TPM: 142 (59%) vs 97 (41%); VPA: 143 (60%) vs 95 (40%).
Treatment history: untreated: Total 628 (87.7%). LTG 210 (87.9%); TPM 209 (87.5%); VPA 209 (87.8%); monotherapy (not optimally treated): Total 60 (8.4%) LTG 19 (8%); TPM 20 (8.4%); VPA: 1 (8.8%); recent seizures after remission: Total: 28 (3.9%); LTG 10 (4.2%); TPM 10 (4.2%); VPA 8 (3.4%).
Epilepsy syndrome:
- idiopathic partial: Total 3 (0.4%); LTG: 1 (90.4%); TPM 2 (0.8%); VPA: 0 (0%).
- symptomatic or cryptogenic partial: Total 49 (6.9%); LTG 18 (7.5%); TPM 11 (4.6%); VPA 20 (8.4%);
- idiopathic generalised: Total: 450 (62.9%); LTG: 145 (60.7%); TPM 151 (63.5%); VPA 154 (64.7%);
- other syndrome: Total: 22 (3.1%); LTG 9 (3.8%); TPM 8 (3.4%); VPA (2.1%).
- unclassified: Total: 191 (26.7%); LTG 66 (27.6%); TPM 66 (27.7%); VPA 59 (24.8%).

### Recruitment
Patients presenting to participating clinicians were cued for entry if met inclusion criteria.

### Setting
Multicentre study hospital outpatient clinics UK.

### Interventions/ Test/ Factor being investigated
At start of study information was recorded including patient demographics, presence of a history of learning disability or developmental delay, prior neurological history including head injury, stroke, intracerebral infection and acute symptomatic seizures, and a history of epilepsy in a first-degree family member. Clinicians were asked to classify seizures and epilepsy syndromes according to ILAE classifications or at least differentiate between focal or generalised onset seizures. Where there was uncertainty patients were recorded as having unclassified convulsive or other unclassified seizures. Any EEG or brain imaging results at time of randomisation were recorded.

Clinicians involved in the study were asked to choose either CBZ or VPA as the most appropriate treatment for an individual patient. When CBZ was chosen the patient entered arm A and were then allocated to either CBZ, GBP, LTG, OXC, or TPM in ratio of 1:1:1:1:1 (OXC was included in randomisation only after 1st June 2001). If VPA was chosen patients entered arm B and were randomised to either VPA, LTG or TPM in ratio of 1:1:1.

Drug was randomised but drug, dosage and preparation were those used typically by the clinician.

### Comparisons
Two arms. Arm A: carbamazepine versus gabapentin versus lamotrigine versus oxcarbazepine versus topiramate.

Arm B: sodium valproate versus lamotrigine versus topiramate.

### Length of Study/ Follow-up
Follow-up at 3, 6, 12 months and at successively yearly intervals from randomisation. First randomisation was Jan 1999 and continued to randomise until 31st August 2004. Patients were followed up at least until the end of the study (31st August 2005).

### Outcome measures studied
Primary clinical outcomes:
- Time from randomisation to treatment failure.
- Time from randomisation to the achievement of a 1-year period of remission of seizures. Quality of life.

### Results
Arm B:
The following outcomes were calculated on an ITT analysis; withdrawal due to lack of efficacy, withdrawal due to adverse events, incidence of tiredness/drowsiness/fatigue/lethargy (all participants in arm B) and incidence of other adverse events (sorted by descending total frequency: diarrhoea, headache, other neurological, sleep disturbance, tremor, vomiting, word finding difficulty, alopecia, accidental injury, dizziness/vertigo, worsening of seizures, anorexia, hallucinations, other haematological, other renal tract/genital, other skin and appendages, short of breath, vaginal bleeding) (all participants in arm B).

Time to first seizure and time to exit/withdrawal of allocated treatment (IIEG only) was calculated on data from a sample of 441 patients with IGE and no specified type of analysis.

Time to first seizure and time to exit/withdrawal of allocated treatment (entire recruitment period, generalised syndrome only) was calculated on data from a sample of 324 patients with IGE and no specified type of analysis.

**ITT analysis:**
- Withdrawal due to adverse events:
  - 25/239 (10.5%) in LTG, 57/239 (23.8%) in TPM and 35/238 (14.7%) in VPA;
  - Withdrawal due to lack of efficacy:
    - 53/239 (22.2%) in LTG, 28/239 (11.7%) in TPM and 21/238 (8.8%) in VPA;

**HR estimates and 95% CI (IIEG only):**
- time to first seizure: LTG vs VPA: 1.73 (1.32 to 2.26); TPM vs VPA: 1.26 (0.96 to 1.65);
- time to treatment failure: LTG vs VPA: 1.56 (1.08 to 2.25); TPM vs VPA: 1.90 (1.33 to 2.71); p=0.12.

**Time to first seizure - generalised syndromes only for entire recruitment period**

**HR (95% CI) Baseline drug**
- VPA: LTG 0.59 (0.45 too 0.77) TPM 0.80 (0.61 to 1.05)
LTG: VPA 1.69 (1.29 to 2.22)  TPM 1.35 (1.04 to 1.76)
TPM: VPA 1.25 (0.95 to 1.64) LTG 0.74 (0.57 to 0.96)

Time to treatment failure for entire recruitment period (generalised syndrome only):
HR (95% CI): Baseline drug
VPA: LTG 0.65 (0.45 to 0.93) TPM 0.53 (0.37 to 0.76)
VPA: TPM 1.55 (1.07 to 2.24) LTG 0.82 (0.59 to 1.14)
TPM: VPA 1.89 (1.32 to 2.70) LTG 1.22 (0.88 to 1.70)

Incidences of adverse events:
- tiredness/drowsiness/fatigue/lethargy: 25/239 (10.5%) in LTG, 25/239 (10.5%) in TPM, 18/238 (7.6%) in VPA,
- other (sorted by descending total frequency): diarrhoea, headache, other neurological, sleep disturbance, tremor, vomiting, word finding difficulty, alopecia, accidental injury, dizziness/vertigo, worsening of seizures, anorexia, hallucinations, other haematological, other renal tract/genital, other skin and appendages, short of breath, vaginal bleeding: 40/239 (16.7%) in LTG, 40/239 (16.7%) in TPM, 36/238 (15.1%) in VPA

QoL outcomes; QoL questionnaire sent to a sample of 397 patients with IGE. No specified type of analysis.
Two year anxiety scores:
LTG: TPM 0.97 (-0.28 to 2.22) VPA 0.89 (-0.34 to 2.12)
TPM: LTG -0.97 (-2.22 to 0.28) VPA -0.08 (-1.31 to 1.15)
VPA: LTG -0.89 (-2.12 to 0.34) TPM 0.08 (-1.15 to 1.30)

Two year depression scores:
LTG: TPM -0.08 (-1.03 to 0.87) VPA -0.48 (-1.41 to 0.45)
TPM: LTG 0.08 (-0.87 to 1.03) VPA -0.40 (-1.34 to 0.54)
VPA: LTG 0.48 (-0.45 to 1.41) TPM 0.40 (-0.54 to 1.34)

Two year AEP scores:
LTG: TPM 0.75 (-2.56 to 4.06) VPA 0.73 (-2.52 to 3.98)
TPM: LTG -0.93 (-3.29 to 5.14) VPA -0.37 to 2.00)
VPA: LTG -0.73 (-3.98 to 2.52) TPM 0.02 (-3.26 to 3.29)

Two year neurotoxicity scale score:
LTG: TPM -0.93 (-5.14 to 3.29) VPA -1.29 (-5.34 to 2.75)
TPM: LTG 0.93 (-3.29 to 5.14) VPA -0.37 (-4.48 to 3.75)
VPA: LTG 1.29 (-2.75 to 5.34) TPM 0.37 (-3.75 to 4.48)

Two year EQ-5D scores:
LTG: TPM -0.02 (-0.08 to 0.04) VPA 0.02 (-0.04 to 0.08)
TPM: LTG 0.02 (-0.04 to 0.08) VPA 0.04 (-0.02 to 0.10)
VPA: LTG 1.29 (-2.75 to 5.34) TPM 0.37 (-3.75 to 4.48)

Two year anxiety scores - ordinal
LTG: TPM 1.62 (0.71 to 3.72) VPA 1.40 (0.64 to 3.10)
TPM: LTG 0.62 (0.27 to 1.42) VPA 0.87 (0.37 to 2.00)
VPA: LTG 0.71 (0.32 to 1.58) TPM 1.16 (0.50 to 2.68)

Two year depression scores - ordinal
LTG: TPM 1.02 (0.38 to 2.78) VPA 0.82 (0.33 to 2.07)
TPM: LTG 0.98 (0.36 to 2.67) VPA 0.81 (0.31 to 2.09)
VPA: LTG 1.22 (0.48 to 3.08) TPM 1.24 (0.48 to 3.23)

Two year GQoL scores:
LTG: TPM 1.24 (0.66 to 2.34) VPA 1.17 (0.64 to 2.16)
TPM: LTG 0.81 (0.43 to 1.53) VPA 0.95 (0.51 to 1.77)
VPA: LTG 0.85 (0.46 to 1.57) TPM 1.06 (0.57 to 1.97)

Analysis of generalised epilepsy (data not published yet):
HRs (95% CI) for relative treatment effects:
Time to 12-month remission  Time to treatment failure  Time to 1st seizure
LTG: VPA Absence: 0.74 (0.43, 1.26) 1.66 (0.75, 3.66) 1.63 (0.98, 2.72)
LTG: VPA TC on waking: 0.88 (0.44, 1.74) 1.14 (0.39, 3.35) 2.27 (0.95,
Yes. The authors concluded: There is a statistically significant difference between drugs for time to treatment failure ... there was only one significant result which favoured valproate over topiramate in the treatment of absence seizures.

**Safety and adverse effects**

37% (LTG), 45% (TPM), 36% (VPA) patients reported at least one adverse event at some point in the study (ITT).

Incidence of adverse events (10% or over):
- LTG: VPA Other: 0.62 (0.39, 0.99)
- TPM: VPA Absence: 1.02 (0.61, 1.72)
- TPM: VPA TC on waking: 0.81 (0.41, 1.57)
- TPM: VPA Other: 0.67 (0.43, 1.05)

n.b Time to 12-month remission HR<1 implies valproate favoured, time to treatment failure and time to 1st seizure HR>1 implies valproate favoured.

**Does the study answer the question?**

Yes. The authors concluded: There is a statistically significant difference between drugs for time to treatment failure for any reason and VPA is best option. Pair wise comparisons show it is statistically superior to topiramate which is the least favoured option and lamotrigine is intermediate.

Cumulative risk analysis of withdrawal for UAEs and ISC indicates that LTG is least likely to be associated with UAEs and TPM most likely. HRs for TPM indicate that it is statistically inferior to both VPA and LTG for failure due to UAEs. However LTG is most likely to be associated with treatment failure due to ISC, with VPA least likely. LTG HRs indicate it is twice as likely to fail because of ISC than VPS which is significant.

Also that when analyses were restricted to those who were identified as having a generalised epilepsy syndrome, VPA is is markedly more superior for time to treatment failure. It is significantly superior to TPM and LTG for the outcome.

For time to first seizure the drugs differ with VPA being the preferred option, LTG the worst and TPM intermediate between the two but significantly superior to LTG. The differences appear larger for patients with definite generalised epilepsy than for all patients randomised to arm B of the study.

In the generalised epilepsy analysis (unpublished) there was only one significant result which favoured valproate over topiramate in the treatment of absence seizures.

**Effect due to factor in study?**

Wanted to establish an overall response rate of 70% for both outcomes at a median of 2.5 years of follow-up with power of 90% would require 445 patients for each treatment group.

**Consistency of results with other studies?**

Wanted to establish an overall response rate of 70% for both outcomes at a median of 2.5 years of follow-up with power of 90% would require 445 patients for each treatment group.

The population had a lot of unclassified seizure type so not all of the population had idiopathic generalised epilepsy.

**Internal Validity**

**Question:** How effective and cost-effective are anti-epileptic drugs for absence seizures
Lamictal (lamotrigine) monotherapy for typical absence seizures in children. [see comment]

**Patient Characteristics**

- **Inclusion/Exclusion Criteria**
  - **Inclusion:** aged 2 to 16 years old, newly diagnosed TASs (evidenced by the clinical and EEG features of TAS on one of two 3 minute hyperventilation tests), women of reproductive capability required to use contraception and provide a statement stating avoiding pregnancy
  - **Exclusion:** known or suspected structural lesion, history of poor compliance with medication, abuse of drugs, progressive neurologic illness, psychiatric disorder requiring medication, chronic cardiovascular, renal or hepatic disease, use of an investigational drug in previous 12 weeks, any disease thought to interfere with absorption, distribution, metabolism or excretion of drugs in general. Taking drugs other than methylphenidate, dexamphetamine or clonidine to treat ADHD

- **Setting**
  - USA

- **Interventions/ Test/ Factor being investigated**
  - Lamotrigine

- **Comparisons**
  - Lamotrigine versus placebo

- **Length of Study/ Follow-up**
  - Not reported

- **Outcome measures studied**
  - Seizure free, side effects

- **Results**
  - 48 out of 64 patients became seizure free (18 of which had the maximal dose of 15 mg/kg/day.
  - 17 patients reported adverse events; there were 5 reports of abdominal pain, 10 patients had skin rash (11 reports). No children withdrew due to side effects. 5 patients had clinically significant changes post treatment neurologic examination (1 – nystagmus, 1 – depression).

- **Safety and adverse effects**
  - 17 patients reported adverse events; there were 5 reports of abdominal pain, 10 patients had skin rash (11 reports). No children withdrew due to side effects. 5 patients had clinically significant changes post treatment neurologic examination (1 – nystagmus, 1 – depression).

- **Does the study answer the question?**
  - Lamotrigine monotherapy was a very effective treatment for children with newly diagnosed typical absence seizures. These results confirm previous and subsequent experience with lamotrigine in such patients.

- **Effect due to factor in study?**
  - Yes. Power calculation: needed a sample size of 13 per treatment group to give a power of 0.869. Their sample size was over this. Methodology good except for no details of allocation concealment.
Valproic acid versus ethosuximide in the treatment of absence seizures

Patient Characteristics

<table>
<thead>
<tr>
<th>Interventions/Test/Factor being investigated</th>
<th>Comparisons</th>
<th>Length of Study/Follow-up</th>
<th>Outcome measures studied</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding NINCDS- National institute of neurological and communicative disorders and stroke.</td>
<td>45 in total. 16 drug naïve patients. 29 refractory patients. Group I: VPA: 10 (2 drug naïve, 8 refractory); ESM: 13 (4 drug naïve, 8 refractory). Group II: VPA: 12 (5 drug naïve, 7 refractory); ESM: 10 (5 drug naïve, 5 refractory). Crossover of non-responders: Group I: VPA: 7 (1 drug naïve, 6 refractory); ESM: 8 (2 drug naïve, 6 refractory). Group II: VPA: 7 (1 drug naïve, 6 refractory); ESM: 7 (3 drug naïve, 4 refractory)</td>
<td>Not reported.</td>
<td>In previously untreated patients: seizure free, side effects. In refractory patients: patients who had an 80% reduction in number of seizures. Group 1: VPA started on a daily dose of 15 to 20 mg/kg, 5 days later this was increased to a maximum of 30 mg/kg if 12 hour telemetered EEG showed generalised spike wave discharges. ESM started on a daily dose of 250-1500 mg. Group 2: VPA started on a daily dose of 12.5 to 20 mg/kg, increasing every 2 days for 2 weeks to a maximum of 60 mg/kg. ESM started on a daily dose of 250-1500 mg. Patients were initially in hospital for the first 10 days and were then followed every 2 weeks for each drug. The patients were split into two groups within the treatment groups, those who were previously untreated with anti-absence drugs and those who were not responsive to the currently available anti-absence drugs. Patients who did not respond to the first drug or who has serious adverse effects crossed over to the second drug.</td>
<td></td>
</tr>
</tbody>
</table>
Seizure free: 
6 out of 7 patients who received VPA first became seizure free. 4 out of 9 patients who received ESM first became seizure free. 
3 out of 5 patients who received VPA second became seizure free. 2 out of 2 patients who received ESM second became seizure free.

Side effects 
Nausea was reported in 5 out of 12 patients in VPA group and in 3 out of 11 patients in the ESM group. 
Vomiting was reported in 1 out of 12 patients in VPA group and in 3 out of 11 patients in the ESM group. 
Drowsiness was reported in 4 out of 12 patients in VPA group and in 5 out of 11 patients in the ESM group. 
Headache was reported in 1 out of 12 patients in VPA group and in 2 out of 11 patients in the ESM group. 
Leukopenia was reported in 2 out of 12 patients in VPA group and in 3 out of 11 patients in the ESM group. 
Thrombocytopenia was reported in 2 out of 12 patients in VPA group and in 0 out of 11 patients in the ESM group.

Refractory patients: 
80% response: 
3 out of 15 patients who received VPA first had an 80% response rate. 4 out of 14 patients who received ESM first had an 80% response rate. 
2 out of 10 patients who received VPA second had an 80% response rate. 5 out of 12 patients who received ESM second had an 80% response rate.

Safety and adverse effects 
Nausea, vomiting, drowsiness, headache, leukopenia, and thrombocytopenia in previously untreated patients (see results). 

Does the study answer the question? 
The authors discuss that it is difficult to isolate the efficacy of VPA in refractory patients who were taking ESM and other medications. This was supported by the fact that naïve patients showed a statistically significant response to VPA treatment (9 became completely seizure free and 3 did not), whereas refractory patients showed a rather complex response pattern without a statistically significant correlation between EEG findings and VPA treatment.

Effect due to factor in study? 
No. No power calculation given. Methodology very confusing. They have two groups receiving the same drugs but one at slightly different starting dosage for no apparent reason. Also split up patients by drug naïve/refractory, by comparison, and then by the crossover. Methodology poor.

Consistency of results with other studies? 
Direct.

Directly applicable to guideline population? 
Direct.

Internal Validity 

Question: How effective and cost-effective are anti-epileptic drugs for myoclonic seizures
The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults

Ref ID 4668 2005

Study Type Randomised Controlled Trial  
Funding Sponsored by GSK.

Number of participants  
Focal Epilepsy group (FE)  
CBZ n=88  
LTG n=88  
Generalised Epilepsy Group (GE)  
VPA n=30  
LTG n=33

Inclusion/Exclusion Criteria  
Adolescents and adults aged ≥ 12 years. Seizure classification, EEG data, age at onset of the disease and syndrome classification were anonymously sent to one of the investigators, who if agreed with the syndrome classification would allow patients to continue. Three different epilepsy syndromes (juvenile absence epilepsy, juvenile myoclonic epilepsy, epilepsy with generalised tonic-clonic seizures on awakening) were included.

Patient Characteristics  
Mean ages (SD):  
FE group CBZ 43.1 ± 17.3; LTG 46.6 ± 18.8  
GE group LTG 22.3 ± 13.0; VPA 23.3 ± 10.7

Recruitment Not reported.

Setting Germany. Secondary Care

Interventions/ Test/ Factor being investigated  
LTG versus CBZ or VPA in newly diagnosed focal and generalised epilepsies.

Comparisons LTG versus CBZ or VPA.

Length of Study/ Follow-up 24-26 weeks.

Outcome measures studied  
percentage of seizure-free patients between weeks 17 and 24 was the primary efficacy outcome. Overall retention rates based on lack of efficacy or adverse events, adverse events and tolerability.

Results  
FE group  
Between treatment weeks 17 and 24, 94.3% of the CBZ patients (83/88) and 88.6% of the LTG patients (78/88) were seizure-free during that last period of study.

Excluding the titration phase patients, the number of patients who stayed seizure-free during the whole study period without seizures during the titration phase was 73 (81.8%) with CBZ and 62 (70.5%) with LTG. The difference between CBZ and LTG was not significant.

GE group (not extracted as we cannot tell which subtype or syndrome). Subgroup of patients with myoclonic seizures: 10 patients in the LTG group (30.3%) and 4 patients in the VPA group (13.3%). Among these patients 3/10 (30%) became seizure free while on LTG and 3/4 (75%) became seizure-free on VPA. No statistical data was given, but difference between VPA and LTG was not significant.

Withdrawal due to lack of efficacy  
CBZ (FE group) n=0  
LTG (FE group) n=1  
LTG (GE group) n=2
Safety and adverse effects

VPA (GE group) n=0

Withdrawal due to AE:
CBZ (FE group) n=17
LTG (FE group) n=7
LTG (GE group) n=2
VPA (GE group) n=1

Adverse Events:
CBZ (FE group) (n=88)
Fatigue 38 (43.2%)
Amnesia 9 (10.2%)
Pruritus 9 (10.2%)

LTG (FE group) (n=88)
Fatigue 13 (14.8%)

LTG (GE group ) (n=33)
Erythematous rash 4 (12.1%)

LTG (both groups) (n=121)
Fatigue 16 (13.2%)

Valproate (GE group) (n=30)
Increased appetite 7 (23.3%)
Fatigue 5 (16.7%)
Weight Increase 5 (16.7%)

Does the study answer the question?

Reports on the effectiveness of LTG in a FE and GE group.

Effect due to factor in study?

No blinding. No clear inclusion/exclusion criteria, unclear risk of bias in this study.

Consistency of results with other studies?

Population was partially direct, as the GE group results were mainly amalgamated. Intervention direct to the question.

Directly applicable to guideline population?


Question: How effective and cost-effective are anti-epileptic drugs for (primary) generalised tonic-clonic seizures
Grading: 1+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy

Ref ID 4726 1997

Study Type Randomised Controlled Trial  Funding International Adult Oxcarbazepine/Phenytoin Trial Group and Novartis Pharma

Number of participant 287 total: 143 to OXC and 144 to PHT

Inclusion/Exclusion Criteria
Inclusion: Ages 16-65 years with newly diagnosed epilepsy with two seizures separated by at least 48 hours within 6 months before trial
Exclusion: No AED drug except for emergency treatment; Pregnancy risk, status, psychiatric illness or mental retardation, progressive neurological disorder, alcoholism, drug abuse or significant organic disease.

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>OXC (n=143)</th>
<th>PHT (n=144)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean; range)</td>
<td>27.1(16-63)yrs</td>
<td>26.6(15-91)yrs</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>82/61</td>
<td>92/52</td>
</tr>
<tr>
<td>Race (Cauc/B/Other)</td>
<td>72/22/49</td>
<td>68/23/53</td>
</tr>
<tr>
<td>Body wt.</td>
<td>63.6 (41-104)kg</td>
<td>64.9 (43-101)kg</td>
</tr>
</tbody>
</table>

Recruitment Unknown

Setting Argentina, Brazil, Mexico and South Africa

Interventions/ Test/ Factor being investigated Use of oxcarbazepine vs. phenytoin as monotherapy in newly diagnosed epilepsy patients

Comparisons oxcarbazepine vs. phenytoin

Length of Study/ Follow-up A flexible titration period of 8 weeks followed by 48 weeks of maintenance treatment

Outcome measures studied The primary efficacy variable was the proportion of seizure free patients who had at least one seizure assessment during the maintenance period.
Secondary outcomes: Treatment group differences in time and rate of premature discontinuation

Results

<table>
<thead>
<tr>
<th></th>
<th>OXC (n=118)</th>
<th>PHT (n=119)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure frequency per week: Mean/median</td>
<td>0.08/0</td>
<td>0.06/0</td>
<td>p=0.72</td>
</tr>
<tr>
<td>Total number of seizures mean/median</td>
<td>3.57/0</td>
<td>2.13/0</td>
<td></td>
</tr>
<tr>
<td>Number of patients with:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No seizures</td>
<td>70</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>1 seizure</td>
<td>17</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>2-15 seizures</td>
<td>26</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>16-50 seizures</td>
<td>3</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>More than 50 seizures</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Five patients receiving OXC and 16 patients receiving PHT treatment were withdrawn due to adverse experiences. There was a statistically significant difference between groups in favour of the OXC treatment (p=0.02). There was no significant treatment difference due to premature discontinuations (p=0.63). Physicians and patients’ overall assessment of tolerability on a 4 point scale, favoured the OXC treatment (p=0.032 for physicians and p=0.026 for patients).
Safety and adverse effects
5 patients in the OXC group and 16 in the PHT group discontinued for tolerability reasons. The most common side effects were somnolence, headache, dizziness, nausea, rash.

Does the study answer the question?
This trial provides support for the efficacy and safety of OXC as first line treatment in adults with PS

Effect due to factor in study?
Yes

Consistency of results with other studies?
See GRADE

Directly applicable to guideline population?
See GRADE

Internal Validity
Small sample size and high dropout rate

Biton V; Sackellares JC; Vuong A; Hammer AE; Barrett PS; Messenheimer JA;
Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures
Ref ID 457 2005 Dec 13

Study Type
Randomised Controlled Trial

Funding
Funded by GlaxoSmithKline, manufacturer of Lamotrigine

Number of participant
184 entered into baseline phase
Lamotrigine: 58 entered the escalation phase
Placebo: 59 entered escalation phase

Inclusion/Exclusion Criteria
Inclusion criteria: At least 2yrs of age, weighing at least 13Kg, diagnosis of epilepsy with PGTC seizures (classified by the International Classification of Seizures), history of PGTC seizures with no focal onset, at least 3 PGTC seizures during the 8 week baseline study phase and at least 1 PCGT seizure in each 4 week period of the baseline phase, and receiving 1 or 2 antiepileptic drugs at a stable dose for at least 4 weeks before screening.
Exclusion criteria: History of partial seizures or ictal expression of partial seizures as revealed by EEG. Diagnosis of Lennox-Gastaut syndrome; use of any investigational drug within 30 days of study entry or previous exposure to lamotrigine; pregnancy, breastfeeding, attempting to become pregnant or being capable of bearing children but not using acceptable contraception; following the ketogenic diet; presence of a disease or condition that could interfere with the study conduct; abuse of alcohol or other substances; chronic treatment with medication that could influence seizure control; or planned vagal nerve stimulation or surgery to control seizures during the study.
(No further details or definitions provided).

Patient Characteristics
Lamotrigine vs Placebo:
Mean age: 26.9 vs. 24.9 years
Age range: 2 to 53 vs. 2 - 55 years
Female: n=29 (50%) vs. n=26 (44%)
Race: White 57% vs. 47%, Black 16% vs. 17%, Hispanic 28% vs. 36%
Age stratum: 2 to 12 yrs 21% vs. 19%, >12 yrs 79% vs. 81%
Mean age at first seizure: 11.9 vs. 12.1
Median number of all seizures per month: 2.3 vs. 3.0
Seizure classification*: tonic-clonic 100% vs 100%, absence 31% vs. 34%, myoclonic 29% vs. 27%, Other (clonic, tonic, atonic, unclassified) 15% vs. 17%
* a patient could have more than one generalised seizure type. Myoclonic seizures were counted as days of myoclonus.
Antiepileptic regimen at study entry: included valproate 43% vs. 47%, included an enzyme-inducing antiepileptic drug 47% vs. 41%, included another anticonvulsant 10% vs. 12%
No. of antiepileptic drugs at study entry: one drug 50% vs. 59%, two drugs 50% vs. 41%

Recruitment
Not reported.
### Study

Study comprised a baseline phase, an escalation phase during which study lamotrigine/placebo were titrated to a target dose and a maintenance phase where doses of lamotrigine/placebo and concomitant antiepileptic drugs were maintained.

### Comparisons

Comparison between treatment (lamotrigine) and placebo

### Length of Study/Follow-up

Not reported.

### Outcome measures studied

Seizure frequency: \( \geq 25\% \) reduction, \( \geq 50\% \) reduction, \( \geq 75\% \) reduction

### Results

**Primary outcomes:**

Seizure frequency:

- Median seizure counts during the baseline phase did not differ between the lamotrigine and placebo group for PGTC seizure (\( p=0.325 \)) or for all generalised seizures (\( p=0.297 \)).

- Significantly larger median reductions in seizure frequency occurred during the escalation phase, the maintenance phase and the escalation and maintenance phases combined for PGTC seizures and all seizures in patients treated with lamotrigine compared to placebo (\( p<0.05 \)).

- During the combined escalation and maintenance phases, median reduction in seizure frequency was 66.5% with lamotrigine compared to 34.2% with placebo (\( p=0.006 \)) for PGTC seizures, and 46.8% with lamotrigine compared to 15.9% with placebo for all generalised seizures (\( p=0.04 \)).

- During the maintenance phase and the escalation and maintenance phase combined, significantly more patients in the lamotrigine group compared to the placebo group experienced greater than or equal to a 75% and 50% reduction from the baseline phase in frequency of PGTC seizures (\( p<0.05 \)).

- Significantly more patients in the lamotrigine compared to the placebo group experienced greater than or equal to a 50% reduction in all generalised seizures in the maintenance phase and greater than 75% reduction in all generalised seizures in the maintenance phase and maintenance and escalation phases combined, from the baseline phase (\( p<0.05 \)).

**Lamotrigine versus placebo:**

\( \geq 50\% \) reduction in the frequency of PGTC seizures:

- maintenance phase: 42/58 (72.4%) vs 29/59 (49.2%), \( p<0.05 \);
- escalation + maintenance phase: 37/58 (63.8%) vs 23/59 (39%), \( p<0.05 \);

**Safety and adverse effects**

Potential deterioration of control of other seizures, but authors report that there was no evidence of this.

**Tolerability:** adverse events were reported in the double-blind period in 22% of patients in the lamotrigine group and 10% of patients in the placebo group - none of these were over 10% for any one adverse event.

### Does the study answer the question?

Yes. Authors conclude that adjunctive lamotrigine is effective at controlling PGTC seizures and all generalised seizures and the efficacy profile of lamotrigine makes it an appropriate therapeutic option when it is not possible to determine whether a patient having generalised seizures has idiopathic or focal epilepsy.

### Effect due to factor in study?

Authors report that a sample size of 104 patients was determined to provide 80% power to detect a difference between lamotrigine and placebo of 25% in the median percent reduction from baseline in the PGTC seizures at a significance level of 0.05 and an estimated SD of 45%.

The results are more favourable for adults, but the sample sizes for 2 to 12 year olds were too small to permit definite conclusions.
Consistency of results with other studies? Yes.

Directly applicable to guideline population? Direct.

Internal Validity Allocation concealment not reported

Callaghan N; Kenny RA; O'Neill B; Crowley M; Goggin T;

A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy

Ref ID 4629

Study Type Randomised Controlled Trial

Funding Supported by grants from Labaz, Geigy and Warner-Lambert.

Number of participant 181 recruited. 102 had generalised seizures, 79 had partial seizures. Generalised tonic clonic seizures: 28 in the carbamazepine group; 37 in the phenytoin group; 37 in the valproate group.

Inclusion/Exclusion Criteria

Inclusion criteria:
- Previously untreated;
- Recently diagnosed;
- General or partial seizures;
- Minimum of 2 seizures over six months period before referral for assessment;

Patient Characteristics

Patients with generalised tonic clonic seizures (without focal features):

Carbamazepine vs phenytoin vs valproate:
- Sex: male: 13 vs 21 vs 20; female: 15 vs 16 vs 17;
- Age (year) range (mean): 4-72 (26) vs 7-69 (26) vs 5-71 (23);
- Duration of seizures prior to treatment months range (median): 0-132 (18) vs 3-156 (9) vs 0-120 (9);
- Duration of treatment months range (median): 3-44 (15) vs 3-42 (18) vs 3-44 (24);
- Total no. of seizures since the onset of attacks range (median): 2-1277 (4) vs 2-900 vs 2-720 (3).

Patients with partial seizures with or without secondary generalised attacks:

Carbamazepine vs phenytoin vs valproate:
- Sex: male: 15 vs 12 vs 14; female: 16 vs 9 vs 13;
- Age (yr) range (mean): 8-75 (28) vs 7-64 vs 6-68 (25);
- Duration prior to treatment months range (median): 0-180 (12) vs 6-168 (24) vs 3-36 (12);
- Duration of treatment months range (median): 3-42 (14) vs 3-47 (24) vs 3-48 (24);
- Total no. of seizures since the onset of attacks range (median): 2-1095 (6) vs 3-300 (6) vs 2-732 (26).

Recruitment Not reported.

Setting Cork, Ireland.

Interventions/ Test/ Factor being investigated

Assessments at seizure clinic of response to treatment and side effects documented and sample of blood taken to estimate serum AED levels.

The participants were instructed to take the drug twice daily. If they did not respond to the first preference of drug the dose of that drug was decreased by 200mg decrements of sodium valproate and carbamazepine and by 100mg phenytoin at two weekly intervals and then second preference drug was allocated from randomisation list.

CBZ was prescribed in a dosage of 600mg daily for adults and 5-10mg/kg body weight for children; phenytoin in a dosage of 300mg daily for adults and 5-10mg/kg
body weight for children; sodium valporate in a dose of 600mg daily for adults and 5-10mg/kg body weight for children.

**Comparisons**

Carbamazepine versus phenytoin vs sodium valproate.

**Length of Study/Follow-up**

Patients are seen at one month after prescription then intervals of one to three months, depending on how they responded to treatment.

Follow up ranged from 3 to 9 weeks.

**Outcome measures studied**

Response to treatment: excellent control - complete freedom from seizures; good control - greater than 50% reduction in seizure frequency; poor control no response or less than 50% reduction in seizure frequency.

**Results**

Response in patients with generalised seizures:

Phenytoin vs carbamazepine vs valproate: Control (number (%)):

Excellent control (complete freedom from seizures): 27 (73%) vs 11 (39%) vs 22 (59%). Total 60 (59%).
Good control (greater than 50% reduction in seizure frequency): 3 (8%) vs 10 (36%) vs 7 (19%). Total 20 (20%).
Poor control (no response or less than 50% reduction in seizure frequency): 7 (19%) vs 7 (25%) vs 8 (22%). Total 22 (21%).
Phenytoin vs carbamazepine - excellent control, p<0.01.

Overall patients with primary generalised attacks: 71% achieved excellent or good control.

Overall response in patients with partial seizures with or without secondary generalised attacks:

Phenytoin vs carbamazepine vs valproate: Control (number (%)):

Excellent control: 12 (57.1%) vs 11 (33.5%) vs 12 (44.4%). Total 35 (44.3%).
Good control: 4 (19%) vs 12 (38.7%) vs 9 (33.3%). Total 25 (31.6%).
Poor control: 5 (23.8%) vs 8 (25.8%) vs 6 (22.2%). Total 19 (24%).
[partial also subdivided for partial complex and simple partial].

When compared response in patients with generalised seizures and those with partial seizures, with or without secondary generalised attacks, the overall response was better in patients with generalised seizures (p<0.05).

Withdrawal of treatment: 26 patients, 8 taking carbamazepine, 7 valproate and 11 phenytoin. 4 relapsed, 1 taking carbamazepine, 2 taking phenytoin and one taking sodium valproate. Not mentioned whether these were generalised or partial seizure types.

Safety and adverse effects

12 patients dropped out. 10 with generalised seizures and 2 with partial seizures.

Of these 5 with generalised took phenytoin, 3 carbamazepine and 2 sodium valproate.

One with partial seizures was taking phenytoin, one carbamazepine.

Does the study answer the question?

Yes.

Authors conclusion was that sodium valproate, carbamazepine and phenytoin are effective in the control of generalised and partial seizures, and that all three drugs can be prescribed as anti-convulsant of first choice. Irrespective of the drug prescribed, partial seizures were less responsive to treatment.

Effect due to factor in study?

Unsure as no blinding and no power calculation given.

Consistency of results with other studies?

Yes.
No blinding; 

A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy 

Ref ID 4770  

Number of participant 249 in total, 128 in oxcarbazepine, 121 in sodium valporate  

Inclusion/Exclusion Criteria 

Inclusion: aged 15 to 65 years, newly diagnosed epilepsy with PS or GTCS, at least 2 seizures at least 48 hours apart in previous 6 months, no previous AED except for emergency treatment in previous 3 weeks  
Exclusion: pregnancy or risk of becoming pregnant, history of status epilepticus, severe psychiatric illness or severe mental retardation, progressive neurological disorder, alcoholism or drug abuse, significant other organic disease  

Patient Characteristics 

In the oxcarbazepine group the mean age was 32.45 years (range 15 to 65 years), 60 out of 128 were male. The mean weight was 69.9 kg (range 42 to 119 kg). 76 patients had partial seizures with or without secondary generalised seizures and 52 had generalised seizures without partial onset. 

In the sodium valporate group the mean age was 32.47 years (range 15 to 64 years), 67 out of 121 were male. The mean weight was 70.2 kg (range 44 to 115 kg). 78 patients had partial seizures with or without secondary generalised seizures and 43 had generalised seizures without partial onset.  

Setting europe, brazil, south africa  

Interventions/ Test/ Factor being investigated 

300mg oxcarbazepine  

Comparisons 300 mg sodium valporate  

Length of Study/ Follow-up No follow up reported  

Outcome measures studied Number of patients who were seizure free, side effects, withdrawal  

Results 

The trial was conducted in Belgium, Brazil, France, Germany, Netherlands, South Africa, Spain, UK  

The trial was split into two periods, an 8 week titration and 48 week maintenance period. No concomitant AEDs were allowed. 
During the titration period patients received 300 mg oxcarbazepine or sodium valporate, this was gradually increased depending upon response, there was no fixed titration schedule. After 8 weeks patients were on daily doses of 900 to 2400 mg oxcarbazepine or sodium valporate, this dose was continued for the maintenance period. However this dose could be changed according to response.  

214 patients reached the maintenance period, of theses 212 had at least 1 seizure assessment during the maintenance period and were therefore included in the results  

Number of patients who were seizure free: 
In the oxcarbazepine group 60 out of 106 were seizure free compared to 57 out of 106 in the sodium valporate group  

In the oxcarbazepine group 46% of patients with partial seizures (with or without secondary generalised seizures) were seizure free compared to 48% of patients with partial seizures (with or without secondary generalised seizures) in the sodium valporate group.
In the oxcarbazepine group 72% of patients with generalised seizures (without partial onset) were seizure free compared to 62% of patients with generalised seizures (without partial onset) in the sodium valporate group.

Withdrawal:
A total of 52 patients in the oxcarbazepine group withdrew compared to 41 in the sodium valporate group. In the oxcarbazepine group 15 patients withdrew due to adverse events compared to 10 in the sodium valporate group.

In the oxcarbazepine group 6 withdrew due to allergic reaction, 1 due to pregnancy, 1 due to nausea, 1 due to drowsiness, 5 due to other adverse experiences, 14 due to non-compliance, 6 due to unsatisfactory therapeutic effect, 4 due to lost to follow up, 7 due to protocol violation, 3 due to administrative reasons, 2 due to concomitant illness and 1 due to death.

In the sodium valporate group 4 withdrew due to hair loss, 2 due to pregnancy, 2 due to nausea, 5 due to other adverse experiences, 7 due to non-compliance, 6 due to unsatisfactory therapeutic effect, 7 due to lost to follow up, 3 due to protocol violation, 5 due to administrative reasons, 2 due to concomitant illness, and 1 due to abnormal laboratory results.

Side effects:
In the oxcarbazepine group 115 out of 128 had at least 1 adverse event compared to 106 out of 121 in the sodium valporate group.

In the oxcarbazepine group 115 out of 128 had at least 1 adverse event compared to 106 out of 121 in the sodium valporate group. In the oxcarbazepine group 15 patients withdrew due to adverse events compared to 10 in the sodium valporate group.

Safety and adverse effects

Does the study answer the question?
There was no significant difference in the number of patients becoming seizure free, withdrew or had at least 1 adverse event between the oxcarbazepine group and the sodium valporate group.

Effect due to factor in study?

Consistency of results with other studies?

Directly applicable to guideline population?

Internal Validity

Guerreiro MM; Vigonius U; Pohlmann H; de M; Fejerman N; Antoniuk SA; Moore A;

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy

Ref ID 4615 1997

Study Type Randomised Controlled Trial Funding None reported

Number of participant 193 in total, 97 in oxcarbazepine, 96 in phenytoin

Inclusion/Exclusion Criteria

Inclusion: aged 5 to 18 years, newly diagnosed epilepsy with PS or GTCS, at least 2 seizures at least 48 hours apart in previous 6 months, no previous AED except for emergency treatment in previous 3 weeks

Exclusion: pregnancy or risk of becoming pregnant, history of status epilepticus, severe psychiatric illness or severe mental retardation, progressive neurological disorder, alcoholism or drug abuse, significant other organic disease

Patient Characteristics

In the oxcarbazepine group the mean age was 10.22 years (range 5 to 17 years), 41 out of 97 were male, 80 were Caucasian, 11 were black, 6 were of other race. The mean weight was 36.4 kg (range 16 to 72 kg). 73 patients had partial seizures with or without secondary generalised seizures, 22 had generalised seizures without partial onset and 2 had no main type of seizure. 18 patients had localization-related idiopathic syndrome, 7 had localization-related symptomatic syndrome, 46 had localization-related cryptogenic syndrome, 11 had generalised idiopathic syndrome, 6
had generalised cryptogenic or symptomatic syndrome, 2 had had generalised symptomatic syndrome, 6 had other syndromes and 1 was not classified.

In the phenytoin group the mean age was 10.85 years (range 6 to 17 years), 50 out of 96 were male, 80 were Caucasian, 6 were black, 10 were of other race. The mean weight was 40.7 kg (range 21 to 96 kg). 78 patients had partial seizures with or without secondary generalised seizures, 17 had generalised seizures without partial onset and 1 had no main type of seizure. 20 patients had localization-related idiopathic syndrome, 5 had localization-related symptomatic syndrome, 50 had localisation-related cryptogenic syndrome, 11 had generalised idiopathic syndrome, 5 had generalised cryptogenic or symptomatic syndrome, 1 had had generalised symptomatic syndrome, and 4 had other syndromes.

Recruitment
Between 1991 and first quarter 1995

Setting
Brazil and Argentina

Interventions/ Test/ Factor being investigated
300mg oxcarbazepine

Comparisons
100 mg phenytoin

Length of Study/ Follow-up
No follow up reported

Outcome measures studied
Number of patients who were seizure free, side effects, withdrawal

Results
The trial was split into two periods, an 8 week titration and 48 week maintenance period. No concomitant AEDs were allowed.

During the titration period patients received 150 mg oxcarbazepine or 50 mg phenytoin, this was gradually increased depending upon response, there was no fixed titration schedule. After 8 weeks patients were on daily doses of 450 to 2400 mg oxcarbazepine or 150 to 800 mg phenytoin, this dose was continued for the maintenance period. However this dose could be changed according to response.

161 patients reached the maintenance period, of these 158 had at least 1 seizure assessment during the maintenance period and were therefore included in the results

Number of patients who were seizure free:
In the oxcarbazepine group 49 out of 81 were seizure free compared to 46 out of 77 in the phenytoin group

In the oxcarbazepine group 60% of patients with partial seizures (with or without secondary generalised seizures) were seizure free compared to 62% of patients with partial seizures (with or without secondary generalised seizures) in the phenytoin group

In the oxcarbazepine group 59% of patients with generalised seizures (without partial onset) were seizure free compared to 54% of patients with generalised seizures (without partial onset) in the phenytoin group

Withdrawal:
In total 24 patients withdrew from the oxcarbazepine group compared to 34 in the phenytoin group.
In the oxcarbazepine group 8 patients withdrew due lost to follow up, 2 due to adverse events, 6 due to non-compliance, 4 due to unsatisfactory therapeutic effect, 3 due to protocol violation and 1 due to concomitant illness
In the phenytoin group 9 patients withdrew due lost to follow up, 14 due to adverse events, 5 due to non-compliance, 3 due to unsatisfactory therapeutic effect, 2 due to protocol violation and 1 due to discontinuations at baseline

Side effects:
In the oxcarbazepine group 79 out of 96 had at least 1 adverse event compared to 84 out of 94 in the phenytoin group

Safety and adverse effects
In the oxcarbazepine group 79 out of 96 had at least 1 adverse event compared to 84 out of 94 in the phenytoin group. In the oxcarbazepine group 2 patients withdrew due to adverse events compared to 14 in the phenytoin group.

29 July 2010

Page 187 of 306
There was no significant difference in the number of patients becoming seizure free between the oxcarbazepine group and the phenytoin group. More patients in the phenytoin group experienced side effects and more patients withdrew from the phenytoin group due to adverse events compared to the oxcarbazepine group.

**Does the study answer the question?**

Effect due to factor in study?

Consistency of results with other studies?

Directly applicable to guideline population?

**Internal Validity**

Ramsay RE; Widler BJ; Murphy JV; Holmes GL; Uthman B; Slater J;

Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalised tonic-clonic seizures.

Ref ID 4682 1992

**Study Type** Randomised Controlled Trial

**Funding** Not reported.

**Number of participant** N=86 Valproate and n=50 phenytoin.

**Inclusion/Exclusion Criteria**

Inclusion: only patients with newly diagnosed primary Generalised Tonic-Clonic Seizures (GTCS); at least 2 GTCS occurred within 14 days of starting the study; and that no antiepileptic agents had been administered previously.

Exclusion: presence of neurological disease other than epilepsy or; evidence for focality to the epilepsy, either by history, neurologic examination, or EEG criteria.

**Patient Characteristics**

Although the study was restricted to patients with GTCS, some patients also experienced seizures of other types (i.e., atonic, myoclonic, or absence seizures). There was a greater representation of coexistent seizure types in the valproate groups. Seventeen patients in the valproate group and only one in the phenytoin group had other generalised seizure types (myoclonic, absence, or atonic). The mean age was 21.1 years in the valproate group and 20.6 in the phenytoin group.

**Recruitment** Not reported. 16 participating centres.

**Setting** Outpatient setting.

**Interventions/ Test/ Factor being investigated** Pharmacological interventions. Valproate versus phenytoin.

Valproate was started at 10-15mg/kg daily; the drug was given as 250mg capsules of Depakene. Phenytoin was started at 3-5mg/kg daily and was given as 100mg capsules of Dilantin. The dosage was gradually increased thereafter until trough serum concentrations of at least 50mg/ml of valproate or 9 mg/ml of phenytoin were reached. Dosage was titrated depending on the occurrence of seizures or side-effects.

**Comparisons** Valproate versus phenytoin.

**Length of Study/ Follow-up** None reported.

**Outcome measures studied** Seizure recurrence rates, serum drug levels and adverse events.

**Results** Of the 136 patients originally enrolled in the study, 10 were nonevaluable. Eight were found to have partial seizures. Three of these patients had evidence of both generalized and partial seizures. Additional analysis was done excluding patients found to have partial seizures.

The 6 month recurrence rates for tonic-clonic seizures were 49± 6% for patients with spike-wave abnormalities and 24± 7% for those without spike-wave abnormalities.
In this group, the 6 month recurrence rates for tonic-clonic seizures were 36± 6% for the valproate group and 47 ± 9% for the phenytoin group (mean ± SEM, p=NS). In the 77 patients with generalised spike-wave abnormalities, the 6 month recurrence rates for tonic-clonic seizures were 42 ± 8% for the valproate group and 63 ± 11% for the phenytoin group (p=NS).

Early termination n=26 for the valproate group and n=15 in the phenytoin group (this includes withdrawal due to side-effects, which is listed below).

Fourteen percent of the phenytoin group (n=50) withdrew due to adverse events compared to 4% of the valproate group (n=86).

The only statistically significant difference was the higher percentage of patients in the phenytoin group with low serum glucose (29% vs. 13% in the valproate group; p=0.037).

Other adverse events included 12% of nausea in the valproate group compared to 4% in the phenytoin (p=0.210), and 9% somnolence in the valproate group compared to 10% in the phenytoin group (p=0.999).

No significant difference in the efficacy or safety of valproate and phenytoin in the treatment of primary GTCS.

No.

Yes.

External Validity

Open design.

Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy

Ref ID 4662

1991

Study Type Randomised Controlled Trial

Funding Unknown

Number of participant 94 - 49 received sodium valproate and 45 received phenytoin

Inclusion/Exclusion Criteria

Inclusion: Patients with at least 2 fits per month

Patient Characteristics

70 males and 24 females ranging in age from 8-52 years.

Recruitment Not described

Setting Epilepsy Clinic at SVBP Hospital, Meerut India

Interventions/ Test/ Factor being investigated

Sodium valproate 15 mg/kg/day in 3 divided doses with increments as needed; Phenytoin in dose of 5 mg/kg/day as a single bedtime dose and increased as needed

Comparisons

Sodium valproate vs. phenytoin for control of seizures

Length of Study/ Follow-up

None reported.

Outcome measures studied

Seizure reduction: excellent (100% reduction), good (75-99% reduction), fair (50-74% reduction) and poor (less than 50% reduction).
It appears that while sodium valproate and phenytoin were equally effective in controlling generalised epilepsy, valproate was a better drug for controlling partial seizures.

<table>
<thead>
<tr>
<th>Seizure Type</th>
<th>Patients (49)</th>
<th>Excellent</th>
<th>Good</th>
<th>Fair</th>
<th>Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonic Clonic</td>
<td>28</td>
<td>16(57%)</td>
<td>8(29%)</td>
<td>3(10%)</td>
<td>1(4%)</td>
</tr>
<tr>
<td>Tonic</td>
<td>5</td>
<td>2(40%)</td>
<td>2(40%)</td>
<td>1(20%)</td>
<td>--</td>
</tr>
<tr>
<td>Myoclonic</td>
<td>2</td>
<td>--</td>
<td>2(100%)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Simple partial</td>
<td>8</td>
<td>5(62.5%)</td>
<td>2(25%)</td>
<td>1(12.5%)</td>
<td>--</td>
</tr>
<tr>
<td>Complex partial</td>
<td>3</td>
<td>--</td>
<td>1(33.3%)</td>
<td>--</td>
<td>2(66.7%)</td>
</tr>
<tr>
<td>Sec. gen. of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partial seizures</td>
<td>3</td>
<td>1(33.3%)</td>
<td>2(66.7%)</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

Sodium Valproate Response

Phenytoin Response

Safety and adverse effects

The most common side effects seen with valproate included GI disturbances (12%), drowsiness (6.12%), and weight gain (2.04%). Side effects with phenytoin included gum hyperplasia (17.7%), nystagmus (13.33%), ataxia (2.2%), GI disturbances (4.44%) and drowsiness (4.44%).

Does the study answer the question?

It appears that while sodium valproate and phenytoin were equally effective in controlling generalised epilepsy, valproate was a better drug for controlling partial seizures.

Effect due to factor in study?

Yes

Consistency of results with other studies?

See GRADE

Directly applicable to guideline population?

See GRADE

Internal Validity

Allocation concealment

Richens A; Davidson DL; Cartlidge NE; Easter DJ;

A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group

Ref ID 123

Study Type Randomised Controlled Trial

Funding Unknown

Number of participant 140 in sodium valproate (SV) arm and 141 in the carbamazepine (CBZ) arm.

Inclusion/Exclusion Criteria

Inclusion: Idiopathic generalised tonic clonic seizures or partial seizures with or without generalisation with two seizures in the previous six month. Patients had to be over age 16. Excluded: Patients with an accompanying renal, hepatic or CNS disorder, abnormal liver function tests, low platelet count or other blood dyscrasias; with absences or myoclonic jerks alone; females who were pregnant, lactating or planning a pregnancy. No other anticonvulsants were permitted.

Patient Characteristics

The distribution of age, sex, weight, EEG, medical history, intellectual status, seizure type, and seizure frequency was similar in each treatment group. The mean age of SV and CBZ groups was 33 years and 34 years respectively.

Recruitment

Not discussed.

Setting 22 outpatient clinics in the United Kingdom.
The long term efficacy and tolerability of SV and CBZ in untreated newly diagnosed adults.

Comparison

SV vs. CBZ.

Length of Study/Follow-up

Three years.

Outcome measures studied

Seizure remission (length of time patient was seizure free).

Results

There was no difference between SV and CBZ in the 12 month remission rates in patients with primary generalised seizures. In partial seizures, similar overall 12 month remission rates were achieved for each treatment (SV 72% and CBZ 76%) by the end of the three year trial. Patients with primary generalised seizures had higher 12 month remission rates on SV (76%) than on CBZ (62%, RR=1.41, 95% CI 0.91-2.18). Patients with partial seizures had similar overall remission rates (62% vs. 66%) on either drug. Neither difference was statistically significant.

Study reported that those who received sodium valproate were significantly more likely to remain on the treatment than those who received carbamazepine (RR=0.34, CI 0.16 - 0.72) but the figures were not given to report withdrawal.

Safety and adverse effects

Skin rashes occurred significantly more often in CBZ patients than in SV patients (p<0.05) and CBZ was associated with higher withdrawal rates because of adverse events (15% vs. 5%) in the first six months, including dizziness, headaches and ataxia - all non significant. Drug events with SV included weight gain (p<0.05). Tremor, alopecia and appetite increase.

Does the study answer the question?

SV and CBZ were both associated with a high degree of overall seizure control regardless of seizure type and both have good long term tolerability in adult patients with newly diagnosed epilepsy.

Effect due to factor in study?

Yes.

Consistency of results with other studies?

See GRADE.

Directly applicable to guideline population?

See GRADE.

Internal Validity

Steiner TJ; Dellaportas CI; Findley LJ; Gross M; Gibberd FB; Perkin GD; Park DM; Abbott R;

Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin

Ref ID 4705

Study Type Randomised Controlled Trial

Number of participant 181 patients with newly diagnosed untreated partial seizures or secondarily or primary generalised tonic-clonic seizures were randomised to two treatment groups. One group (n = 86) received LTG titrated over 6 weeks from a starting dose of 100 mg/day. The other (n = 95) received PHT titrated from 200 mg/day.

Inclusion/Exclusion Criteria

Inclusion: ages 14-75 after two or more partial, secondarily generalised or primary generalised tonic-clonic seizures in the previous 6 months

Exclusion: absence seizures; previous AEDs; clinically significant abnormal lab values; other chronic medical disorders, severe mental subnormality; abuse of alcohol and pregnancy or risk of pregnancy.

Patient Characteristics

<table>
<thead>
<tr>
<th>Male/female (%)</th>
<th>LTG, n=86</th>
<th>PHT, n=95</th>
<th>All, n=181</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTG, n=181</td>
<td>LTG, n=86</td>
<td>PHT, n=95</td>
<td>All, n=181</td>
</tr>
<tr>
<td>Male/female (%)</td>
<td>55/45</td>
<td>57/43</td>
<td>56/44</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>28 (13-70)</td>
<td>27 (13-74)</td>
<td>28 (13-74)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>28 (13-70)</td>
<td>27 (13-74)</td>
<td>28 (13-74)</td>
</tr>
</tbody>
</table>
Median                        68                                       68                                   68
Age at first seizure (yr)  Median                         25                                       25                                    25

Recruitment
Unknown

Setting
UK (authors from 6 settings)

Interventions/ Test/
Factor being investigated
Comparison of LTG with PHT monotherapy for efficacy and tolerability in previously untreated patients with newly diagnosed epilepsy

Comparisons
Comparison between lamotrigine and phenytoin.

Length of Study/
Follow-up
6 week titration and a treatment phase for less than or equal to 48 weeks.

Outcome measures studied
Primary: Percentages of patients remaining on each treatment and seizure free and the numbers of seizures with each treatment during the last 24 and 40 weeks of the study.
Secondary: time to first seizure and time to discontinuation.

Results
The percentages of patients remaining on each treatment and seizure free during the last 24 and 40 weeks of the study, and times to first seizure after the first 6 weeks of treatment (dose-titration period), did not differ significantly between the treatment groups. Time to discontinuation, a composite index of efficacy and safety, likewise did not distinguish between treatments.

In last 24 weeks: for primary generalised tonic-clonic the proportion of seizure-free participants was 19 (44%) in the lamotrigine group vs 17 (34%) in the phenytoin group. 95% CI for difference was -10.30%.

In last 40 weeks: for primary generalised tonic-clonic the proportion of seizure-free participants was 13 (30%) in the lamotrigine group vs 16 (32%). 95% CI for difference was -21.17%.

For primary generalised tonic-clonic the time to first seizure after the first 6 weeks of treatment was 1.5 (95% CI 0.7-3.2).

Adverse events led to discontinuation of 13 (15%) patients from LTG and 18 (19%) from PHT.

Adverse events affected more than 10% of patients:
LTG:
- Asthenia: 14/86*
- Rash: 12/86
- Headache: 9/86
- Dizziness: 8/86
- Somnolence: 6/86*
- Ataxia: 0/86

PHT:
- Asthenia: 28/95*
- Rash: 12/95
- Headache: 9/95
- Dizziness: 8/95
- Somnolence: 6/95*
- Ataxia: 0/95

* P<0.05

A quality-of-life instrument, the SEALS inventory, favoured LTG. Patients taking PHT showed the biochemical changes expected of an enzyme-inducing drug, whereas those taking LTG did not.

Safety and adverse effects
Adverse events led to discontinuation of 13 (15%) patients from LTG and 18 (19%) from PHT. The adverse-event profile for LTG was dominated by skin rash [discontinuation of 10 (11.6%) patients compared with five (5.3%) from PHT] rather than central nervous system side effects: asthenia, somnolence, and ataxia were each significantly more frequent in the PHT group. The high rate of rash with LTG was probably due to the high starting dose and may be avoidable.
LTG and PHT monotherapy were similarly effective against these seizure types in patients with newly diagnosed epilepsy. LTG was better tolerated, more frequently causing rash, but with a lower incidence of central nervous system side effects.

**Does the study answer the question?**
Yes

**Effect due to factor in study?**
See GRADE

**Consistency of results with other studies?**
See GRADE

**Directly applicable to guideline population?**
High discontinuation rate

Turnbull DM; Howel D; Rawlins MD; Chadwick DW;

Which drug for the adult epileptic patient: phenytoin or valproate?

Ref ID 4672 1985

**Study Type** Randomised Controlled Trial

**Number of participants**
140 in total sample with 70 in each arm, valproate and phenytoin respectively.

**Inclusion/Exclusion Criteria**
Inclusion: a history of two or more seizures in the previous three years; over age 16 and had received no previous anticonvulsants.

**Patient Characteristics**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Valproate (70 patients)</th>
<th>Phenytoin (70 patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>36</td>
<td>31</td>
</tr>
<tr>
<td>Male</td>
<td>34</td>
<td>39</td>
</tr>
</tbody>
</table>

**Recruitment**
Unknown.

**Setting**
Dept of Neurology, Royal Victoria Infirmary.

**Interventions/Test/Factor being investigated**
Valproate vs. phenytoin in newly diagnosed adult patients with epilepsy.

PHT 100mg 3 times a day; VPA 200mg 3 times a day; if further seizures occurred medication was increased PHT depending on plasma concentration if less than 10mg/l the dose was increased by 50mg/day and if greater than 10mg/l it was increased by 25mg/day, doses were further increased until seizures stopped or adverse effects seen; valproate was increment of 1200mg/2100mg and 3000mg/day given in 3 divided doses regardless of serum concentration.

**Comparisons**
Comparison is made between two treatments< valproate vs. phenytoin

**Length of Study/Follow-up**
48 months.

**Outcome measures studied**
Achievement of a two year remission and 'time to first seizure'.

**Results**

<table>
<thead>
<tr>
<th></th>
<th>Valproate</th>
<th>Phenytoin</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>70</td>
<td>70</td>
</tr>
<tr>
<td>No achieving 2 year remission</td>
<td>36</td>
<td>31</td>
</tr>
<tr>
<td>No controlled for &lt;2 years</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>No continuing to have seizures</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>Idiosyncratic adverse effect requiring drug withdrawal</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Death</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Non-compliant or lost to follow-up</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

In patients with tonic clonic seizures 27 of 37 patients on valproate and 22 of 39 on phenytoin achieved 2 year remission.
In patients with partial seizures 9 of 31 patients on valproate and 9 of 31 on phenytoin achieved 2 year remission.

Sodium valproate and phenytoin in the treatment of tonic clonic or partial seizures showed no significant difference in the efficacy as regards time to two year remission. However patients with a clinical history of partial seizures did significantly less well than those with a history of tonic clonic seizures only (p<0.025) and to time to first seizure (p<0.001). There were not figures to report time to first seizure in evidence review.

<table>
<thead>
<tr>
<th>Safety and adverse effects</th>
<th>Valproate dose related adverse effects: tremor, irritability and restlessness and alopecia. Phenytoin dose related adverse effects: nystagmus, ataxia, tremor, diplopia and mental change. Idiosyncratic effects of phenytoin: skin eruption, erythoderma and jaundice.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does the study answer the question?</td>
<td>This study showed no major difference in efficacy between sodium valproate and phenytoin in adults with recent onset of epilepsy.</td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>Yes</td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>See GRADE</td>
</tr>
<tr>
<td>Directly applicable to guideline population?</td>
<td>See GRADE</td>
</tr>
<tr>
<td>Internal Validity</td>
<td>High drop out rate</td>
</tr>
</tbody>
</table>
Clobazam as adjunctive therapy in uncontrolled epileptic patients.

Ref ID 4683 1985

**Study Type**  Randomised Controlled Trial  **Funding**  Not reported

<table>
<thead>
<tr>
<th>Number of participants</th>
<th>12 patients in total.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion/Exclusion Criteria</strong></td>
<td>Inclusion: uncontrolled longstanding epilepsy – 2 or more seizures in the 2 weeks before trial, patients were institutionalized.</td>
</tr>
<tr>
<td><strong>Patient Characteristics</strong></td>
<td>All patients were institutionalized. Age range 17 to 53 years. 50% were male, 9 patients had generalised tonic-clonic seizures, 3 had focal with secondary generalised seizures. Patients with generalised tonic-clonic seizures: 2 were taking carbamazepine, 3 were taking carbamazepine and diphenylhydantoin, 3 were taking carbamazepine and sodium valproate, 1 was taking diphenylhydantoin and phenobarbital. Patients with focal with secondary generalised seizures: 1 was taking carbamazepine, 1 was taking carbamazepine and diphenylhydantoin, 1 was taking carbamazepine and sodium valproate.</td>
</tr>
<tr>
<td><strong>Recruitment</strong></td>
<td>Not reported.</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>South Africa.</td>
</tr>
<tr>
<td><strong>Interventions/ Test/ Factor being investigated</strong></td>
<td>Clobazam 0.5 mg/kg/day in three equal doses.</td>
</tr>
<tr>
<td><strong>Comparisons</strong></td>
<td>Identical placebo.</td>
</tr>
<tr>
<td><strong>Length of Study/ Follow-up</strong></td>
<td>No follow up reported.</td>
</tr>
<tr>
<td><strong>Outcome measures studied</strong></td>
<td>Number of patients who were seizure free</td>
</tr>
</tbody>
</table>

**Results**

Cross over trial, 9 weeks on each treatment with a 5 week wash out. Serum levels of at least one or more of the existing anticonvulsant medications were within the accepted therapeutic range, no change of dosage was allowed.

Number of patients who were seizure free:

Overall:
While treated with clobazam 8 out of 12 patients were seizure free, while on placebo 1 out of 12 patients was seizure free.

Patients with generalised tonic-clonic seizures:
While treated with clobazam 7 out of 9 patients were seizure free, while on placebo 1 out of 9 patients was seizure free.

Patients with focal with secondary generalised seizures:
While treated with clobazam 1 out of 3 patients was seizure free, while on placebo 0 out of 3 patients were seizure free.

**Safety and adverse effects**

No patients reported any side effects

**Does the study answer the question?**

More patients became seizure free while being treated with clobazam compared to those treated with placebo. There were no side effects reported in either treatment group.
Internal Validity

Effect due to factor in study? No.
Consistency of results with other studies? Yes.
Directly applicable to guideline population? Yes.

In the topiramate group 24 out of 39 were male. The mean age was 26.8 sd 12.8 years; the age range was 5 to 59 years; 31 patients were white, 6 were black and 1 was Hispanic. The mean weight was 71.8 sd 28.5 kg, the range was 22 to 143 kg. The mean number of PGTC seizures per month was 5 (range 1 to 298). The mean number of all seizures was 15.3 (range 1-1134). 39 had tonic-clonic seizures, 13 tonic-clonic only seizures, 16 had absence seizures, 9 had tonic seizures, 8 had myoclonic seizures, 2 had drop attack seizures, 2 atypical absence seizures, 1 had colic seizures and 1 had other types of seizures.

Background AEDs: 9 had one AED, 19 had two AEDs and 11 had more than two AEDs. 19 had valproic acid, 12 had phenytoin, 11 had carbamazepine, 6 had lamotrigine, 8 had phenobarbital, 6 had clonazepam and 5 had gabapentin.

In the placebo group 21 out of 41 were male. The mean age was 25.6 sd 13.4 years; the age range was 3 to 50 years; 28 were aged over 16 years old. 36 were white and 5 were black. The mean weight was 61.3 sd 25.1 kg, the range was 17 to 129 kg. The mean number of PGTC seizures per month was 4.5 (range 1 to 300). The mean number of all seizures was 17.5 (range 2-79,109). 40 had tonic-clonic seizures, 13 tonic-clonic only seizures, 16 had absence seizures, 10 had tonic seizures, 8 had myoclonic seizures, 5 had drop attack seizures, 4 atypical absence seizures, 1 had colic seizures and 1 had other types of seizures.

Background AEDs: 9 had one AED, 22 had two AEDs and 10 had more than two AEDs. 20 had valproic acid, 13 had phenytoin, 9 had carbamazepine, 10 had lamotrigine, 3 had phenobarbital, 6 had clonazepam, 3 had gabapentin and 6 had primidone.

Recruitment 
Not reported.

Setting 
17 sites in USA and 1 in Costa Rica.
## Interventions/ Test/ Factor being investigated

Topiramate – dose based on patients weight.

Matching placebo.

No follow up reported.

### Comparisons

Number who were seizure free, number who had 75% reduction in the number of seizures, number who had 50% reduction in the number of seizures, withdrawal, side effects.

### Length of Study/ Follow-up

20 week trial, with 8 weeks of titration and 12 week stabilization period.

For patients weighing 25 to 33.9 kg during the titration period weeks 1 to 4 patients had 50 mg in the pm, during weeks 5 to 6 they received 50 mg twice a day; during the stabilization period weeks 7 to 8 patients received 75 mg twice a day and during weeks 9 to 20 they received 75 mg twice a day. They had a target dose of 5.2 to 7 mg/kg/day.

For patients weighing 34 to 42.9 kg during the titration period weeks 1 to 4 patients had 50 mg in the pm, during weeks 5 to 6 they received 50 mg twice a day; during the stabilization period weeks 7 to 8 patients received 75 mg twice a day and during weeks 9 to 20 they received 100 mg twice a day. They had a target dose of 5.2 to 6.6 mg/kg/day.

For patients weighing greater than or equal to 43 kg during the titration period weeks 1 to 4 patients had 50 mg in the pm, during weeks 5 to 6 they received 75 mg twice a day; during the stabilization period weeks 7 to 8 patients received 150 mg twice a day and during weeks 9 to 20 they received 200 mg twice a day. They had a target dose of 9.3 mg/kg/day.

### Outcome measures studied

Number who were seizure free:

PGTC seizures: In the topiramate group 5 out of 39 became seizure free compared to 2 out of 40 in the placebo group.

All generalised seizures: In the topiramate group 2 out of 39 became seizure free compared to 0 out of 41 in the placebo group.

Number who had 75% reduction in the number of seizures:

PGTC seizures: In the topiramate group 13 out of 39 had a 75% reduction in the number of seizures compared to 5 out of 40 in the placebo group.

All generalised seizures: In the topiramate group 10 out of 39 had a 75% reduction in the number of seizures compared to 3 out of 41 in the placebo group.

Number who had 50% reduction in the number of seizures:

PGTC seizures: In the topiramate group 22 out of 39 had a 50% reduction in the number of seizures compared to 8 out of 40 in the placebo group.

All generalised seizures: In the topiramate group 18 out of 39 had a 50% reduction in the number of seizures compared to 7 out of 41 in the placebo group.

### Results

Withdrawal:

In the topiramate group 5 patients withdrew, 2 due to patient choice, 1 due to limiting adverse events and 1 due to non compliance and 1 due to inadvertent premature discontinuation.

In the placebo group 3 patients withdrew, 1 due to patient choice, 1 due to limiting adverse event and 1 due to lost to follow up.

Side effects:

In the topiramate group: 26% had somnolence, 15% had anorexia, 13% had difficulty with memory, 10% had nervousness, 10% had psychomotor slowing, 41% had upper respiratory tract infection, 10% had pharyngitis, 18% had fatigue, 15% had weight loss, 13% had headache, 10% had dizziness, 10% had speech disorders and related speech problems and 10% had abdominal pain.

In the placebo group: 15% had somnolence, 7% had anorexia, 0% had difficulty with memory, 0% had nervousness, 2% had psychomotor slowing, 32% had upper
More patients became seizure free or had a reduction in the number of seizures when treated with topiramate compared to those treated with placebo.

Safety and adverse effects

In the topiramate group: 26% had somnolence, 15% had anorexia, 13% had difficulty with memory, 10% had nervousness, 10% had psychomotor slowing, 41% had upper respiratory tract infection, 10% had pharyngitis, 18% had fatigue, 15% had weight loss, 13% had headache, 10% had dizziness, 10% had speech disorders and related speech problems and 5% had abdominal pain.

In the placebo group: 15% had somnolence, 7% had anorexia, 0% had difficulty with memory, 0% had nervousness, 2% had psychomotor slowing, 32% had upper respiratory tract infection, 5% had pharyngitis, 7% had fatigue, 2% had weight loss, 20% had headache, 15% had dizziness, 2% had speech disorders and related speech problems and 5% had abdominal pain.

Does the study answer the question?

More patients became seizure free or had a reduction in the number of seizures when treated with topiramate compared to those treated with placebo.

Effect due to factor in study?

No.

Consistency of results with other studies?

Directly applicable to guideline population?

Yes.

Internal Validity

Allocation concealment.

Brodie MJ; Richens A; Yuen AW;

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

Ref ID 4808

Study Type Randomised Controlled Trial

Funding Supported by the Welcome foundation.

Number of participant

N= 260; n=131 lamotrigine and n=129 carbamazepine.

Inclusion/Exclusion Criteria

No specific inclusion and/or exclusion criteria.

Patient Characteristics

Patients 13 years and older with newly diagnosed epilepsy with partial seizures without secondary generalisation, and primary or secondary generalised tonic-clonic seizures. No patient had received previous treatment with an AED. Lamotrigine group had a median baseline seizure count of 4 (mean 36) versus 3 mean (mean 22) for the carbamazepine group.

Recruitment

Not reported.

Setting

8 centres in the UK.

Interventions/ Test/ Factor being investigated

Pharmacological interventions. Patients received increasing doses of identical 50mg lamotrigine or 200mg carbamazepine tablets. At the end of 4 weeks, all patients were taking 150mg lamotrigine or 600mg carbamazepine daily. During weeks 6-24 the daily dose could be increased by one tablet at each visit if seizures continued and no clinically relevant adverse events had been reported provided the drug concentration was in the lower half of the target range or lower.

Comparisons

Lamotrigine versus carbamazepine.

Length of Study/ Follow-up

For 48 weeks.
time to first seizure and adverse events.

Results

No significant difference between the drugs in time to first seizure after 6 weeks treatment for the whole study population (hazard ratio 0.8, 95% CI 0.6-1.2), or for the subgroup with partial seizures with or without secondary generalisation or the subgroup with primary tonic-clonic seizures.

Percentage seizure-free (for primary generalised tonic-clonic seizures) at last 40 weeks:
LTG: 37% - calculated as 22/60
CBZ: 35% - calculated as 22/62

Percentage seizure-free (for primary generalised tonic-clonic seizures) at last 24 weeks:
LTG: 47% - calculated as 28/60
CBZ: 47% - calculated as 29/62

Percentage seizure-free (for partial seizures with or without generalisation) at last 40 weeks:
LTG: 22%
CBZ: 31%

Percentage seizure-free (for partial seizures with or without generalisation) at last 24 weeks:
LTG: 35%
CBZ: 37%

Percentage seizure-free (all seizures) at last 40 weeks:
LTG: 26%
CBZ: 29%

Percentage seizure-free (all seizures) at last 24 weeks:
LTG: 39%
CBZ: 38%

A greater proportion of the LTG group completed the study compared to the CBZ group (65 vs. 51%, p=0.018).

Safety and adverse effects

Adverse events: Headache 30% LTG group vs. 25% CBZ group (95% CI -6 to 16); Astenia 21% LTG group vs. 29% CBZ group (95% -18 to 3); rash 19% LTG vs. 19% CBZ group (95% CI -10 to 9); nausea 15% LTG group vs. 12% CBZ group (95% CI -3 to 14); dizziness 12% LTG vs. 17% CBZ (95% CI -13 to 4); sleepiness 12% LTG group vs. 22% CBZ group (95% CI -19 to -1); and flu-like symptoms 11% LTG group vs. 8% for the CBZ group (95% CI -3 to 11). The only significant adverse event is sleepiness.

Nineteen patients withdrew from the LTG group (n=131) and 35 withdrew from the CBZ group (n=129).

Does the study answer the question?

Similar efficacy for both LTG and CBZ. LTG seems to be better tolerated.

Effect due to factor in study?

No.

Consistency of results with other studies?

Yes.

Directly applicable to guideline population?

Yes.

Internal Validity

No ITT analysis.
### Study Type
Randomised Controlled Trial

### Number of participant
VPA n=130; CBZ n=130. 118 VPA and 126 were evaluable on ITT basis.

### Inclusion/Exclusion Criteria
Inclusion: primary generalised epilepsy or partial with or without generalisation. 5-16 years old; Newly diagnosed epilepsy or seizures recurred after withdrawal of AEDs but not received any AEDs in 6 months prior. Had at least 2 generalised tonic-clonic or partial seizures with or without generalisation in previous 6 months. Exclusions: Children with accompanying renal hepatic or other CNS disorders who had abnormal liver function tests, a low platelet count or other bloody dyscrasia; Children with absences or myoclonic jerks alone; Girls on contraceptive medication at entry; No concomitant AEDs allowed during study, and if needed were withdrawn.

### Patient Characteristics
**VPA vs CBZ:**
- boys 54 (mean age 9.7 years), girls 64 (mean age 9.9 years);
- boys 59 (mean age 9.5 year), girls 67 (mean 9.3 years).
- Mean no of seizures in 6 months prior to entry: 3 in each group.
- No children over 15 years.

### Recruitment
Not reported.

### Setting
63 outpatient clinics in UK/Ireland.

### Interventions/ Test/ Factor being investigated
Sodium valproate versus carbamazepine.

### Comparisons
Sodium valproate versus carbamazepine.

### Length of Study/ Follow-up
See above.

### Outcome measures studied
Withdrawal due to lack of efficacy and adverse events.

### Results
VPA vs CBZ 04/07/2010
Withdrawal due to lack of efficacy: 14/118 (12%) vs 16/126 (13%)
Withdrawal due to adverse events: /118 (7%) vs 7/126 (5%) in 1st 6 months: 14/118 vs 8/126 at 12 months.

11 further (4 VPA and 7 CBZ treatment failures due to poor seizure control and adverse events on sub-optimal drug doses.

Can't use efficacy data as not over 80% for PGTC or partial.

Over 10% incidence of adverse events:
somnolence: 11/118 vs 25/126.
fatigue: 6/118 vs 13/126.

### Safety and adverse effects
See results above.

### Does the study answer the question?
Yes.

### Effect due to factor in study?
No details of allocation concealment or blinding so uncertainty that overall effect is due to the study intervention.

### Consistency of results with other studies?
Internal Validity

Question: How effective and cost-effective are anti-epileptic drugs for Infantile spasms
Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms

**Study Type**  
Randomised Controlled Trial

**Number of participants**  
Total: 40 patients.  
Vigabatrin arm: 20 patients.  
Placebo arm: 20 patients.

**Inclusion/Exclusion Criteria**  
**Inclusion criteria:**  
Aged 1 to 20 months;  
Newly diagnosed and previously untreated infantile spasms whose EEG demonstrated classic or modified hypsarrhythmia;  
Infants whose parents/guardians could give informed consent and investigators thought them capable of completing a seizure diary and attending clinic as required;  

**Exclusion criteria:**  
Use of any medication, including prednisolone, hydrocortisone, or ACTH, that could be considered an AED within 2 months before entry into the study.

**Patient Characteristics**  
Placebo vs vigabatrin:  
- Male: 8 vs 11.  
- Age in months at onset of spasms: mean (range): 6 (1-15) vs 7 (2-18).  
- Age in months at entry into study: mean (range): 8 (4-17) vs 8 (5-20).  
- Duration of spasms in weeks before entry: mean (range): 7 (2-12) vs 6 (2-13).  
- EEG findings:  
  - typical hypsarrhythmia: 13 vs 15.  
  - modified hypsarrhythmia: 7 vs 5.  
- Denver developmental test:  
  - normal: 2 vs 1.  
  - untestable (severely abnormal): 0 vs 4.  
  - missing data: 3 vs 1.

* Only two patients were older than 12 months (17 and 12 months, respectively) on study entry.

**Recruitment**  
Not reported.

**Setting**  
Canada, Finland, France, Hungary, Holland, Serbia & UK.

**Interventions/ Test/ Factor being investigated**  
Patients were given starting dose of 50mg/kg/day of either vigabatrin or placebo and this was continued for 24 hours.  
If spasms were not ceased completely the dosage was increased to 100mg/kg/day and maintained for a further 48 hours.  
The investigator assessed spasm frequency and if needed increased to 150mg/kg/day.  
Once a dose was established for >48 hours the dose could be changed only if there were safety concerns.  
After the double-blind period (5 days) there was an open phase where dosage of vigabatrin could be altered or another AED prescribed in addition to vigabatrin.

The open phase included some of the patients who had been non-responders in the VGB treated group and the placebo group. They received vigabatrin as monotherapy or as polytherapy - with ACTH/sodium valproate or prednisolone. 15/16 of the monotherapy and 4/20 of the polytherapy group became spasm free. We will not include this data in the meta-analysis as comparing monotherapy to polytherapy is not relevant to the review.

**Comparisons**  
Comparisons between treatment and placebo.

29 July 2010  
Page 202 of 306
There was a five day double-blind period. Those patients continuing with the study entered a 24-week open phase. Outcomes: cessation of spasms; reduction in spasms; resolution of hypsarrhythmia; relapse rates.

Main conclusions of the authors: vigabatrin has shown efficacy for infantile spasms and could be considered as the drug of first choice. They found with the 24 hour assessment of spasm frequency that vigabatrin was more effective than placebo in reducing spasms, however when they used 2 hour data this reduction was not statistically significant between the groups. This could be explained by variability of the time of day that the spasms appeared. Spasm freedom was higher in the vigabatrin group compared with the placebo group but this did not reach statistical significance (p=0.063). Explanation could be that there was a short double-blind period.

Power: Type 1 error of 0.05 and power of 90%, 12 protocol correct patients needed in each group to show a 45% difference between the two groups, therefore allowing a drop-out rate of 20%, 15 patients were needed in each treatment group, giving a study sample of 30 patients. Methodology was good.

### Results

Vigabatrin vs placebo:

The last 24 hours of the double-blind period compared to baseline:

* Complete spasm control: 7 (35%) vs 2 (10%); p=0.063.

Average percentage reduction in spasms: 77.9% (CI 95% = 55 to 89%) vs 25.9% (CI 95% = -56 to 65%); p=0.020.

* >70% improvement in reduction in spasms: 8 (40%) vs 3 (15%).

* The number of spasm-free patients was not recorded by the 2-hour monitoring method.

The last two hours of the double-blind period compared to baseline:

Average percentage reduction in spasms: 71.9% (CI 95% = 42 to 86%) vs 54.6% (CI 95% = 4 to 78%).

* >70% improvement in reduction in spasms: 13 (76%) vs 11 (55%).

The open phase - 36 (90%) of the double-blinded patients entered the open phase, 16 (44%) from the vigabatrin group and 20 (56%) from the original placebo group. Four failed failed to reduce spasm frequency adequately. Five withdrew from the open phase because of lack of response to vigabatrin and two were lost to follow-up.

On completion of the open study:

Number of spasm free: 4/20 who originally randomised to receive vigabatrin monotherapy vs 11/20 originally randomised to receive placebo.

Safety and adverse effects

Treatment-emergent adverse events during the double-blind phase (none withdrew):

One or more adverse event occurred in: 12 (60%) vs 6 (30%). Fisher’s exact test, p=0.111.

The most common side effect in the vigabatrin group:

- Drowsiness: 8 patients.
- Behaviour change (marked irritability): 1 patient.

Open phase:

24 (67%) of patients had one or more adverse event, including bronchitis (8); drowsiness (7), rhinitis (7), fever (5), k throat irritation (4), and otitis media (4). None were clinically serious and none withdrew.

One child died of acute respiratory infection and a cardiac arrest and was receiving many AEDs and the death was not considered to be related to the study drug.

Does the study answer the question?

Yes.

Main conclusions of the authors: vigabatrin has shown efficacy for infantile spasms and could be considered as the drug of first choice.
Consistency of results with other studies?
Yes.

Directly applicable to guideline population?
Direct.

Internal Validity

Yes overall effect likely due to the study intervention.
High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study

Ref ID 1 1996

Study Type Randomised Controlled Trial Funding Not reported.

Number of participant Total: 29 patients. ACTH arm: 15. Prednisone arm: 14.

Inclusion/Exclusion Criteria Inclusion: Parental consent to randomised treatment; No previous steroid or ACTH treatment; Presence of hypsarrhythmia or its variants (assessed by a 24-hour video EEG) Presence and frequency of epileptic myoclonic events.

Exclusion: Severe hypertension; Resolution of spasms after shunt placement; Parental refusal; Unavailability of legal guardian;

Patient Characteristics Twelve infants had Hispanic surnames - six in each group; 11 infants were white non-Hispanic - five in ACTH group); three Asian; three African American. 22 infants had symptomatic IS with known or suspected cause; seven had cryptogenic IS but only two were entirely developmentally and neurologically normal at time of diagnosis. Mean age prednisone group 7.5 vs. ACTH group 5.1. Difference was not statistically significant (p=0.06, Mann-Whitney test). Cryptogenic aetiology, gender, other seizures, duration of IS did not differ statistically significantly between the treatment groups.

Recruitment Consecutive infants (in Hospital) who fulfilled criteria.

Setting Children's Hospital Los Angeles.

Interventions/ Test/ Factor being investigated Two weeks treatment of either ACTH (ACTHARGEL) 75 U/m2/day intramuscularly twice daily vs. prednisone 1mg/kg/day given orally twice daily. Parents kept seizure diaries and monitored seizure frequency; Monitoring of side effects such as hypertension and hyperglycemia: glycosuria was checked for duration of treatment and blood pressure measured bi-weekly; After 2 weeks a repeat video-EEG (lasting 4 to 24 hours including a full sleep-wake cycle) was performed and clinical and EEG response was assessed; Those who had not responded to treatment (had not complete cessation of IS events and hypsarrhythmia) were offered the alternative treatment; Responders were tapered off ACTH or prednisone.

Comparisons Comparisons made between treatments: ACTH vs. prednisone.

Length of Study/ Follow-up Followed up for two weeks. Then non-responders crossed over to the other treatment for two weeks.

Outcome measures studied Cessation of seizures;

Results Cessation of seizures: ACTH: 13/15 86.6% responded by EEG and clinical criteria; seizures stopped in an additional infant (EEG remained hypsarrhythmic so considered a failure). Prednisone: 4/14 (28.6%) responded by EEG and clinical criteria).

The difference in response rate between groups was significant: p=0.002 X2 test; even after accounting for confounding effect of age: Mantel-Haenszel test 3.94 (CI 1.44-10.77, p=0.0026).
The 2 infants who failed ACTH received prednisone for 2 weeks, one responded on clinical and EEG criteria. Of 10 infants failing prednisone, nine received ACTH (for 2 weeks) and 8 responded (88%). 2/5 infants who were ineligible for the study received ACTH and responded.

Adverse events:
Irritability and voracious appetite were the most frequent side effects, but no infant required stopping or modifying treatment.

Safety and adverse effects
Adverse events: Side effects such as hypertension and hyperglycaemia were monitored; glycosurria was checked for the duration of treatment and blood pressure checked bi-weekly. Irritability and voracious appetite were the most frequent side effects, but no infant required stopping or modifying treatment.

Does the study answer the question?
Partially regarding cessation of seizures with ACTH and prednisone.

The authors concluded that in their study a 2-week course of high-dose ACTH is superior to 2 weeks of prednisone for treatment of infantile spasms (from both clinical and EEG criteria).

Effect due to factor in study?
Not sure. No concealment allocation and no power calculation given.

Consistency of results with other studies?
Authors say Hrachovy (1991) found a comparable efficacy for ACTH.

Directly applicable to guideline population?
Direct.

Internal Validity
No allocation concealment;

Askalan R; Mackay M; Brian J; Otsubo H; McDermott C; Bryson S; Boyd J; Snead C; Roberts W; Weiss S;

Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms
Ref ID 604 2003

Study Type Randomised Controlled Trial
Funding Supported in part by Bloorview Children’s Hospital Foundation.

Number of participant
Total: 9 patients.
Vigabatrin arm: 6
ACTH arm: 3

Inclusion/Exclusion Criteria
Inclusion criteria:
Aged 3 to 16 months at onset of spasms.
Families who could comply with follow-up visits.

Exclusion criteria:
Previous exposure or known allergy to vigabatrin or corticosteroids.
A known visual disturbance.
Have a medical condition for which corticosteroids would be contraindicated.

Patient Characteristics
Gender: 4 males, 5 females.
2 females and 1 male in the vigabatrin group and 3 males and 3 females in the ACTH group.
4 patients had symptomatic infantile spasms and 5 patients had idiopathic infantile spasms.

Recruitment
Patients who presented to the Hospital for Sick Children in Toronto were recruited.

Setting
Toronto, Canada.
Patients were evaluated for cause of infantile spasms with CT and or MRI and metabolic, infectious and genetic work-up. Baseline psychologic evaluation and ophthalmologic assessments were performed. All participants had prolonged daytime video-EEG to capture awake and sleep states and document their infantile spasms.

The infants were categorised by aetiology (symptomatic or idiopathic) and by sex, which made up 4 possible cells, each cell was randomised to vigabatrin or ACTH using a computerised programme.

For cognitive and motor development the Bayley Scales of Infant development, Second Edition, was administered at baseline and 3, 12, and 24 months after start of treatment.

Phase 1: ACTH group: received 150 IU/m2/day of ACTH divided into two doses given intramuscularly for a period of 1 week and then reduced to 75 IU/m2/day in a single dose for a second week.

Vigabatrin group: vigabatrin 100mg/kg/day which was increased to 150mg/kg/day divided into two doses orally by the third day and continued at that dose for the remaining 2 weeks.

Both groups had a sleep and waking EEG at end of first week and a 4 and 8 hour daytime video-EEG to capture sleep and waking state at the end of the second week to see the response to treatment.

Phase 2:
2 weeks of treatment. Responders remained in their initial group and completed tapering off for 12 weeks for ACTH or 18 months for vigabatrin.
Non-responders crossed over to the alternate drug and while tapering off the other drug (1 week).
A sleep and waking EEG was obtained for all patients at end of phase 2 (4 weeks).

Comparisons
Comparisons between treatments.
Vigabatrin versus ACTH.

Length of Study/ Follow-up
4 weeks of treatment.
Followed up at 2 weeks, 4 weeks, 3 months, 12 months and 24 months after beginning medication.

Outcome measures studied
Cognitive and motor development; language; autistic symptomology; cessation of spasms; resolution of hypsarrhythmia.

Results
Most received treatment within 1 to 2 months of presentation.
3 patients had 3 to 6 month history of infantile spasms prior to initial evaluation.
All patients had modified hypsarrhythmia prior to start of treatment.

All patients had resolution of spasms and hypsarrhythmia on EEG safer 2 weeks of treatment.
But 2/3 of the ACTH group and 3/6 of the vigabatrin group continued to have moderate to severe abnormal EEGs after 2 weeks of treatment. These patients were crossed over to the alternate drug.

Cognitive outcomes:
Baseline cognitive assessment done at 5-13 months of age showed that 7/8 had mild to significant cognitive delay before starting treatment.
Follow-up cognitive assessments at 19 to 34 months of age: 4 patients (including the only ACTH responder) showed improved cognitive function after treatment. All four had idiopathic infantile spasms.
Of the three vigabatrin responders two had worsening cognitive delay and the third remained significantly delayed.

Safety and adverse effects
None reported.

Does the study answer the question?
Partially regarding outcomes of cessation of spasm and cognitive outcomes.

The authors found that patients with idiopathic infantile spasms had a more favourable outcome. They say that because of the small sample it cannot determine which of the two drugs is more effective. Although looking at the trends vigabatrin may be more effective of patients with symptomatic infantile spasms; patients with idiopathic infantile spasms tended to have a better cognitive outcome and patients
with symptomatic infantile spasms tend to develop both epilepsy and autism.

**Effect due to factor in study?**
No, study too small and methodology was unclear.

**Consistency of results with other studies?**

**Directly applicable to guideline population?**
Direct.

**Internal Validity**
allocation concealment, blinding, small sample

Chiron C; Dumas C; Jambaque I; Mumford J; Dulac O;

Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis

Ref ID 4616 1997

**Study Type** Randomised Controlled Trial  **Funding** Not reported.

**Number of participant**
Total: 22 patients were randomised.
Vigabatrin arm: 11.
Hydrocortisone arm: 11.
6 non-responders and one infant with severed hydrocortisone side effects were crossed over at the end of the first month from hydrocortisone to vigabatrin for another month.

**Inclusion/Exclusion Criteria**
Inclusion:
Tuberous sclerosis according to Gomez criteria;
Epileptic spasms recorded on EEG or seen by experienced physician;
Diffuse interictal paroxysmal activity

**Patient Characteristics**
Vigabatrin vs hydrocortisone:

Gender:
Male 5 vs 5.
Female 6 vs 6.

Age at onset of infantile spasms: (months, mean, s.d):
3-9 (5.8 +/- 1.8) vs 1-14 (5.9 +/- 3.2).

Age at onset of vigabatrin: (months, mean, s.d):
4-9 (6.6 +/- 1.7) vs 2-17 (7.9 +/- 4.4).

Duration of IS before vigabatrin: (days, mean, s.d):
15-90 (24.4 +/- 25.6) vs 15-300 (36.4 +/- 31.9).

All showed statistically non-significant differences.

**Recruitment**
Selected from several French centres.

**Setting**
French health centres.

**Interventions/ Test/ Factor being investigated**
150mg/kg/day vigabatrin vs 15mg/kg/day hydrocortisone.
After the end of the first month, those who did not respond were crossed over to the alternative treatment. While vigabatrin was withdrawn over 24 hours and hydrocortisone was tapered off over 2 weeks.

A daily seizure calendar maintained by the parent or guardian plus an EEG was used to assess cessation of spasms. The EEG was done at 1 and 2 months.

Adverse events were reported to or noted by the investigator.

**Comparisons**
Comparison between treatments: vigabatrin vs hydrocortisone.
Length of Study/ Follow-up
Final assessment at 2 months after randomisation (initial non-responders) or cross-over (responders).

Outcome measures studied
Cessation of spasms; resolution of hypsarrhythmia; relapse rates; adverse events.

Results
Cessation of spasms:

After 1 month: 11/11 vigabatrin and 5/11 hydrocortisone patients were spasm-free (p<0.01).

The 6 non-responders to hydrocortisone and one infant who had severed side effects after hydrocortisone were crossed over to vigabatrin:

All 7 responded to vigabatrin.

Mean time to response:
Vigabatrin: 4 days (range 0.5-14 days, SEM=1.53)
vs hydrocortisone: 12.8 days (range 3-30 days, SEM=4.37), p=0.058.

If look at whole population of responders to vigabatrin (n=18) mean time to response after initiation of vigabatrin (2.5 days, SEM=0.96), p<0.01.

Psychomotor evaluation:
17 patients were measured for developmental quotient at baseline and it was found to be lower in the vigabatrin group (mean=51, n=9) than in the hydrocortisone group (mean=74, n=8). No deteriorations were found but some children showed a slight increase in their developmental quotient.

Safety and adverse effects
14 children had at least one adverse event.
Vigabatrin: 5 patients (3 during initial treatment, two after cross-over).
Hydrocortisone: 9 patients.  P=0.006.

Does the study answer the question?
Yes as it includes cessation of spasms, psychomotor evaluation and adverse events.

The authors concluded that vigabatrin should be considered as the first choice treatment for infantile spasms due to tuberous sclerosis.

Effect due to factor in study?
No as only 22 participants and an open study with unclear methodology.

Consistency of results with other studies?
Direct.

Directly applicable to guideline population?
Direct.

Internal Validity
allocation concealment; blinding;

Infantile spasms. Comparative trial of nitrazepam and corticotropin

Ref ID 4636

Study Type Randomised Controlled Trial
Funding Not reported.

Number of participant Total: 52 patients.
Nitrazepam arm: 27.
ACTH arm: 25.
Number where drug efficacy was evaluable:
Nitrazepam: 27.
ACTH: 21.

Inclusion/Exclusion Criteria
Inclusion criteria:
1 to 24 months old;
Infantile spasms documented by a hypsarrhythmic or modified hypsarrhythmic pattern on the EEG;
Administration of phenobarbital, phenytoin, carbamazepine, or succinimides for the
control of other seizures was allowed;
No immunisations to be done during the study's four-week treatment period;
Exclusion:
No prior treatment with ACTH, steroids or NTZ;
Concomitant administration of valproic acid derivatives or benzodiazepines other
than nitrazepam was not permitted;

**Patient Characteristics**  Nitrazepam group vs ACTH group(figures in brackets is for those whose efficacy data
was evaluable):

Sex:
Male: 14 (14) vs 15 (12).
Female: 13 (13) vs 10 (9).

Age in months:
Mean: 8.70 vs 8.04.
Range 2-23 vs 3-21.

Spasm frequency at baseline:
Mean 174.3 vs 176.1.
Range 6-542 vs 10-1616.

Recruitment  Over a three year period of recruitment. No further details given.

Setting  8 centres in USA: medical centres and hospitals.

**Interventions/ Test/ Factor being investigated**

Before enrolment, patients were hospitalised for 24 hours and underwent complete
neurologic evaluation. The videotapes and polygraphic recordings were scored by
an assessor who was unaware of the treatment sequence of the recording of the
drug treatment group to which the patient had been assigned.
Nitrazepam group received doses of 0.2mg/kg/day in two divided doses or 1mg twice
daily (whichever greater). This was adjusted twice weekly by increments of 0.3 to
0.4mg/kg/d. This was reduced if it was too rapid for the patients. A maintenance
dosage of 4.80 to 9.00mg/d was achieved in most by the end of the third week and
kept constant for the remainder of the study if possible.
Corticotrophin gel was given as a single daily intramuscular dose of 40 units.
At the end of the four weeks each patient was hospitalised for 24 hours, where a
second videotape-polygraphic recording was made.

**Comparison**  Between treatments: nitrazepam vs ACTH.

**Length of Study/ Follow-up**  Four weeks.

**Outcome measures studied**  Reduction in seizure frequency;

**Results**

Mean reduction in seizure frequency (from baseline):
Nitrazepam:
122.1 +/- 20.8 seizures per day
p<= 0.05, two-sided comparison

ACTH:
89.7 +/- 23.6 seizures per day
p<= 0.05, two-sided comparison

* The proportion of patients experiencing a reduction in seizure frequency by at least
50% was:
Nitrazepam: 18 (67%).
ACTH: 12 (57%).

[^ Outcome of interest].

**Safety and adverse effects**  Side effects (percentage of patients who developed):

Nitrazepam:
Drowsiness: 50%.
Pooling of secretions in the upper respiratory passages: 45%.
Muscle hypotonia: 40%.
New seizure activity: 26%
ACTH group:
Leukocytosis: 52%.
Irritability: 40%.
Hypertension: 30%.
Emesis: 30%.
Peripheral edema: 20%.
New seizure activity: 19%.
Cushingoid facies: 15%.
Melena: 8%.
Hyponatremia: 4%.

Three of the ACTH group were no included in the analysis as they had side effects:
- two were removed after less than one week because of side effects (hypertension and melana).
- one patient died while asleep before a final evaluation could be made. The cause of death was not determined.

Four further ACTH patients had treatment discontinued early due to side effects but were entered into the analysis as completed from 14 to 22 days.

The two treatments were compared for their effect on blood pressure by calculating slopes of systolic blood pressure over time:
Nitrazepam n=26, mean 0.14, SEM 0.46.
ACTH n=23, mean 1.53, SEM 0.47.
p<0.005.
BP measurements were unavailable for one patient in the nitrazepam group and for two patients in the ACTH treatment group.

**Does the study answer the question?**
Yes partially. There are two outcomes of interest to us included in this study.

The authors state that both treatments resulted in a statistically significant reduction in spasm frequency from that of baseline but the difference between treatments was not significant.

The number of patients who experienced side effects was similar in the two treatment groups but the ACTH group were qualitatively more severe and required the discontinuation of the treatment for 6 of the patients.

**Effect due to factor in study?**
No power calculation given. But methodology not clear.

**Consistency of results with other studies?**
Direct.

**Directly applicable to guideline population?**
Direct.

**Internal Validity**
Concealment allocation; uneven no.s;

Grant NS11535 and Contract NS-9-2321 from the National Institute of Neurological and Communicative Disorders and Stroke.

Ref ID 49

**Study Type**
Randomised Controlled Trial

**Number of participant**
Total: 24 infants.
ACTH arm: 12 patients.
Inclusion/Exclusion Criteria

Inclusion:
Patients with infantile spasms and hypsarrhythmic EEG patterns on serial 24-hour video and polygraphic monitoring.
15 had previously been given various anticonvulsants, including phenobarbital, phenytoin, clonazepam, sodium valproate, and diazepam;

None had received ACTH or corticosteroid therapy for their spasms;

Patient Characteristics

Aged 3 and a half to 24 months; 22 patients were under 1 year of age;

Recruitment

Not reported.

Setting

Not reported.

Interventions/ Test/ Factor being investigated

Informed consent obtained from each infant's parent or guardian after a full explanation of the procedure;
Baseline 24-hour monitoring study;
Patient assigned at random to either ACTH gel 20 U/day or prednisone placebo or prednisone 2mg/kg/day and an ACTH gel placebo for two weeks;
If patient responded in first two weeks dosage was immediately tapered and drug discontinued over a one-week period. Then the patient was monitored at 2 and 6 weeks after discontinuation of therapy, to substantiate a continued response.
If patient did not respond after the first two weeks therapy was continued (ACTH gel 30U/day or prednisone 2mg/kg/day) for an additional four weeks and then the dosage was tapered and the drug discontinued over a 2-week period.
Final 24-hour monitoring study performed.
Nonresponders were crossed over to the other drug after a one week 'washout' period and protocol was repeated.
Those who responded to neither were treated with clonazepam (0.03 to 0.18 mg/kg/day) for 8 weeks and 24 hour monitoring was continued during this time to evaluate response.

Comparisons

Treatment versus treatment.
ACTH vs. prednisone.
ACTH also had a prednisone placebo and the prednisone group received an ACTH placebo.

Length of Study/ Follow-up

Baseline 24-hour monitoring period.
After randomisation patients were followed up at two weeks.
They were monitored at 2 weeks and 6 weeks after discontinuation of treatment.
If no response after first two weeks treatment was continued for 4 weeks.

Outcome measures studied

Response to therapy (defined as total cessation of spasms and disappearance of the hypsarrhythmic EEG pattern); relapse rates.

Results

Overall response: 67% (16/24) of the patients resounded to either ACTH (9 patients) or prednisone (7).

Results of initial and crossover phases:
ACTH initial drug: 42% (5/12) responded.
Prednisone initial drug: 33% (4/12) responded.
ACTH at crossover: 50% (4/8) responded.
Prednisone at crossover: 43% (3/7) responded when prednisone was the crossover drug.

Duration of treatment:
Of those who responded 75% (12/16) received only a two-week course of therapy (ACTH 7, prednisone 5) after which the medication was tapered and discontinued and 25% received a six-week course of therapy (ACTH 2, prednisone 2).

Side effects of hormonal therapy:
- Hypertension of >140/90 in 25% (6/24) of the patients. In four of these hypertension developed with both drugs, in two only with prednisone.
- Cerebral shrinkage occurred 62% (10/16) of those on ACTH gel 20U/day or prednisone 2mg/kg/day showed evidence of increased ventricular size or increased subarachnoid space or both compared to baseline CT scans. Of the patients who had a 3rd CT scan 4-6 weeks after discontinuance of all hormonal therapy 42% (6/14) showed these changes.
Partially, the only outcomes are cessation of seizures and adverse events. The authors conclude that there was no major difference in stopping the spasms an between ACTH and that of prednisone.

Safety and adverse effects

Does the study answer the question?

Effect due to factor in study?

Consistency of results with other studies?

Directly applicable to guideline population?

Internal Validity

Allocation concealment;

Clonazepam response: of the 8 patients who did not respond to ACTH or prednisone, 7 were given clonazepam. None responded.

See side effects.

Power calculation of 24 infants given and they had 24 infants included in the study. The methodology not described well and so can not be sure effect overall is due to intervention.

Does the study answer the question?

The authors conclude that there was no major difference in stopping the spasms an between ACTH and that of prednisone.

Consistency of results with other studies?

Direct.

Internal Validity

Allocation concealment;

Lux AL; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Newton RW; O’Callaghan FJ; Verity CM; Osborne JP;

The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial

Ref ID 4649 2004

Study Type Randomised Controlled Trial Funding Grant from the Bath Unit for Research in Paediatrics. FJKO’C was supported by the wellcome trust and AL and EH by Cow and Gate.

Number of participant Total: 107 patients.

Vigabatrin: 52.

Hormonal treatment - prednisolone: 30; tetracosactide: 25.

Inclusion/Exclusion Criteria

Inclusion criteria:

Clinical diagnosis of infantile spasms by the consultant in charge and a hypsarrhythmic or similar EEG with almost continuous, high-voltage multifocal spike and wave.

Exclusion criteria:

Aged under 2 months or over 12 months old;

Diagnosis or high risk of tuberous sclerosis;

Previous treatment (within past 28 days) with or a contraindication to vigabatrin or hormonal treatments;

A lethal or potentially lethal disorder other than infantile spasms;

Inability of parents or guardians to give informed signed consent or to know when spasms stop;

Known that leaving the UK within 1 month or randomisation;

Enrolment in a concurrent trial that used treatment that may affect the outcome measures of the trial or one that was labour-intensive for the patients, guardians or medical practitioners.

Patient Characteristics Vigabatrin vs prednisolone vs tetracosactide

Gender:

Male: 32 vs 18 vs 14

Female: 20 vs 12 vs 11

Medium age (IQR) in completed months at onset of spasms: 5 (4-7) vs 5 (4-6)* vs 5 (3.5-7)*.

Medium age (IQR) at randomisation (months): 6 (4-9) vs 6 (4-8) vs 6 (5-8).

Mean duration of spasms (IQR) at randomisation (months): 1 (0-1) vs 0 (0-1.5)* vs 1
Higher risk of neurodevelopmental delays**: 22 vs 15 vs 12.
Chromosomal abnormality: 2 vs 2 vs 0.
Syndrome: 2 vs 3 vs 2.
Neonatal encephalopathy with seizures: 8 vs 4 vs 5.
Cerebral palsy before spasms: 10 vs 8 vs 4.
Delayed development before spasms: 19 vs 13 vs 12.

Underlying aetiology:
Prenatal: 15 vs 8 vs 6
Perinatal: 9 vs 5 vs 3.
Postnatal: 0 vs 2 vs 1.
Other (uncertain classification) 6 vs 2 vs 2.
No aetiology found: 21 vs 13 vs 12.
Not known (cranial imaging not reported) 1 vs 0 vs 1.
*unknown in two infants. # Unknown in one infant. ***Some infants had more than one risk factor.

### Recruitment
Local consultants enrolled infants from 150 hospitals in the UK.

### Setting
Hospitals, UK. Central randomisation - Bath, UK.

### Interventions/ Test/ Factor being investigated
Prednisolone (originally Prednesol, Glaxo Wellcome, then soluble prednisolone tablets after a change of license); Tetracosactide depot and vigabatrin. The drugs were randomised to 1:1:2 respectively.

Prednisolone was given orally (10mg four times a day for 2 weeks increasing to 20mg three times a day after 1 week if spasms continued).

Tetracosactide depot was given intramuscularly (0.5mg on alternated days for 2 weeks and increased to 0.75mg on alternate days after 1 week if seizure control had not been achieved.

Those on prednisolone or tetracosactide after 2 weeks received a reducing dose of prednisolone with reductions of 10mg every 5 days or, if on the higher dose of treatment, 40mg daily, then 20mg, then 10mg for 5-day periods.

Vigabatrin was given orally in two divided doses per day (50mg/kg per day for the first two dose; increasing to 100mg/kg/per day after 24 hours and if the spasms continued to 150mg/kg per day after 96 hours.

A daily diary was used to record the treatment given, the number of spasm clusters, the largest no. of spasms in a cluster, any treatment missed and any adverse events. T

The local investigator reviewed diaries on day 14. Diaries and the investigator's report were used to confirm the days on which spasms occurred.

B.P and urine were checked. BP twice a day for 2 days then weekly and urine checked for glucose at 48 hours and weekly.

### Comparisons
Comparisons between treatments.

### Length of Study/ Follow-up
Follow-up 14 days then every 3 months until aged 14 months.

### Outcome measures studied
Cessation of spasms; resolution of hypsarhythmia; relapse rates; development at 14 months old; seizure rates at 14 months old.

### Results
Cessation of spasms:
40/55 infants (73%) allocated hormonal treatment; prednisolone group: 21, tetracosactide 19.
Vigabatrin group: 28/52 (54%) - difference 19%, 95% CI 1%-36%; X2=4.1, p=0.043.

Cessation of spasms occurred in 53 (64%) of 83 infants who the initial EEG was reported as hypsarhythmia and in 15 (63%) of 24 in who the EEG was not (hormonal treatments 30/39 (77%) and 10/16 63%) respectively: vigabatrin 23/44 (52%) and 5/8 (63%).
| Safety and adverse effects | Vigabatrin vs prednisolone vs tetracosactide:  
No. of infants with adverse events: 28 vs 19 vs 11.  
Treatment unchanged: 19 vs 14 vs 8*.  
Treatment not increased as protocol required: 7 vs 3 vs 2*.  
Treatment reduced: 2 vs 1 vs 1*.  
Specific adverse events:  
Gastrointestinal: 11 vs 7 vs 5.  
Irritability: 2 vs 12 vs 7.  
Drowsiness: 14 vs 5 vs 1.  
Infection: 5 vs 3 vs 0.  
Increased appetite: 1 vs 4 vs 3.  
Dermatological: 2 vs 1 vs 3.  
Fluid and electrolyte (including high blood pressure): 0 vs 3 vs 2.  
Neuropsychiatric (including sleep disturbance): 4 vs 1 vs 0.  
Hypertonia: 0 vs 1 vs 1.  
Treatment for varicella exposure: 0 vs 1 vs 1.  
Other: 5 vs 3 vs 4.  
*Treatment actions not mutually exclusive.  
The authors point out that adverse events were reported in similar number s for hormonal and vigabatrin treatments. These events didn’t occur in the three infants not receiving their allocated treatments. One had a blood pressure of above 120/90mm Hg, but was asymptomatic and did not need treatment. Infants showed increased irritability and appetite on hormonal treatments and more drowsiness on vigabatrin.  
Treatment had to be stopped for one child in each hormonal group.  
No deaths occurred in the first 14 days after randomisation. Blood pressure above 110/80mm Hg occurred in 11 (20%) of 55 infants allocated to hormonal treatments (7 (23%) on prednisolone, 4 (16%) on tetracosactide) and above 120/90mm Hg in 8 (15%) of 55 (four (13%) on prednisolone, four (16%) on tetracosactide), and two infants allocated prednisolone were given diuretics. Glycosuria was recorded in one patient allocated to tetracosactide, but no infants needed treatment for this or for treatment to be stopped for diabetes mellitus. |
| Does the study answer the question? | Partially as includes cessation of spasms and adverse events as outcomes.  
The authors concluded that cessation of spasms was more likely in infants given hormonal treatments than those who were given vigabatrin. Adverse events were common in both treatments. |
| Effect due to factor in study? | For 90% power they needed 250 patients. They had to finish study early due to absence of funds and the authors said that the number of infants enrolled by the end of December 2002 should give them nearly 80% power to detect the difference in effect seen by Vigean (1997).  
There was adequate randomisation and allocation concealment but a lack of blinding of participants or outcome assessors which could have a bias. |
| Consistency of results with other studies? | Direct for the prednisolone and vigabatrin interventions but not applicable for the tetracosactide intervention. The population is of direct interest. |
| Directly applicable to guideline population? | No blinding, |
| Internal Validity | Omar FZ;Al-AbdulWahab NO;Ali BM;Karashi FA;Al-Musallam SA;  
Vigabatrin versus ACTH in the treatment of infantile spasms  
Ref ID 3134 |
| Study Type | Randomised Controlled Trial  
Funding | Not reported. |
**Patient Characteristics**

- **Age:** 3 and 10 months of age (mean age 5.2 months).
- **Gender:** Males: 20; Females: 12.
- **25 patients (78.1%)** showed hypersynchronia and 7 patients (21.8%) had burst suppression pattern
- **28 patients (87.5%)** showed typical flexor spasms and 4 (12.5%) showed extensor spasms.
- **Newly diagnosed and had not been previously treated before.**

**Aetiology:**
- Cryptogenic: 16 (50%).
- Hypoxic ischemic encephalopathy at birth: 4 (12.5%).
- Tuberous Sclerosis: 2 (6.25%).
- Cortical dysplasia: 1 (3.125%).
- Prematurity: 2 (6.25%).
- Metabolic: 3 (9.375%).
- Others: 4 (12.5%).

**Recruitment**

- Not reported.

**Setting**

- Sulaimania Children Hospital, Saudi Arabia.

**Interventions/ Test/ Factor being investigated**

- Complete history taken form mother or caregiver.
- Systemic examination performed on all patients including systems review, chorionic villus sampling, respiratory, abdomen as well as general growth and presence or absences of dysmorphism.
- Skin examination by wood's light and neurodevelopmental evaluation was conducted.
- One group received ACTH (20 IU intramuscular daily) and the other received vigabatrin (average 87mg/kg/day) monotherapy.

**Comparisons**

- Comparison between treatments:
  - ACTH vs vigabatrin.

**Length of Study/ Follow-up**

- Median follow-up: 6.4 months (range 2 months- 1 year).

**Outcome measures studied**

- Seizure cessation: Partial recovery (improvement but not complete disappearance); Time taken to recovery.

**Results**

**ACTH vs vigabatrin:**

- **Seizure cessation:**
  - 12 patients (75%) seizures completely disappeared vs 11 patients (68.7%).

- **Partial recovery:**
  - 4 patients (25%) vs 5 patients (31.2%).
  - Time taken for recovery was shorter in vigabatrin group: median 5 days.

- **Time to initial improvement:**
  - 10 infants (62.5%) had a median response time of 9 days, in the first 10 days vs 9 infants (56.25%) in 4 days.

- **Response was more appreciated in the vigabatrin group with a known etiology.**

**Safety and adverse effects**

- Vision was checked by Ophthalmologist before and at 6 monthly intervals for at least one year after stopping vigabatrin - no significant changes found at 6 months.
- Other side effects: weight gain, somnolence, agitation were encountered in the vigabatrin group but were mild and did not require the cessation of medication.

- Side effects were noted in the younger age group (5 months or below): 14 patients (78.5%) out of 16 suffered side effects in the ACTH group vs 4/16 patients (25%) in the vigabatrin group had some drowsiness, none had visual disturbances.

---

29 July 2010  Page 216 of 306
Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study

Ref ID 4613

**Does the study answer the question?**

Partially as includes cessation of seizures.

The author concluded that vigabatrin is an effective therapy for infantile spasms and has been shown to be as effective as ACTH, with less hospital dependency and milder side effects.

Differences were probably due to the underlying aetiology.

**Effect due to factor in study?**

No the methodology is unclear so cannot have certainty.

**Consistency of results with other studies?**

Direct.

**Internal Validity**

allocation concealing, randomisation, blinding.

**Vigevano F; Cilio MR;**

Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study

Ref ID 4613

1997

**Study Type**

Randomised Controlled Trial

**Funding**

Not reported.

**Number of participant**

Total: 42 infants.
Vigabatrin arm: 23.
ACTH arm: 19.

**Inclusion/Exclusion Criteria**

Inclusion:
Newly diagnosed and previously untreated infantile spasms.

**Patient Characteristics**

Vigabatrin vs ACTH

Gender:
Males: 14 vs 7.
Females: 9 vs 12.

Cryptogenic: 7 vs 8.
Symptomatic: 16 vs 11.

Age at onset: 2.5-9 months (mean 5.8) vs 2-9 months (mean 5.3).

**Recruitment**


**Setting**

Italy. Not reported where.

**Interventions/ Test/ Factor being investigated**

All patients had an ictal video-EEG recording before treatment and CT scan or MRI. They were classified as cryptogenic and symptomatic. Therapy was started 1-3 weeks after the onset of spasms.

Phase 1:
Randomised to receive either 100-150mg vigabatrin in two daily doses or 10 IU Depot ACTH in one morning dose.
If spasms did not cease after 20 days of therapy or they had intolerance the patient received the alternative drug for at least 20 days (crossover phase 2).

ACTH dosage was constant; Vigabatrin was administered initially ~100mg/kg/day once a day. If efficacy was poor and no side effects after 3 days the viagabatrin dose was increased to 125mg/kg per day then to 150mg/kg day after another 3 days.

EEG was recorded every 10 days with prolonged (at least 2 hours) video-EEG recording of a sleep/wake cycle.
Comparison between treatments:
Vigabatrin versus ACTH.

Follow-up of study was 40 days: 20 days for phase 1 and 20 days for phase 2.

No outcome measures explicitly stated. Cessation of spasms; adverse events.

Vigabatrin vs ACTH:
Cessation of spasms: 11 (48%) vs 14 (74%), p=0.12.

Phase 1 and Phase 2 results:
Cessation of spasms: 2/5 (40%) vs 11/12 (92%) p=0.052.
Total efficacy results 12/28 (46%) vs 25/31 (81%) p=0.007.

Vigabatrin vs ACTH:
3 (13%) vs 7 (37%) not statistically significant p=0.14.
Drowsiness: 2 (9%) vs 0.
Hypotonia 2 (9%) vs 0.
Irritability 1 (4%) vs 7 (37%).
Hypertension 0 vs 7 (37%).

Discontinuation due to side effects: 1 (4%) vs 1 (5%).

The authors conclude that vigabatrin offers an effective and possibly safer therapy for managing infantile spasms than ACTH. It should be considered for use as first-line therapy for infantile spasms.

No. No power calculation and methodology is limited, it is open and has no statement of concealed allocation.

Yes.

Allocation concealment; blinding.

Question: How effective and cost-effective are anti-epileptic drugs for Lennox-Gastaut syndrome
Grading: 1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias

Motte J; Trevathan E; Arvidsson JF; Barrera MN; Mullens EL; Manasco P;


Ref ID 4614 1997

Study Type Randomised Controlled Trial

Funding Glaxo Wellcome

Number of participant 169 in total
Lamotrigine: 79; Placebo: 90

Inclusion/Exclusion Criteria

Inclusion: aged 3 to 25 years, more than one type of predominantly generalised seizure (including tonic-clonic seizures and drop attacks) for at least 1 year, aged under 11 years old when epilepsy first started, seizures at least every other day or with similar average frequency, intellectual impairment or clinical impairment of intellectual impairment, recent electroencephalogram demonstrating an abnormal background and pattern of slow spike-and-wave complexes.

Exclusion: progressive neurodegenerative disorder, receiving more than 3 antiepileptic drugs, weighed less than 15 kg and taking valporate

Patient Characteristics

In the lamotrigine group the mean age was 9.6 (sd 5.2) years, 54 were male, the mean weight was 32.5 (sd 18.1) kg, the mean height was 129.4 (sd 27) cm. 74 were white, 3 were black and 2 were of other race. Concomitant treatment with antiepileptic drugs: 53 valporate, 16 carbamazepine, 10 phenytoin, 11 other. 73 had moderate or severe intellectual impairment, 31 had a history of infantile spasms, 20 had a history of status epilepticus, 3 did not know if they had a history of status epilepticus.

In the placebo group the mean age was 10.9 (sd 5.9) years, 45 were male, the mean weight was 34.3 (sd 19.7) kg, the mean height was 130.9 (sd 26.8) cm. 84 were white, 3 were black and 3 were of other race. Concomitant treatment with antiepileptic drugs: 50 valporate, 30 carbamazepine, 13 phenytoin, 9 other. 82 had moderate or severe intellectual impairment, 37 had a history of infantile spasms, 24 had a history of status epilepticus, 2 did not know if they had a history of status epilepticus.

Recruitment Not reported.

Setting Not reported

Interventions/ Test/ Factor being investigated Lamotrigine added to patients standard antiepileptic drugs

Comparisons Placebo added to patients standard antiepileptic drugs

Length of Study/ Follow-up 16 weeks of treatment
4 weeks of follow up was reported

Outcome measures studied Number of patients who had greater than 50% reduction in the frequency of seizures, adverse events.

Results The study reported that valporate can inhibit the clearance of lamotrigine and increase plasma lamotrigine concentrations. Therefore patients were assigned to one of 4 dosage schedules (see below). These were according to weight and if the patient was taking valporate. At the end of treatment the drug was gradually discontinued, continuing the double blinded method) by reducing to dose to 50% for 2 weeks then 25% for another 2 weeks.

Dosage schedule:
For patients weighing less than or equal to 25 kg and who were taking valporate: for weeks 1 and 2 they were given 5 mg lamotrigine, for weeks 3 and 4 they were given 10 mg, weeks 5 and 6 they were given 25 mg, week 7 and 8 the were given 50 mg, for weeks 9 to 16 they were given 50 to 100 mg.
For patients weighing more than 25 kg and who were taking valporate; for weeks 1 and 2 they were given 10 mg lamotrigine, for weeks 3 and 4 they were given 25 mg, weeks 5 and 6 they were given 50 mg, week 7 and 8 the were given 100 mg, for weeks 9 to 16 they were given 100 to 200 mg.

For patients weighing less than or equal to 25 kg and not taking valporate; for weeks 1 and 2 they were given 25 mg lamotrigine, for weeks 3 and 4 they were given 50 mg, weeks 5 and 6 they were given 100 mg, week 7 and 8 the were given 200 mg, for weeks 9 to 16 they were given 200 to 300 mg.

For patients weighing more than 25 kg and not taking valporate; for weeks 1 and 2 they were given 50 mg lamotrigine, for weeks 3 and 4 they were given 100 mg, weeks 5 and 6 they were given 200 mg, week 7 and 8 the were given 300 mg, for weeks 9 to 16 they were given 300 to 400 mg.

Number of patients who had greater than 50% reduction in the frequency of seizures:
In the lamotrigine group 33% had a greater than 50% reduction in the frequency of all major seizures compared to 16% in the placebo group. 26/78 vs 14/89 (p=0.01)

In the lamotrigine group 37% had a greater than 50% reduction in the frequency of drop attacks seizures compared to 22% in the placebo group. 28/75 vs 20/89 (p=0.04).

In the lamotrigine group 43% had a greater than 50% reduction in the frequency of tonic-clonic seizures compared to 20% in the placebo group. 26/60 vs 13/64 (p=0.007).

Adverse events:
In the lamotrigine group 11/79 (14%) patients had pharyngitis, 10/79 (13%) had fever and 10/79 (13%) had infection.
In the placebo group 9/90 (10%) patients had pharyngitis, 12/90 (13%) had fever and 7/90 (8%) had infection.

Safety and adverse effects

Does the study answer the question?
Yes, In the lamotrigine group 33% had a greater than 50% reduction in the frequency of all major seizures compared to 16% in the placebo group. 26/78 vs 14/89 (p=0.01).
In the lamotrigine group 11/79 (14%) patients had pharyngitis, 10/79 (13%) had fever and 10/79 (13%) had infection.
In the placebo group 9/90 (10%) patients had pharyngitis, 12/90 (13%) had fever and 7/90 (8%) had infection.

Effect due to factor in study?
This was a well conducted double blind randomized study. However, no prior consideration of statistical power has been made.

Consistency of results with other studies?
Direct.

Directly applicable to guideline population?
Direct.

Funding

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group

Ref ID 4606

Study Type Randomised Controlled Trial

29 July 2010 Page 220 of 306
Participants aged 1 to 30 years were eligible if they had an EEG showing a slow spike and wave pattern and seizure types ... before the study; nephrolithiasis; treatment with an experimental drug or use of an experimental device within 60 days of baseline; treatment with a ketogenic diet or adrenocorticotropic hormone within 6 months before the study; use of benzodiazepines on more than an occasional basis; presence of clinically significant EKG abnormalities; or history of an inability to take medication or maintain a seizure calendar.

Patient Characteristics
Participants aged 1 to 30 years were eligible if they had an EEG showing a slow spike and wave pattern and seizure types including drop attacks and atypical absence seizures, with a frequency of at least 60 seizures during the month prior to the baseline phase while being maintained on one or two standard AEDs. At study entry 39/98 of the patients were receiving maintenance doses of one concomitant AED. 56/98 were receiving two AEDs, and 3/78 were receiving 3 concomitant AEDs (one patient randomised to placebo and 2 patients randomised to topiramate).

Recruitment
Not reported.

Setting

Interventions/ Test/ Factor being investigated
Topiramate versus placebo

Comparisons
Topiramate versus placebo

Length of Study/ Follow-up
Outcomes reported were cessation and reduction in drop attacks and overall reduction of all seizure types.

Results
Placebo n=50 and Topiramate n=48.
The trial consisted of a baseline phase of four weeks and an 11 week treatment phase. The participants were titrated up to a dose of 6 mg/kg/day or their maximal tolerated dosage of either topiramate or placebo over the first three weeks of the treatment period.

Results were given for 97 participants.
This study reported the effect of treatment on drop attacks and the reduction of overall seizures. Thirteen out of 46 (28%) of the topiramate participants achieved a ≥50% reduction in drop attacks compared to 7/49 (14%) of the control group (p=0.071). A ≥75% reduction in drop attacks was achieved in 8/46 (17%) of the topiramate group compared to 3/49 (6%) in the control group. One out of 46 participants treated with topiramate had complete cessation of their drop attacks compared with none of the 50 participants treated with placebo.

The percentage of patients with ≥50% reduction from baseline in major seizure during the double-blind was 15/46 (33%) for the topiramate group and 4/50 (8%) for the control group (p=0.002). Eight participants treated with topiramate and two participants treated with placebo had a 75% to 100% reduction.

This study did not report the effect of treatment on stopping or reducing the number of absence, tonic, clonic, myoclonic, tonic-clonic or partial seizures or the effect on stopping all seizure types.

Adverse events (at least 10% of study arm):
Placebo (n=50): 22% somnolence; 20% anorexia; 10% nervousness; 10% behavioural problems; 4% fatigue; dizziness 0%; weight loss 0%. Topiramate (n=48): 42% somnolence; 40% anorexia; 21% nervousness; 21% behavioural problems; 19%
fatigue; 10% dizziness; 10% weight loss.

Safety and adverse effects

Does the study answer the question?

Effect due to factor in study?

Consistency of results with other studies?

Directly applicable to guideline population?

Internal Validity

No participant was reported as having had treatment stopped due to adverse effects and no deaths were reported.
Glauser T; Kluger G; Sachdeo R; Krauss G; Perdomo C; Arroyo S; Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. [see comment]

Patient Characteristics

Rufinamide: 74; Placebo: 64.

Inclusion: aged 4 to 30 years, history of multiple seizure types including atypical absence seizures and drop attacks, minimum of 90 seizures in previous month, EEG within previous 6 months showing slow spike-and-wave complexes (<2.5Hz), weighed at least 18kg, fixed regime of 1 to 3 concomitant antiepileptic drugs during baseline period, CT or MRI confirming absence of progressive lesion.

Exclusion: on more than 3 antiepileptic drugs, pregnant or not using adequate contraception, correctable etiology of their seizures, history of generalised tonic-clonic status epilepticus within previous 30 days, history of clinically significant nonneurological medical condition.

Recruitment

Not reported.

Setting

Not reported.

Interventions/ Test/ Factor being investigated

Rufinamide, the target dose of 45mg/kg was achieved by 65 patients (87.8%).

Placebo, the target dose of 45mg/kg was achieved by 64 patients (all patients).

Comparisons

Length of Study/ Follow-up

Outcome measures studied

Number of patients who were seizure free, number of patients who had at least 50% reduction in seizure frequency; adverse events; drop outs.

Results

Number of patients who were seizure free:

No patients were seizure free in either group.

Number of patients who had at least 50% reduction in seizure frequency per 28 days:

In the rufinamide group the number of patients who had at least 50% reduction in tonic-atomic seizure frequency per 28 day was greater than in the placebo group 42.5% compared to 16.7% (OR 3.81, p=0.002).

In the rufinamide group the number of patients who had at least 50% reduction in total seizure frequency per 28 day was greater than in the placebo group 31.1% compared to 10.9% (p=0.0045).

Drop outs:

10 patients in the rufinamide group dropped out; 6 due to adverse events, 3 due to unsatisfactory, 1 due to withdrawal of consent.
5 patients dropped out of the placebo group; 2 due to protocol violations, 1 due to unsatisfactory treatment effect, 1 due to administrative problems and 1 withdrawal of consent.

Adverse events:
In the rufinamide group 60 patients had adverse events. 18 had somnolence, 16 had vomiting, 10 had pyrexia, 4 had diarrhea.
In the placebo group 52 patients had adverse events. 4 had somnolence, 4 had vomiting, 11 had pyrexia, 7 had diarrhea.

Safety and adverse effects
In the rufinamide group 60 patients had adverse events. 18 had somnolence, 16 had vomiting, 10 had pyrexia, 4 had diarrhea.
In the placebo group 52 patients had adverse events. 4 had somnolence, 4 had vomiting, 11 had pyrexia, 7 had diarrhea.

Does the study answer the question?
Effect due to factor in study?
Consistency of results with other studies?
Directly applicable to guideline population?
Internal Validity

Children aged 6 months to 5 years. This study evaluates a specific sub-group of children with prolonged convulsive febrile seizures.

intranasal midazolam (0.2mg/kg) and intra-venous diazepam (0.3mg/kg) in the treatment of prolonged febrile seizure (a seizure of at least 10 minutes duration). Treatment was successful if the clinical features of the seizure stopped within 5 minutes. If the seizure stopped between 5 and 10 minutes this was identified as a delayed but successful treatment. Treatment failures (continued seizure activity after 10 minutes) received intravenous diazepam and then phenobarbital as per local guidelines.

Comparisons
intranasal midazolam and intra-venous diazepam

Study Type
Randomised Controlled Trial

Number of participant
A total of 44 patients of both sexes with a total of 52 seizure episodes were evaluated. In midazolam was given for 26 episodes of febrile seizures in 21 children and IV diazepam for 26 episodes in 23 children.

Inclusion/Exclusion Criteria
All children aged 6 months to 5 years who presented with febrile seizures lasting for at least 10 minutes were included. Children who had received an anticonvulsant or had an intravenous line sited by paramedics prior to hospital attendance were excluded from the study.

Patient Characteristics
Children aged 6 months to 5 years. This study evaluates a specific sub-group of children with prolonged convulsive febrile seizures.

Recruitment
From a paediatric emergency department at a General Hospital.

Setting
paediatric emergency department, Israel.

Interventions/Test/Factor being investigated
intranasal midazolam and intra-venous diazepam

Comparisons
intranasal midazolam and intra-venous diazepam

Length of Study/Follow-up
Children were observed up to 24 hours after cessation of seizures.
<table>
<thead>
<tr>
<th>Outcome measures studied</th>
<th>Cessation of seizures within a given time frame (7-10 minutes), and seizure-recurrence at 1 hour.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Results</td>
<td>Treatment was successful if the seizure stopped within 5 minutes. Seizures that stopped between 5 and 10 minutes after treatment were defined as successful but delayed control of seizure. Seizures that did not stop within 10 minutes after treatment were defined as treatment failures, and IV diazepam 0.3 mg/kg was given. Intranasal midazolam and intravenous diazepam were found to be equally effective in prolonged febrile convulsions. 23/26 (88%) in the midazolam group and 24/26 (92%) in the diazepam group, RR 0.96 (95% CI 0.8 - 1.14). Mean time from arrival in hospital to seizure cessation was shorter in the midazolam group (6.1 minutes [6.3-6.7] versus 8.0 minutes [7.9-8.3]). Time of cessation of seizure from drug administration was shorter in the diazepam group (2.5 [2.4-2.6] versus 3.1 [2.9-3.3]). No children in either group had clinical signs of respiratory depression (as assessed by continuous pulse oximetry and 15 minute-blood pressure measurements) during or in the 60 minutes following the seizure.</td>
</tr>
<tr>
<td>Safety and adverse effects</td>
<td>No adverse events, including respiratory depression were identified in either group.</td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>the study showed that time from hospital admission to seizure cessation was significantly faster despite the fact that intravenous diazepam was faster acting when drug administration to seizure cessation was measured. Although not stated in the paper, this presumably reflects the time to obtain intravenous access.</td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>Randomisation was allocated in advance by way of a random number table and investigators received an opaque envelope with each allocation at the time of administration. Randomisation is adequate with similar patient demographics in both groups. In addition this study evaluates a specific sub-group of children with prolonged convulsive febrile seizures. This is important as the aetiology of seizures varies across the age ranges during childhood thereby potentially affecting results. The study was unblinded.</td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>Direct study</td>
</tr>
<tr>
<td>Directly applicable to guideline population?</td>
<td>Direct study</td>
</tr>
<tr>
<td>Internal Validity</td>
<td></td>
</tr>
</tbody>
</table>
### Grading: 1-
Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*

Eriksson AS; Nergardh A; Hoppu K;

The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study

Ref ID 4612 1998

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Randomised Controlled Trial</th>
<th>Funding</th>
<th>Funded with grants from the voluntary sector.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participant</td>
<td>Thirty participants of whom 20 had Lennox Gastaut Syndrome. Each patient acted as his or her own control during the double-blind cross-over phase.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>Exclusion criteria: presence of liver, renal or progressive neurologic disease, or the diagnosis of focal epilepsy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Characteristics</td>
<td>Children and adolescents aged older than 2 years with refractory (defined as not seizure free despite attempts with at least 3 conventional AEDs) or intractable generalised epilepsy. Thirty consecutive patients of whom 20 had Lennox Gastaut Syndrome. 15 boys and 15 girls took place in the study. The median age was 9.9 years (range 2.5-22 years). The median duration of epilepsy was 8.3 years (range 1.4-19.1 years).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td>Referred to the Department of Child Neurology, Karolinska Hospital if they had more than 2 seizures per month.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Setting</td>
<td>Secondary Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interventions/ Test/ Factor being investigated</td>
<td>Lamotrigine and placebo were randomly added to existing Aeds.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparisons</td>
<td>Lamotrigine compared to placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length of Study/ Follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>Reduction rates of all seizures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td>The trial consisted of six phases: an 8 week baseline phase during which each child was observed on pre-study medication. An open phase during which an attempt was made to find the optimal lamotrigine dose for each child. A double-blind phase of two 12-week periods during which, for each child, lamotrigine and placebo tablets were administered in random order. The treatment periods were separated by a 3-week washout phase. Results were given for 13 patients. At the end of the open phase, 7 out of 27 children showed a ≥50% seizure reduction, and 2 had &gt;75% seizure reduction. Ten children were classified as non-responders. The authors reported that 9 out of 15 children who completed the double-blind phase of the trial showed a &gt;50% seizure reduction during the Lamotrigine phase, compared with the placebo phase. One child showed a 100% reduction and another child showed &gt;75% reduction in seizure frequency. The effect of treatment on the reduction in number of tonic, atonic, myoclonic and partial seizures was not reported. From the non-responders group (10 children), one child had ataxia and double vision. This symptom disappeared when carbamazepine dose was reduced by 100mg in patient 29 to 600mg/day and when the LTG dose was decreased by 50mg to 200mg/day in patient 10. No adverse events were reported during the Lamotrigine phase in the double-blind period. When receiving placebo, 10 children complained of fatigue, and four children had more intense seizures.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

29 July 2010 Page 226 of 306
Does the study answer the question?

Effect due to factor in study?

Consistency of results with other studies?

Directly applicable to guideline population?

Internal Validity

ITT not performed. Cross-over trial

The Felbamate Study Group in Lennox Gastaut syndrome;

Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

Ref ID 4676 1993

Study Type Randomised Controlled Trial

Funding Wallace Laboratories, Division of Carter-Wallace, Inc and Public health services grant

Number of participant 79 patients in total
Felbamate: 37; Placebo: 36

Inclusion/Exclusion Criteria

Inclusion: history of multiple types of seizures, minimum of 90 atonic seizures or atypical absence seizures per month during the previous 8 weeks, not taking more than 2 antiepileptic drugs, no evidence of progressive central nervous system lesions on MRI or CT, weighed over 11.3 kg, slow spike-wave complex (greater than or equal to 2.5 Hz) on electroencephalography

Exclusion: history of identifiable neurological disorders, anoxic episodes within the last year, poor compliance with past antiepileptic therapy, recent drug or alcohol abuse, a major medical illness or previous suicide attempts, received corticosteroids on ketogenic diet, inadequate supervision by parents or guardians, females who were pregnant or not using adequate contraception

Patient Characteristics

51 out of 73 were male, 22 out of 73 were female

In the felbamate group (37 in total) the mean age was 12 years, range 4 to 24 years, the mean weight was 37 kg, range 18 to 99.5kg, 27 were male, 33 were white, 2 were black and 2 were of other race. The baseline seizure frequency in 28 days was 370 atonic seizures, 1617 in total, 9 tonic-clonic. The mean number of antiepileptic drugs previous taken was 8, range 3 to 16.

In the placebo group (36 in total) the mean age was 14 years, range 4 to 36 years, the mean weight was 40 kg, range 14.2 to 86.4kg, 24 were male, 33 were white, 1 was black and 2 were of other race. The baseline seizure frequency in 28 days was 228 atonic seizures, 716 in total, 6 tonic-clonic. The mean number of antiepileptic drugs previous taken was 8, range 4 to 12.

Recruitment Not reported

Setting Not reported

Interventions/ Test/ Factor being investigated Felbamate (200mg)

Comparisons between felbamate and placebo.

Length of Study/ Follow-up 14 day titration period and 56 day maintenance period.
No follow up reported

Outcome measures studied Number who were seizure free; adverse events
The trial consisted of a 14 day titration period and a 56 day maintenance period. The first dose of 15mg per kg was given which was increase to 30 mg per kg after 7 days and to 45 mg per kg or 3600mg per day after 14 days. Patients were monitored by close circuit television and electroencephalography on days 42, 49, 70 and 98.

During the treatment phase in the felbamate 3 out of 37 were seizure free as recorded by close circuit television and electroencephalography compared to 1 out of 36 in the placebo group. During the maintenance phase 6 of 37 were seizure free in the felbamate group compared to 1 out of 35 in the placebo group.

During the treatment phase in the felbamate 3 out of 28 were seizure free of atonic seizures compared to 0 out of 22 in the placebo group. During the maintenance phase 5 of 28 were seizure free in the felbamate group compared to 0 out of 22 in the placebo group.

During the treatment phase in the felbamate 0 out of 37 were seizure free of total seizures compared to 0 out of 36 in the placebo group. During the maintenance phase 4 of 37 were seizure free in the felbamate group compared to 1 out of 36 in the placebo group.

During the treatment phase in the felbamate 2 out of 16 were seizure free of generalized tonic-clonic seizures compared to 1 out of 13 in the placebo group. During the maintenance phase 7 of 16 were seizure free in the felbamate group compared to 1 out of 13 in the placebo group.

Adverse events:
In the felbamate group 14 patients had upper respiratory tract infections, 18 had anorexia, 15 had vomiting, 16 had somnolence, 6 had injury, 8 had fever, 6 had insomnia, 5 had nervousness, 4 had headaches, 1 had diarrhoea, 6 had fatigue, 4 had purpura, 5 had abnormal gait, 4 had ataxia and 1 had rhinitis.
In the placebo group 10 patients had upper respiratory tract infections, 5 had anorexia, 5 had vomiting, 3 had somnolence, 10 had injury, 5 had fever, 5 had insomnia, 5 had nervousness, 5 had headaches, 8 had diarrhoea, 2 had fatigue, 3 had purpura, 0 had abnormal gait, 1 had ataxia and 4 had rhinitis.

Safety and adverse effects

Does the study answer the question?

During the treatment phase in the felbamate 0 out of 37 were seizure free of total seizures compared to 0 out of 36 in the placebo group. During the maintenance phase 4 of 37 were seizure free in the felbamate group compared to 1 out of 36 in the placebo group.

During the treatment phase in the felbamate 2 out of 16 were seizure free of generalized tonic-clonic seizures compared to 1 out of 13 in the placebo group. During the maintenance phase 7 of 16 were seizure free in the felbamate group compared to 1 out of 13 in the placebo group.

Adverse events:
In the felbamate group 14 patients had upper respiratory tract infections, 18 had anorexia, 15 had vomiting, 16 had somnolence, 6 had injury, 8 had fever, 6 had insomnia, 5 had nervousness, 4 had headaches, 1 had diarrhoea, 6 had fatigue, 4 had purpura, 5 had abnormal gait, 4 had ataxia and 1 had rhinitis.
In the placebo group 10 patients had upper respiratory tract infections, 5 had anorexia, 5 had vomiting, 3 had somnolence, 10 had injury, 5 had fever, 5 had insomnia, 5 had nervousness, 5 had headaches, 8 had diarrhoea, 2 had fatigue, 3 had purpura, 0 had abnormal gait, 1 had ataxia and 4 had rhinitis.

Effect due to factor in study?

Uncertain due to high risk of selection bias (absence of allocation concealment).
Consistency of results with other studies?

Directly applicable to guideline population?

Internal Validity

Question: How effective and cost-effective are anti-epileptic drugs for Severe myoclonic epilepsy of infancy (SMEI)
Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial.

**Grading:** 1+

Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias

**Chiron C;Marchand MC;Tran A;Rey E;d’Athis P;Vincent J;Dulac O;Pons G;**

**Study Type** Randomised Controlled Trial

**Funding** Biocodex, France.

**Number of participant** N=21, n stiripentol=21 and n placebo=20

**Inclusion/Exclusion Criteria**

Inclusion criteria: children 3 years and older, SMEI, defined as onset of the epilepsy in the first year of life with clonic (or tonic-clonic) generalized seizures but normal psychomotor development and normal EEG, appearance of myoclonia after 1 year of age, atypical absences, generalised spikes and waves on EEG, mental delay, at least four clonic (or tonic-clonic) generalized seizures a month, valproate and clobazam as ongoing antiepileptic drugs. Exclusion criteria: patients receiving other drugs (except progabide) and those whose parents were unable to comply regularly with drug delivery and daily seizure diary.

**Patient Characteristics**

Mean age was 9.4 years and 9.3 years for stiripentol and placebo groups respectively. 6/21 were males in stiripentol and 5/20 in placebo. The two groups had similar mean weights (32 kg for the stiripentol and 21 kg for the placebo). The mean dose valproate was 23.7 and 24 mg/kg daily for the stiripentol and placebo groups respectively, and the mean dose of clobazam was 0.53 and 0.55 mg/kg a day for the stiripentol and placebo groups respectively. 5/21 patients in stiripentol group and 2/20 in placebo were on progabide.

**Recruitment**

Not reported.

**Setting**

15 French centers.

**Interventions/ Test/ Factor being investigated**

Stiripentol as add-on therapy of epilepsy for children with SMEI.

**Comparisons**

Comparison are made between patients received stiripentol and the placebo group.

**Length of Study/ Follow-up**

1 month baseline (no treatment), 2 months follow up (double blind treatment phase) and 1 month open treatment. Results are reported for the assessment of outcomes at the end of 2 months follow up.

**Outcome measures studied**

1) >50% reduction in seizure frequency
2) seizure freedom
3) experience of adverse events (>10%)

**Results**

1) 5/21 in stiripentol group and 1/20 on placebo were responders (>50% reduction in seizure frequency).
2) 9/21 patients in stiripentol and 0/20 in placebo became free of clonic (or tonic-clonic) seizures.
3) experience of adverse events (above 10%):
   - drowsiness: 15/21 in stiripentol group and 2/10 in placebo
   - hyperexcitability: 5/21 in stiripentol and 0/20 in placebo
   - aggressiveness: 3/21 in stiripentol and 0/20 in placebo
   - ataxia: 3/21 in stiripentol and 1/20 in placebo
   - tremor: 3/21 in stiripentol and 0/20 in placebo
   - loss of appetite: 7/21 in stiripentol and 1/20 in placebo
   - loss of weight: 6/21 in stiripentol and 0/20 in placebo
   - weight gain: 5/21 in stiripentol and 4/20 in placebo
   - neutropenia (1000-1500/ML): 3/21 in stiripentol and 0/20 in placebo

**Safety and adverse effects**

See Q2-9 in adverse events.

**Ref ID** 4631

**Biocodex, France.**

**Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial.**

**STICLO study group.**

2000

N=21, n stiripentol=21 and n placebo=20

6/21 were males in stiripentol and 2/20 in placebo. The two groups had similar mean weights (32 kg for the stiripentol and 21 kg for the placebo). The mean dose valproate was 23.7 and 24 mg/kg daily for the stiripentol and placebo groups respectively, and the mean dose of clobazam was 0.53 and 0.55 mg/kg a day for the stiripentol and placebo groups respectively. 5/21 patients in stiripentol group and 2/20 in placebo were on progabide.

**Recruitment**

Not reported.

**Setting**

15 French centers.

**Interventions/ Test/ Factor being investigated**

Stiripentol as add-on therapy of epilepsy for children with SMEI.

**Comparisons**

Comparison are made between patients received stiripentol and the placebo group.

**Length of Study/ Follow-up**

1 month baseline (no treatment), 2 months follow up (double blind treatment phase) and 1 month open treatment. Results are reported for the assessment of outcomes at the end of 2 months follow up.

**Outcome measures studied**

1) >50% reduction in seizure frequency
2) seizure freedom
3) experience of adverse events (>10%)

**Results**

1) 5/21 in stiripentol group and 1/20 on placebo were responders (>50% reduction in seizure frequency).
2) 9/21 patients in stiripentol and 0/20 in placebo became free of clonic (or tonic-clonic) seizures.
3) experience of adverse events (above 10%):
   - drowsiness: 15/21 in stiripentol group and 2/10 in placebo
   - hyperexcitability: 5/21 in stiripentol and 0/20 in placebo
   - aggressiveness: 3/21 in stiripentol and 0/20 in placebo
   - ataxia: 3/21 in stiripentol and 1/20 in placebo
   - tremor: 3/21 in stiripentol and 0/20 in placebo
   - loss of appetite: 7/21 in stiripentol and 1/20 in placebo
   - loss of weight: 6/21 in stiripentol and 0/20 in placebo
   - weight gain: 5/21 in stiripentol and 4/20 in placebo
   - neutropenia (1000-1500/ML): 3/21 in stiripentol and 0/20 in placebo

**Safety and adverse effects**

See Q2-9 in adverse events.
Yes. More patients in stiripentol were responders and seizure free compared to placebo group. However, more participants in stiripentol experienced adverse events compared to placebo.

The study was a well conducted randomized double blind trial, however the absence of allocation concealment may have an impact on the results observed. The study may be underpowered, limited number of events (wide confidence intervals).

Direct.

Question: How effective and cost-effective are anti-epileptic drugs for Benign rolandic epilepsy/benign epilepsy with centrotemporal spikes (BECTS)
Grading: 1+  Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias

Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group

Ref ID 4663 2000

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Randomised Controlled Trial</th>
<th>Number of participant</th>
<th>N=66, n sulthiame group=31, n placebo=35.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>Inclusion criteria: children with a diagnosis of BECTS who had two or more seizures during the past 6 months, between 3 and 10 years of age and weighted between 10-50 kg. Exclusion criteria: patients with severe organic diseases, acute porphyria, a history of mental illness, relevant hypersensitivity, somatic signs of puberty, or relevant renal, thyroid, or hepatic dysfunction, patients pretreated with AEDs after the sixth month of life (an exception was made for those who received acute AED intervention of less than 1 week).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length of Study/ Follow-up</td>
<td>6 month historic baseline period and a 6 month double blind treatment phase.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>Primary outcome measure: rate of treatment failure events (TFEs) in each group. Patients had a TFE if they experienced first seizure after a 7 day run in period, had intolerable AEs, developed another epileptic syndrome or were terminated from the trial.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td>25/31 in STM group and 10/35 in placebo group completed the trial without any treatment failure events. The treatment failure events in sulthiame group were: 4/31 seizures after study admission, 2/31 were taken out of the study when results of the interim analysis available. The treatment failure events for the placebo group were: 21/31 had seizures after a 7 day study admission, 2/35 were taken out of the study when results of the interim analysis available and 2/35 had seizures in the 7 day run in period and requested termination (drop outs). Time to first seizure: 0/31 in STM group and 2/35 in placebo had seizures in the 7 day run in period. 25/31 (80.6%) in STM group and 10/35 (28.6%) in placebo were seizure free. 0/31 in STM group and 0/35 in placebo group had withdraws due to adverse events.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety and adverse effects</td>
<td>No intolerable adverse events were noticed. Leukopenia occurred in two placebo treated patients, and loss of strength and fatigue were each observed in two STM treated patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>Yes. Sulthiame was found to be more effective than placebo in seizure prevention in patients with BECTS aged 3-11 years.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Effect due to factor in study?

This was a well conducted double blind randomized clinical trial. However, the sample size in this trial (N=66) was lower than the minimum sample size calculated for this study (N=140), therefore the study was underpowered.

Consistency of results with other studies?

Direct.

Directly applicable to guideline population?

Direct.

Internal Validity
Grading: 1-

Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*

Coppola G; Franzoni E; Verrotti A; Garone C; Sarajlija J; Operto FF; Pascotto A;

Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial

Ref ID 271

Study Type Randomised Controlled Trial

Funding Not reported.

Number of participant N=38, n LEV =21, n OXC=18.

Inclusion/Exclusion Criteria
Inclusion criteria: age comprised between 3-12 years, newly diagnosis of BECTS according to the International League Against Epilepsy (ILAE) classification, frequent seizures and/or seizures that recur during wakefulness in the last 6 months, partial motor seizures, typically hemifacial or hemiclonic, with or without generalization, EEG features consisting of peculiar focal or multifocal centrotemporal spikes (CTS), increasing in frequency during sleep, on a normal background activity and sleep organization, MRI disclosing normal or slight abnormal findings, absence of neurological and mental deficits, no previous therapy, informed consent by parents or carers. Exclusion criteria were: poor compliance by parents/caregivers to fill in the diary of seizure frequency and adverse events and to undergo the requested clinical controls, progressive neurological and/or systemic disease, patients with pseudoseizures (as diagnosed by MRI scans).

Patient Characteristics
The participants were aged between 3.3 and 14 years (mean 10.7 years) with 21 of them males and 18 females. Mean seizure frequency before starting therapy was 1.6/month during the last 6 months and seizure type was secondary generalised tonic-clonic in about 80% of children.

Recruitment
From the outpatient clinics of Child Neuropsychiatry (Second University of Naples, University of Bologna, University of Chieti, Italy).

Setting
The outpatient clinics of Child Neuropsychiatry.

Interventions/ Test/ Factor being investigated
Levetiracetam (LEV) monotherapy versus oxcarbazepine (OXC) monotherapy.

Comparisons
Between levetiracetam and oxcarbazepine.

Length of Study/ Follow-up
Mean follow up period of 18.5 months (range 12-24 months).

Outcome measures studied
Primary outcome: seizure freedom, proportion of participants having treatment withdrawn, incidence of adverse events, withdrawal due to adverse events.

Results
19/21 (90.5%) in the LEV group and 13/18 (72.2%) in OXC group were seizure free. 2/21 (9.5%) in LEV group and 1/18 (5%) in OXC group had treatment withdrawn due to adverse events. 1/21 (4.8%) in LEV group and 5/18 in OXC (27.7%) had treatment withdrawn due to lack of efficacy. The proportion of adverse side effects was 3/21 (14.3%) in LEV (two participants had decreased appetite, one moderate decreased appetite combined with daily frontal cephalagia) and 2/18 (11.1%) in OXC group respectively (one patient with headache and the other with sedation).

Safety and adverse effects
See Q2 on adverse events.

Does the study answer the question?
Within the limitations of an open trial, both levetiracetam and oxcarbazepine were effective in seizure prevention. However, more participants in LEV group compared to OXC had treatment withdrawn due to adverse events and a higher proportion of children in OXC withdrawn due to lack of efficacy compared to LEV.

29 July 2010
Effect due to factor in study? The study was unblinded, and there was no preconsideration of minimum sample size required to test the efficacy of the two interventions. The study may be underpowered.

Consistency of results with other studies? Serious indirectness. Maximum dose for both levetiracetam and oxcarbamazepine was 20 mg/kg daily (recommendations by BNF for children; maximum dose for levetiracetam is 30mg/kg twice daily and for oxcarbamazepine 23mg/kg twice daily).

Internal Validity

Kang H; Eun B; Wu LC; Ku MH; Kim J; Wook KD; Soo LJ; Young CK; Ho CB; Sook SE; Chae PJ; Lim K; Hye HE; Ho SD; Dong KH;

The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy

Ref ID 1556

2007

Study Type Randomised Controlled Trial

Funding By a grant of JANSSEN, KOREA LIMITED, a Jonhson & Johnson company.

Number of participant N=112 patients, n topiramate =58, n carbamazepine = 54.

Inclusion/Exclusion Criteria Inclusion criteria: 5-15 years old with normal intelligence and had at least two partial onset seizures during 6 months at baseline, parent and/or patient wanted to take AEDs, daytime seizures, at least 1 episode of a convulsive seizure during 6 months, absence of a progressive cerebral lesion. Exclusion criteria: evidence of a progressive cerebral lesion or neurodegenerative metabolic disorder, cognitive impairment that could interfere with cognitive testing procedure, history of psychiatric disorder requiring major tranquilizers in the past 6 months, regular treatment with antihistamines, CNS active compounds during the past 30 days, history of poor compliance with antiepileptic treatment or inability to maintain a seizure calendar independently or with assistance, history of nephrolithiasis and patients who have taken any medication associated with nephrolithiasis. Patients previously treated with TPM or CBZ were also excluded.

Patient Characteristics The mean age was similar to both groups (mean (sd) was 8.7 (1.9) and 8.7 (2.0) for the TPM and CBZ groups respectively). 32/58 in TPM and 32/54 in CBZ were males and participants in both groups had similar baseline weights (mean weight was 30.6 and 31 kg for the TPM and CBZ groups respectively).

Recruitment Not reported.

Setting The study was conducted at 12 centers. No more inf

Interventions/ Test/ Factor being investigated Topiramate versus carbamazepine.

Comparisons Comparison between topiramate and carbamazepine.

Length of Study/ Follow-up 1st week: screening phase, 2nd- 7th week: dose escalation phase, additional escalation was allowed up to the maximum tolerated until the 22th week (from the screening phase), maintenance period between 22th-28th weeks (from the screening phase).

Outcome measures studied Seizure freedom, incidence of adverse events.

Results 40/58 (69.6%) of patients in TPM and 38/54 (70%) in CBZ were seizure free during the trial.

6/58 (10.3%) in TPM group and 5/54 (9%) in CBZ group withdrawn due to adverse
Almost similar high proportions of TPM and CBZ groups were seizure free during the trial. Almost similar proportions of patients in both groups, TPM and CBZ, withdrawn due to adverse events.

### Safety and adverse effects

Incidence of adverse events (above 10%):
- Somnolence: 7/58 (12.1%) in TPM and 5/54 (9%) in CBZ group
- Rash: 1/58 (1.7%) in TPM and 8/54 (14.8%) in CBZ group

See adverse events in Q2.

### Does the study answer the question?

Almost similar high proportions of TPM and CBZ groups were seizure free during the trial.

Almost similar proportions of patients in both groups, TPM and CBZ, withdrawn due to adverse events.

### Effect due to factor in study?

The sample size of this study was larger than the minimum required to detect a difference in the effect between the two groups (however the calculation of sample size as it is stated is incomplete in relation to size of effect). The study was a single blinded trial with no information on allocation concealment. Uncertain about the overall effect of the intervention.

### Consistency of results with other studies?

Serious indirectness. Maximum dose for topiramate was 4mg/kg daily and for carbamazepine was 30mg/kg daily (recommendations by BNF for children; maximum dose for topiramate is 7.5mg/kg twice daily and for carbamazepine 20mg/kg twice daily).

### Directly applicable to guideline population?

Question: What is the clinical effectiveness and cost-effectiveness of a ketogenic diet?
The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial.

**Ref ID**: 135

**Study Type**: Randomised Controlled Trial

**Funding**: HAS, Smiths Charity, Scientific Hospital Supplies, and the Milk Development Council.

**Number of participants**: Seventy-three randomised to the diet group and 72 randomised to control group.

**Inclusion/Exclusion Criteria**
Inclusion: children aged between 2 and 16 years who had seizures at least daily or more than 7 seizures per week, had not responded to at least two antiepileptic drugs, and had not previously been treated with the ketogenic diet.
Exclusion: history of hyperlipidaemia, renal stones, or organic-acid-deficiency syndromes: which did not apply to any referred children.

**Patient Characteristics**
Epilepsy syndrome were combined into 2 categories: those with generalised symptoms and those that had focal symptoms.
78 children had generalised epilepsy and 57 children had focal epilepsy. Children had a mean of 11.6 seizures per day (13.3 in the diet group and 10.1 in the control group).

**Recruitment**
Recruited from referrals from epilepsy clinics and from paediatric neurologists and paediatricians around the UK.

**Setting**
Secondary Care.

**Interventions/ Test/ Factor being investigated**
Ketogenic diets, either the classical or Medium-chain tryglycerides (MCT), compared to normal diet until 3 months, then KD versus MCT (at additional 3, 6 and 12 months results).

**Comparisons**
Ketogenic diet compared to normal diet with no dietetic input until 3 months
Ketogenic diet compared to MCT (at 3, 6 and 12 months results).

**Length of Study/ Follow-up**
Up to 12 months.

**Outcome measures studied**
Decrease in seizure frequency.

**Results**
All ketogenic diets were calculated on an individual basis by a dietitian after a telephone consultation with the parents or carers with regard to the child's current food preferences. The children's pre-study calorific intake was calculated with a computer program from a 4-day food record. The initial calorie prescription for the ketogenic diets was based on an average between their pre-diet intake and the recommendations for energy requirements on the ketogenic diet and taking into account current and previous weight and height. UK recommended calorific requirements, levels of physical activity, seizure activity, and medications.

(Neal et al 2008) KD group (n=73) vs control group at 3 months (n=72):
>90% reduction 5 (7%) vs 0 (0%) p = 0.0582.
>50% reduction (already includes >90%) 28 (38%) vs 4 (6%) p < 0.001.

At 3 months, freedom from seizures was attained in 1 child in the KD group and none in the control group.

Side effects reported at 3 months on the KD diet:
Vomiting 13 (24%).
Diarrhoea 7 (13%).
Abdominal pain 5 (9%).

Neal EG; Chaffe H; Schwartz RH; Lawson MS; Edwards N; Fitzsimmons G; Whitney A; Cross JH;
Constipation 18 (33%).
Medication for constipation needed 13 (24%).
Lack of energy 13 (24%).
Hunger 12 (22%).

Results from Neal et al (2009) (Classical Ketogenic Diet versus MCT diet- patients had been on the previous phase KD versus control)

At 3 months:
Classical group (n=73) vs MCT diet group (n=72):
>90% reduction 5 (6.8%) vs 2 (2.7%) p=0.442.
>50% reduction 18 (24.7%) vs 21 (29.2%) p=0.578.

At 6 months:
Classical group (n=73) vs MCT diet group (n=72):
>90% reduction 6 (8.2%) vs 4 (5.6%) p=0.745.
>50% reduction (already includes >90%) 18 (24.7%) vs 14 (19.4%) p=0.549.

At 12 months:
Classical group (n=73) vs MCT group (n=72)
>90% reduction 7 (9.6 %) vs 7 (9.7%) p = 1.000.
>50% reduction (already includes >90%) 13 (17.8 %) vs 16 (22.2%) p=0.539.

There was no significant differences between the 2 types of diet, except increased reports of lack of energy after months and vomiting after 12 months of classical diet.

The mean beta-hydroxybutyrate level was higher in the classical diet group after 3, 6 and 12 months of treatment; this was significant at 3 and 6 months only.

Adverse events from (n=55) who continued the KD for 3 months:
Classical
Vomiting 13 (28%).
Diarrhoea 7 (15%).
abdominal pain 5 (11%).
Constipation 21 (45%).
Lack of energy 17 (36%).
Hunger 12 (26%).
Taste problems 10 (21%).

MCT
Vomiting 11 (26 %).
Diarrhoea 6 (14%).
abdominal pain 8 (19%).
Constipation 14 (33 %).
Lack of energy 6 (14 %).
Hunger 14 (33 %).
Taste problems 7 (17%).

Adverse events from those who continued the classical and MCT diets for 6 months:
Classical
Vomiting 9 (36%).
Constipation 12 (48%).
Hunger 6 (24%).
Taste problems 4 (16%).

MCT
Vomiting 7 (22%).
Diarrhoea 4 (13 %).
abdominal pain 4 (13%).
Constipation 13 (41%).
Lack of energy 5 (16%).
Hunger 6 (19 %).
Taste problems 11 (34%).

Adverse events from those who continued the classical and MCT diets for 12 months
Classical
Vomiting 9 (45 %).
Diarrhoea 2 (10 %).
abdominal pain 2 (10 %).
Constipation 9 (45 %).
Lack of energy 2 (10 %).
Hunger 5 (25 %).
Taste problems 3 (15 %).

MCT
Vomiting 3 (13 %).
Diarrhoea 4 (17 %).
abdominal pain 4 (17 %).
Constipation 9 (39 %).
Lack of energy 3 (13 %).
Hunger 4 (17 %).
Taste problems 5 (22 %).

Safety and adverse effects
Of the 45 children on the classical diet and 49 on the MCT diet, 9 and 11 respectively discontinued at 3 months. This was due to limited efficacy, the psychosocial costs of following the strict dietary regimen outweighing the benefit seen in terms of seizure reduction. After the 6 months follow-up, an additional 12 children (6 on each diet) discontinued. By 12 months, 57 of the 125 who had started a dietary treatment had discontinued dietary treatment.

Does the study answer the question?
The findings support the use of ketogenic diet in children with intractable epilepsy.

Effect due to factor in study?
Study is not blinded, however a good quality study.

Consistency of results with other studies?

Directly applicable to guideline population?
Direct population.

Internal Validity
Grading: 1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*

Freeman JM;Vining EP;Kossoff EH;Pyzik PL;Ye X;Goodman SN;

A blinded, crossover study of the efficacy of the ketogenic diet.[see comment]

**Ref ID** 4832  2009 Feb

**Study Type** Randomised Controlled Trial  **Funding** Supported by the NIH and by the Paediatric Clinical Research Unit.

**Number of participant** Twenty children were enrolled. Eleven given glucose first.

**Inclusion/Exclusion Criteria**
- Inclusion: children aged 1 to 10 years, prior exposure to at least 2 anticonvulsants, electroencephalography (EEG) evidence within 6 months of the typical LGS pattern of 2-2.5 Hz spike and slow wave discharges, and an average of at least 15 atonic-myoclonic seizures per day by parental records over the prior month. Exclusions: evidence for a metabolic disorder, treatment with steroids or adrenocorticotropic hormone (ACTH) in the prior month (which would theoretically negate ketosis), or previous KD treatment.

**Patient Characteristics**
- Mean age of 3.9 years (range 1.0-7.4 years), and eleven (55%) were male.

**Recruitment**
- Not specified.

**Setting**
- Secondary Care.

**Interventions/ Test/ Factor being investigated**
- Ketogenic Diet. 60g of glucose solution as placebo and artificial sweetener (saccharin) as treatment arm.
- During each day of the study, the child was given a solution of sweetened, flavored water that replaced an equivalent portion of the typical carbohydrate-free fluid allotment. Children were randomised to either receive a solution containing 60g of glucose or a similar saccharin solution.

**Comparisons**
- Ketogenic diet versus placebo.

**Length of Study/ Follow-up**
- Up to 12 months after discharge.

**Outcome measures studied**
- >50% reduction in seizures, median change of seizures, urinary ketones, EEG-identified events.

**Results**
- Other seizures, including absence, tonic, and generalised tonic-clonic seizures were not recorded by the parents.

- Between the ends of the saccharin and glucose arms, 6 children showed both >50% seizure reduction with saccharin in addition to <50% improvement in glucose, compared to 3 children who demonstrated to opposite response (p=0.50). The sequence of treatment arms did not make a difference in EEG-identified events (p=0.32).

- At day 6, 65% of patients experienced a >50% reduction in seizures.

- At 6 months after discharge, 80% had a >50% decrease in reported seizures, and at 12 months 65% had a >50% decrease.

- On the final days of each saccharin arm of the study, urinary ketones were uniformly large (80-160mg/dL); however even during the glucose arm, ketones were still typically trace to moderate (15-60mg/dL). There was a significant difference between the serum BOH of children during the glucose arm compared to the saccharin arm (2.7 versus 6.0mmol/L, p<0.001).

**Safety and adverse effects**
- Six children had emesis, during the fasting period or after, one of which required 1 day glucose free intravenous fluids. Three additional children were fatigued.
- Hypoglycaemia occurred in 25% of children.

29 July 2010  Page 240 of 306
Does the study answer the question? Moderate evidence of reduction of parent reported seizures.

Effect due to factor in study? No ITT analysis, lack of detail on blinding and randomisation concealment. Medium risk of Bias.

Consistency of results with other studies? Direct intervention and population.

Directly applicable to guideline population? Direct intervention and population.

Internal Validity

Question: Which AEDs are clinically effective and cost-effective for people with Convulsive status epilepticus?
Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial.

**Number of participant**  
N= 80 in the Lorazepam group and n=80 in the paraldehyde group.

**Inclusion/Exclusion Criteria**  
Children with features of hepatic or hypertensive encephalopathy or organophosphate poisoning were excluded as were children who had received an anticonvulsant agent within one hour of presentation.

**Patient Characteristics**  
Children of both sexes and aged 2 months to 12 years children presenting to a paediatric emergency centre with a generalised convulsion continuing for a minimum of 5 minutes.

Because of the geographical location of this study the majority of the children had acute symptomatic seizures mainly due to acute brain infection (cerebral malaria or bacterial meningitis in 2/3 of each of the two study groups).

For children in whom clinical seizure activity continued after 10 minutes, investigator followed a locally agreed protocol.

In the intranasal Lorazepam group seizure were exclusively due to acute brain infection secondary to cerebral malaria or bacterial meningitis in 51 (64%) of 80 children, and 53 (66%) of 80 children in the intramuscular paraldehyde group.

**Recruitment**  
Patients entering the paediatric emergency department within the Blantyre region in Malawi.

**Setting**  
Resuscitation room.

**Interventions/ Test/ Factor being investigated**  
Intranasal lorazepam versus intramuscular paraldehyde.

**Comparisons**  
Intranasal lorazepam versus intramuscular paraldehyde.

**Length of Study/ Follow-up**  
Not clear.

**Outcome measures studied**  
Seizure cessation, incidence of cardiorespiratory depression, need for further anticonvulsant/s.

**Results**  
Intranasal lorazepam and intramuscular paraldehyde were equally effective in the management of prolonged seizures, with 60/80(75%) in the lorazepam group and 49/80(61%) in the intramuscular paraldehyde group successfully terminating (RR 1.9, 95% CI 0.96-3.74). 8/80 (10%) children in the lorazepam group and 21/80 (26%) in the paraldehyde group required 2 or more further anticonvulsant doses to terminate the seizures (RR 0.38, 95%CI 0.18 - 0.81).

The median time for the presenting seizure to stop after drug administration did not differ between groups.

No significant difference was found between either treatment in terms of seizure recurrence within 24 hours.

No difference was found between either treatment group in terms of clinically important cardiorespiratory events.
IN Lorazepam group: 15 children whose SBP fell by at least 5 mm Hg, with a median reduction of 7 mm Hg (range 5-20 mm Hg) and 12 children whose DBP fell by at least 5 mm Hg with a median of 7.5 mm Hg (5.16 mm Hg)

IM Paraldehyde group: 16 children with SBP reduction of at least 5 mm Hg with a median of 6.5 mm Hg (5.10 mm Hg) and 4 children with a DBP reduction of at least 5 mm Hg, median 6.5 mm Hg (5.10 mm Hg)

Safety and adverse effects

Seventy-five children had a pretreatment-seizure duration of less than 2 hours, 8 of whom died (absolute risk 0.1, 95% CI 0.04-0.2). Of the 85 patients with a pretreatment-seizure duration of greater than 2h, 20 died (absolute risk 0.23, 95% CI 0.15-0.34; RR 0.45, 95% CI 0.21-0.86, p=0.03). Proportion of deaths was greater in those with HIV infection. Seven deaths occurred in the 19 HIV infected children compared to 21 of the 141 non infected (RR 2.51, 95% CI 1.23-5.10, p=0.02).

Does the study answer the question?

Relevant study.

Effect due to factor in study?

Overall well conducted study, with appropriate power calculations.

Consistency of results with other studies?

Sub-saharan population, otherwise direct comparisons.

Directly applicable to guideline population?

Sub-saharan population, otherwise direct comparisons.

Internal Validity

Alldredge BK; Gelb AM; Isaacs SM; Corry MD; Allen F; Ulrich S; Gottwald MD; O’Neil N; Neuhaus JM; Segal MR;Lowenstein DH;

A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus

Ref ID 4792 2001

Study Type Randomised Controlled Trial

Funding Supported by a grant from the National Institutes of Health.

Number of participant

Total randomised: 258. Some patients were enrolled more than once. Report data from the first enrollment of each patient. Total patients: 205: Lorazepam group: 66 patients; Placebo group: 71 patients; Diazepam group: 68 patients.

Inclusion/Exclusion Criteria

Inclusion criteria:
1. Meets clinical diagnosis of status epilepticus
   A. Paramedics or reliable witnesses verify continuous or repeated convulsive seizure activity of more than 5 minutes.
   B. Patient does not regain consciousness (operationally defined as meaningful speech or obeying commands) between seizures.
2. Patient is still seizing on paramedic arrival; or, if not, patient was unresponsive on paramedic arrival and has a qualifying generalised seizure without regaining consciousness (as defined in 1b)
3. Adult patient (18 years or older).

Exclusion criteria:
1. Pulse <60 bpm
2. Systolic blood pressure <100 mm Hg
3. Second or third degree atrioventricular block
4. Sustained ventricular tachyarrhythmia
5. Asthma or chronic obstructive pulmonary disease
6. Known history of chronic benzodiazepine use
7. Known sensitivity to benzodiazepines
8. Known pregnancy
9. No IV access
10. Transport to nonparticipating emergneyc department
11. Patient in custody

29 July 2010 Page 243 of 306
Patient Characteristics

Lorazepam vs diazepam vs placebo:
Age (years): 49.9+/-20.1 vs 50.4+/-19.1 vs 52.0+/-18.2;
Male sex: 69.7% vs 60.3% vs 59.1%.
Race or ethnic group (%):
American Indian or Alaskan: 1.5 vs 1.5 vs 4.2.
Asian or Pacific Islander: 21.2 vs 7.4 vs 9.9.
Black: 18.2 vs 16.2 vs 29.6.
Hispanic: 9.1 vs 20.6 vs 8.5.
White: 48.5 vs 54.4 vs 46.5.
Other: 1.5 vs 0 vs 0.
Unknown: 0 vs 0 vs 1.4.

History of seizures: 54.6% vs 69.1% vs 66.2%.

Cause of status epilepticus (%):
Low blood levels of antiepileptic drugs: 16.7% vs 25 vs 23.9.
Refractory epilepsy: 13.6 vs 13.2 vs 8.5.
Alcohol abuse: 9.1 vs 11.8 vs 9.9.
Metabolic derangement: 3 vs 2.9 vs 7.
Toxic effects of drugs (recreational or prescribed): 10.6 vs 7.4 vs 7.
Anoxia or cardiopulmonary arrest: 1.5 vs 0 vs 0.
Infection in the central nervous system: 7.6 vs 7.4 vs 5.6.
Trauma: 6.1 vs 8.8 vs 4.2.
Tumor in the central nervous system: 6.1 vs 4.4 vs 9.9.
Stroke: 16.7 vs 13.2 vs 9.9.
Nonepileptic seizures: 3 vs 4.4 vs 7.
Other: 0 vs 0 vs 1.4.
Unknown: 6.1 vs 1.5 vs 5.6.

Duration of SE before study treatment (min): 34+/-17.8 vs 31.3+/-14.5 vs 46.7+/-38.8.
Interval from study treatment to arrival at emergency department (min): 16.2+/-9.3 vs 15.9+/-9.3; 16.5+/-8.2.

Recruitment
If attended by a paramedic ambulance.

Setting
San Francisco.

Interventions/Test/Factor being investigated
Ongoing training given to affiliated personnel; Paramedics instructed to call the base hospital to confirm suspected status epilepticus (SE). Base Hospital radio contact logs reviewed for quality assessment and population details. Drug kits prepared by drug pharmacist and labelled with unique identifying number (study drug number) from a master list of computer-generated randomised numbers which were prepared at the study start.

Each kit had two 2mL glass syringes with 1mL each of identical study medication: diazepam 5mg, lorazepam 2mg or placebo propylene glycol 20% v/v in 0.9% sodium chloride. The drugs were administered during general tonic-clonic seizures. If seizures recurred or continued four minutes or more after then a 2nd identical injection was given.

Comparisons
Intravenous Diazepam versus intravenous lorazepam versus placebo.

Length of Study/Follow-up
Not reported.

Outcome measures studied
Primary outcome: termination of SE by time of arrival at the ED. Secondary outcomes: out-of-hospital complications; complications at transfer; duration of SE before arriving at hospital; neurological outcome at discharge; disposition of patient from ED.

Results
Status epilepticus at the time of arrival at the emergency department:

SE terminated:
Lorazepam 39 (59.1) vs diazepam 29 (42.6) vs placebo 15 (21.1). P=0.001.

Ongoing SE:
Lorazepam 27 (40.9) vs diazepam 39 (57.4) vs placebo 56 (78.9).
It has one outcome of interest. The authors concluded that benzodiazepines are safe and effective when administered by paramedics for out-of-hospital status epilepticus in adults. Lorazepam is likely to be a better therapy than diazepam.

**Safety and adverse effects**
Interim safety analyses performed. O'Brien-Fleming procedure applied to each of comparisons of treatments. Data and monitoring board and external advisory committee concluded data as whole did not support early termination of study.

**Does the study answer the question?**
It has one outcome of interest. The authors concluded that benzodiazepines are safe and effective when administered by paramedics for out-of-hospital status epilepticus in adults. Lorazepam is likely to be a better therapy than diazepam.

**Effect due to factor in study?**
Yes. 80% power with 5% significance level with target sample size of 210 patients, 208 patients included in study so slightly underpowered. Good methodology.

**Internal Validity**
Leppik IE;Derivan AT;Homan RW;Walker J;Ramsay RE;Patrick B;
Double-blind study of lorazepam and diazepam in status epilepticus
Ref ID 4782 1983

**Study Type** Randomised Controlled Trial

**Number of participant**
N=37 in the Lorazepam group and n=33 in the Diazepam group.

**Inclusion/Exclusion Criteria**
Exclusion: presence of illness, cardiac arrhythmia, hypotension, any acute metabolic disorder causing SE, a history of sensitivity to benzodiazepines, or childbearing potential. Persons who had received diazepam or other drug treatment for status before referral to the study were not included.

**Patient Characteristics**
Mean age of the Diazepam group was 56 years and 50 years for the Lorazepam group.

**Recruitment**
Not clear.

**Setting**
USA

**Interventions/ Test/ Factor being investigated**
Arm 1 = lorazepam
Arm 2 = diazepam

After an IV infusion and all the emergency measures to ensure patient airway and safety were initiated, 2 mL of the study drug (10mg of diazepam or 4mg of lorazepam) was injected over a period of two minutes. The 2nd 2mL dose of the same drug was administered at the discretion of the treating physician if seizures continued or recurred after 10 minutes. Because the know duration of action of diazepam is 20-30 minutes, most patients were given a loading dose of phenytoin even if seizures had not recurred 30 minutes after administration of study drug.

**Comparisons**
IV Lorazepam versus IV Diazepam

**Length of Study/ Follow-up**
Not clear.

**Outcome measures studied**
Cessation of seizures.
Recovery at discharge.
Mortality.
Requirement for ventilatory support.
Complications.
Adverse effects.

Results
Seizure activity was terminated by a single injection of diazepam in 19 (58%) of 33 episodes, as compared with 29 of 37 terminating after lorazepam administration. A second dose of diazepam was given to 13 of the 14 persons not responding initially; seizures ceased to 6. For Lorazepam, a second dose was given to 8 persons; seizures ceased to four.

One or two doses (10 or 20mg) of diazepam terminated seizure activity in 25 (76%) of 33 episodes, and lorazepam (4 or 8 mg) was effective in 33 (89%) of 37 cases (p=n.s).

Latency for action ranged from immediate effectiveness to 10 minutes (median, two minutes) for diazepam in all patients whose seizures were controlled. For lorazepam, the range was immediate to 15 minutes (median, 3 minutes) (p=n.s).

Adverse effects occurred in 5 of the 41(12%) treatments with diazepam and 5 of the 40 (13%) treatments with lorazepam.

Safety and adverse effects
Adverse effects occurred in 5 of the 41(12%) treatments with diazepam and 5 of the 40 (13%) treatments with lorazepam.

Does the study answer the question?
Relevant study to the clinical question.

Effect due to factor in study?
Uncertain. No details on randomisation nor allocation concealment.

Consistency of results with other studies?

Directly applicable to guideline population?
Direct population.

Internal Validity

Mehta V;Singhi P;Singhi S;

Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial

Ref ID 202 2007 Oct

Study Type Randomised Controlled Trial Funding Not reported.

Number of participant N=20 VPA and n=20 in DIA

Inclusion/Exclusion Criteria Children aged 5 months to 12 years, with refractory convulsive SE. SE was defined as 30 minutes of continuous seizure activity or 2 or more sequential seizures without full recovery of consciousness between seizures. Neonates and infants up to 3 months of age as well as known or suspected cases of mitochondrial disorders were excluded.

Patient Characteristics Most common cause of SE was central nervous system infection.

Recruitment Children admitted to an Emergency and Neurology Ward.

Setting India. Emergency Care Unit.

Interventions/ Test/ Factor being investigated Sodium Valproate initial bolus of 30mg/kg diluted 1:1 in normal saline from 2 to 5 min. If SE not controlled within 10 min after the bolus dose, a repeat bolus dose of 10mg/kg was given. Followed by infusion at a rate of 5mg/kg/hr continued until a seizure-free period of 6 hours and then reduced at a rate of 1mg/kg/hr every 2 hours. After discontinuation of IV infusion, a maintenance dose of 10mg/kg IV every 8 hours was continued until the child could take oral anticonvulsants.
In the DIA group, infusion was 10 microg/kg/min and was increased every 5 minutes by 10 microg/kg/min until SE was controlled or a maximum dose of 100 microg/kg/min was reached. If seizures were not controlled within 30 min of giving IV sodium valproate, DIA was given as the next line of treatment. If there was no response to the maximum dose of DIA, thiopental infusion was given.

### Comparisons
IV Sodium Valproate versus DIA infusion

### Length of Study/Follow-up
Not clear.

### Outcome measures studied
1) proportion of patients whose SE was controlled within 30 minutes; 2) time taken for control of SE. Adverse events.

### Results
Refractory SE controlled within 30 min
- VPA group: 16/20 (80%)
- DIA group: 17/20 (85%) (p=1.0)

Time interval for control of RSE after giving study drug (min) (mean±SD)
- VPA group: 8.8±7.4
- DIA group: 26.6±26.7 (p=0.001)

Four children in the VPA group, whose SE was not controlled were given DIZ infusion. SE was controlled in 3, whilst 1 required thiopental.

### Safety and adverse effects
Respiratory Depression
- VPA group: 0
- DIA group: 12/20 (60%)

Deaths
- VPA group: 4/20
- DIA group: 3/20
5 had meningoencephalitis with raised intracranial pressure and 1 each had uremic encephalopathy and intractable epilepsy.

Hypotension after drug administration
- VPA group: 0
- DIA group: 10/20 (50%)

Breakthrough seizures
- VPA group: 8/20 (40%)
- DIA group: 8/20 (40%)

### Does the study answer the question?
Relevant study to the clinical question.

### Effect due to factor in study?
Overall well conducted study, however open-label.

### Consistency of results with other studies?
Direct population.

### Directly applicable to guideline population?
Direct population.

### Internal Validity
Singhi S; Murthy A; Singhi P; Jayashree M;
Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus

Ref ID 4784 2002

### Study Type
Randomised Controlled Trial

### Funding
Not reported.

### Number of participant
N=21 continuous Midazolam and 19 diazepam infusion.

29 July 2010 Page 247 of 306
### Inclusion/Exclusion Criteria
Children 2 months to 12 years of age in refractory convulsive status epilepticus who were consecutively admitted over a period of 1.5 years to the Emergency and Intensive Care Services of the Advance Pediatric Centre. Neonates and children with primary cardiac or respiratory diseases or any other chronic illness were excluded.

### Patient Characteristics
Status Epilepticus was defined as 30 minutes of continuous seizure activity or two or more sequential seizures without full recovery of consciousness between seizures. Patients whose seizures were not controlled after 2 bolus doses of diazepam (0.3mg/kg) and phenytoin infusion (20mg/kg in normal saline infusion over 20 minutes) followed by a repeat dose of benzodiazepine were considered to have refractory SE.

### Recruitment
Patients admitted to the Emergency and Intensive Care Services of the Advance Pediatric centre, Postgraduate Institute of Medical Education and Resarch.

### Setting
Chandigarh, India.

### Interventions/ Test/ Factor being investigated
<table>
<thead>
<tr>
<th>Arm 1</th>
<th>Arm 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>midazolam</td>
<td>diazepam</td>
</tr>
</tbody>
</table>

In both groups, infusion was continued for at least 6 hours after control of the last seizure and then was gradually tapered over 12 to 24 hours under clinical monitoring. If the seizures were not controlled with the maximum dose of the study drug, thiopental (loading dose of 3mg/kg followed by a continuous infusion of 0.2mg/kg/min) was used.

### Comparisons
IV Midazolam versus IV Diazepam.

### Length of Study/ Follow-up
Appears to be at 24 hours.

### Outcome measures studied
- Cessation of seizures.
- Recovery at discharge.
- Mortality.
- Complications.
- Adverse effects

### Results
Refractory SE was controlled successfully in 18/21 (85.7%) of patients in the midazolam group and 17/19 (89.5%) of patients in the diazepam group (p=n.s).

The mean time interval between starting the infusion and initial control of seizure activity was about 16 minutes in both groups (p=n.s)

13 patients on midazolam and 16 on diazepam required intubation either for protection of the airway, poor respiratory efforts requiring ventilation, or both. 11 of 21 in the midazolam group and 9/19 in the diazepam group required ventilation (p=n.s).

Hypotension occurred in 8 patients in the Midazolam group and 8 in the Diazepam group. 2 patients in each group had hypotension even before diazepam or midazolam infusion was started, whereas 13 (32.5%) of patients developed hypotension on the drug infusion.

Eight patients died in the Midazolam group, compared to 2 in the Diazepam group (p<0.1 > 0.05), 5 because of meningocerebralitis and one each from acute hyponatremia (caused by diarrhea) and hepatic encephalopathy.

### Does the study answer the question?
Relevant study

### Effect due to factor in study?
Yes.

### Consistency of results with other studies?

### Directly applicable to guideline population?
Direct population

### Internal Validity
Grading: 1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias*

Agarwal P; Kumar N; Chandra R; Gupta G; Antony AR; Garg N;

Randomized study of intravenous valproate and phenytoin in status epilepticus

Ref ID 220 2007 Sep

Study Type Randomised Controlled Trial Funding Not reported.

Number of participant VPA group: n=50; PHT n=50.

Inclusion/Exclusion Criteria

Inclusion criteria:
Patients with status epilepticus which was refractory to IV diazepam.
Definition of SE: continuous or repeated seizure activity for more than 5 minutes without recovery of consciousness.
Exclusion criteria:
Pregnant women.
Children less than 2 years of age.
Patients with: hepatic encephalopathy, myoclonic status epilepticus, neurological emergency requiring immediate surgical intervention, or contraindication to therapy with hydantoins, benzodiazepine or barbiturates.
Only first episode included if patient enrolled more than once by mistake.

Patient Characteristics VPA vs PHT:

Mean age (years): 27.4+/-16.8 vs 27+/-15.1.
Male sex: 35 (70%) vs 32 (64%).
Below 18 years: 22 vs 16.
Most common etiology of SE:
- AED noncompliance or withdrawal: 12 (24%) vs 14 (28%).
- Inflammatory granuloma 12 (24%) vs 12 (24%).
- CNS infections 10 (20%) vs 12 (24%).
- Primary generalised epilepsy 8 (16%) vs 6 (12%).
- Stroke 2 (4%) vs 2 (4%).
- Head injury with extradural hematoma 2 (4%).
Duration of SE at time of presentation:
<2 hours: 30/50 (60%) vs 26/50 (52%).
>3 hours: 20/50 (40%) vs 24/50 (48%).

Recruitment Those admitted to the emergency ward and ICU.

Setting Emergency ward and intensive care unit.

Interventions/ Test/ Factor being investigated

Patients were switched to other group if seizures not controlled or recurred within 12 hours of the treatment.

Comparisons Intravenous sodium valproate versus intravenous phenytoin.

Length of Study/ Follow-up 7 days.

Outcome measures studied Treatment success: success was defined as all motor/EEG seizure activity ceasing within 20 mins after beginning drug infusion & no return of seizure activity during the next 12 hrs; Secondary: in-hospital complications & neurological outcome at discharge.

Results Response to treatment:
VPA vs PHT:

SE controlled: 44/50 (88%) vs 42/50 (84%) p>0.05.
SE < 2 hours: 30/30 (100%) vs 25/26 (96%) p<0.05.
SE > 2 hours: 14/20 (70%) vs 17/24 (71%) p<0.05.
IV sodium valproate was found to be as effective as IV phenytoin, with better tolerability compared to IV phenytoin. IV sodium valproate was found to be as effective as IV phenytoin, with better tolerability compared to IV phenytoin. IV sodium valproate can be used to treat all types of status including myoclonic status, where, this is the only drug which is effective. It can be used as first line treatment of SE after benzodiazepines as an alternative to phenytoin, especially in patients of cardio-respiratory disease. The response to treatment was better in patients of SE over 2 hours than under 2 hours reflecting need of immediate treatment.

Safety and adverse effects

Mortality rate in both groups was 8% (4/50) in group A and 4/50 in group B. One patient in group A and one in group B left against medical advice due to the cost of total treatment.

Hypotension was found in 0/50 in group A and 6/50 in group B.

Total adverse events 4/50 in group A and 8/50 in group B.

Does the study answer the question?

< 18 years of age responding to treatment: 20/22 vs 12/16.

Treated with both drugs: 4/7 (57%) vs 2/5 (40%).

Does the study answer the question?

18- to 65-year-olds responding to treatment: 20/22 vs 12/16.

Directly applicable to guideline population?

Yes.

Consistency of results with other studies?

Yes.

Effect due to factor in study?

No. Small population and no power calculation made. Methodology not explained clearly.

Internal Validity

Cereghino JJ; Mitchell WG; Murphy J; Kriel RL; Rosenfeld WE; Trevathan E;

Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The North American Diastat Study Group

Ref ID 4776 1998

Funding

Athena. One of authors has been a paid consultant to provide expert testimony to the FDA Advisory Board for Diastat. Another author has owned stocks in the company (Athena) that sponsored the study.

Number of participant

Total randomised: n=158. 33 excluded as did not have an ARS episode during study period. The others were excluded as they were randomised but not treated due to withdrawal of consent (1), protocol violation (1), loss to follow-up (3) or other life event (1) and 5 placebo randomised because they were not treated because of protocol violation (1) or other life event (4). Of those not treated none were due to adverse events, change in medical condition or death. Total n=114. Diazepam (diastat) n=56 vs placebo n=58.

Inclusion/Exclusion Criteria

Inclusion criteria:

Outpatient or institutionalised patients aged 2 years or older with documented history of Acute repetitive seizures (ARS);

Epileptic seizure type within the episode of ARS: primary generalised, complex partial with or without secondary generalised or simple partial with a motor component epileptic seizure;

At least 2 episodes of ARS had to have occurred within 1 year and one episode within 6 months of study entry;

Maximal weight 111 kg.

Postmenarcheal women had to used a standard form of birth control, or abstinence, if capable of becoming pregnant.

Normal results on rectal examination and a negative result for blood in stool at study entry.

Availability of a caregiver to administer drug accurately and to monitor the patient...
ARS - various definitions of ARS given.

Diastat versus placebo:
Sex: male: 31 (55%) vs 26 (45%) female: 25 (45%) vs 32 (55%).
Age group (years): 
>=2 to <6: 9 (16%) vs 16 (28%).
>=6 to <12: 13 (23%) vs 12 (21%).
>=12: 34 (61%) vs 30 (52%).
Race: white 45 (80%) vs 51 (88%); black 6 (11%) vs 2 (3%) vs other 5 (9%) vs 5 (9%).
Residence: with family at home: 42 (75%) vs 48 (83%); residential facility 8 (14%) vs 5 (8%), other 6 (11%) vs 5 (9%).
Duration of illness (years): 
<5: 12 (21%) vs 21 (36%).
>=5: 44 (79%) vs 36 (62%).
ARS episode frequency/m: 
mean: 13.8 vs 6.5.
median: 2 vs 2.
Minimum: 0.2 vs 0.2.
Maximum: 150 vs 90.

Patient Characteristics

Interventions/Test/Factor being investigated
Single administration of Diastat (diazepam gel) versus matching placebo.
Characteristics of each patients' individual ARS episode defined in writing at beginning of study by caregivers, nurse coordinator and investigaor. Caregivers were instructed by use of video-tape and illustrated written material on the proper methods of rectal administration and monitoring of patient respiration and response. Nurse coordinators maintained telephone contact every 2 weeks with a caregiver (to review recognition, treatment and documentation of the event) until an ARS episode occurred. When the caregivers identified an ARS they were to administer treatment and call the investigator immediately. 24 hour phone coverage available. Seizures were counted at 15 minutes after treatment then observed for 12 hours. If they continued to seize, or increase in severity or frequency or adverse event occurred the caregivers were to contact the study centre. The patients were seen within 72 hours after treatment. Caregivers and investigators completed a global assessment each.

Comparisons
Diazepam versus placebo.

Length of Study/Follow-up
Primary: seizure count. Secondary: time to the next seizure, the time elapsed between administration plus 15 minutes to the occurrence of the next seizure within the 12-hour observation period and the caregiver and global assessments.

Outcome measures studied
Seizure free at 12-hour observation period after treatment: diastat group (55%) vs placebo group (34%), p=0.031.

At least one adverse event: diastat group (46%) vs placebo (28%), p=0.0518.
Somnolence in all of the population: diastat 7 (13%) vs placebo 2(3).
The authors conclude that administration of a single rectal dose of Diastat was significantly more effective than placebo in reducing the number of seizures following an episode of ARS. Also that diastat increased the probability that patients would remain seizure free for the 12 hours after Diastat treatment compared with those who received placebo. Caregivers could administer treatment safely and effectively in a nonmedical setting.

Safety and adverse effects

A concern in the study design was that placebo-treated patients, or event the Diastat-treated patients may continue to have uncontrollable seizures. Caregivers were instructed in first aid procedures and some received cardiopulmonary resuscitation training, although not required by protocol. They were to call the study site after administering the study medication to site personnel could monitor the patients response. 3 of 56 diastat-treated patients (5%) required additional treatment in an ER or hospital compared with 7 out of 58 (13%) in the placebo group.

Does the study answer the question?

The authors conclude that administration of a single rectal dose of Diastat was significantly more effective than placebo in reducing the number of seizures following an episode of ARS. Also that diastat increased the probability that patients would remain seizure free for the 12 hours after Diastat treatment compared with those who received placebo. Caregivers could administer treatment safely and effectively in a nonmedical setting.

Effect due to factor in study?

To detect a significant treatment difference of 0.30, at a power of 80% 56 patients were needed in each group. For a treatment difference of 0.25 there would need to be 39 patients per group for 80% power. Therefore the power of the study was adequate.

Consistency of results with other studies?

Directly applicable to guideline population?

Direct.

Internal Validity

Chamberlain JM;Altieri MA;Futterman C;Young GM;Ochsenschlager DW;Waisman Y;

A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children.[see comment]

Ref ID 74  1997 Apr

Study Type  Randomised Controlled Trial  Funding  Not reported.

Number of participant

Total randomised: n=28. 3 randomised to diazepam were excluded because seizures did not persist for 10 minutes and did not receive medication. 1 child was randomised to receive diazepam but received midazolam after 25 minutes of unsuccessful attempts at IV access, so was excluded. One child was enrolled twice so is represented in both groups.


Inclusion/Exclusion Criteria

Inclusion criteria:
Children with motor seizures of at least 10 minutes duration.
Aged between birth and 18 years.

Exclusion criteria:
Already had an IV line established or had received anticonvulsants for the current seizure episode.

Patient Characteristics

Midazolam versus diazepam:
Age (months) median (range): 42 (9-165) vs 39 (3-112).
Sex (male/total): 8/13 vs 9/11.
Prior seizure disorder: 9/13 vs 8/11.
Generalised tonic-clonic: 10/13 vs 5/11, p=0.12.

Recruitment

Presenting at the ED.

Setting

ED of children and general hospitals (3), USA.
| Interventions/ Test/ Factor being investigated | Intramuscular midazolam versus intravenous diazepam. |
| Recorded times of: arrival, administration of medication, IV access, seizure cessation and seizure recurrence (if they had any). |
| Treatment successful: If patients’ seizures ended in five minutes after administration. Seizure cessation: between 5 and 10 minutes after medication was successful, but delayed seizure control. Treatment failure: If seizures were not stopped within 10 minutes. Recurrent seizures: if seizures stopped then recurred within 60 minutes. Early recurrence: seizures that stopped but recurred within 15 minutes. |

| Comparisons | IM midazolam versus IV diazepam. |
| Length of Study/ Follow-up | Not reported. |
| Outcome measures studied | Time to cessation of seizures. |

**Results**

Midazolam versus diazepam:

One treatment failure in each group has been excluded from the analysis. All times are in minutes (mean+/− SD):

- Time to cessation after medication: 4.5+/− 3 vs 3.4 +/− 2, p=0.32.
- 22/24 patients responded to initial treatment with diazepam or midazolam. There was a treatment failure in each group.
- All 23 patients had cessation for seizures within 15 minutes after arrival except for one patient who was started on diazepam but after 25 minutes of unsuccessfully attempts at IV access was given midazolam and the seizures stopped 6 minutes after administration.
- 4 patients in each group had recurrent seizures which required additional anticonvulsants within 60 minutes after medication. One case of early recurrence in each group. Phenytoin was used successfully when siezures recurred.

Safety and adverse effects

No respiratory depression and no complications in the study.

Does the study answer the question?

The authors concluded that IM midazolam is an effective anticonvulsant for children with motor seizures. Compared to IV diazepam there was more rapid cessation of seizures due to more rapid administration. The IM route of administration may be particularly useful in physicians' offices, in the prehospital setting and for children with difficult IV access.

Effect due to factor in study? No. No power calculation given and small sample size.

Consistency of results with other studies? Direct.

Internal Validity

Dreifuss FE; Rosman NP; Cloyd JC; Pellock JM; Kuzniecky RI; Lo WD; Matsuo F; Sharp GB; Conry JA; Bergen DC; Bell WE;

A comparison of rectal diazepam gel and placebo for acute repetitive seizures

**Study Type** Randomised Controlled Trial

**Funding** Supported by contracts with then national institute of neurological disorders and...
Number of participant

Randomised n=125. Treated patients n=91. For those randomised, diazepam n=64 vs placebo n=61. For those treated diazepam n=45 vs placebo n=46.

Inclusion/Exclusion Criteria

Inclusion criteria: boys and girls aged 2 to 14 years; adults aged 15 to 60 years; Maximal weight 100kg; At least 4 episodes of acute repetitive seizures (ARS) during the preceding year and at least one in the preceding 3 months; ARS defined as an episode of multiple complex partial or generalised (tonic, clonic, tonic-clonic, atypical absence or myoclonic) seizures occurring with a 24-hour period in adults or a 12-hour period in children, with a pattern distinguishable from the patient's usual seizure pattern, and with onset readily recognisable by a caregiver, such as a parent; On a stable AED regimen for at least 4 weeks before enrolling; Brain computed tomography or MRI and lab screening had shown no evidence of a treatable cause of seizures; Women of childbearing potential were eligible if used contraception and had a negative pregnancy test;

Exclusion criteria:
Plasma phenobarbital concentrations greater than 30mg per litre;
Current treatment with drugs other than anticonvulsants, long-term use of benzodiazepines, use of CNS depressants or drugs interacting with diazepam, more than one previous treatment with rectal diazepam, nonepileptic seizures within the preceding five years, habitual progression to status epilepticus, clinically significant psychiatric disorder o, lack of a suitable caregiver, or use of an investigational drug or device within the preceding 5 months.

Patient Characteristics

Diazepam versus placebo

Randomised patients:
sex (number) male: 38 vs 32; female 26 vs 29.
race (number): white 44 vs 53; black 14 vs 7; other 6 vs 1;
age group (number): 36 vs 31;
median age (year): child 8vs 8; adult 28 vs 30;
median body weight (kg) child: 23.6 vs 22.4; adult 57.1 vs 60.2;

Treated patients:
sex (number) male: 29 vs 22;
race (number): white 29 vs 40; black 12 vs 5; other 4 vs 1;
age group (number): child 25 vs 22;
median age (year) child 7 vs 7; adult 18.5 vs 23;
median body weight (kg): child 23 vs 21.9; adult 55.6 vs 56.8;

Recruitment

Not reported.

Setting

Not reported.

Interventions/ Test/ Factor being investigated

Diastat rectal gel versus placebo.
An instructional videotape taught caregivers how to identify ARS, give medication and record respiration, skin color, seizures, adverse event and global assessment of treatment outcome in a booklet.

Study nurses maintained telephone contact with caregivers during episodes of ARS to review the procedures, monitor patients and intervene if patients needed additional treatment.

Comparisons

Diazepam versus placebo.

Length of Study/ Follow-up

Caregivers and patients returned to the clinic 72 hours after treatment to review the recorded data.
Seizure frequency and global assessment of treatment outcome by caregiver. Two outcome variables were retrospectively defined: time to first recurrence of seizures after initial treatment and number of patients remaining seizure-free (in 1st 12 hours).

Results

Somnolence n=15 patients vs 5.

Safety and adverse effects

Adverse effects over 10%:
See results section.

Does the study answer the question?

The authors conclude that rectal diazepam gel, administered at home by trained caregivers, is an effective and well-tolerated treatment for acute repetitive seizures.

Effect due to factor in study?

Calculated that a sample size of 144 patients was planned on the basis of estimates of the sample size for a 2-sided test to detect a 50% reduction in seizure frequency with diazepam and a significance level of 0.05 and a power of 0.80.

Consistency of results with other studies?

ARS not status epilepticus.

Internal Validity

Comparison of intravenous lidocaine and midazolam infusion for refractory convulsive status epilepticus in children

Ref ID 608

Study Type Randomised Controlled Trial

Funding Grant for the Shaheed Beheshti University of Medical Sciences and Health Services, Tehran, Iran.

Number of participant Total n=20. Lidocaine group: n=10; midazolam group n=10.

Inclusion/Exclusion Criteria

Inclusion: Children aged 1 month to 12 years.
Exclusion criteria:
Liver of kidney dysfunction, hypotension, cardiac arrhythmia or block and electrolyte abnormalities;
Second admission with status epilepticus.

Patient Characteristics

Sex: male: 9; female: 11;
Aged 1 month to 12 years.
Mean age: group 1: 3.4+/-.2.9 years; group 2: 4.2+/-.4.4 years, not stat sig diff p=0.6.
Females more in both groups: group 1: 50% vs group 2: 60%.
Neurodevelopmental delay occurred in: group 1: 4/10 (40%) vs group 2: 6/10 (60%);
Neuroimaging abnormality: in both groups 50%.
EEG abnormalities: group 1: 40%; group 2: 80%;
No sig diff seen regards age, sex, concomitant fever, EEG and neuroimaging abnormalities and neurodevelopmental delay.
Etiology of status epilepticus:
Lidocaine vs midazolam group:
- symptomatic epilepsy: 8 vs 9;
- idiopathic epilepsy: 2 vs 1;

Recruitment Patients admitted in the ICU of children's hospital.

Setting Mofid children's hospital, Iran.
Blood samples drawn at admission to measure serum sodium, potassium, total calcium and glucose levels. All patients received: Intravenous diazepam (0.2-0.3mg/kg) which was repeated after 5 minutes if seizures recurred. Followed by phenytoin (15-20mg/kg) infused intravenously over 20 minutes. If seizures recurred, midazolam drip or intravenous lidocaine was administered as second line anticonvulsant.

Group 2 received: midazolam 0.15mg/kg followed by continuous intravenous infusion of 1microgram/kg/min with increase of 1 microgram/kg/min every 15 minutes until control of seizures or maximum dose of 6micrograms/kg/min reached.

If drug effective infused with same dose for 24 hours then decreased by 1 microgram/kg/min every 2 hours until cessation.

Group 1 lidocaine given at 1mg/kg intravenously at 25mg/min. A second dose of 1mg/kg infused if no response occurred or recurrent seizures. If did not stop in 15 minutes continuous lidocaine infusion of 1mg/kg/hour used and increased at 1mg/kg/h every 15 minutes until control of seizures or max dose of 5mg/kg/h. If effective then infused for 12 hours then decreased by 0.5mg/kg/h until cessation. If seizures did not cease with full dose of drugs then discontinued and pentobarbital coma induced.

The authors concluded that lidocaine can be used in refractory status epilepticus treatment especially when respiratory care and intubation facilities are not present.

**Comparisons**

IV lidocaine vs IV midazolam as second line treatment.

**Length of Study/ Follow-up**

Not reported.

**Outcome measures studied**

Cessation of seizures; safety of drugs;

**Results**

Lidocaine vs midazolam infusion group:

Cessation of seizures: 5/10 (50%) vs 2/10 (20%), p=0.17.

In lidocaine group: 2 stopped seizing with initial dose of 1mg/kg and in other 2 with 2nd dose of 1mg/kg and 1 with infusion of 1mg/kg/h. In midazolam group: 2micrograms/kg/min stopped 2 seizing.

**Safety and adverse effects**

No electrolyte impabaliance or elevated liver enzymes or rise in blood urea nitrogen and creatine seen. Hypothermia and acidosis seen in 3 patients (30%) with midazolam and one lidocaine (10%) patient showed transient bradycardia. Intubation needed less in lidocaine than midazolam group (2 vs 7, p=0.03);

**Does the study answer the question?**

The authors concluded that lidocaine can be used in refractory status epilepticus treatment especially when respiratory care and intubation facilities are not present.

**Effect due to factor in study?**

No. No power calculation. Poor methodology.

**Consistency of results with other studies?**

Direct.

**Directly applicable to guideline population?**

Direct.

**Internal Validity**

Mahmoudian T;Zadeh MM;

Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children

Ref ID 696

2004 Apr

**Study Type**

Randomised Controlled Trial

**Funding**

Not reported.

**Number of participant**

Total n=70. Midazolam group n=35; Diazepam group n=35.
### Patient Characteristics

<table>
<thead>
<tr>
<th>Etiology of seizures:</th>
<th>Midazolam versus diazepam:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypocalcemia: 2 vs 8.</td>
<td>Etiology of seizures:</td>
</tr>
<tr>
<td>Hypoglycemia: 0 vs 2.</td>
<td>Hypocalcemia: 2 vs 8.</td>
</tr>
<tr>
<td>Head trauma: 0 vs 1.</td>
<td>Epilepsy: 14 vs 13.</td>
</tr>
<tr>
<td>CNS infection: 4 vs 10.</td>
<td>Head trauma: 0 vs 1.</td>
</tr>
<tr>
<td>Hyponatremia: 1 vs 0.</td>
<td>CNS infection: 4 vs 10.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Types of seizures:</th>
<th>Etiology of seizures:</th>
</tr>
</thead>
<tbody>
<tr>
<td>GTC: 25 vs 25.</td>
<td>Types of seizures:</td>
</tr>
<tr>
<td>SPS: 3 vs 3.</td>
<td>GTC: 25 vs 25.</td>
</tr>
<tr>
<td>CPS: 4 vs 8.</td>
<td>SPS: 3 vs 3.</td>
</tr>
<tr>
<td>Myoclonic: 3 vs 2.</td>
<td>CPS: 4 vs 8.</td>
</tr>
</tbody>
</table>

### Inclusion/Exclusion Criteria

**Inclusion criteria:**
2 months and 15 years age;  
Acute seizures (febrile or afebrile);

**Exclusion criteria:**
Children who had received anticonvulsants before admission;

### Recruitement

Patients admitted to the pediatric emergency department of the medical university.

### Setting

ER Alzahra Hospital, Isfahan, Iran.

### Interventions/Test/Factor being investigated

Intranasal midazolam vs Intravenous diazepam.

Diazepam was given intravenously to patients with odd numbers after an intravenous line was introduced. Midazolam solution dropped into syringe into both nostrils in equal doses with even numbers and an intravenous line immediately introduced.

If seizures did not stop within 10 minutes of treatment IV diazepam was given to the midazolam group and phenobarbital to the diazepam group.

High flow oxygen by mask and routine life support provided.

### Comparisons

IN midazolam vs IV diazepam.

### Length of Study/Follow-up

Not reported.

### Outcome measures studied

Time from treatment to cessation of seizures.

### Results

All patients in both groups had seizure control within 10 minitues, and no significant difference in effectiveness between IN midazolam and IV diazepam p>0.05.

Mean interval between drug administration and seizure control: midazolam 3.58 (sd 1.68) vs diazepam 2.94 (sd 2.62) minutes, p=0.007. This did not include time to get IV line.

### Safety and adverse effects

No significant side effects in either group. No patient had to be intubated or mechanically ventilated.

### Does the study answer the question?

The authors concluded that although intranasal midazolam was as safe and effective as diazepam, seizures were controlled more quickly with intravenous diazepam than with intranasal midazolam. Intranasal midazolam can possibly be used not only in medical centres but in general practice and at home after appropriate instructions given to families of children with recurrent seizures.

### Effect due to factor in study?

No. No power calculation and quasi-randomised study.

### Consistency of results with other studies?

No consistent studies found.
**Internal Validity**

Mahvelati F; Tonekaboni H; Javadzade M; Ghofrani M;

The efficacy of propofol and midazolam in treatment of refractory status epilepticus in children

Ref ID 1372 2007

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Randomised Controlled Trial</th>
<th>Funding</th>
<th>Not reported.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participant</td>
<td>N=16 to the MID group and n=16 to the PROP group.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>Criteria for Refractory SE: a) acute seizures persisting more than 60 min despite being treated with first-line antiepileptic drugs including IV diazepam, phenytoin and phenobarbital and b) seizures recurring at a rate of at least 2 times per hour without any recovery of the consciousness between attacks.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Characteristics</td>
<td>All patients had generalized tonic-clonic seizures. Sixteen patients had a mean ± SD age of 3.83 ± 3.79 years and received Midazolam. Another 16 patients with a mean ± age of 5.08±4.82 were treated with Propofol.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td>Patients being treated at an Intensive Care Unit.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Setting</td>
<td>Iran. ICU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interventions/ Test/Factor being investigated</td>
<td>Propofol versus Midazolam.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparisons</td>
<td>IV Propofol versus IV Midazolam.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length of Study/Follow-up</td>
<td>Appears to be up to 48 hours.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>Complete seizure control, seizure recurrence and side effects.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td>Complete seizure control was achieved in 6/16 (38%) in the MID group and 10/16 (63%) in the PROP group.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety and adverse effects</td>
<td>MID group: Bradycardia followed by cardiac arrest in 1 patient (successfully resuscitated) and elevated serum creatine phosphokinase in another patient. PROP group: rise in serum creatine phosphokinase in 5 patients (31%) and increase in serum triglyceride and cholesterol in 5 patients (31%). Both alteration were significant (p=0.04). Apnea was present in 9 patients in the MID group and 11 patients in the PROP group (p=0.71)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>Relevant to the clinical question.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>No details on randomisation nor allocation concealment. Unblinded study. Risk of bias in this study.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>Direct Population.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sodium valproate vs phenytoin in status epilepticus: a pilot study

29 July 2010  Page 258 of 306
**Study Type**  
Randomised Controlled Trial  

**Funding**  
Not reported.

**Number of participant**  
VPA n=35 and PHT n=33.

**Inclusion/Exclusion Criteria**  
Patients with SE defined as two or more convulsive seizures without full recovery of consciousness between seizures or continuous convulsive seizures lasting for more than 10 minutes. Patients with nonconvulsive and subtle SE, hypotension, cardiac arrhythmia, congestive heart failure, pregnancy, pancreatitis, and drug allergy and those requiring immediate neurosurgery were excluded.

**Patient Characteristics**  
N=27 adults in the VPA group and n=29 adults in the PHT group (>15 years). N=8 children in the VPA group and n=4 children in the PHR group (<15 years). N=24 male in the VPA group and n=17 male in the PHT group. N=12 had associated medical illnesses in the VPA group and n=10 in the PHT group. Seizure duration (hours) 1.76 ± 0.49 for VPA group and 1.70 ± 0.47 for the PHT group. Etiology of SE was CNS infection in 38, stroke in 9, metabolic-toxic encephalopathy in 16, drug withdrawal in 2, and idiopathic in 3 patients.

**Recruitment**  
Not reported.

**Setting**  
Emergency care. India.

**Interventions/ Test/ Factor being investigated**  
Sodium Valproate versus IV Phenytoin. Subsequent failure was treated by diazepam or lorazepam.

**Comparisons**  
IV VPA vs IV PHT.

**Length of Study/ Follow-up**  
UP to 24 hours.

**Outcome measures studied**  
Seizure cessation after infusion and seizure freedom at 24 hours.

**Results**  
SE was aborted by VPA in 23 patients (66%) and by PHT in 14 (42%) (p=0.046). In refractory patients, as a second choice, VPA was effective in 15/19 patients (79%), whilst PHT was effective in 3/12 patients (25%) (p=0.004). Twenty-four hour seizure freedom was achieved in 29/55 patients, of whom 8 achieved control with PHT, 10 achieved control with VPA and 11 achieved control with a combination (p=n.s).

**Safety and adverse effects**  
After therapy, hypotension occurred in 4, liver dysfunction occurred in 12 and respiratory depression occurred in 12 patients, 5 of which needed artificial ventilation. Nineteen patients died during the hospital stay: 11 in the 1st week, 6 in the 2nd week, and 2 in the 3rd week. Six of these patients had metabolic encephalopathy, 16 had CNS infection, and 3 had stroke.

**Does the study answer the question?**  
Relevant study to the clinical question.

**Effect due to factor in study?**  
No details on allocation concealment, nor blinding.

**Consistency of results with other studies?**  
Direct population.

**Internal Validity**

Shaner DM; McCurdy SA; Herring MO; Gabor AJ;

Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin484
Patient Characteristics

Diazepam and phenytoin versus phenobarbital:

Mean age +/- SD (*years): 43.8 +/- 16.5 versus 55.9 +/- 19.4.
History of previous seizures (n): 14 vs 11.
Focal features (n): 9 versus 10.
Phenobarbital or phenytoin present in serum prior to treatment (n)*: 10 vs 7.
Criterion for entrance into study (N):
Criterion 1: 8 vs 4;
Criterion 2: 11 vs 14;
Criterion 3: 0 vs 0;
Criterion 4: 1 vs 0.

Presumed seizure etiologies (n):
Alcohol withdrawal: 5 vs 5.
Subtherapeutic anticonvulsants: 11 vs 7.
Infections: 2 vs 0.
Structural lesions: 5 vs 7.
Toxic/metabolic: 2 vs 2.
* One patient in the diazepam group and no patients in the phenobarbital group had pretreatment phenobarbital levels in the therapeutic range (15 to 40mg/l). 2 patients in the diazepam group and 1 in the phenobarbital group had pretreatment phenytoin levels in the therapeutic range (10 to 20mg/l).

Recruitment

Presenting to the ER with status epilepticus.

Setting

USA?

Interventions/ Test/ Factor being investigated

Diazepam and phenytoin versus phenobarbital as initial therapy.

Comparisons

IV Diazepam and IV phenytoin versus IV phenobarbital as initial therapy.

Length of Study/ Follow-up

Not reported.

Outcome measures studied

Response latency; cumulative convulsion time; adverse events; death.
Results

Convulsions were controlled within 7 hours in all patients. The median cumulative convulsion time for those on phenobarbital was shorter than the median cumulative convulsion time for those receiving diazepam (5 versus 9 minutes, p<0.06).

The median response latency was shorter for the phenobarbital group compared to the diazepam group (5.5 vs 15 minutes, p<0.10).

There was data on how many of the phenobarbital group were controlled with phenobarbital alone (11/18) and that five of the phenobarbital group ultimately received phenytoin for presumed additional clinical efficacy although no additional seizures were documented. No data given for the other group but assume from statement that convulsions were controlled within 7 hours in all patients that all patients seizures were controlled in this group.

Safety and adverse effects

Arrhythmias n = 0 vs 1, not significant.
Hypotension n= 3 vs 2, not significant.

Does the study answer the question?

The authors conclude that the phenobarbital regime is rapidly effective and comparable in safety and has some practical advantages in comparison to the diazepam and phenytoin regime.

This does not point out that some of the patients who were on phenobarbital (5) were then put on phenytoin.

Effect due to factor in study?

No power calculation and small sample.

Consistency of results with other studies?

Directly applicable to guideline population?

Reports the no of events in each group rather than the number of participants having events.

Consistency of results with other studies?

Internal Validity

Sreenath TG; Gupta P; Sharma KK; Krishnamurthy S;

Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial

Ref ID 582

Number of participant

N=178. 90 subjects in lorazepam group and 88 in diazepam-phenytoin group.

Inclusion/Exclusion Criteria

Aged between 1-12 years and presenting with a clinical diagnosis of convulsive status epilepticus. Exclusion criteria: if children had received any antiepileptic medication in the preceding 4 weeks, sustained acute head trauma, jaundice, suspended renal failure or diarrhea presenting with seizures and history of poisoning.

Patient Characteristics

The mean age (Sd) in months was 84 (36.8) and 78.8 (32.4) in lorazepam and in diazepam+ phenytoin groups respectively. The majority of children in both groups were boys (61.1% in lorazepam and 53.4% in diazepam+ phenytoin). The predominant type of seizures in both groups was generalised tonic clonic seizures (55.5% in lorazepam and 69.3% in diazepam and phenytoin).

Recruitment

Invited when attended a tertiary centre attached to a medical college in North India.

Setting

A tertiary centre attached to a medical college

Interventions/ Test/ Factor being investigated

Comparison of efficacy between intravenous lorazepam and diazepam +phenytoin.

Comparisons

Between iv/rectal lorazepam and iv/rectal diazepam + phenytoin.
Seizure freedom was assessed within 10 min of the first intervention and there was no recurrence of seizure for the next 18 hours.

Outcome measures studied
- Seizure freedom
- Recurrence of seizure
- Proportion of children with respiratory depression

Results
- Seizure freedom: 100% in both groups
- Recurrence of seizures after 18 h: None in both groups
- Incidence of respiratory depression: Lorazepam 4/90 (4.4%) and Diazepam + phenytoin 5/88 (5.6%)
- Number of patients requiring transfer to the ICU for mechanical ventilation: none in both groups.

Safety and adverse effects
None adverse event.

Does the study answer the question?
Yes. No significant difference was found between iv/rectal lorazepam and iv/rectal diazepam + phenytoin on the proportion of participants achieving seizure freedom, had another episode of seizures after 18 hours and on the incidence of respiratory depression.

Effect due to factor in study?
The study was unblinded so even though the study used a randomization process with allocation concealment and achieved the minimum required sample size, the effect of intervention is uncertain.

Consistency of results with other studies?
Direct.

Safety and adverse effects
- None adverse event.

Study Type
- Randomised Controlled Trial

Number of participant
- N=120, N buccal midazolam =60 and N iv diazepam=60

Inclusion/Exclusion Criteria
- Children with an episode of convulsion irrespective of cause and duration was enrolled in the study. In a child with recurrent convulsions, only the first episode was included in the study. Seizure types included were partial and generalized tonic, clonic and tonic-clonic. Myoclonic, atonic and absence seizures were excluded.

Patient Characteristics
- Out of 120 cases, 82 were males and 38 females. 53.3% were below 1 year of age, 20.2% were between 2-5 years and 26.7% between 6-12 years. None of the children received any pre hospital treatment.

Recruitment
- Children attending the pediatric emergency department.

Setting
- Department of pediatrics, Maulana Azad Medical sch

Interventions/ Test/ Factor being investigated
- Efficacy of buccal midazolam compared to iv diazepam in controlling convulsions in children.

Comparisons
- Comparison are made between buccal midazolam and iv diazepam.

Length of Study/ Follow-up
- For 48 hours.
1) seizure freedom
2) time to first seizure
3) incidence of adverse events

Results
1) seizure freedom: Buccal midazolam 51/60 (85%) and iv diazepam 56/60 (93.3%) (p=0.14)
2) mean time (sd) in minutes to first seizure (after drug administration): buccal midazolam 1.69 (0.93) and iv diazepam 1.13 (0.5) (p<0.001)
3) adverse events (unusual CNS depression, respiratory depression, apnea or cardiac dysrhythmia): 0% in both groups.

Safety and adverse effects
No issues. Neither adverse events not death experienced by any participant in the study.

Does the study answer the question?
Yes. No difference in achieving seizure freedom between buccal midazolam and iv diazepam but iv diazepam needed significantly less time to cessation of seizures compared to buccal midazolam.

Effect due to factor in study?
The uncertainty over the effect of this intervention comes from the unblinded type of the study and the lack of preconsideration of study's statistical power.

Consistency of results with other studies?
Direct.

Directly applicable to guideline population?
Direct.

Internal Validity

A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group

Ref ID 4783

Number of participant
Total n= 570.
Lorazepam n=146.
Phenobarbital n=133.
Diazepam and phenytoin n=146.
Phenytoin n=145.

Inclusion/Exclusion Criteria
Evidence of overt of subtle generalised convulsive status epilepticus at time of evaluation, regardless of prior drug treatment. Definitions: overt generalised convulsive status epilepticus- 2 or more generalised convulsions, without full recovery of consciousness between seizures, or continuous convulsive activity for more than 10 minutes (treatment after 10 minutes of continuous seizure activity was considered essential to protect against neuronal and systemic damage from ongoing seizure activity). Subtle generalised convulsive status epilepticus - coma and ictal discharges on the EEG, with or without subtle convulsive movements (rhythmic twitching of the arms, legs, trunk, or facia muscles, tonic eye deviation, or nystagmoid eye jerking).
Exclusion criteria:
Previously received treatment and whose seizures had stopped.

29 July 2010
Status epilepticus of a type other than generalised convulsive.
Aged less than 18 years.
Pregnant.
A neurologic emergency requiring immediate surgical intervention.
Presence of a specific contraindication to therapy with hydantoin, benzodiazepine, or
barbiturate drugs.
If patients (with inrepeated episodes) were inadvertently enrolled more than once, on
the first episode was included in analysis.

### Patient Characteristics
Population characteristics stated according to the type of generalised convulsive
status epilepticus:
Overt (n=384) vs Subtle (n=134):
Age (years, s.d.): 58.6+/− 15.6 vs 62.0+/−15.1.
Veteran (%): 70.1 vs 80.6.
Male sex (%): 82.3 vs 85.1.
Not previously treated for current episode (%): 51.3 vs 51.5.
History of acute seizures (%): 54.2 vs 25.4.
History of epilepsy (%): 42.4 vs 12.7.
History of status epilepticus (%): 12.8 vs 4.5.
Median duration of status epilepticus at enrollment (hr) 2.8 vs 5.8.
Causal factors (%) (some patients had more than one causal factor):
- remote neurologic cause: 69.5 vs 34.3.
- acute neurologic cause: 27.3 vs 37.3.
- Life-threatening medical condition: 32.0 vs 56.7.
- Cardiopulmonary arrest: 6.3 vs 38.1.
- Toxic effects of therapeutic or recreational drug: 6.3 vs 5.2.
- Alcohol withdrawal: 6.1 vs 0.7.

### Recruitment
Not reported.

### Setting
16 Veterans medical centes & 6 uni hospitals USA

### Interventions/Test/Factor being investigated
IV lorazepam versus phenobarbital vs phenytoin vs diazepam.

Phenytoin and diazepam were in the identical vials at appropriate concentrations so
each drug could be administered at 1ml per minute to produce maximal rates of drug
infusion. Lorazepam was given by Tubex injection at maximal rate of 0.5ml per
minute.

The drug treatment kits looked identical and all contained a first, second and third
treatment box within it. The first treatment box held a tubex syringe and five vials
labelled A to E. A nomogram (based on weight of patient) determined the volume of
solution to be administered (to ensure blinding). The tubex and vial A were injected
simultaneously. Tubexes and vials with active drug contained propylene glycol, as
did dummy tubexes; dummy vials contained saline. Second and third treatment
boxes provided for further treatment if needed without revealing the identity of the
study drug.

<table>
<thead>
<tr>
<th>Contents of 1st treatment box:</th>
<th>Lorazepam</th>
<th>Phenobarbital</th>
<th>Diazepam &amp; Phenytoin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin Tubex</td>
<td>Dummy</td>
<td>Dummy</td>
<td>Dummy</td>
</tr>
<tr>
<td>Vial A</td>
<td>Dummy</td>
<td>Phenobarbital</td>
<td>Dummy</td>
</tr>
<tr>
<td>Dummy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vial B</td>
<td>Dummy</td>
<td>Phenobarbital</td>
<td>Diazepam</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Dummy</td>
<td>Phenobarbital</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Vial C</td>
<td>Dummy</td>
<td>Phenobarbital</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Dummy</td>
<td>Phenobarbital</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Vial D</td>
<td>Dummy</td>
<td>Dummy</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Dummy</td>
<td>Dummy</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Vial E</td>
<td>Dummy</td>
<td>Dummy</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Dummy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active drug in second treatment box:</td>
<td>Phenytoin</td>
<td>Phenytoin</td>
<td>Lorazepam</td>
</tr>
<tr>
<td>Lorazepam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active drug in third treatment box:</td>
<td>Phenobarbital</td>
<td>Lorazepam</td>
<td>Phenobarbital</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Comparisons
Lorazepam versus phenobarbital versus phenytoin versus diazepam.

Length of Study/ Follow-up
30 days after treatment.

Outcome measures studied
Rate of successful initial treatment.

Treatment successful if all clinical and electrical evidence of seizure activity stopped within 20 minutes from start of drug infusion and no recurrence from 20 to 60 minutes after starting treatment.

Results
Rates of successful initial treatment:
Lorazepam: overt gcse 67%; subtle gcse 26.1% [67/100; 12/46].
Phenobarbital: overt gcse 63%; subtle gcse 24.4% [58/92; 10/41].
Diazepam and Phenytin: overt gcse 59.6%; subtle gcse 23.4% [59/99; 11/47].
Phenytoin: overt gcse 51.5%; subtle gcse 19.5% [53/104; 8/41].

12 hour study period: 67 of the patients with over status epilepticus (17%) regained full consciousness before end of 12 hour study period, with no significant differences among the four treatment groups (p=0.59) [figures not given]. None of the patients with subtle status epilepticus completely regained consciousness during the 12-hour study period.

30 days after treatment:
50.1% of overt status epilepticus were discharged from hospital compared with 8.8% with subtle status epilepticus. 22.9% with overt status epilepticus were still in the hospital compared with 26.5% with subtle status epilepticus. Mortality rates were 27% and 64.7% respectively.
There were no significant differences in outcome at 30 days among the four treatments for either over or subtle status epilepticus.

It does not give figures for those who regained consciousness at 12 hours or at 30 days apart from saying that there was no significant difference. It gives initial treatment effect data but separates overt from subtle generalised convulsive status epilepticus.

Safety and adverse effects
Incidence of adverse events:
Lorazepam vs phenobarbital vs diazepam & phenytoin vs phenytoin
Hypventilation: 10.3% vs 13.2% vs 16.8% vs 9.9%.
Hypotension: 25.8% vs ±34.1% vs 31.6% vs 27%.

Subtle:
Hyperventilation: 12.8% vs 15.2% vs 2.9% vs 7.7%.
Hypotension: 59% vs 48.5% vs 58.3% vs 57.7%.

Does the study answer the question?
Yes.

Effect due to factor in study?

Consistency of results with other studies?

Directly applicable to guideline population?
Direct.

Internal Validity
### Grading: 2++
High-quality systematic reviews of case–control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal

Mahmoudian T; Najafian M;

Comparing the effect of intravenous midazolam with rectal sodium valproate in controlling children with refractory status epilepticus

Ref ID: 4886 2006

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Randomised Controlled Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participants</td>
<td>N=18 in the odd group and n=18 in the even group.</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>Children referred with seizures to pediatric emergency ward that continued despite IV DIA (0.3mg/kg) followed by IV bolus Phenytoin (20mg/kg) and then IV bolus Phenobarbitol (20mg/kg).</td>
</tr>
<tr>
<td>Patient Characteristics</td>
<td>Children within the range of 2 months to 18 years of age. Seizures lasting 60-90 min were considered as refractory SE.</td>
</tr>
<tr>
<td>Recruitment</td>
<td>Children referred with seizures to pediatric emergency ward.</td>
</tr>
<tr>
<td>Setting</td>
<td>Iran. Pediatric Emergency ward.</td>
</tr>
<tr>
<td>Interventions/Test/Factor being investigated</td>
<td>Sodium Valproate (20mg/kg) diluted with equal volume of water through rectal enema (IV SV was not available). If seizure stopped within 20 minutes of enema, oral SV would be continued 20mg/kg/24h divided into 2 equal doses after 12 hours from first administration. IV bolus of Midazolam 400 microgram/kg, followed by 200microgram/kg through infusion up to 20 minutes. If seizure stopped, MID continued for extra 6 hours and was discontinued gradually. If there was no postive response after 20 minutes in both groups, then treatment was discontinued and treatment with barbiturates coma (sodium thiopental or Nesdonal) was started and the child was excluded from the study.</td>
</tr>
<tr>
<td>Comparisons</td>
<td>IV Midazolam vs Sodium Valproate through rectal enema.</td>
</tr>
<tr>
<td>Length of Study/Follow-up</td>
<td>Appears to be up to 24 hours.</td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>Response to treatment (cessation of seizures)</td>
</tr>
<tr>
<td>Results</td>
<td>MID: 16/19 (84.2%) responded to treatment after 4.5±0.5 minutes (even group); SV: 12/19 (63%) responded to treatment within 16.5±0.8 minutes (odd group), (p&lt;0.00001) between the 2 groups.</td>
</tr>
<tr>
<td>Safety and adverse effects</td>
<td>No side effects reported during or after treatment.</td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>Relevant study to the clinical question.</td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>High risk of bias as there is inadequate randomisation methods (odd, even method), no allocation concealment, nor blinding. Main outcome not clearly reported in the study. Baseline characteristics between groups not clear.</td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>Direct population.</td>
</tr>
<tr>
<td>Directly applicable to guideline population?</td>
<td>Direct population.</td>
</tr>
</tbody>
</table>
Internal Validity

Question: Which AEDs are clinically effective, cost-effective and safest for use in pregnancy?
Grading: 2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal.

Adab N; Tudur SC; Vinten J; Williamson P; Winterbottom J;

Common antiepileptic drugs in pregnancy in women with epilepsy

Ref ID 5217 2004

Study Type Systematic Review

Funding not reported.

Number of participant cohort

Inclusion/Exclusion Criteria

Patient Characteristics

Recruitment

Setting

Interventions/ Test/ Factor being investigated

Comparisons

Length of Study/ Follow-up

Outcome measures studied

Results

Safety and adverse effects

Does the study answer the question?

1) any monotherapy exposure in utero compared to non exposed in the general population; 6 studies were included. Neither study found a significant difference in neurodevelopmental scores between children exposed to monotherapy and normal population.

2) carbamazepine exposure compared to non exposed in the general population; early years; only one out of 4 studies included found a significantly lower score in Bayle's mental index in children exposed to carbamazepine compared to non exposed. Early years to school years; two out of four studies found children exposed to CBZ have a significantly lower scores (using the McCarthy General cognitive index) than the general population.

3) phenytoin exposure in utero compared to the general population; early years; four out of five studies found no difference between those exposed to PHT in utero and the general population. Early years to school years; 1 study found no difference using the overall Bayle scale of development, but it was found that children exposed to phenytoin in utero scored significantly lower in the language domain compared to controls. Preschool to school years; unclear results due to studies limitations.

4) phenobarbital exposure in utero compared to the general population; early years; no differences were found in three studies. Preschool to school years; one out of three studies found a higher proportion of children with delayed school career and impaired results in tests of spelling, arithmetic, and reading.

5) Any polytherapy exposure in utero compared to the general population. Early years; all 5 studies found lower scores in those children exposed to any polytherapy regime in utero compared to unexposed children of mothers without epilepsy. Preschool to school years; 4 studies found no difference. Two studies found a poorer
performance in those exposed to polytherapy in all areas tested using a variety of scales. (the group of polytherapy was a very heterogeneous group).

6) polytherapy compared to monotherapy exposure in utero; early years; one of two studies found significant difference in the neurodevelopmental scores between the two groups. Preschool to school years; one of the two studies found evidence for lower scores in verbal and motor categories of intelligence in those exposed to polytherapy compared to monotherapy.

7) Any AED exposure in utero with non exposed in the general population; early years; five out of six studies found that those exposed to AEDs in utero had significantly lower scores for development than controls from the general population. Preschool to school years; four out of seven studies found that exposed children scored significantly lower in general scores of IQ than control children.

8) Any AED exposure in utero compared to non exposed children of mothers with epilepsy; one out of three studies found a higher proportion of children with poor performance in arithmetic and school career in the exposed group (small numbers of non exposed children).

9) Any monotherapy exposure in utero compared to non exposed children of mothers with epilepsy; no significant differences found (small numbers of non exposed children).

10) Phenytoin compared to carbamazepine exposure in utero; 2 out of three studies showed significantly lower scores in the phenytoin exposed group.

11) Phenytoin compared to phenobarbital exposure in utero; no difference was found in all three studies.

12) Phenobarbitone compared to carbamazepine exposure in utero; in both studies, a higher proportion of children exposed to phenobarbitone had a lower mean developmental score and were poor achievers using the Dutch test for reading, spelling and arithmetic or in an inappropriate class for their age compared to children exposed to carbamazepine.

13) Valproate compared to carbamazepine exposure in utero; no difference between the two groups in developmental problems and mental delay.

Effect due to factor in study?
Consistency of results with other studies?
Directly applicable to guideline population?

Internal Validity

Banach R; Boskovic R; Einarson T; Koren G;

Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies.

Ref ID 5215 2010

Study Type Systematic Review Funding No sources of funding were used for this study.

Number of participant cohort studies
Inclusion/Exclusion Criteria
Patient Characteristics
Recruitment
Setting
Valproic acid group: The mean verbal IQ, performance IQ and full scale IQ were significantly lower in the valproic acid group compared with the control group (comprising mothers with and without epilepsy). The mean VIQ, PIQ and FSIQ scores in children exposed to valproic acid in utero were 83.9 (64.2, 103.6), 93.7 (72.6, 114.7) and 88.3 (69.6, 106.9) respectively. The mean VIQ, PIQ and FSIQ in the control all group (mothers with epilepsy) were 98.6 (70.4, 128.8) and 95.7 (73.1, 124.3) respectively.

2 meta-analyses conducted for exposure to carbamazepine; in the first meta-analysis using the Wechsler scale, the mean VIQ and FSIQ of children exposed to carbamazepine were not statistically significantly different from the control all group (p=0.097 and p=0.095). The mean PIQ of children exposed to carbamazepine was significantly lower than the control all group (mothers with and without epilepsy) (p<<0.002). The mean VIQ, PIQ and FSIQ of children exposed to carbamazepine was not statistically different from the control epilepsy group. In the second meta-analysis using the Bayley McCarth scale, the mean FSIQ of children exposed to carbamazepine was not statistically different from the unexposed control group.

**Internal Validity**

D’Souza SW; Robertson IG; Donnai D; Mawer G;

Fetal phenytoin exposure, hypoplastic nails, and jitteriness

Ref ID 4937 1991 Mar

**Study Type** Cohort  **Funding** North Western Regional Health Authority.

**Number of participant** N=123, group of epileptic mothers=61 and group of controls=62

**Inclusion/Exclusion Criteria** Group of epileptic mothers= pregnant women with a history of grand mal epilepsy and were referred to out antenatal clinic from September 1980- August 1982. Control mothers were selected at the time of antenatal booking and were matched for age, parity and social class. Exclusion criteria: no heavy smokers (more than 20 cigarettes/day), medical complications (diabetes, hypertension). Drug use.

**Patient Characteristics** Pregnant women in both groups had similar ages (mean (sd) for epileptic mothers was 26.5 (4.9) and for control was 26.6 (4.8), and the majority of them gave a spontaneous vaginal birth delivery (37/61 in epileptic women and 40/62 in controls). Both groups attended the antenatal clinic in St Mary's Hospital, Manchester.
Comparisons are made between the group of epileptic mothers and the control group. One comparison is made for the incidence of hypoplastic nails in infants with congenital anomalies within epileptic mothers.

Length of Study/ Follow-up


Outcome measures studied

1) proportion of children with congenital anomalies 2) proportion of children with neonatal conditions 3) proportion of neonatal deaths 4) developmental impairment

Results

1) 26/61 children from epileptic mothers and 0/62 in controls had congenital anomalies. These anomalies occurred in 15/31 mothers with a monotherapy, 10/18 whose mothers had a mixture of drugs and 1/8 whose mothers had no drugs during pregnancy.

2/61 children from epileptic mothers had congenital heart disease, 1/61 had ventricular septal defect, 1/61 had patent ductus arteriosus, 1/61 had hypoplastic left heart syndrome, 2/61 had cranial nerve palsy.

Hypoplasia of nails affected 11/61 (18%) of children of epileptic mothers.

2) neonatal conditions were diagnosed in 26/61 children in the study group (43%) and 6/62 (10%) in control group.

3) 2/61 neonatal deaths among children of epileptic mothers.

4) excluding one child with Down’s syndrome, 0/61 children in the study group had a major developmental impairment. The median developmental quotients for children of epileptic mothers and of controls were 94 (75-134) and 98 (90-120) respectively.

Safety and adverse effects

See outcomes of the study.

Does the study answer the question?

Yes. A higher proportion of children of epileptic mothers had congenital anomalies with the most frequent the hypoplasia of nails and neonatal conditions compared to controls. Two neonatal deaths observed in the study group. Developmental delay was not observed in either group, study or control.

Effect due to factor in study?

The study had a good methodological, however no estimation of statistical power was performed so uncertain about the effect of the exposure on the outcomes measures.

Consistency of results with other studies?

Not consistent.

Directly applicable to guideline population?

Direct.

Internal Validity

Adequately addressed

Gaily E;Kantola-Sorsa E;Granstrom ML;

Intelligence of children of epileptic mothers

Ref ID 4943 1988 Oct

Study Type Cohort

Funding Not reported.

Number of participant


Inclusion/Exclusion Criteria

Inclusion criteria for children of epileptic mothers: having epileptic mother and born at the obstetric clinic of the Helsinki University Central Hospital from December 1975 to December 1979. Inclusion criteria for controls: absence of epilepsy or other chronic disorder in the mother, absence of intrauterine drug exposure (other than iron and vitamins), gestational period of at least 37 weeks and no major perinatal illness or
The children were examined at 66+/-3 months of age.

The children of epileptic mothers were recruited from the obstetric clinic of the Helsinki University Central Hospital (HUCH). The controls were enrolled in the study from the same clinic and from 2 welfare centers in Helsinki.

The obstetric clinic of the HUCH.

Having epileptic mother.

Comparison are made between the case group (children of epileptic mothers) and the control (children of non epileptic mothers). Comparisons are also made within groups of different antiepileptic drugs and control (no medication)

66+/-3 months.

intelligence (measured by a verbal measure, the Wechsler Preschool and Primary Scale of Intelligence (WPPSI), and a nonverbal measure of intelligence, the Leiter International Performance Scale (LIPS))

1) Any monotherapy (N=67) compared to general population (N=104): no statistically significant between the two groups (the mean WPPSI for the monotherapy was 109.7 (20.5) and for the general population 114.5 (13.3) (difference in means and 95% confidence interval was -4.8 (-10.3, 0.7), P=0.09. The mean LIPS for the monotherapy was 108.9 (16.4) and for the general population 113.2 (13.3) (difference in means and 95% confidence interval was -4.3 (-9.0, 0.4), P=0.07).

2) Any polytherapy (N=38) compared to monotherapy (N=67): no statistically significant difference between the two groups: the mean (sd) WPPSI for the monotherapy and polytherapy groups were 109.7 (20.5) and 110.7 (13.6) respectively (difference in means was -1.8 (-7.5, 5.5), P=0.8. The mean LIPS for the monotherapy group was 108.9 (16.4) and for the polytherapy was 109.5 (14.2) (difference in means -0.6 (-6.6, 5.4), P=0.8).

3) Any AED exposure in utero compared to the general population: borderline significance with lower scores in exposed group: the mean WPPSI for the exposed group was 110 (18.4) and for the general population 114.5 (13.3) (mean difference was 4.5 (-8.85, -0.15), P=0.04. The mean LIPS for the exposed group was 109.1 (15.4) and for the general population was 113.2 (13.3) (mean difference -4.10 (-8, -0.2), P=0.06).

4) Any AED exposure in utero vs non exposed children of mothers with epilepsy: no significant difference between the two groups: The mean WPPSI score for the study group was 110 (18.4) and for the control group was 116 (18.4) (the mean difference was -1.6 (-12.6, 9.4), P=0.08). The mean (sd) of LIPS was 109 (15.4) and 104.7 (13.2) for the study and control groups respectively (the mean difference was 4.40 (-3.6, 12.4), P=0.3.

5 perinatal deaths in the epileptic group of mothers compared to controls. No other perinatal complications or premature deaths.

Yes. No significant differences were found on the prevalence of mental deficiency among children of epileptic mothers compared to the general population.

Unknown. The sample size was not based on a preconsideration of statistical power. There was not a matched control group although there was an exploration of potential confounding factors.

Consistent.

Directly applicable to guideline population?

Direct.

Adequately addressed
The two groups of children had mothers well matched for age, parity and race. The mean educational level was higher in the control group than the case group, but the difference was not of statistical significance.

Antiepileptic drugs during pregnancy. Comparisons are made between the cases (children of epileptic mothers) and the controls (children of non epileptic mothers). Children were followed for 12 months.

1) minor anomalies 2) mental development 3) psychomotor development

Results

1) There was a statistically significant difference on the mean number of minor anomalies between the two groups (p=0.002); in the case group the mean number of minor anomalies was 4.7 whereas in the control was 3.1. The features more frequently seen in the case group were a flat nasal bridge (33%) (for the control group was 15%), an epicantal folds (28%) (for the control group was 15%), a broad alveolar ridge (19%) (for the control group was 3%), a pigmented nevi (17%) (for the control group was 3%), a metopic suture ridging (4%) (for the control group was 9%), and hypoplastic toenails (14%) (for the control group was 6%). The only statistically significant difference was between the two groups on the broad alveolar ridge.

2) The mean Mental Development Index was significantly higher in the control group (mean 119, range 97-137) than in the case (mean 113, range 86-134) (P=0.017).

3) There was no statistically significant difference between the two groups on the Psychomotor Development Index.

4) In the subgroup analysis; there was a statistically significant difference in the mean mental development index score between the monotherapy group (mean 116) and the polytherapy (mean 108) (P=0.038). The subgroup with the highest mean mental development index score was the carbamazepine (mean 122), that was higher than the polytherapy (mean 108) and the control (mean 119).

Safety and adverse effects

See Q2.

Does the study answer the question?

Yes. There was a significantly higher mean number of minor anomalies in the case group compared to control. The mean mental development index was significantly lower in the case group compared to control. Among the subgroups, children having mothers taking carbamazepine during pregnancy had the higher mean mental development index. No differences were found on the psychomotor development between the two groups.

Effect due to factor in study?

Uncertain. There was no prior calculation of the minimum required sample size and unknown if the study had the statistical power to detect an effect if there was.
**Internal Validity**

- Adequately addressed

**Results**

- **MDI (n=16)**
  - PHT: 108.2 (17.8)
  - CBZ: 114.2 (17.8)
  - Difference in means (95%ci) (by Cochrane Review): -6 (-17.26, 5.26) P=0.3

- **PDI (n=16)**
  - PHT: 106.0 (12.1)
  - CBZ: 104.8 (14.6)
  - Difference in means (95%ci) (by Cochrane Review): 1.2 (-9.84, 7.44) P=0.8

- **Cogn (n=3.4)**
  - PHT: 0.75 (3.4)
  - CBZ: -0.96 (3.3)
  - Difference in means (95%ci) (by Cochrane Review): 0.21 (-1.92, 2.34) p=0.8

- **Lang (n=3.3)**
  - PHT: -3.13 (3.3)
  - CBZ: -1.96 (3.0)
  - Difference in means (95%ci) (by Cochrane Review): -1.17 (-3.18, 0.84) p=0.3

- **Mo (n=4.1)**
  - PHT: 0.38 (4.1)
  - CBZ: -0.29 (4.1)
  - Difference in means (95%ci) (by Cochrane Review): 0.67 (-1.92, 3.26) p=0.6

- **PHT (n=13)**
  - T score 99.3 (28)
  - CBZ: 93.5 (11.2)
  - Difference in means (95%ci) (by Cochrane Review): 5.80 (-12.31, 23.91) p=0.5

- **Verbal (n=15.9)**
  - PHT: 50.3 (5.7)
  - CBZ: 46.0 (5.7)
  - Difference in means (95%ci) (by Cochrane Review): 4.30 (-5.68, 14.28) p=0.4

- **Perceptual (n=14.6)**
  - PHT: 48.8 (7.1)
  - CBZ: 46.0 (7.1)
  - Difference in means (95%ci) (by Cochrane Review): 2.80 (-7.29, 12.89) p=0.6

- **Quantitative (n=15.1)**
  - PHT: 45.9 (5.0)
  - CBZ: 45.8 (5.0)
  - Difference in means (95%ci) (by Cochrane Review): 0.10 (-9.21, 9.41) p=1.0

- **Memory (n=14.5)**
  - PHT: 47.7 (14.5)
  - CBZ: 39.3 (3.8)
  - Difference in means (95%ci) (by Cochrane Review): 8.4 (-0.16, 16.96) p=0.05

- **Motor (n=13.7)**
  - PHT: 48.3 (7.9)
  - CBZ: 38.5 (7.9)
  - Difference in means (95%ci) (by Cochrane Review): 7.8 (-2.37, 17.97) p=0.13
Safety and adverse effects

Does the study answer the question?
Yes. Lower scores in phenytoin exposed group.

Effect due to factor in study?
Unknown. The assessment of outcome measures were not available for all the participants in the study, therefore the statistical power of the study has been negotiated. However, the proportion of eligible mother child pairs in the clinic was 90%.

Consistency of results with other studies?
Unknown.

Directly applicable to guideline population?
Direct.

Internal Validity
Adequately addressed

Vanoverloop D; Schnell RR; Harvey EA; Holmes LB;

The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age

Ref ID 4935 1992 Sep

Study Type Cohort Funding In part by NIH Grant no 10910 and the Easter Seal Research Fund.

Number of participant
N study group (exposed to phenytoin)=20 and n controls (unexposed)=98.

Inclusion/Exclusion Criteria

Patient Characteristics
The average age of exposed children was 60 months and of the matched controls was 62 months. All exposed children were the same sex as their assigned controls. All except one, the oldest girl, was the same parity as the control. For 12 out of 20 exposed children, the SES match was with the same Hollingshead category, and for 5 more, the socioeconomic status of the exposed child was in the same major category as that of the matched unexposed child.

Recruitment
Children in the study group were recruited from a sample of 7085 children born at the Boston Hospital for Women, Lying in Division who were exposed during pregnancy to phenytoin. 38 (0.5%) mothers reported this exposure.

Setting
Boston Hospital for Women, Lying-in Division.

Interventions/Test/Factor being investigated
Maternal epilepsy.

Comparisons
Comparisons were made between the study group (intrauterine exposure to phenytoin only or with additional anticonvulsants) and the controls (non epileptic mothers).

Length of Study/Follow-up
4-8 years.
Outcome measures studied

1) intelligence (and two subtypes; verbal and performance intelligence) 2) visual motor integration 3) psycholinguistic abilities (two subtypes; grammatic closure and auditory association)

Results

1) the intelligence full scale significantly differed between the two groups; the mean total intelligence score (sd) for the study group was 109.3 (10.9) and for the control was 118.16 (11.94) (difference in means given by the Cochrane review -8.86 (-14.19, -3.53), P=0.001). The mean performance score was significantly lower in the study group (105 (10.11)) compared to controls (115.64 (11.75)) (difference in means given by the Cochrane review -10.64 (-15.64, -5.64, P=0.00003). No significant differences were found between the two groups on the verbal intelligence scores (for the study group the mean (sd) verbal intelligence score was 111.4 (11.59) and for the control 117.14 (12.17) (difference in means given by the Cochrane review -5.74 (-11.36, -0.12, P=0.05).

2) Significant differences were found on the mean scores of visual motor integration test between the two groups; for the study group the mean (sd) was 7.97 (4.37) and for the control group was 14.15 (8.23) (the difference in means given by the Cochrane review was 6.18 (-8.74, -3.62, P<0.00001).

3) No significant differences were found in either the auditory association test or the grammatic closure. The mean (sd) for the auditory association test was 42.56 (7.54) and 43.80 (6.57) for the study and control groups respectively (the difference in means given by the Cochrane review was 1.24 (-5.17, 2.69, P=0.5). The mean (sd) for the grammatic closure test was 44.75 (9.12) and 44.94 (7.83) for the study and control groups respectively (the difference in means given by the Cochrane review was 0.19 (-4.51, 4.13, P=0.9).

Safety and adverse effects

The 16 exposed children who were not evaluated included one with growth retardation at birth and 2 with a major malformation and 2 were dead at the date of evaluation.

Does the study answer the question?

Yes. The intelligence full scale and the performance subscale were significantly lower in the study group compared to controls. The average visual motor integration score was significantly lower in the exposed group compared to unexposed. No differences were found between the two groups on the verbal intelligence scale, on the auditory association test or the grammatic closure.

Effect due to factor in study?

Uncertain. No priori calculation of minimum required sample size to detect a statistically significant difference if it exists. Study may have been underpowered.

Consistency of results with other studies?

With some but not all studies in the field.

Directly applicable to guideline population?

Direct.

Internal Validity

Adequately addressed

Funding

Research grant K97-17z-12225-01A from the Swedish Medical Research Council, the Foundation of Samariten, the May Flower Foundation, the Research Foundation of Glaxo-Welcome company and the Research Foundation of Pediatric Research of the Freemasons.

Number of participant

N (exposed to any AED) =67, N(unexposed)=66, N (phenytoin)=15, N(carbamazepine)=35
| **Inclusion/Exclusion Criteria** | Inclusion criteria for the exposed to any AEDs children were: giving birth during 1985-1995 and attending antenatal clinics in the south east region of Stockholm. For the non exposed children: baby matched for gestational age, gender and mode of delivery was recruited within +2 days of the birth of a study child. Exclusion criteria: children were excluded if the birth examination was not performed by any of the participating paediatricians. |
| **Patient Characteristics** | The main characteristics for the whole exposed group (including several AEDs) compared to unexposed group; the number of families with only one child was significantly higher in the exposed group (p<0.01). Ten of the 67 exposed women had the lowest educational level, compared to only 2 women in the unexposed group (p<0.001). |
| **Recruitment** | They were recruited during early pregnancy from antenatal clinics and their epilepsy treatment was monitored carefully throughout pregnancy. |
| **Setting** | population study in the south east of Stockholm. |
| **Interventions/ Test/ Factor being investigated** | Exposure to any of the following antiepileptic drugs: carbamazepine, phenytoin, other antiepileptic drug and polytherapy. |
| **Comparisons** | Comparisons were made between exposed and unexposed groups and within the different subgroups of exposed group; phenytoin and carbamazepine. |
| **Length of Study/ Follow-up** | 4.5-5 years. |
| **Outcome measures studied** | psychomotor development as assessed by the 6 subsets of Griffiths' test: locomotor function, personal and social behaviour, hearing and speech, eye and hand coordination, performance and practical reasoning. |
| **Results** | 1) Children exposed to carbamazepine had a higher mean score on locomotor function; 104 compared to phenytoin children; 98 2) Children exposed to carbamazepine had a higher mean score on personal and social behaviour; 107 compared to children exposed to phenytoin; 105 3) Children exposed to phenytoin had a higher mean score on hearing and speech; 111 compared to carbamazepine group; 105 4) Almost similar mean scores had the both groups (carbamazepine: 100 and phenytoin; 101 on eye and hand coordination 5) A higher mean score had the phenytoin group on performance; 110 compared to carbamazepine 105 6)A higher mean score had the phenytoin group on practical reasoning;110 compared to carbamazepine 101. 7) The mean total score of psychomotor development was higher for the phenytoin group (635) compared to carbamazepine (618) |
| **Safety and adverse effects** | Not reported. |
| **Does the study answer the question?** | Unclear. The mean total scores of psychomotor development of exposed children to phenytoin was higher compared to carbamazepine group. |
| **Effect due to factor in study?** | The sample size calculation were based on comparison of an exposed group to various AEDs and to unexposed group. Therefore, the numbers in the groups of phenytoin and carbamazepine is unknown whether they have enough statistical power. No information on confidence intervals for the comparison of these two drugs. |
| **Consistency of results with other studies?** | Unclear. |
| **Directly applicable to guideline population?** | Direct. |
| **Internal Validity** | Adequately addressed |
### Grading: 2-
Case–control or cohort studies with a high risk of confounding bias, or chance and a significant risk that the relationship is not causal*

Barqawi R;

Evaluation of antiepileptic drugs in pregnancy in a Jordanian army hospital

Ref ID 448 2005 Jul

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Cohort</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of participant</td>
<td>N=50, Group A (carbamazepine)=16, Group B (carbamazepine and phenytoin)=16, group C (no medication)=18.</td>
<td>Not mentioned.</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td>Inclusion criteria: pregnant women aged 25-35 years, multiparous, with known past history of epilepsy for the last 5 years and no obvious cause of the disease, attending regularly the internal medicine clinic at King Hussein Medical Centre, Amman, Jordan.</td>
<td></td>
</tr>
<tr>
<td>Patient Characteristics</td>
<td>They were recruited from the medical clinic at King Hussein Medical Centre, Amman, Jordan. See inclusion criteria.</td>
<td></td>
</tr>
<tr>
<td>Recruitment</td>
<td>Women with a history of epilepsy being regular attenders of the internal medicine clinic at King Hussein Medical Centre were recruited in the study.</td>
<td></td>
</tr>
<tr>
<td>Setting</td>
<td>The internal medical clinic at King Hussein Centre</td>
<td></td>
</tr>
<tr>
<td>Interventions/Test/Factor being investigated</td>
<td>Being born by a mother treated on carbamazepine during pregnancy.</td>
<td></td>
</tr>
<tr>
<td>Comparisons</td>
<td>Comparison are made between participants and their children on carbamazepine, on carbamazepine and phenytoin and on no medication.</td>
<td></td>
</tr>
<tr>
<td>Length of Study/Follow-up</td>
<td>throughout pregnancy until the delivery.</td>
<td></td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>1) minor congenital anomalies 2) major congenital anomalies</td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td>1) A statistically significant difference was found between the three groups on the proportions of minor congenital anomalies (p=0.01); in group A (carbamazepine), 4/16 children were born with minor congenital anomalies (25%) (distal digital hypoplasia and ear flap abnormalities), in group B (carbamazepine and phenytoin) 4/16 (25%) and in group C (no medication) 0/18. 2) No statistically significant difference was found between the three groups on the proportions of major congenital anomalies (p=0.07); major congenital anomalies were detected only in group B (carbamazepine and phenytoin) 2/16 (12.5%).</td>
<td></td>
</tr>
<tr>
<td>Safety and adverse effects</td>
<td>See results in Q2</td>
<td></td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>Unclear. 25% of children of mothers treated on carbamazepine during pregnancy and 25% of children born by mothers on carbamazepine and phenytoin were born with minor congenital anomalies. 12.5% of children born by mothers on carbamazepine and phenytoin had major congenital anomalies.</td>
<td></td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>Unclear. The study had a small sample size and no information are given for the allocation of treatment to groups and any confounding factors on the outcome measure.</td>
<td></td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>Consistent.</td>
<td></td>
</tr>
<tr>
<td>Directly applicable to guideline population?</td>
<td>Direct.</td>
<td></td>
</tr>
</tbody>
</table>
### Patient Characteristics

#### Recruitment

All pregnant with epilepsy whose babies were delivered at Helsinki University Central Hospital from December 1975 to December 1979 were enrolled in this study. The controls was sampled for the maternity hospital and child welfare centre records.

#### Setting

Not clear.

#### Interventions/ Test/ Factor being investigated

Any AED exposure in utero.

#### Comparisons

Comparison was made between any AED exposure compared to the general population.

#### Length of Study/ Follow-up

Mean 5.5 years (range 5.2 to 5.8 years for both groups).

#### Outcome measures studied

Mental deficiency, borderline intelligence (defined as both scores for WIPPSI and LIPSI<85, and at least one<70), proprotion of children with specific cognitive dysfunction.

#### Results

The proportion of children with mental deficiency in the study group (of epileptic mothers) was 1.4% (2/148), whereas 0% of control children had mental deficiency. The proportion of children with borderline intelligence was 1.7% (2/117) and 0% in the study and control groups respectively. The proportion of children with specific cognitive dysfunction (defined as performing below the 5th centile for one or more of: visuoconstructive score of Wechsler Preschool and Primary Scale, auditory phonemic score of Illinois Test of Psycholinguistic Abilities and/or comprehension score of Neuropsychological test battery NEPS) was 23% (22/94) and 7% (7/100) in the study and control groups respectively.

#### Safety and adverse effects

See results (Q2-9).

#### Does the study answer the question?

A higher proportion of children of epileptic mothers had specific cognitive dysfunction at the age of 5.5 years compared to controls. No significant differences were found on the neuropsychological impairment between study and control groups.

#### Effect due to factor in study?

Uncertain. Due to absence of information the methodological rigous of the study couldn't be assessed. Uncertain about the statistical power of the study to detect a significant difference if it existed.
Consistency of results with other studies? Consistent with some but not all studies.

Directly applicable to guideline population? Direct.

Internal Validity Adequately addressed

Hanson JW; Myrianthopoulos NC; Harvey MA; Smith DW;

Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome

Ref ID 4958 1976 Oct

Study Type Cohort Funding Not reported.

Number of participant Unclear. Based on Cochrane Review information n study group=83 and n control=83

Inclusion/Exclusion Criteria Inclusion criteria for exposed to AED group of children: born to mothers with a convulsive disorder treated with hydantoins continuously throughout pregnancy. Inclusion criteria for controls: born to mothers without seizures and who received no anticonvulsants during pregnancy. The controls were matched for maternal socioeconomic status, maternal age, race and institution of birth.

Patient Characteristics Among the 104 women identified as receiving hydantoins, 62 were whites, 39 were black, and 3 were Puerto Rican. 24 women were treated with hydantoins alone, the remainder were treated with hydantoins and barbiturates, from whom 17 mothers also received other anticonvulsant drugs. Approximately 11% of infants exposed prenatally to hydantoins have enough unusual features to be clearly classified as having fetal hydantoin syndrome, while an additional 31% display some features compatible with the prenatal effects of hydantoins.

Recruitment The exposed group was recruited from the Collaborative Perinatal Project of the National Institute of Neurological and Communicative Disorders and Stroke.

Setting Not reported.

Interventions/ Test/ Factor being investigated Intrauterine exposure to AED.

Comparisons Any AED exposure in utero compared to the general population.

Length of Study/ Follow-up 7 years.

Outcome measures studied mental performance (measured by WISC full scale mental performance scores), intelligence (measured by IQ)

Results The mental performance scores were significantly lower in the exposed group compared to controls; mean (sd) WISC full scale for the exposed group to AED was 91.7 (17.29) and for the general population 96.83 (15.5) (difference in means (95%ci) reported by the Cochrane Review was -5.13 (-10.3, -0.13), P=0.04).

Data on IQ as reported by the Cochrane Review (extracted from graph); the proportion of children with IQ<70 was 7.5% in the exposed group and 5.8% for the general population respectively.

Safety and adverse effects dysmorphic features?

Does the study answer the question? The mental performance score was significantly lower in the exposed group compared to placebo.

Effect due to factor in study? Poor methodology. Uncertain about the statistical power of the study and whether the effect observed was due to exposure to anticonvulsants.
Consistency of results with other studies? Unclear.

Directly applicable to guideline population? Direct.

Internal Validity Not addressed

Koch S; Titze K; Zimmermann RB; Schroder M; Lehmkuhl U; Rauh H;

Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents

Ref ID 4929 1999 Sep

Study Type Cohort Funding Not reported.

Number of participant N=116, n monotherapy=31, n polytherapy=23, n no therapy (epileptic mothers)=13, controls (no epileptic mothers)=49.

Inclusion/Exclusion Criteria Inclusion criteria for the study groups: born between 1976 and 1984 ad being members of the prospective longitudinal panel on "Epilepsy, pregnancy and development" (Steinhausen et al., 1994). The control mother (non epileptic)/child pairs were matched on five variables: socioeconomic status, age of the mother at delivery, birth order, cigarette consumption during pregnancy, and number of previous abortions.

Patient Characteristics The age of children ranged from 10-19 years. The children of mothers who received polytherapy during pregnancy were generally from older birth cohorts, and the children of mothers who received monotherapy during pregnancy were generally from younger birth cohorts. Many of the children in the control group entered the longitudinal study later, so were on average younger at the time of this examination.

Recruitment Both study and control participants were recruited from the obstetric departments where pregnant women with epilepsy were cared for during pregnancy and at delivery.

Setting Not reported.

Interventions/ Test/ Factor being investigated Intrauterine AED exposure.

Comparisons 1) any monotherapy exposure in utero compared to the general population, 2) any polytherapy compared to any monotherapy exposure in utero, 3) any monotherapy exposure in utero compared to non exposed children of mothers with epilepsy.

Length of Study/ Follow-up 10.9-19 years.

Outcome measures studied General intelligence; measurement of performance (non verbal) and verbal components.

Results 1) any monotherapy exposure in utero compared to the general population: study does not report significance of this comparison. Performance and total score of intelligence significantly lower in the monotherapy group. No significant difference between groups in terms of verbal scores. Mean (sd) score of verbal intelligence for the monotherapy group was 99.7 (14.2) and for the controls 103.1 (12.6) (difference in means by Cochrane review (95%ci): -3.40 (-9.52, 2.72), P=0.3). Mean (sd) score of performance intelligence for the monotherapy group was 100.0 (15.2) and for the controls 106.7 (11.0) (difference in means by Cochrane review (95%ci): -6.70 (-12.87, -0.53), P=0.03). Mean (sd) score of total intelligence for the monotherapy group was 99.7 (13.8) and for the controls 105.4 (11.5) (difference in means by Cochrane review (95%ci): -5.70 (-11.53, 0.13), P=0.06).

2) any polytherapy compared to any monotherapy exposure in utero: trend suggests that scores are lower on polytherapy although the differences are not statistically significant; mean (sd) score of verbal intelligence for the monotherapy group was 99.7 (14.2) and for the polytherapy 92.7 (14.3) (difference in means by Cochrane review (95%ci): -7.00 (-12.70, 1.70), P=0.06).
review (95%ci): 7.0 (-0.69, 14.69), P=0.07. Mean (sd) score of performance intelligence for the monotherapy group was 100.0 (15.2) and for the polytherapy 92.2 (17.69) (difference in means by Cochrane review (95%ci): 7.80 (-1.19, 16.79), P=0.09). Mean (sd) score of total intelligence for the monotherapy group was 99.7 (13.8) and for the polytherapy 92.2 (17.6) (difference in means by Cochrane review (95%ci): -7.50 (-1.18, 16.18), P=0.09).

3)any monotherapy exposure in utero compared to non exposed children of mothers with epilepsy: study does not specifically report this comparison. Scores do not differ significantly between groups. Mean (sd) score of verbal intelligence for the monotherapy group was 99.7 (14.2) and for the controls 100.8 (17.7) (difference in means by Cochrane review (95%ci): -1.10 (-11.94, 9.74), P=0.8). Mean (sd) score of performance intelligence for the monotherapy group was 100.0 (15.2) and for the controls 98.6 (21.6) (difference in means by Cochrane review (95%ci): 1.40 (-11.50, 14.3), P=0.8). Mean (sd) score of total intelligence for the monotherapy group was 99.7 (13.8) and for the controls 101.8 (18.4) (difference in means by Cochrane review (95%ci): -2.10 (-13.22, 9.02), P=0.7).

Safety and adverse effects

Does the study answer the question?
Yes. Performance and total score of intelligence were significantly lower in the monotherapy group compared to the general population. Trend suggests that all three intelligence scores were lower on polytherapy compared to monotherapy although the differences were not statistically significant. Intelligence scores did not differ significantly between the monotherapy group and the non exposed children of epileptic mothers.

Effect due to factor in study?
Uncertain, as only 41% of the original study has been followed up. Unclear the risk of attrition bias and its impact on the statistical power of the study.

Consistency of results with other studies?
Unclear.

Directly applicable to guideline population?
Direct.

Internal Validity
Adequately addressed

Mawer G;Clayton-Smith J;Coyle H;Kini U;

Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate

Ref ID 4925 2002 Dec

Study Type Cohort Funding No funding.

Number of participant
43 mothers and 56 children were assessed; 1 pregnancy had no drug. monotherapy: 23 pregnancies in 14 women had sodium valproate, 18 pregnancies in 13 women had carbamazepine, 7 pregnancies in 3 women had phenytoin, 4 pregnancies in 3 women had lamotrigine, 1 pregnancy had ethosuximide. Polytherapy: 15 pregnancies in 12 women had combined AEDs

Inclusion/Exclusion Criteria
Inclusion criteria: Pregnant women attending the Epilepsy Clinic at Manchester Royal Infirmary between January 1990 and December 1999. No exclusions were made.

Patient Characteristics
Pregnant women attending a hospital unit. 26/45 had focal epilepsy, 17 had idiopathic generalised epilepsy and in 2 the epilepsy was unclassified.

Recruitment
From the Epilepsy Clinic at Manchester Royal Infirmary. No further information are given.

Setting
the Epilepsy Clinic at Manchester Royal Infirmary.

Interventions/ Test/ Factor being investigated
Epilepsy.
Comparisons were made within the population of women with epilepsy between different treatment groups (sodium valproate monotherapy, carbamazepine monotherapy and polytherapy).

Length of Study/ Follow-up

10 years?? (4 pregnancies were assessed retrospectively)

Outcome measures studied

1) number of miscarriages 2) dysmorphic features 3) developmental delay 4) structural anomalies

Results

1) 10/69 pregnancies were lost (miscarriages) 2) dysmorphic features were found in more than half the children with some evidence of developmental delay in about one quarter. Structural anomalies were found in about one third of children. 3) monotherapy with valproate: in each assessment, a positive association was found between adverse outcome and VPS dose (the significance was borderline for developmental delay but high for the other two areas). At higher doses above 1000mg/day moderate or severe features were found in one area of assessment at least, in half the children. (3/4 women who had adverse outcomes to earlier pregnancies on doses of 1400-2500 mg/day on VPS, after withdrawal of AED, reduction of VPS dose or transfer to CBZ, conceived again producing normal children. 4) monotherapy with carbamazepine: no significant association with adverse outcome and CBZ dose in any assessment area. 5) monotherapy with phenytoin and lamotrigine: adverse features were absent or mild. 6) polytherapy (clobazam, ethosuximide, gabapentin, lamotrigine, phenytoin, topiramate or vigabatrin with CBZ or VPS): adverse events were absent or mild except one case (VPS 1200 mg/day with LTG 125 mg/day) that spinal bifida was seen on anomaly scan and the pregnancy was terminated.

Safety and adverse effects

See Q2 9-10

Does the study answer the question?

The study has several limitations; VPS in pregnancy at doses above 1000 mg/day carries a particular risk of adverse outcomes.

Effect due to factor in study?

Uncertain, small sample size, some comparisons could not be made and several methodological limitations.

Consistency of results with other studies?

In some but not all studies.

Directly applicable to guideline population?

Not clear.

Internal Validity

Not reported

Ornoy A;Cohen E;

Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy

Ref ID 4930 1996 Dec

Study Type Cohort

Funding No mentioned.

Number of participant 47 children whose mothers were treated on carbamazepine during pregnancy (Group A) and 47 control children (Group B).

Inclusion/Exclusion Criteria

Inclusion criteria for children in Group A: aged 6 months to 6 years, having mothers with epilepsy who were treated on carbamazepine monotherapy during pregnancy and attending the Israeli Teratogen Information Service during 1988-1994. Exclusion criteria were: premature babies (born before 32 weeks of gestation). The children in control group were matched by birth weight, gestational age and parental socioeconomic status.

Patient Characteristics Children were aged 6 months to 6 years. 19 children were Ashkenazi, 24 children were of Oriental origin and six children were of unknown ethnic origin. Their mothers were patients at the Israeli Teratogen Information Service during 1988-1994.
Their mothers were patients at the Israeli Teratogen Information Service during 1988-1994. Not reported how matched controls were recruited.

Not clearly stated.

Being born by mothers with epilepsy who were taking carbamazepine monotherapy during pregnancy.

Comparisons were made between the children whose mothers were epileptic and taking carbamazepine during pregnancy (Group A) and the matched control children (Group B).

Not clear.

1) proportion of children born with major anomalies 2) proportion of children with facial dysmorphic features 3) proportion of children with cognitive, motor and mental delay (scores were given based on Bayley and McCarthy tests).

1) 3/47 children in Group A had major anomalies (1 had hydrocephalus, 1 had ventricular septal defect, 1 had dilatation of the pelvis of the kidney and 2 had cleft plate). 3/47 in Group B had major anomalies (pulmonic stenosis, hypospadias and a solitary cyst of the kidney)

2) in Group A 6/47 children had typical facial dysmorphic features as described in carbamazepine syndrome (upslanting palpebral fissure, epicanthic folds, micrognathia, broad nasal bridge, high arched palate or cleft palate. 0/47 children in Group B had dysmorphic features.

3) There was a lower average mental and cognitive score in children born to mothers treated with carbamazepine when compared with controls (mean (sd) mental score for Group A 101.1 (14.8) and for group B 112 (10), mean cognitive score for group A 99.4 (21.1) and for group B 113 (15)). There were no differences on motor scores (mean (sd) for group A 97.5 (18) and for group B 101 (11.6)). 4/41 children in Group A had mental or cognitive scores between 81 and 90 and 5/41 had scores of 80 or below. In Group B there was no child with mental or cognitive scores below 81 and 2/47 had these scores below 90.

4) All children with facial dysmorphic features (carbamazepine syndrome) had a development quotient or intelligence quotient below 90.

8/48 women who were pregnant had spontaneous or induced abortions.

No difference was found on the incidence of major anomalies between children born to epileptic mothers who were on carbamazepine monotherapy and matched controls. However, 6/47 children of epileptic mothers had typical facial dysmorphic features (carbamazepine syndrome) whereas none of the control children had it. Children from epileptic mothers had a lower average mental and cognitive score compared to control children.

Uncertain, the group of children of epileptic mothers who had major anomalies was too small (4) to be related to carbamazepine, especially as three control children had congenital anomalies.

Partly.

Unclear.

Adequately addressed

Shapiro S; Hartz SC; Siskind V; Mitchell AA; Slone D; Rosenberg L; Monson RR; Heinonen OP;

Anticonvulsants and parental epilepsy in the development of birth defects

Ref ID 4947

Cohort 1976 Feb 7

Study Type

Funding NIH-NINDS-72-2322 and by National Institute of
They mentioned that epileptic and non-epileptic mothers and their children differed with respect to a number of characteristics but no further information were given.

Inclusion/Exclusion Criteria
Inclusion criteria for the study group: children whose mothers had used an anticonvulsant during pregnancy with central nervous system, skeletal and/or craniofacial defects.

Patient Characteristics
They mentioned that epileptic and non-epileptic mothers and their children differed with respect to a number of characteristics but no further information were given.

Recruitment
Not reported (part of the Collaborative Perinatal Project USA).

Setting
Not reported.

Interventions/Test/Factor being investigated
exposure to anticonvulsants during pregnancy.

Comparisons
2 comparisons were made; 1) between phenobarbitone in utero and general population, 2) between phenytoin and phenobarbitone exposure in utero

Length of Study/Follow-up
8 months to 4 years.

Outcome measures studied
mental development (mental, motor) at 8 months, intelligence (IQ) for 4 years.

Results
All results were adjusted for ethnic group, SES and hospital.

1) comparison on the mental development between phenobarbitone exposure in utero (n=35) compared to the general population (n=27,832) at 8 months: The mental score (sd) of the phenobarbitone group was 78.6 (7.10) compared to 79.5 (5) of the general population (the difference in means (95% cl) -0.90 (-3.25,1.45), P=0.5). The motor score (sd) of the phenobarbitone group was 32.3 (5.32) compared to 33.6 (5) of the general population (the difference in means (95% cl) -1.30 (-3.06,0.46), P=0.15).

2) comparison on the intelligence between phenobarbitone exposure in utero (n=27) compared to the general population (n=28,273) at 4 years: The intelligence score (sd) of the phenobarbitone group was 96.4 (16.11) compared to 97.0 (15.13) of the general population (the difference in means (95% cl) -0.60 (-6.68,5.48), P=0.8).

3) comparison on the intelligence between phenytoin (n=35) compared to phenobarbitone exposure in utero (n=27): The IQ score (sd) of the group was 91.1 (15.97) compared to 96.4 (16.11) of the phenobarbitone group (the difference in means (95% cl) was -5.30 (-13.36, 2.76), P=0.2).

Safety and adverse effects
Malformations reported elsewhere (Hartz et al).

Does the study answer the question?
No statistically significant differences were found on either the mental and motor development of children at 8 months or the intelligence of 4 years old between the group of children exposed to phenobarbitone in utero and to the general population. No differences were found on the intelligence scores between the children exposed to phenytoin and phenobarbitone in utero.

Effect due to factor in study?
Unclear. Unable to assess study's methodology due to absence of information.

Consistency of results with other studies?
Uncertain.
Antiepileptic medication in pregnancy: late effects on the children's central nervous system development

Ref ID 4938 1991 Jan

Study Type Cohort

Number of participant N study group (children of epileptic mothers)=61, N children exposed to phenobarbitone only=13, N children exposed to carbamazepine only=12. N children exposed to phenobarbitone and carbamazepine=12 and children not exposed to any antiepileptic medication=24. N control children (non epileptic mothers)= 61.

Inclusion/Exclusion Criteria Inclusion criteria for the study group: documentation of maternal epilepsy by a neurologist, antiepileptic medication (none, phenobarbitone and/or carbamazepine), absence of seizures during pregnancy and delivery, no evidence of intraterine infection or chromosomal abnormalities and absence of additional drug exposure. Control children were selected from singletons born in the same period and they were matched for their mother's parity and for birth weight, gestational age, sex, age at follow up and social class.

Patient Characteristics The children were followed for 6 years.

Recruitment During the years 1973 to 1981, children of epileptic mothers who had received extensive ante and perinatal care were recruited in the study. Controls of non epileptic mothers were selected from singletons born in the same period.

Setting Groningen University Hospital.

Interventions/ Test/ Factor being investigated Having an epileptic mother (exposure to antiepileptic drug in utero or not).

Comparisons Comparisons were made between the study and the control groups. Comparisons were also made between the different groups of drugs used in the study group and the control group.

Length of Study/ Follow-up 7-13 years.

Outcome measures studied 1) Children’s ability for reading, spelling and arithmetic (proportion with score<10th centile) 2) school career (proportion of children in inappropriate class for age and learning disorders)

Results 1) Phenobarbitone exposure in utero compared to the general population: higher proportion of children in phenobarbitone group had spelling and arithmetic problems; a) 2/9 in phenobarbitone and 4/43 in controls had reading problems b)5/7 and 7/37 had spelling problems in phenobarbitone and general population respectively c)3/7 and 2/37 had arithmetic problems in phenobarbitone and general population respectively. 4/12 and 10/54 children in phenobarbitone and general population respectively were in inappropriate class for age and learning disorders.

2) Any AED exposure in utero compared to the general population: a higher proportion of children with poorer outcomes was found in the exposed group. 5/28 in the study group and 4/43 in the control had problems with reading, 7/24 and 7/37 in the study and control groups respectively had problems with spelling and 4/24 in the study group and 2/37 in the control groups had problems in arithmetic. The proportion in inappropriate class was 6/34 for the study group and 10/54 for the controls.

3) Any AED exposure in utero compared to non exposed children of mothers with epilepsy: a higher proportion of children were found with poor outcomes in the exposed group for arithmetic and school career; 6/34 children in the group of any AED exposure had problems in reading compared to 5/22, 5/28 children in the study group had problems in spelling compared to 2/15 in the control and 7/24 children with any AED exposure in pregnancy had problems in arithmetic compared to 2/13 in the
Yes. No significant differences were found in the occurrence of (minor) neurologic dysfunction either between the control and the study groups as a whole, or between the control and specific drug groups.

4) Any monotherapy exposure in utero compared to non exposed children of mothers with epilepsy; 2/18 and 2/15 children in the study and control groups respectively had problems with reading, 5/15 and 2/13 in the two groups had problems with spelling and 3/15 in the study group and 5/22 had problems with arithmetic. 4/22 and 5/22 children in the exposed and non exposed groups were in inappropriate classes for age and learning disorders.

Safety and adverse effects
One child in the non medication group died of complications of spina bifida.

Does the study answer the question?
Yes. No significant differences were found in the occurrence of (minor) neurologic dysfunction either between the control and the study groups as a whole, or between the control and specific drug groups.

Effect due to factor in study?
Unclear. No a priori consideration of statistical power. Small numbers of groups of children being exposed to different groups thus making statistical analysis weak.

Consistency of results with other studies?
Consistent.

Directly applicable to guideline population?
Direct.

Internal Validity
Adequately addressed

Wide K; Winbladh B; Tomson T; Sars-Zimmer K; Berggren E;

Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. [Erratum appears in Dev Med Child Neurol 2000 May; 42(5):356]

Ref ID 4957

Study Type Cohort

Funding
Research Grant from the Swedish Medical Research Council (K97-17X-12225-01A), the Foundation of the First of May Flower, The Foundation of Samariten, the Orion, Pharma Research Foundation and the Holmia Insurance Company.

Number of participant
For phase I (birth) N=170, N study group (epileptic mothers)=87, N control group=83, for phase II (9 months), N=162, N study group=81, N control group=81.

Inclusion/Exclusion Criteria
The inclusion criteria for the study group were; mothers were continuously treated with AEDs from conception throughout pregnancy, the mothers were identified during the first trimester, from which time they attended the outpatient clinic for pregnant women with epilepsy at the department of neurology, and followed the protocol at this clinic. Parents gave permission for their children to participate in the follow up, the children were born at one of the two delivery wards in the departments of paediatrics and neurology at the South Hospital, one of the participating paediatricians was available to organize the examination of the newborn infant within 4 days of birth. No home deliveries were included. The controls were born in the same hospital within 2 days of the study subjects and matched for gestational age and mode of delivery and for sex.

Patient Characteristics
Children from epileptic mothers treated continuously with AEDs throughout pregnancy and attended the departments of neurology and paediatrics at a hospital. Controls were born in the same hospital within 2 days of the study subjects. 71 mothers (83%) of children in the study group were receiving monotherapy, carbamazepine and phenytoin were the most frequent used. The mean gestational age was 39.3 weeks for the subjects and 39.5 for the control infants.

Recruitment
All children in the study were recruited from the departments of neurology and paediatrics at the Sodersjukhuset Hospital in the south east region of Stockholm.
Comparisons are made between the group of subjects (having antiepileptic mothers under treatment during pregnancy with carbamazepine, phenytoin, others and polytherapy) and the control group (mothers non epileptic). 9 months follow up.

1) minor anomalies 2) major anomalies 3) psychomotor development

There was a significant difference on the proportions of children with minor anomalies born from mothers treated in carbamazepine and 5/37 in control group had minor anomalies (OR 11, 95% CI 1.42-85.2).

2) 5/21 children in phenytoin (2 facial anomalies, 1 digital anomalies, 4 skin anomalies) and 6/19 in control group had minor anomalies (OR 0.8, 95% CI 0.22-2.98)

3) For children exposed to AEDs (no separate information): 1/84 had ventricular septal defect and a nail hypoplasia, 1/84 had an isolated hypospadias and in the control group 1/83 had a ventricular septal defect and a simian crease.

4) No statistically significant difference between the study and control groups for the results from the five subscales of Griffith’s scale (measure gross motor function, personal and social behaviour, hearing and speech, eye and hand coordination, and performance). Mean (range) of Griffith’s scale for carbamazepine group (N=35) was 350 (324-435) and for controls 335 (307-396) (mean difference -0.59, 16.57). Mean (range) of Griffith’s scale for phenytoine group (N=21) was 346 (307-385) and for controls 344 (318-378) (mean difference -7.13, 11.34).

There was a significant difference on the proportions of children with minor anomalies born from mothers treated in carbamazepine compared to controls. No difference on the proportion of children with minor anomalies was found between children in phenytoin and controls. Small numbers in major anomalies incidence to allow interpretations. No significant differences in the psychomotor development between carbamazepine and matched control groups and phenytoin and matched controls.

Question: Which AEDs are most tolerable for people with learning disabilities?
A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life

Ref ID 367

Study Type Randomised Controlled Trial

Number of participant 88 enrolled but 14 withdrew before randomisation. Total 74 patients randomised: 37 topiramate vs 37 placebo.

Patient Characteristics Topiramate (n=37) vs placebo (n=35):

Majority were caucasian (95.8%).
Age in years, mean (s.d): 29.9 (12.1) vs 31.9 (10.3);
Gender: males: 20 vs 19; females: 17 vs 16;
Epileptic seizure history, number (%):
- generalised tonic-clonic 17 (45.9) vs 19 (54.3);
- partial seizures only 28 (75.7) vs 26 (74.3);
- partial seizures with generalisation 16 (43.2) vs 18 (51.4);
- other seizure types: 15 (40.5) vs 18 (51.4);

Seizure and general medical histories were similar for the groups; patients in the topiramate group had on average more seizures of all types in the last 6 months, but the variation was wide; half of all patients had a history of status epilepticus; all patients had abnormal neurological history and 38 (52.85) had an abnormal psychological history; antiepileptics were taken by all patients before the start of the study;

Recruitment Not reported.

Setting 24 sites in the UK.

Interventions/ Test/ Factor being investigated Maximum 400mg/day topiramate (adults) or 9mg/kg/day topiramate (children);
Study medication was administered twice daily. For adults (16 years or over) treatment was initiated at 25mg daily for 1 week, and increased in 25 to 50mg increments at one to two weekly intervals, to recommended daily dose of 200 to 400mg daily according to each individual's response.
For children (12-16 years) treatment as initiated at 25mg nightly for 1 week, and increased in 1 to 3mg/kg/day increments at one to two weekly intervals to a recommended daily dose of 5 to 9 mg/kg/day according to individual's response. Subjects were withdrawn at investigators discretion if seizure control inadequate, any serious adverse events occurred or consent was withdrawn.

Kerr MP; Baker GA; Brodie MJ;
Participants were assessed in the clinic at weeks -4 and 0 (baseline) at weeks 4, 8, 12, and 18 (titration) at weeks 24 and 30 (maintenance) at early termination and at additional and final visits during the taper period.

Medical history, vital signs, body weights were recorded and physical and neurological examinations and hematology and biochemistry parameters were assessed. Records of medication use and adverse events were reviewed. Subjects recorded seizures on diary cards.

**Comparisons**

Topiramate vs placebo.

**Length of Study/ Follow-up**

4 week baseline period: routine AEDs remained constant; 18 week titration period to achieve optimum dose of study drug. 12 week maintenance period - doses remained constant. Option to stop study medication over 4 -8 week taper phase or crossover to TPM.

**Outcome measures studied**

Response: 50% reduction in seizure frequency; seizure severity during the treatment phase; National hospital severity scale; various scales for behaviour and quality of life.

**Results**

17 withdrew from the study (9 topiramate and 8 placebo), 12 due to adverse events (7 topiramate and 5 placebo): 7/37 vs 5/37.

11/37 in the topiramate and 9/25 in the placebo groups had >50% reduction in seizure frequency. There was no statistical difference between the two groups in the number of responders. However the % change from baseline indicated that topiramate provided a beneficial effect by reducing seizure frequency by 32% (compared to 1% for placebo).

Adverse events (>10%): topiramate group: somnolence (32.4%), abnormal gait (10.8%), weight loss (21.6%), anorexia (24.3%), infection (24.3%), hostility (13.5%), asthesia (10.8%) placebo group: somnolence (10.8%), abnormal gait (5.4%), weight loss (8.1%), anorexia (2.7%), infection (16.2%), hostility (8.1%), asthesia (8.1%).

There was no significant difference between the groups in the mean total of Epilepsy Outcome Scale, Aberrant Behaviour Checklist, Epilepsy and Learning Disabilities Quality of Life during the on drug phase. However, there was a trend toward significance for improvement of the mean Epilepsy and Learning Disabilities Quality of Life behaviour subscale score for patients treated with topiramate (P=0.080). Only 34 patients (16 in topiramate and 18 in placebo groups) gave a global assessment of their treatment and of these 22 were better or much better. No significant differences were found between the groups in the global assessments of patients made by patients themselves, or by their carers.

**Safety and adverse effects**

Adverse events:

Topiramate vs placebo:

- accidental injury: 1/37 (2.7%) vs 6/35 (16.2%);
- asthesia: 4/37 (10.8%) vs 3/35 (8.1%);
- hostility: 5/37 (13.5%) vs 3/35 (8.1%);
- infection: 9/37 (24.3%) vs 5/35 (16.2%);
- anorexia: 9/37 (24.3%) vs 1/35 (2.7%);
- weight loss: 8/37 (21.6%) vs 3/35 (8.1%);
- abnormal gait: 4/37 (10.8%) vs 2/35 (5.4%);
- convulsion: 2/37 (5.4%) vs 4/35 (10.8%);
- nervousness: 1/37 (2.7%) vs 5/35 (13.5%);
- somnolence: 12/37 (32.4%) vs 4/35 (10.8%);

**Does the study answer the question?**

The author concludes that there was no significant differences between groups in mean seizure severity and other outcome measures. Topiramate was well tolerated and blood pressure reduced. Suggests that topiramate reduces seizure frequency in patients with epilepsy and intellectual disability without the added burden of behaviour effects, and was potentially advantageous to physical well-being.

**Effect due to factor in study?**

Uncertain, the study was underpowered as the minimum sample size of 120 patients was not achieved thus the observed treatment effect may be overestimated. In addition, unclear is the risk of selection bias due to absence of allocation concealment.
Consistency of results with other studies?

Directly applicable to guideline population?

Internal Validity

Direct.
Grading: 1-

A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy

Ref ID 4729

2001

Study Type Randomised Controlled Trial

Funding Parke-Davis Research and Development.

Number of participant 109 patients were screened, 83 patients were randomised; 39 patients entered the titration phase of gabapentin and 44 patients entered the titration phase of lamotrigine.

Inclusion/Exclusion Criteria

Inclusion criteria: aged at least 12 years and over, either sex, had to have a degree of learning disability and to meet any level of the DSM-IV criteria for mental retardation, had a localization-related epilepsy which was not satisfactorily controlled by their existing antiepileptic medication, taking one, two or three standard AEDs (not including gabapentin or lamotrigine) but still achieving satisfactory seizure control. A minimum of four seizures in each 28 day period and no seizure free 29 day period in the preceding 3 month was required for entry.

Exclusion criteria: primary generalized seizures, symptomatic generalized epilepsy or a history of non-epileptic seizures. Concurrent therapy with antacids or a recent participation in any clinical trial, women if they were pregnant or lactating or of child bearing potential and sexually active and not practising a reliable method of contraception. A known hypersensitivity to gabapentin or lamotrigine, or significant renal or hepatic dysfunction.

Patient Characteristics

All patients had a learning disability with a mean age of 38 years (sd 11.1) in the gabapentin group and a mean age of 33 years (sd 11.5) in lamotrigine group. 61.5% and 65.9% of patients were male in the gabapentin and lamotrigine groups respectively. The number of AEDs started before enrolment for each treatment group were very similar (41% and 50% in the gabapentin and lamotrigine groups respectively), with approximately the same numbers taking one or three.

Recruitment

The study population comprised either outpatients or inpatients of specialist hospitals with an identified key worker/carer who was available for the trial, able to keep a record of seizures.

Setting

Multicentre study in 44 UK sites.

Interventions/ Test/ Factor being investigated

gabapentin or lamotrigine as add on therapy to their existing AED therapy.

Comparisons

Comparison are made between gabapentin and lamotrigine.

Length of Study/ Follow-up

There was an initial baseline period of a 8 weeks, followed by a maximum 14 weeks titration period, and a minimum 10 weeks add on evaluation period (gabapentin or lamotrigine).

Outcome measures studied

> 50% reduction in seizures frequency, % of seizure free patients, withdrawal due to adverse events, mood, behaviour and dependency.

Results

- No statistically significant difference on the proportion of reduction in seizure frequency between gabapentin and lamotrigine. 50% of patients in gabapentin group experience >50% reduction in seizure frequency, compared to 48.6% of patients in lamotrigine groups.

- Three patients (7.7%) on gabapentin and 5 patients (11.4%) on lamotrigine were seizure free during the evaluation phase.

- Three patients (8%) in the gabapentin group and four (9%) in the lamotrigine group were withdrawn due to adverse events. The most commonly occurring adverse event was convulsions in two patients (one in each group). Two patients on lamotrigine group reported cases of respiratory infection and a further two reported urinary tract infections. Four patients experienced serious adverse events on gabapentin, and five
suffered serious adverse events on lamotrigine. 1 patient in gabapentin experienced drowsiness.

-Results showed a significantly greater improvement on gabapentin than on lamotrigine (P<0.05) in the measurement of co-operation, communication and restlessness. There was a significant improvement in general health from gabapentin P<0.01.

**Safety and adverse effects**

4 patients (11%) in gabapentin and 10 (26%) patients in lamotrigine experienced adverse events during evaluation period.

**Does the study answer the question?**

Yes. Main conclusions:

-50% of patients in gabapentin group experience >50% reduction in seizure frequency, compared to 48.6% of patients in lamotrigine groups.

Three patients (7.7%) on gabapentin and 5 patients (11.4%) on lamotrigine were seizure free during the evaluation phase.

-3 patients (8%) in the gabapentin group and four (9%) in the lamotrigine group were withdrawn due to adverse events.

- a significantly greater improvement on gabapentin than on lamotrigine (P<0.05) in the measurement of co-operation, communication and restlessness. There was an significant improvement in general health from gabapentin P<0.01.

**Effect due to factor in study?**

Uncertain. The sample size was smaller than the one calculated a prior of the study. Thus, the study may lack some statistical power. In addition, unclear the risk of selection bias due to absence of randomization and allocation concealment.

**Consistency of results with other studies?**

Direct.

**Directly applicable to guideline population?**

Direct.

**Internal Validity**
Grading: 2- Case–control or cohort studies with a high risk of confounding bias, or chance and a significant risk that the relationship is not causal

Losche G; Steinhausen H C; Koch S; Helge H;

The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors

Ref ID 4932 1994 Sep

Study Type Cohort Funding German Research Council.

Number of participants Not reported. Different sample sizes for different outcomes measures. Not clear.

Inclusion/Exclusion Criteria Inclusion criteria for the exposed children; having epileptic mothers treated with anticonvulsants during pregnancy. The controls were matched for socioeconomic status, age of the mother of deliver, parity, amount of smoking during pregnancy and number of abortions previous to the subject's birth.

Patient Characteristics No information on the main characteristics of the population was given.

Recruitment Randomly recruited from five obstetric departments with the city of Berlin, from the Department of Neurology, Free University of Berlin, during 1976 and 1983.

Setting Not reported.

Interventions/Test/Factor being investigated Exposure to one or more anticonvulsant during pregnancy.

Comparisons 1) any monotherapy exposure in utero compared to the general population 2) any polytherapy exposure in utero compared to monotherapy exposure.

Length of Study/Follow-up up to preschool years.

Outcome measures studied At 15 months: Bayley mental and motor scale, home inventory. At preschool years: verbal IQ (WPPSI), intelligence (CMMS), Psycholinguistic Abilities (ITPA), Frostig Test of Visual Perception (FTVP), motor performance (LOS), motor McCarthy scale (McC).

Results A) Any monotherapy exposure in utero compared to the general population. 15 months:

No significant difference was found between the two groups but scores were slightly lower in monotherapy group. The mean motor score (sd) for monotherapy group and general population was 56.3 (4.3) and 57.2 (7.2) respectively (n monotherapy= 24, n general population=42) (difference in means (95% c.i) given by the Cochran Review was -0.90 (-3.68, 1.88), P=0.5). The mean mental score (sd) for monotherapy group and general population was 127.1 (12.8) and 129.2 (12.9) respectively (n monotherapy= 44, n general population=67) (difference in means (95% c.i) given by the Cochran Review was -2.10 (-6.98, 2.78), P=0.4). No data for the home inventory.

Preschool years:

No significant difference was found between the two groups on the WIPPSI, CMMS, ITPA, FTVP and LOS scales, but scores were slightly lower in monotherapy exposed group compared to the general population. The mean verbal score (sd) for monotherapy group and general population was 50.9 (9.2) and 53.2 (8.8) respectively (n monotherapy= 52, n general population=67) (difference in means (95% c.i) given by the Cochran Review was -2.20 (-5.57, 0.97), P=0.17).The mean performance score (sd) for monotherapy group and general population was 52.1 (9.9) and 53.8 (9.3) respectively (n monotherapy= 52, n general population=67) (difference in means (95% c.i) given by the Cochran Review was -1.70 (-5.19, 1.79), P=0.3).

The mean CMMS score (sd) for monotherapy group and general population was 53.3 (9.8) and 53.8 (8.0) respectively (n monotherapy= 50, n general population=66)
(difference in means (95% c.i) given by the Cochrance Review was -0.50 (-3.83, 2.83), P=0.8). The mean ITPA score (sd) for monotherapy group and general population was 51.6 (3.3) and 52.1 (7.1) respectively (n monotherapy= 51, n general population=61) (difference in means (95% c.i) given by the Cochrance Review was -1.10 (-3.58, 1.38), P=0.4). The mean FTVP score (sd) for monotherapy group and general population was 52.7 (8.8) and 53.9 (8.5) respectively (n monotherapy= 45, n general population=66) (difference in means (95% c.i) given by the Cochrance Review was -1.20 (-4.49, 2.09), P=0.5). The mean LOS score (sd) for monotherapy group and general population was 48.7 (9.1) and 51.9 (7.7) respectively (n monotherapy= 49, n general population=64 (difference in means (95% c.i) given by the Cochrance Review was -3.20 (-6.37, -0.03), P=0.05). The mean McC score (sd) for monotherapy group and general population was 50.8 (9.8) and 51.9 (10.1) respectively (n monotherapy= 48, n general population=64) (difference in means (95% c.i) given by the Cochrance Review was -1.10 (-4.82, 2.62), P=0.6).

2) Any polytherapy compared to any monotherapy exposure in utero.

At 15 months:

Paper reports that there were no significant differences in motor and mental scales between the polytherapy and monotherapy groups, however results from the Cochrance review are contradictory; the mean motor score (sd) for polytherapy group and polytherapy was 56.3 (4.3) and 51.2 (3.3) respectively (n monotherapy= 24, n polytherapy=10) (difference in means (95% c.i) given by the Cochrance Review was 5.10 (2.43, 7.77), P=0002). The mean mental score (sd) for monotherapy group and general polytherapy was 127.1 (12.8) and 121.7 (7.3) respectively (n monotherapy= 44, n general population=15) (difference in means (95% c.i) given by the Cochrance Review was 5.40 (0.11, 10.69), P=0.05).

Safety and adverse effects

Does the study answer the question?

Yes. No significant differences were found on any scale between the monotherapy and the general population for both the mental and the motor scores when compared to polytherapy group.

Effect due to factor in study?

Uncertain, as no information were given regarding the original sample size, the drop outs and the minimum sample size required to detect a statistically significant difference if it exists in the study.

Consistency of results with other studies?

Unclear.

Directly applicable to guideline population?

Direct.

Internal Validity

Adequately addressed

Steinhausen HC;Losche G;Koch S;Helge H;

The psychological development of children of epileptic parents. I. Study design and comparative findings

Ref ID 4933 1994 Sep

Study Type Cohort

Funding German Research Council.

Number of participant N children exposed to anticonvulsants=73, N controls=65.

Inclusion/Exclusion Criteria Inclusion criteria for the exposed children; having epileptic mothers treated with anticonvulsants during pregnancy or without any anticonvulsant treatment or having epileptic fathers. The controls were matched for socioeconomic status, age of the mother of deliver, parity, amount of smoking during pregnancy and number of abortions previous to the subject's birth.

Patient Characteristics No information on the main characteristics of the population was given.

Recruitment Randomly recruited from five obstetric departments with the city of Berlin, from the Department of Neurology, Free University of Berlin, during 1976 and 1983.

29 July 2010 Page 295 of 306
<table>
<thead>
<tr>
<th>Setting</th>
<th>Not reported.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interventions/ Test/ Factor being investigated</td>
<td>Exposure to anticonvulsant during pregnancy, born to epileptic mother (without treatment during pregnancy), having epileptic fathers.</td>
</tr>
<tr>
<td>Comparisons</td>
<td>1) any AED exposure in utero compared to the general population 2) any AED exposure in utero compared to non exposed children of mothers with epilepsy.</td>
</tr>
<tr>
<td>Length of Study/ Follow-up</td>
<td>4-6 years.</td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>Mental development, motor abilities, quality and quantity of home support, intelligence, mental maturity, visual perception, motor performance.</td>
</tr>
</tbody>
</table>

### Results

1) any AED exposure in utero compared to the general population: at 15 months children exposed to AED scored significantly less in Bayle motor scales but no significant differences in mental development and home inventory; the mean (sd) of mental development index was 128 (12) and 130 (12) for the study group (children of mothers taking AED during pregnancy) and the controls respectively (the difference in means (95%ci) given by the Cochrane Review was -2 (-6.2, 2.2) P=0.4). The mean (sd) of motor scale for the study group was 55(4) and for the controls was 57(4) (the difference in means (95%ci) given by the Cochrane Review was -2 (-3.81, -0.19) P=0.03). The mean(sd) of home inventory was 34.5 (6.5) and 35.5 (6.5) for the exposed group to AED and the controls respectively (the difference in means (95%ci) given by the Cochrane Review was -1 (-3.47, 1.47) P=0.4).

At 4-6 years, exposed children to AED scored significantly lower in verbal and performance intelligence scores, in mental maturity scale, in visual perception and in motor performance. The mean(sd) of verbal intelligence was 48 (9.5) and 52.5 (10) for study and controls groups respectively (mean difference by Cochrane -4.5 (-7.69, -1.31), P=0.006). The mean(sd) of performance intelligence was 51 (9) and 55 (8) for study and controls groups respectively (mean difference by Cochrane -4 (-6.77, -1.23), P=0.005). The mean(sd) of mental maturity scale was 51 (8) and 54 (9) for study and controls groups respectively (mean difference by Cochrane -3 (-5.82, -0.18), P=0.04). The mean(sd) of psycholinguistic abilities scale was 50 (7) and 52 (7) for study and controls groups respectively (mean difference by Cochrane -2 (-4.37, 0.37), P=0.10). The mean(sd) of visual perception scale was 52 (9) and 55 (8) for study and controls groups respectively (mean difference by Cochrane -3 (-5.88, -0.12), P=0.04). The mean(sd) of motor performance scale was 49 (8) and 52.5 (8.5) for study and controls groups respectively (mean difference by Cochrane -3.5 (-6.28, -0.72), P=0.01). The mean(sd) of motor scale was 50 (10) and 52.5 (10) for study and controls groups respectively (mean difference by Cochrane -2.5 (-5.91, 0.91), P=0.15).

2) any AED exposure in utero compared to non exposed children of mothers with epilepsy: at 15 months children exposed to AED did not score significantly in Bayle motor scales, in mental development and home inventory compared to non exposed children; the mean (sd) of mental development index was 128 (12) and 124 (15) for the study group (children of mothers taking AED during pregnancy) and thenon exposed children (of epileptic mothers) respectively (the difference in means (95%ci) given by the Cochrane Review was 4 (-5.02, 13.02) P=0.4). The mean (sd) of motor scale for the study group was 55(4) and for the non exposed children was 51(7) (the difference in means (95%ci) given by the Cochrane Review was 4 (-1.76, 9.76) P=0.17). The mean(sd) of home inventory was 34.5 (6.5) and 31.5 (8.5) for the exposed group to AED and the non exposed respectively (the difference in means (95%ci) given by the Cochrane Review was 3 (-2.59, 8.54) P=0.3).

At 4-6 years, exposed children to AED scored generally similar with borderline or non significant differences in all scales compared to non exposed children. The mean(sd) of verbal intelligence was 48 (9.5) and 47.5 (7.5) for exposed and non exposed groups respectively (mean difference by Cochrane 0.5 (-3.84, 4.84), P=0.8). The mean(sd) of performance intelligence was 51 (9) and 47 (7) for exposed and non exposed groups respectively (mean difference by Cochrane 0.4 (-3.84, 4.84), P=0.8). The mean(sd) of mental maturity scale was 51 (8) and 51 (8) for exposed and non exposed groups respectively (mean difference by Cochrane 4 (0.12,7.88), P=0.04). The mean(sd) of psycholinguistic abilities scale was 50 (7) and 52.5 (3.5) for exposed and unexposed groups to AEDs respectively (mean difference by Cochrane -2.5 (-5.04, 0.04), P=0.05). The mean(sd) of visual perception scale was 52 (9) and 50 (5) for study and controls groups respectively (mean difference by Cochrane 2 (-1.38,5.38), P=0.2). The mean(sd) of motor performance scale was 49 (8) and 45 (7.5) for exposed and unexposed groups respectively (mean difference by Cochrane 4 (-0.34, 8.34).
| Safety and adverse effects | The only significant differences in safety issues between children exposed to anticonvulsants and controls were the speech disorders and sensory/motor disorders. |

| Does the study answer the question? | When the group of children exposed to any AED was compared to the general population, 15 months children exposed to AED scored significantly less in Bayle motor scales compared to controls and 4-6 years exposed children scored significantly lower in verbal and performance intelligence scores, in mental maturity scale, in visual perception and in motor performance. When the group of children exposed to any AED was compared to non exposed children of epileptic mothers, no significant differences were found on any scale at children 15 months, and, only borderline or non significant differences in intelligence, mental maturity, visual perception and motor performance scales compared to non exposed children. |

| Effect due to factor in study? | Uncertain, as no information were given regarding the original sample size, the drop outs and the minimum sample size required to detect a statistically significant difference if it exists in the study. |

| Consistency of results with other studies? | Unknown. |

| Directly applicable to guideline population? | Direct. |

| Internal Validity | Not reported |

**Question:** Which AEDs are the most tolerable for older people
Grading: 1+
Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias

Brodie MJ; Overstall PW; Giorgi L;

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

Ref ID: 4722

Funding: Glaxo Wellcome

**Study Type**
Randomised Controlled Trial

**Number of participant**
150 total: 102 in lamotrigine group (LTG) and 48 in carbamazepine group (CBZ)

**Inclusion/Exclusion Criteria**
Inclusion: Age 65 years or greater with newly diagnosed epilepsy with two or more seizures in previous year with at least one event during the past 6 months

**Patient Characteristics**

<table>
<thead>
<tr>
<th></th>
<th>LTG</th>
<th>CBZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (yrs)</td>
<td>77</td>
<td>76</td>
</tr>
<tr>
<td>Age range (yrs)</td>
<td>65-94</td>
<td>66-88</td>
</tr>
<tr>
<td>Male/female (%)</td>
<td>54/46</td>
<td>58/42</td>
</tr>
<tr>
<td>Wt (kg)</td>
<td>68</td>
<td>68</td>
</tr>
<tr>
<td>Ht (cm)</td>
<td>164</td>
<td>164</td>
</tr>
<tr>
<td>Baseline seizures</td>
<td>4 (mean)</td>
<td>5</td>
</tr>
</tbody>
</table>

**Recruitment**
Unknown

**Setting**
Multi centre UK

**Interventions/Test/Factor being investigated**
Treatment with lamotrigine or carbamazepine

**Comparisons**
LTG and CBZ are compared

**Length of Study/Follow-up**
After a brief titration period, patients were followed for 24 weeks

**Outcome measures studied**
Primary: withdrawal from the study and proportion of patients remaining seizure free during the last 16 weeks of treatment.
Secondary: time to first seizure

**Results**
Drop out due to adverse events - LTG 18% versus CBZ 42%
40 patients on LTG (39%) remained seizure free during the final 16 weeks and did not discontinue compared with 10 (21%) taking CBZ (p=0.027)
Time to first seizure: No significant difference
The hazard ratio of withdrawal rates was 2.4 (95% CI 1.4-4.0) indicating that at any time a patient treated with CBZ was more than twice as likely to withdraw than on taking LTG (p<0.001).

**Safety and adverse effects**

<table>
<thead>
<tr>
<th></th>
<th>LTG(n=102)</th>
<th>CBZ (n=48)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor coordination</td>
<td>13</td>
<td>17</td>
<td>NS</td>
</tr>
<tr>
<td>Somnolence</td>
<td>12</td>
<td>29</td>
<td>4-30</td>
</tr>
<tr>
<td>Dizziness</td>
<td>10</td>
<td>17</td>
<td>NS</td>
</tr>
<tr>
<td>Rash</td>
<td>9</td>
<td>25</td>
<td>4-28</td>
</tr>
<tr>
<td>Headache</td>
<td>9</td>
<td>17</td>
<td>NS</td>
</tr>
<tr>
<td>Constipation</td>
<td>9</td>
<td>6</td>
<td>NS</td>
</tr>
<tr>
<td>Vomiting</td>
<td>9</td>
<td>6</td>
<td>NS</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>7</td>
<td>8</td>
<td>NS</td>
</tr>
</tbody>
</table>

**Does the study answer the question?**
LTG is an acceptable choice as initial treatment for elderly patients with newly diagnosed epilepsy

**Effect due to factor in study?**
Yes
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. [see comment]

Ref ID 534  2005 Jun 14

**Study Type**  Randomised Controlled Trial  **Funding**  Research Grants and consultancy to one of authors from Pfizer, GSK, Novartis. Supported by Department of Veterans Affairs, Cooperative Studies Program. GSK and Pfizer provided study medications, placebos and drug plasma levels.

**Number of participant**  Total randomised: 593; CBZ n=198; GBP n=195; LTG n=200.

**Inclusion/Exclusion Criteria**  Initial inclusion criteria was 65 years and older and newly diagnosed seizures of any type; Changed this after the first year to 60 years and older to improve enrollment.

Inclusion criteria: newly diagnosed with epileptic seizures and were untreated, treated only acutely (<4 weeks), or treated but with subtherapeutic levels; a minimum of one seizure during the 3 months preceding enrollment was required; no restriction regarding concomitant diseases was imposed excepting those conditions likely to lead to a life expectancy of less than 12 months, progressive neurologic disease, or conditions that would significantly affect the response to treatment; all comedications were allowed save chronic AEDs; additional exclusion criteria included those with severe psychiatric conditions; current alcoholism; illicit drug use; history of noncompliance.

**Patient Characteristics**  LTG vs GBP vs CBZ:

- Age: 71.9 (s.d 7.4) vs 72.9 (s.d 7.5) vs 71.9 (s.d 7.7)
- Males: 195 (97.5%) vs 192 (96.7%) vs 183 (93.8%);
- Race:
  - white 139/200 (69.5%) vs 137/195 (70.3%) vs 133/198 (67.2%);
  - african american 47/200 (23.5%) vs 44/195 (22.6%) vs 52/198 (26.3%);
  - hispanic 11/200 (5.5%) vs 10/195 (5.1%) vs 5/198 (2.5%);
- other 3/200 (1.5%) vs 4/195 (2.1%) vs 8/198 (4%);

Pre-study seizure types:
- GTC only 48/200 (24.5%) vs 43/195 (22.4%) vs 56/198 (29%);
- CPS 89/200 (45.4%) vs 81/195 (42.2%) vs 81/198 (42%);
- SPS 28/200 (14.3%) vs 22/195 (11.5%) vs 26/198 (13.5%);
- GTC and partial 23/200 (11.7%) vs 33/195 (17.2%) vs 21/198 (10.9%);
- Mixed partial seizures 8/200 (4.1%) vs 13/195 (6.8%); 9/198 (4.7%);

Primary etiology:
- cerebral infarction 69/200 (34.5%) vs 52/195 (26.7%) vs 56/198 (28.4%);
- unknown 46/200 (23%) vs 43/195 (22.1%) vs 53/198 (26.9%);
- cerebral arteriosclerosis 26/200 (13%) vs 37/195 (19%) vs 30/198 (15.2%);
- head trauma 13/200 (6.5%) vs 13/195 (6.7%) vs 16/198 (8.1%);
- all others 46/200 (23%) vs 50/195 (25.6%) vs 42/198 (21.3%);
Baseline medical problems:
hypertension 138/200 (69%) vs 116/195 (59.5%) vs 137/198 (69.2%); stroke 103/200 (51.5%) vs 104/195 (53.3%) vs 95/198 (48%);
cardiac disease 93/200 (46.5%) vs 91/195 (46.7%) vs 102/198 (51.5%);
mild cognitive decline 72/200 (36%) vs 66/195 (33.8%) vs 69/198 (35%);
diabetes 49/200 (24.5%) vs 62/195 (31.8%) vs 57/198 (28.9%);
cancer 47/200 (23.5%) vs 46/195 (23.6%) vs 48/196 (24.2%);
psychiatric condition 39/200 (11.5%) vs 43/195 (22.1%) vs 47/198 (23.7%);
renal 23/200 (11.5%) vs 26/195 (13.3%) vs 24/198 (12.1%);
liver 5/200 (2.5%) vs 5/195 (2.6%) vs 6/198 (3%);

Baseline neurologic problems:
gait disturbance 108/200 (54%) vs 107/195 (54.9%) vs 97/198 (49%);
sensor abnormality 62/200 (31%) vs 65/195 (33.3%) vs 56/198 (28.9%);
memory problems 46/200 (23%) vs 56/195 (28.7%) vs 51/198 (25.8%);
station, abnormal 42/200 (21%) vs 48/195 (24.6%) vs 50/198 (25.3%);
motor power abnormal 39/200 (19.5%) vs 44/195 (22.6%) vs 49/198 (24.7%);
coordination (excluding gait) abnormal 29/200 (14.5%) vs 30/195 (15.4%) vs 27/198 (13.6%);

Recruitment
No details given.

Setting
18 Veterans Affairs Medical Centres, USA.

Interventions/Test/Factor being investigated
GBP vs LTG vs CBZ.

Comparisons
Comparisons between Gabapentin vs Lamotrigine vs Carbamazepine.

Length of Study/Follow-up
Option of continuing for additional 12 months.

Outcome measures studied
Primary: retention in the trail for 12 months; secondary: seizure freedom at 12 months, time to first seizure and drug toxicity.

Results
LTG vs CBZ:
Reasons for withdrawal prior to 52 weeks:
adverse reaction 24/199 (12.1%) vs 42/194 (21.65) vs 61/197 (31%), p=0.001
(differences between CBZ and LTG p=0.001 and GBP and LTG p=0.015 were significant).

Early terminations for adverse events (6 week titration phase): LTG 8/199 (4%) vs CBZ 41/199 (20.8%) vs GBP 29/194 (14.9%).

Seizure freedom (titration and maintenance phase):
at 3 months: 99/157 (63.1%) vs 84/135 (62.2%) vs 71/110 (64.5%);
at 6 months: 74/132 (56%) vs 64/113 (56.6%) vs 57/88 (64.8%);
at 12 months: 57/111 (51.4%) vs 45/95 (47.4%) vs 45/70 (64.3%).
P=0.93 at 3 months; 0.39 at 6 months; 0.09 at 12 months.

Seizure freedom in maintenance phase:
at 3 months: 126/157 (80.3%) vs 108/135 (80%) vs 88/110 (80%);
at 6 months: 90/132 (68.2%) vs 81/113 (71.7%) vs 64/88 (72.7%);
at 12 months: 68/111 (61.3%) vs 57/95 (60%) vs 50/70 (71.4%).
p=1 at 3 months; 0.73 at 6 months; 0.27 at 12 months;

Dosage reductions for side effects occurred in 31.3% (171/547) while dosage increases above target for inadequate seizure control occurred in 21.4% (117/547);
Dosage increases above target occurred more often in patients receiving LTG as compared to CBZ (27.1% 51/188) vs 14% (25/179), p=0.002.

No. of patients reporting systemic and neurologic toxicities at least once during first 12 months of treatment based on those patients having at least one follow-up visit (over 10%):
GI problems 62/183 (33.9%) vs 43/177 (24.3%) vs 55/171 (32.2%), p=0.11; p=0.11;
Weight gain (>4 lbs) 87/183 (47.5%) vs 120/177 (67.8%) vs 88/171 (51.5%);p=0.001;
Large weight gain (>18 lbs) 7/183 (3.8%) vs 19/177 (10.7%) vs 5/171 (2.9%);
p=0.003;
Weight loss (> 4lbs) 66/183 (36.1%); 37/177 (20.9%); 44/171 (25.7%); p=0.004; Water retention 19/183 (10.4%) vs 35/177 (19.8%) vs 15/171 (8.8%); p=0.004; Hyponatremia 12/183 (6.6%) vs 7/177 (4%) vs 19/171 (11.1%); p = 0.03; Nystagmus 25/183 (13.7%) vs 25/177 (14.1%) vs 23/171 (13.5%); p=0.99; Dysarthria 17/183 (9.3%) vs 22/177 (12.4%); 15/171 (8.8%); p=0.48; Gait problems 51/183 (27.9%) vs 39/177 (22%); 29/171 (17.1%); p=0.93; Tremor 46/183 (25.1%) vs 39/177 (22%) vs 29/171 (17.1%); p=0.18; Sedation 73/183 (39.9%) vs 82/177 (46.3%) vs 86/171 (50.8%); p=0.13; Change in mood or affect: 55/183 (30.1%); 47/177 (26.6%) vs 56/171 (32.9%); p=0.43; Cognitive disturbances: 42/183 (23%) vs 53/177 (29.9%) vs 55/171 (32.4%); p=0.12; Dizziness: 50/183 (27.3%) vs 50/177 (28.2%) vs 55/171 (32.4%); p=0.55; Headaches: 35/183 (19.1%) vs 27/177 (15.3%) vs 30/171 (17.6%); p=0.62.

39 deaths occurred during the trial: 15 in CBZ group; 11 GBP; 8 LTG. There was no clustering of causes for death in any of the treatment arms to suggest a link between drugs and cause of deaths. None determined to be clearly due to study drug. 1 died 2 weeks after stopping study drug due to probable hypersensitivity reaction that led to multiple system organ failure. They were in the CBZ arm and had PHT for 1 week before enrollment thus obscuring the proximate cause.

The main limiting factor in patient retention was adverse drug reactions. Patients on LTG or GBP did better than those taking carbamazepine. Seizure control was similar in all groups. LTG and GBP should be considered as initial therapy for older patients with newly diagnosed seizures.
Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study

Ref ID 4635

**Study Type**  Randomised Controlled Trial  **Funding**  Sanofi UK; Parke Davis;

**Number of participant**  Total randomised n=47; patients available for analysis at 6 weeks: PHT n=20; VPA n=18;

**Inclusion/Exclusion Criteria**  Inclusion criteria: Aged >60 years; History of one or more unprovoked generalised tonic-clonic seizure or two or more partial seizures;
Exclusion criteria: uncertain diagnosis of epileptic seizures; clear provocation (alcohol, acute illness); evidence of a progressive cerebral condition (such as tumor); mental impairment sufficient to preclude cooperation with psychological tests; clinically significant abnormal liver function test; platelet counts <150x10^9/L or other blood dyscrasias on entry; recent myocardial infarction or serious cardiac arrhythmias; history of excessive alcohol intake; treatment with medication known to affect psychomotor function (sedatives, hypnotics, antidepressants and major tranquillizers) or drugs known to affect plasma PHT or VPA levels when the regimen was likely to change during the trial period.

**Patient Characteristics**  Phenytoin vs sodium valproate:
Mean age (range): 74.9 (67-84) vs 6.3 (62-88);
Mean dosage (range): 247 (175-275) vs 688 (400-1000);
Mean level umol/ml (range): 31 (18-80) vs 396 (201-545);
Seizure type: generalised 8 vs 8; partial with generalisation 6 vs 5; complex partial 6 vs 5.

**Recruitment**  Referred by gps or consultants in geriatric medicine.

**Setting**  Salford or adjacent districts.

**Interventions/ Test/ Factor being investigated**  Phenytoin versus sodium valproate.

**Comparisons**  Comparison between phenytoin and sodium valproate.

**Length of Study/ Follow-up**  Participants are tested at 6 weeks, 3 months, 6 months and 1 year.

**Outcome measures studied**  Attention, concentration, psychomotor speed, memory, adverse events.

**Results**  Seizure control: Most had complete seizure control within 3 months: 2 VPA and 5 PHT continued to have infrequent minor seizures after 3 months.

Change in cognitive function between VPA and PHT:
Six week tests: showed no significant difference in impact of VPA or PHT on any of the psychological tests apart form Choice reaction Time. For the two -option tests and the intercept (Ao), PHT had a significantly less adverse impact.

3 month tests: PHT group showed greater improvement in depressison scores and slightly less change in two and four option Choice Reaction times than VPA group.

6 month tests: no significant difference in any psychological tests apart from letter cancellation time, which appeared to be better in PHT group. Significant of this is doubtful as observed only once. Other tests unchanged.

1 year test: No significant difference in any of the psychological tests.
Main conclusions: there was little difference between PHT and VPA regards to impact on cognitive function. Frequent noncognitive adverse events were reported. The choice of AED in the elderly may be more influenced by consideration of other adverse events.

Safety and adverse effects
The following participants were unsuitable for analysis at 6 weeks due to: 3 had cerebral or extracerebral tumors; 1 had a stroke 4 weeks after entry; the consultant decided not to treat in 1 case; the relatives withdrew permission for the study in another; 3 were discontinued because of adverse effects; by the second assessment at 3 months 5 more dropped out (n=33) two were on VPA - a cerebrovascular accident; the other had started receiving antidepressants; 3 lost to PHT - one declined the tests, 1 was started on MST for ischemic foot pain; 1 complained of excessive sleepiness and discontinued PHT; by 6 months 4 more withdrew with events not directly related to the drugs - one of which was a sudden death not apparently related to seizure but in a patient with cardiac disease (VPA) and one by congestive cardiac failure (VPA); one PHT caused by cerebrovascular accident; between 6 months and 1 year - one VPA patient died in a nursing home of pneumonia.

Does the study answer the question?
Main conclusions: there was little difference between PHT and VPA regards to impact on cognitive function. Frequent noncognitive adverse events were reported. The choice of AED in the elderly may be more influenced by consideration of other adverse events.

Effect due to factor in study?
Unclear - no allocation concealment or power calculation, and only 38 participants assessed and no ITT.

Consistency of results with other studies?
Directly applicable to guideline population?
Direct.

Internal Validity
Saetre E; Abdelnoor M; Amlie JP; Tossebro M; Perucca E; Tauboll E; Anfinsen OG; Isojarvi J; Gjerstad L;

Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine
Ref ID 5089 2009 Aug

Study Type Randomised Controlled Trial Funding GlaxoSmithKline, Eastern Norway Regional Health Authority AND Ullevaal University Hospital.

Number of participants
N= 108 (ITT population), N CBZ=54 and N LTG=54
N=75 (completers), N CBZ=36 and N LTG=39.

Inclusion/Exclusion Criteria
People aged >=65 years, a history of at least two partial seizures (with or without secondary generalization) or primarily generalized tonic-clonic seizures, at least one seizure in the preceding 6 months, and a life expectancy of at least 12 months. Subjects treated with any AED for >2 weeks in the previous 6 months and subjects with severe psychiatric disease or intellectual impairment, liver failure, alcohol or substance abuse, significant abnormalities in blood chemistry were excluded.

Patient Characteristics
In both groups, there were almost similar proportions of females and males (M/F in LTG 15/16 and in CBZ 15/14). Both groups had similar age profiles (mean (sd) for LTG was 75.2 (6.8) and for CBZ was 73.6 (5.4). Stroke was the most common identified etiology of epilepsy in both groups.
### Recruitment

Participant recruited at Norwegian centers.

### Setting

Norwegian centers.

### Interventions/ Test/ Factor being investigated

Comparison of efficacy between lamotrigine and carbamazepine in the elderly.

### Comparisons

Between lamotrigine and carbamazepine.

### Length of Study/ Follow-up

There was a 4 week dose escalation and a 36 week maintenance phase.

### Outcome measures studied

1) withdrawal due to adverse events

### Results

1) withdrawal due to adverse events

**ITT analysis:** LTG 15/54 and CBZ 9/54

### Safety and adverse effects

No patient withdrew because of cardiovascular adverse events, except for one death due to a stroke occurred after the 4 week visit in a carbamazepine treated subject.

### Does the study answer the question?

Yes. Although more participants in LTG withdrew due to adverse events compared to those in carbamazepine, this difference was not significant.

### Effect due to factor in study?

This study was not designed to evaluate the proportion of participants withdrawn due to adverse events so uncertain what was the statistical power of the study and whether was enough to estimate this effect.

### Consistency of results with other studies?

Direct.

### Directly applicable to guideline population?

Direct.

### Internal Validity

Saetre E; Abdelnoor M; Perucca E; Tauboll E; Isojarvi J; Gjerstad L;

Antiepileptic drugs and quality of life in the elderly: Results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age

**Ref ID** 611

**Study Type** Randomised Controlled Trial

**Funding** Eastern Norway Regional Health Authority and Ullevaal University Hospital.

### Number of participant

N=167 (CBZ 83 and LTG 84)

### Inclusion/Exclusion Criteria

Inclusion criteria: aged >=65 years, a history of at least two partial seizures with or without secondary generalization or primarily generalized tonic-clonic seizures, at least one seizure during the last 6 months, and a life expectancy of >=12 months. Exclusion: those who had received AEDs for >2 weeks in the previous 6 months and subjects with severe psychiatric disease or intellectual impairment, liver failure, alcohol or substance abuse, significant unpaced atrioventricular conduction defect, or clinically significant abnormalities of blood chemistry.

### Patient Characteristics

Apart from a slightly higher median age and quite higher proportion of females in the LTG group, the characteristics of te evaluable and nonevaluable groups were comparable.

### Recruitment

Enrollment took place at 29 centers in five countries- Croatia, Finland, France, Italy and Norway. Patients from Croatia were not included in these assessments.

### Setting

Centers in these four countries.
<table>
<thead>
<tr>
<th>Interventions/ Test/ Factor being investigated</th>
<th>Comparison on health related quality of life outcomes between lamotrigine and carbamazepine.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparisons</td>
<td>Comparison between lamotrigine and carbamazepine and within drug treatment between baseline and 40 weeks follow up.</td>
</tr>
<tr>
<td>Length of Study/ Follow-up</td>
<td>4 weeks escalation period and 36 week maintenance period.</td>
</tr>
<tr>
<td>Outcome measures studied</td>
<td>Health related quality of life (HRQOL).</td>
</tr>
<tr>
<td>Results</td>
<td>1) HRQOL within LTG treatment: Screening SEALS score median (range): 35 (7-75) and at week 40: 30 (5-80) 2) HRQOL within CBZ treatment: Screening SEALS score median (range): 27.5 (3-77) and at week 40: 27 (3-78) Difference in change of HRQOL for the period of 0-40 weeks between LTG and CBZ: Change in SEALS score for LTG: -2 (-32 TO 44) Change in SEALS score for CBZ: -1.5 (-26 to 44) (p of difference in change between LTG and CBZ 0.54)</td>
</tr>
<tr>
<td>Safety and adverse effects</td>
<td>None.</td>
</tr>
<tr>
<td>Does the study answer the question?</td>
<td>Yes, neither lamotrigine nor carbamazepine caused significant change in health related quality of life measures after 40 weeks of treatment</td>
</tr>
<tr>
<td>Effect due to factor in study?</td>
<td>Uncertain. A single blinded study with drop outs.</td>
</tr>
<tr>
<td>Consistency of results with other studies?</td>
<td>Direct.</td>
</tr>
<tr>
<td>Directly applicable to guideline population?</td>
<td>Direct.</td>
</tr>
</tbody>
</table>

**Internal Validity**

Saetre E; Perucca E; Isojarvi J; Gjerstad L; Study Group.;

An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly

**Ref ID** 231

**Study Type** Randomised Controlled Trial

**Funding** Glaxo-SmithKline Inc.

**Number of participant** Total randomised n=186. Lamotrigine n=94; Carbamazepine n=92.

**Inclusion/Exclusion Criteria**

Inclusion criteria: aged 65 years or over; newly diagnosed epilepsy; history of two or more recurrent unprovoked seizures either partial (with or without secondary generalisation) or primarily generalised tonic-clonic, and at least one of the seizures occurring during the previous 6 months; clinical indication to initiate AED treatment; life expectancy >1 year; willingness to provided written free informed consent.

Exclusion criteria: a history of absence, tonic, atonic or myoclonic seizures; >2-week intake of any AED in the previous 6 months, or any previous intake of CBZ or LTG; treatment with any AED for five elimination half-lives in the period immediately preceding study entry; severe psychiatric disease or severe intellectual impairment; acute or chronic hepatic failure; significant un-paced AV defect; alcohol or substance abuse; clinically significant abnormalities in blood chemistry tests.

**Patient Characteristics**

LTG vs CBZ:

Males/Females: 46/47 vs 56/35; Mean age +/- s.d (range): 71.3 +/- 6.2 (65.91) vs 73.1 +/- 5.5 (65.87); Classification: idiopathic/cryptogenic 33 (35%) vs 37 (41%); symptomatic: 60 (65%) vs 54 (59%);
Lamotrigine (Lamictal 25 and 100mg chewable/dispersible tablets) vs sustained release carbamazepine (tegretol 100 and 200mg divisible tablets).

**Interventions/Test/Factor being investigated**
- Lamotrigine vs carbamazepine.

**Comparisons**
- Those completing the study could continue on an open label basis. Those who withdrew from treatment had a 4-week taper down.

**Outcome measures studied**
- Seizure freedom; Time to withdrawal; no. withdrawn; adverse events;

**Results**
- The ITT population: 25% fractile for the time to first seizure survival curve was 5.6 weeks compared to 4 weeks. No significant differences were identified in the ITT population. In the per protocol population the time to first seizure was significantly longer in the CBZ group (19.3 weeks) than the LTG group (8.4 weeks).
- Seizure freedom of completers after week 20 (% of ITT population): 48(52%) vs 52(57%), p value 0.45, OR (95% CI) 0.80 (0.45-1.43).

**Safety and adverse effects**
- Withdrawal due to adverse events: 13/93 (14%) vs 23/91 (25%).
- No. of patients with treatment-emergent adverse evnts considered to be at least possibly related to study drug:
  - Any drug-related adverse event: 51(55%) vs 51 (55%);
  - Dizziness: 13 (14%) vs 9 (10%);
  - Rash/skin reaction 5 (5%) vs 12 (13%);
  - Headache 10 (11%) vs 10 (11%);
  - Somnolence/sedation/hypersomnia 7 (7%) vs 9 (10%);
  - Asthenia/fatigue 9 (10%) vs 9 (10%);

**Does the study answer the question?**
- Conclusions: There was a trend for higher seizure-free rates for CBZ and better tolerability with LTG. Differences in previous trials may related to different dosing rates and use of a sustained-release formulation for carbamazepine.

**Effect due to factor in study?**
- 190 patients required for 80% power.

**Consistency of results with other studies?**
- Direct. Newly diagnosed epilepsy in the elderly.